Qualifying Therapeutic Discovery Project Grants

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted. Alabama $3,708,304.65

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular Heparan Sulfate Agenta Biotechnologies Delivery in Barrier Membranes $59,614.76 $184,864.48 Inc and Soft Tissue Wound Closure DELIVERY OF GROWTH- AGENTA FACTOR CO-RECEPTOR BIOTECHNOLOGIES HEPARAN SULFATE IN $169,808.39 $6,666.50 INC BONE GRAFT SUBSTITUTES FOR REPAIR BioCryst BCX4208 for Treatment of $244,479.25 Pharmaceuticals Inc Gout BioCryst Peramivir for Treatment of $244,479.25 Pharmaceuticals, Inc Influenza BioCryst Forodesine for Treatment of $244,479.25 Pharmaceuticals, Inc CLL and CTCL BioCryst BCX4161 for Treatment of $86,380.89 Pharmaceuticals, Inc. Hereditary Angioedema JAK Inhibitors for Treatment BioCryst of Psoriasis, Ankylosing $244,479.25 Pharmceuticals, Inc. Spondylitis, & Multiple Sclerosis Disease Diagnostic Panel Diatherix Laboratories, Development Utilizing the $244,479.25 Inc. TEM-PCR Method Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 EGEN-001 in Platinum- EGEN INC $244,479.25 Resistant Ovarian Cancer EGEN, INC. EGEN TheraSilence $244,479.25 Development of an Apparatus iCubate, Inc $244,479.25 for Performing am-PCR Phase 1, Open-label Syudy Evaluting the Safety of PNP Therapeutics Inc $244,479.25 Escalating Doses of Ad/PNP- F-araAMP SER-201 for the treatment of Serina Therapeutics, Inc $244,479.25 colorectal and ovarian cancer Development of an Vaxin Inc. Adenovirus-Vectored Nasal $244,479.25 Anthrax Vaccine Replication-Defective Adenovirus-Vectored Vaxin Inc. $161,175.00 $83,304.25 Influenza Vaccine Development Nanotechnology Enabled Vista Engineering Inc Temporomandibular Joint $29,059.63 $32,059.00 (TMJ) Prosthesis Development of sorptive nasal Volatile Analysis stent for diagnostic biomarker $23,600.00 $182,500.00 Corporation detection

Arizona $7,503,090.80

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 AmpliMed Development of small-molecule $244,479.24 Corporation anti-cancer drugs NeuVax-adjuvant treatment for Apthera, Inc. $244,479.25 node positive breast cancer with Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 low to intermediate HER2 Development of Ultrasound Ardent Sound Inc. Therapy Device for Sebaceous $244,479.25 and Sweat Gland Treatment Ascalon IV Fenretinide $106,406.50 $138,072.74 International Inc Integrated platform for bioVidria, Inc. $47,799.50 $114,302.50 glycoform biomarker discovery TGEN COLLABORATION: BLUE HORSE GENETIC RISK FACTORS $179,589.50 $8,301.50 LABS, INC. FOR ALZHEIMER'S DISEASE (PHASE II) Oxidative stress markers in Blue Horse Labs, multiple matrices as biomarkers $7,160.00 $88,697.00 Inc. for disease Hematopoietic Stem Cell Therapy for HIV/AIDS Usifng Calimmune, Inc. $244,479.25 RNAi to Reduce Expression of CCR5 Cancer Prevention Eflornithine $189,893.77 $54,585.48 Pharmaceuticals Inc Capstone AZX100 for Idiopathic $78,150.00 $166,329.24 Therapeutics Corp Pulmonary Fibrosis (IPF) Cold Plasma Harmonic Cold Plasma medical Medical Technology for the Repair of $244,479.25 Technologies Living Cells, Tissue and organs. Eye Care and Cure Extra-Ocular Motility Monitor $63,720.71 Corporation (EOMM) Eye Care and Cure I-CORE $53,221.15 Corporation Gary A Flynn Multi-targeted Kinase Inhibitors PhD/Spacefill as Imaging and Therapeutic $27,000.00 Enterprises LLC Agents High Throughout qNPA miRNA Development $41,483.00 $5,419.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Genomics, Inc. Project High Throughput Mid Density Platform $73,830.00 $79,962.00 Genomics, Inc Development Project High Throughput qBead Development Project $67,940.00 $38,392.00 Genomics, Inc High Throughput Fusin Gene-SNV Mutation Tests $26,268.50 $28,273.50 Genomics, Inc Development Project High Throughput Pathogen Assay Development $11,131.00 $23,394.00 Genomics, Inc Project High Throughput DLBCL & Cell of Orgin $16,408.50 $8,707.00 Genomics, Inc Development Project High Throughput qSelect Assay Archive $16,026.50 $41,378.50 Genomics, Inc Development Project High Throughput qNPA Platform Technology $71,709.50 $117,348.00 Genomics, Inc Development Project High Throughput Melanoma Screening $20,359.50 Genomics, Inc Development Project High Throughput Radiation Exposure Monitoring $13,797.00 $2,081.00 Genomics, Inc Assay Development Project Hope Medical Treatment of Acute Myocardial $17,542.28 Enterprises, Inc Infarction Hope Medical Treatment of Sickle Cell Disease $3,250.00 $36,907.86 Enterprises, Inc. Recombinant fibrogen & HumaGene Inc $17,985.00 $14,500.00 thrombin InNexus DXL 625 $116,760.00 Biotechnology, Inc. INSYS Therapeutics, Fentanyl Sublingual Spray $244,479.24 Inc INSYS Therapeutics, Dronabinol Oral Solution $244,479.25 Inc Kinetic Muscles Inc Neuro Telerehabilitation System $221,667.65 $22,811.59 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Utilizing the MedApps System MedApps, Inc for Remotely Monitoring $244,479.24 Clinical Drug Therapies MSDx Multiple Biomarkers for Monitoring Sclerosis Multiple Sclerosis Patients - A $82,908.19 $47,063.66 Diagnostics, LLC Window into the Brain Biomarkers for Monitoring MSDx, Inc Multiple Sclerosis Patients - A $74,700.00 window into the Brain Development of molecular PathoGene, LLC assays for the identification and $37,850.50 resistance profiling of MRSA. Engineered Small-Diameter Protein Genomics Artery Grafts Using Synthesized $120,342.50 $124,136.75 Human Elastin Fibrinogen and fibrin Provista Life degradation product lung cancer $137,175.27 Sciences, LLC assay Provista Life Multivariate Breast Cancer $221,153.46 Sciences, LLC Detection and Screening Assay Provista Life Epigenetic Test for Alzheimer's $244,479.25 Sciences, LLC Disease Provista Life Lymphocyte Proliferation Test $180,664.68 Sciences, LLC for Early Alzheimer's Detection Prugen IP Holdings Drug Bioavailability $244,479.25 Inc Enhancement Delivery System Stabilized Chlorine Dioxide for Rowpar Treatment & Prevention of Oral $1,402.50 $3,673.00 Pharmaceuticals, Inc Candidiasis 0.5% Stabilized Chlorine Rowpar Dioxide for the Treatment and $2,881.00 $20,782.50 Pharmaceuticals, Inc Prevention for Gingivitis SALUTARIS SMD-A $244,479.24 MEDICAL Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 DEVICES, INC. Non-invasive boold glucose Sensys Medical Inc monitor for the diagnosis & $244,479.24 treatment of diabetes Southwest Scientific Dietary supplements enhanced Editing & for biofavanoids and antioxidants $2,850.00 $26,200.00 Consulting, LLC to treat human disease Susavion Discovery of Immunotherapeutic $85,997.50 $117,631.00 Biosciences, Inc Drugs Against Viral Infections Kit for noninvasive early Synbuild LLC $11,157.12 detection of pancreatic cancer SYNCARDIA COMPANION 2 DRIVER $54,080.75 SYSTEMS, INC Inline acuator for pMDI Thayer Medical medication delivery in ventilator $66,050.50 $112,333.50 Corporation circuits with 15 mm connection. Pre-Clinical and Clinical Transmed Oncology Development of DNMT1 $70,784.50 Inc inhibiting Compounds Valley Fever Late Stage Valley Fever - Phase $244,479.25 Solutions, Inc. II The Use of Bioelectric Wound Vomaris Care Devices for Improving $244,479.25 Innovations, Inc Healthcare

Arkansas $730,294.80

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Mucosal and Cell Targeted RTB BioStrategies, Delivery of Novel Plant Produced $118,994.00 $125,485.25 LC Protein Therapeutics Pacific Vet Pre-clinical Trials for Unique $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Group - USA Competitive Exclusion Treatment Inc. for Gastrointestinal Disease New Biomarker Assays for Stage I Monitoring and Diagnosis of $171,756.22 $69,580.08 Diagnostics, Inc. Ovarian Cancer

California $276,141,790.10

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 3-V BROAD SPECTRUM HOST BIOSCIENCES FACTOR DIRECTED $244,479.24 INC ANTIVIRAL THERAPEUTIC Application of continous negative 5iSciences, Inc. external pressure (cNEP) to the $22,834.35 $141,124.00 upper airway APF530- Prevention of A.P. Pharma, Inc Chemotherapy-induced Nausea $244,479.25 and Vomiting Aaken Guided Electrical Stimulation $49,026.40 $36,267.00 Laboratories Aardvark Nasal Irrigation/Aspiration $244,479.24 Medical, Inc. System Ablation Rapid and Simple Cure for Atrial $500.00 $243,979.25 Numerics Inc Fibrillation Acadia Pharmaceuticals Pimavanserin $244,479.25 Inc. Acaduceus Developing Novel Platinum Pharmaceutics based Targeted-Nanoparticles for $12,400.00 $132,500.00 Inc Anti-Cancer Drugs Acaduceus Developing Targeted Probe for $56,150.00 $180,000.00 Pharmeceutics PET imaging of Primary and Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Metastatic Melanoma Acceleration of Bone Fracture Accelalox Inc. $54,062.50 $132,430.00 Healing Access Scientific The Wand $244,479.25 Inc Gravitas: Gauging Responsiveness With a Accumetrics, Inc $244,479.25 VerifyNow Assay-impact on Thrombosis & Safety Development of and cancer ACEA treatment with Bis(4- $244,479.25 Biosciences Inc. fluorobenzyl)trisulfide (BFBTS) AcelRx Sufentanil NanoTab ™ Patient Pharmaceuticals, Controlled Anagesia (PCA) $244,479.25 Inc System AcelRx Pharmaceuticals, Triazolam/Sufentanil NanoTab ™ $244,479.24 Inc. ACHN-490 - A Novel Second- Generation Aminoglycoside Achaogen, Inc $244,479.25 Antibiotic for the Treatment of Resistant Bacterial Infections Novel Expanded-Spectrum Aminoglycosides (ES-AGs) for the Treatment of Pan-Resistant Achaogen, Inc $244,479.25 Bacterial Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii Discovery and Development of a Novel Class of Antibacterials, LpxC Inhibitors for the Treatment Achaogen, Inc $244,479.25 of Multi-Drug Resistant Bacterial Infections Caused by Gram- Negative Bacteria Discovery & Development of a Achaogen, Inc. $244,479.24 Novel Orally Bioavailable Beta- Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Lactam for the Treatment of MRSA and Other Multi-Drug resistant Bacterial Infections Acologix Inc AC 100 $88,245.46 Acologix, Inc. AC820 $244,479.25 Acologix, Inc. AC 200 $170,732.65 Acorn T-Fusion ™ Platform for oral $125,005.10 $119,474.15 Biomedical Inc Delivery of Recombinant Proteins Development of Adenosine A3 Acorn Receptor Antagoinst for the $172,773.37 $71,705.88 Biomedical Inc Treatment of Glaucoma. Telatinib is a new cancer drug that Act Biotech , Inc can readily combine with $244,479.25 chemotherapy. ACTB1003 a novel anti-cancer ACT Biotech Inc drug for treatment of cancers with $244,479.25 FGFR gene alterations Active Life Early Diagnosis of Osteoporosis $82,273.03 $162,206.22 Scientific, Inc. ActiveSite Preclinical & Early Clinical Pharmaceuticals, Development of a NCE Targeting $136,104.50 $108,374.74 Inc Diabetic Macular Edema Bi-specific c-Mat anitbodies to A-Cube Inc treat abnormal angiogensis in eye $244,479.25 disease and cancer AcuFocus, Inc. ACI 7000PDT $244,479.25 Once-daily Fixed Dose Adamas Combination (FDC) for Pharmaceuticals, $244,479.25 Moderate-Severe Dementia Inc. Alzheimer's Type Adamas Triple Combination Antiviral Pharmaceuticals, Drug Therapy for the Treatment $244,479.25 Inc. of Infulenza Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Adamas Extended-Release Amantadine for Pharmaceuticals, Treatment of Levodopa-induced $244,479.25 Inc. Dyskinesia in Parkinson's Thermotherapy for the treatment Aduro BioTech $197,978.50 of Cancer Listeria-Based Immunotherapy Aduro BioTech $235,971.50 $8,507.75 for Cancer and Infectious Disease Advanced Advanced Bifurcation Systems Bifurcation Platform for Complete Bifurcation $150,636.50 $93,842.75 Systems and Side Branch Stenting Diagnostic tests based on in situ Advanced Cell RNA detection for personalized $244,479.25 Diagnostics, Inc cancer management Pluripotent Stem Cell Therapy for Advanced Cell the Treatment of Stargardt's $244,479.25 Technology Inc Macular Dystrophy Autologous Skeletal Myoblast Advanced Cell Transplantation to Treat Ischemic $244,479.25 Technology, Inc. Cardiomyopathy Generation of Pluripotent Advanced Cell Embryonic Stem Cells without $244,479.25 Technology, Inc. Destruction of Donor Embryo Inducing Pluripotency fron Advanced Cell Differentiated Somatic Cells for $244,479.25 Technology, Inc. Autologus Stem Cell Therapy Development of a Novel RNA- Advanced protein Complex Inhibitor for $117,108.50 $127,370.75 Genetic Systems Treatment of HIV Advanced Targeting A Novel Cancer Pain Therapeutic $19,705.50 $21,576.50 Systems Inc ADS-NPTMZ-1, A Novel Advantageous Nanotherapeutic for Selective $27,428.00 $63,714.00 Systems, LLC Treatment of Advanced Melanoma Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Adventrx Pharmaceuticals, ANX-530 $244,479.25 Inc ADVENTRX Pharmaceuticals, ANX-514 $244,479.25 Inc. AEGEA Medical endometrial ablation $244,479.25 Incorporation Aeolus Development of AEOL11207 as a Pharmaceuticals, $92,406.00 treatment for Parkinson's disease Inc. Aeolus Development of AEOL10150 as a Pharmaceuticals, $244,479.25 treatment for ARS/DEARE Inc. Aespis Biopharmaceutic A Novel Cancer Therapeutic $244,479.25 al Company Afferent Development of a Novel Pharmaceuticals, $244,479.25 Pharmaceutical, AF-219 Inc Affinity Tumor microenvironment $244,479.25 Pharmaceuticals activated prodrug Affinity PET imaging agents of tumor $244,479.25 Pharmaceuticals microenvironment Affymax, Inc. Peginesatide $244,479.25 Afraxis, Inc Afraxis PAK inhibitor project $244,479.24 Aires Development of Aironite to Treat Pharmaceuticals $244,479.24 Pulmonary Arterial Hypertension Inc Aleeva Medical Alleviate back pain with disc $21,732.00 $222,747.25 Inc shunt Alexza Pharmaceuticals, Staccato Loxapine $244,479.24 Inc. Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Alion Development of a new Pharmaceuticals $167,000.00 Alzheimer's Therapeutic Inc ALS-2135 Improving Nucleoside Alios BioPharma Antiviral Properties through a $244,479.24 Inc Novel Produg Technology ALS-012117 - A Broad-Spectrum Alios BioPharma Antiviral that Activates the RNase $244,479.25 Inc L Pathway ALS-2160 - Novel Sugar Alios Substituted Nucleoside for the $244,479.24 BioPharma, Inc Treatment of Chronic Hepatitis C Glycoferon- A Hyperglycosylated Alios interferon with Improved $244,479.24 BioPharma, Inc Pharmacokinetitc Properties Allele Biotechnology & DNA Ratio Change Technology $12,458.50 $232,020.75 Pharmaceuticals for Prenatal Diagnosis Inc Allele Biotechnology & STEAP4 as a Target for Obesity $17,799.00 $24,170.00 Pharmaceuticals and Diabetes Therapy Inc Allele Biotechnology & Use of UV-Absorbing Biological $26,168.50 $51,717.00 Pharmaceutics, products for Skin Protection Inc Allon Davunetide for the treatment of $244,479.24 Therapeutics Inc PSP Allon AL-309 for the treatment of Therapeutics, $137,166.50 $107,312.74 peripheral neuropathy Inc. Allvivo Vascular, Dual Function Antimicrobial $142,899.52 $101,579.73 Inc. Catheter ALPHA ReleF Technology $59,290.00 $185,189.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ORTHOPAEDIC S, INC Alpha Source System for Production of Medical $238,271.21 $6,208.03 LLC Radioisotopes Altermune Altermune: Chemically Technologies, $244,479.24 Programmable Immunity LLC ATS907: Development of a Novel Topical Rho Kinase Altheos Inc. $10,689.00 $233,790.24 Inhibitor for Treatment of Glaucoma Altlura Medical AAA endograft Altura Medical, system to repair abdominal aortic $244,479.25 Inc aneurysms Alvine ALV003 Therapeutic Pharmaceuticals $244,479.24 Development Project Inc Alvine ALV003 2nd Generation Pharmaceuticals $68,374.00 $176,105.25 Therapeutic Development Project Inc Alvine Celiac Disease Biomarker Pharmaceuticals, $23,076.50 $143,160.00 development Project Inc Coronary Artery Vascular Amaranth Restoration Therapy Drug Eluting $244,479.24 Medical Inc Bioresorbable Stent Drug Eluting Bioresorable Stent Amaranth for PVD Vascular Restoration $244,479.24 Medical, Inc Therapy Ambit AC220 (FLT3) Program $244,479.24 Biosciences Inc Ambit CSF1R/AC710 Kinase Program $244,479.24 Biosciences Inc Ambit AC480 Treatment Program $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Biosciences Inc AMBIT AC430 JAK2 KINASE BIOSCIENCES, $244,479.24 PROGRAM INC. PEG-Leptin for the treatment of Ambrx Inc $244,479.25 obesity and Type 1 Diabetes ARX-Trail for the treatment of Ambrx Inc $217,366.50 $27,112.75 metastatic colon cancer ANTIHER2-DOLOSTAIN AMBRX, INC ANTIBODY ("ARX-AHD) for $244,479.25 the treatment of breast cancer Anti-VEGF-Anti-Ang2 for the Ambrx, Inc treatment of newvascular age $244,479.25 related macular degeneration ARX618(FGF21) for the AMBRX, INC $244,479.25 treatment Type II Diabetes American Life Science Alzheimer's Disease Cathepsin-B $244,479.24 Pharmaceuticals, Inhibitor Therapeutics Inc. AMIRA Lysophospahidic Acid Receptor PHARMACEUT $244,479.25 Antagonist and Inhibitor (LPA) ICALS, INC AMIRA PROSTAGLANDIN D2 PHARMACEUT RECEPTOR ANTAGONIST $244,479.25 ICALS, INC (DP2) Amplyx A Hybrid Therapeutic with Pharmaceuticals superior Efficacy Against $54,626.50 Inc Resistant Infections Amplyx Novel Taxane with Greatly Pharmaceuticals, Reduced Peripheral Neuropathy $96,445.50 Inc for Cancer Therapy Amplyx A Novel Carbapenem Antibiotic $81,777.50 $83,514.50 Pharmaceuticals, to improve Therapeutic Outcomes Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Amplyx Novel, Targeted HIV Protease Pharmaceuticals, Inhibitor to Improve Therapeutic $149,473.50 $71,016.50 Inc Outcomes Amunix Inc Genetic Deficiency $69,238.29 Amunix Inc CANCER $139,116.83 Amunix Inc Immune Diseases $172,881.67 Anacor AN2898, a topical anti- Pharmaceuticals, inflammatory therapy for the $244,479.25 Inc treatment of atopic dermatitis AN5973, a novel agent for Anacor treatment of Enterobacteriaceae Pharmaceuticals, $244,479.25 infections caused by Inc Enterobacteriaceai bacteria. Novel agents to treat Community- Acquired Respiratory Tract Anacor Infections. Novel boron- Pharmaceuticals, containing small molecule $244,479.25 Inc antibacteria agents to treat community-acquired respiratory tract infections (CART1) Anacor AN2728, a novel topical anti- Pharmaceuticals, $244,479.25 inflammatory therapy for psoriasis Inc Anacor AN2690, a novel, broad spectrum Pharmaceuticals, antifungal therapy for $136,082.50 $108,396.75 Inc onychomycosis Anacor AN2718, a topical antifungal Pharmaceuticals, $244,479.25 therapy for tinea pedis Inc. Anadys Pharmaceuticals ANA598 $244,479.25 Inc Anadys ANA773 $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceuticals Inc Anaphore, Inc. TL1A-Atrimer Therapeutic $206,740.50 $37,738.75 Anaphore, Inc. TRAIL-R-Atrimer Therapeutic $244,479.25 IL-23R/IL-10R-Atrimer Anaphore, Inc. $244,479.25 Therapeutic A Novel Therapeutic Antibody AnaptysBio Inc for the Treatment of Chronic $244,479.25 Autoimmune Disease (ANA04) A Novel Therapeutic Antibody AnaptysBio Inc for the Treatment of Bone Loss $237,033.00 (ANA01). A Novel Therapeutic Antibody AnaptysBio Inc for the Treatment of Chronic Pain $244,479.25 (ANA01) A Novel Therapeutic Antibody AnaptysBio Inc for the Treatment of Complement $48,992.00 $85,498.50 Mediated Diseases (ANA06) A New Class of Anti-Androgen AndroScience Targeting Androgen Receptor $244,479.25 Corporation (AR) Angelica Nonimmunogenic Fusion Toxin $244,479.25 Therapeutics Inc Platform for Cancer Therapy Angstrom A6 a Novel CD44 Targeting Pharmaceuticals, $244,479.25 Cancer Therapeutic Inc ANTHERA PHARMACEUT A-001 $244,479.25 ICALS INC Anthera Pharmaceuticals A-623 for Rheumatoid Athritis $10,966.00 $233,513.25 Inc Anthera A-002 $244,479.25 Pharmaceuticals, Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc ANTHERA PHARMACEUT A-623 $10,966.00 $233,513.25 ICALS, INC. AntiCancer, Inc. Targeted Tumor-Killing Bacteria $87,322.16 $83,804.41 Apama Medical RF Project $101,461.50 $143,017.75 Inc Applied BioCode Barcoded Magnetic Beads (BMB) $244,479.25 Inc for Molecular Diagnostics Applied An Orally Delivered Hepatitis B Biotechnology $123,187.50 $115,568.50 Vaccine Institute, Inc. APT Cyclosporine Inhalation Solution Pharmaceuticals, to prevent and treat rejection $244,479.25 Inc. following lung transplant The Aptus Endostape in the Aptus prevention and treatment of $244,479.25 Endosystems, Inc abominal aortic aneurysms AqueSys Inc Aquesys Microfistula Implant $244,479.25 Sprayable biodegradeable Ara Medical, polymers as adhesion barriers & $183,828.00 $60,651.25 LLC drug delivery modality ARD-3100-Liposomal Aradigm Ciprofloxacin for the treatment of $244,479.25 Corporation Cystic Fibrosis ARD-3100 -- Liposomal ARADIGM Ciprofloxacin for the Treatment $244,479.25 CORPORATION of Non-Cf Bronchiectasis ARD-3150-Liposomal ARADIGM Ciprofloxacin for the Treatment $244,479.25 CORPORATION of Non-CF Bronchiectasis Aragon Pharmaceuticals, 3rd Generation Anti-Androgens $244,479.25 Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Aragon Pharmaceuticals, ARN-509 $244,479.25 Inc Aragon Pharmaceuticals, SERD $244,479.25 Inc. Multi-modal drug delivery system Aravasc Inc for local delivery of Cancer $135,274.28 $109,204.97 Chemotherapy Arbor Vita NA-1 $244,479.25 Corporation Arbor Vita AVC Avantage HPV E6 Test $244,479.25 Corporation Arbor Vita Anvantage A/H5N1 Flu Test $244,479.25 Corporation Ardea Next-generation URAT1 $244,479.25 Biosciences Inc Therapeutic Discovery Project Ardea RDEA119-MEK Inhibitor $244,479.25 Biosciences Inc Therapeutic Discovery Project Ardea RDEA594-URAT1 Therapeutics $244,479.25 Biosciences Inc Discovery Project RDX5791 for the treatment of Ardelys Inc. CIC, IBS-C predominant and $244,479.25 OBD RDX002 for the treatment of Ardelyx Inc. elevated phosphorus in chronic $244,479.25 kidney disease RDX008 treatment of salt and fluid overload in heart failure, CKD and hypertension patients Ardelyx, Inc $119,704.00 $124,775.25 congestive heart failure (CHF), chronic kidney disease and hypertension. Argusina, Inc. Novel Small Molecular Modulator $171,732.44 $72,746.80 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 of GLP1 Receptor for Anti- Diabetes/Obesity Treatment Aridis Aridis Formulation Technology Pharmaceuticals $244,479.25 Program LLC Aridis Aridis Novel Anti-Infective Pharmaceuticals, $244,479.25 Therapies Program LLC ArKal Medical ArKal Continuous Glucose $244,479.24 Inc Monitor ArmaGen Drug Development of Brain- $244,479.24 Technologies Inc Penetrating Biopharmaceuticals AB0024, a Novel Inhibitor of Arresto LOXL2 for the Treatment of $244,479.25 Biosciences, Inc Cancer and Fibrotic Diseases Arrowhead Research Rondel $244,479.25 Corporation ArtasisONE Vascular Access Arstasis, Inc. $244,479.25 System Noninvasive Prenatal Diagnosis Artemis Health, of Down Syndrome Using Next- $244,479.25 Inc. Generation DNA Sequencing Artery Artery Therapeutic, Inc: $41,602.96 $202,876.29 Therapeutic, Inc Diagnostic Program Artery Artery Therapeutic, Inc: $172,743.80 $71,735.45 Therapeutics, Inc Therapeutic Program Aryx Tecarfarin Novel Oral $244,479.24 Therapeutics Inc Anticoagulant Therapeutic ATI-7505 for the treatment of Aryx gastrointestinal motility $148,714.50 $95,764.74 Therapeutics Inc dysfunctions ARYX Budiodarone oral therapeutic for $244,479.24 THERAPEUTIC the tratment of atrial fibrillation Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 S INC ARYX ATI-9242 for the treatment of THERAPEUTIC $111,106.50 $99,439.50 schizophrenia and depression S, INC. Asante Solutions, Personal Infusion System $244,479.24 Inc. TREATING CHRONIC Asthmatx, Inc. RESPIRATORY DISEASES $244,479.25 WITH ALAIR SYSTEM ASTRAEA POLYDRUG ADDICTION THERAPEUTIC $4,682.50 $93,112.00 TREATMENT S, LLC Astraea Novel Therapies for Parkinsons Therapeutics, $38,713.50 Disease and Dyskinesia LLC A Novel Biomaker Panel for the Astute Medical, Early Detection of Acute Kidney $244,479.24 Inc Injury AtheroMed, Inc. Phoenix Atherectomy System $244,479.25 Tmax, an Innovative Biological aTyr Pharma Inc. $244,479.24 Therapy for Thrombocytopenia ATYR1920, a novel aTyr Pharma Inc. $244,479.24 immunomodulatory agent for IBD Sustained Release Apomorphine Auritec for the Treatment of Parkinson's $80,827.37 $46,125.17 Pharmaceuticals Disease Intravaginal ring releasing Auritec acyclovir for the prevention of $105,580.61 $92,197.62 Pharmaceuticals HSV transmission Sustained Release Cyclosporine Auritec for the Prevention of Graft $51,081.86 $193,397.39 Pharmaceuticals Rejection Auritec Sustained Release Nevirapine for $65,989.98 $14,366.85 Pharmaceuticals the Treatment of HIV Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Sustained Release Olanzapine for Auritec the Treatment of Schizophrenia $68,881.55 Pharmaceuticals and Mania Auspex SD-560-Deuterated pirfenidone Pharmaceuticals, analog for treatment of idiopathic $239,933.37 $4,545.88 Inc. pulmonary fibrosis Automedics HepGuide Decision Support Medical Systems, $157,334.50 $87,144.74 Software Inc. Autonomic Delivery of Therapeutics for $244,479.25 Technologies Inc Migraine and Cluster Headache Avanir Pharmaceuticals, Zenvia $244,479.25 Inc Development and Clinical Trials of the Third Eye Retroscope, a Avantis Medical Device to Enhance Detection and $244,479.25 Systems Treatment of Colonic Adenomas and Prevent Colorectal Cancer R-Type Pyocins as Novel AvidBiotics Corp $244,479.24 Antibacterials Targeted MICA Molecules to AvidBiotics Corp Recruit Innate Immunity Cells to $38,082.50 $82,718.00 Kill Specific Viruses Aviir Blood Test for Heart Aviir, Inc. $244,479.24 Disease Axikin Axikin Pharmaceuticals: Novel Pharmaceuticals, Small Molecule Therapy for $244,479.25 Inc. Asthma Development of a new class of Azee Inc. antibacterial and antiviral drugs $27,619.85 $77,000.00 using SMAT technology Developing the first potential drug Balance to treat the cognitive impairment $14,389.84 $230,089.41 Therapeutics, Inc in Down Syndrome Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 BARnova, Inc TransPyloric Shuttle $244,479.24 Trans-oral Endoscopic Restrictive BaroSense Inc $244,479.24 Implant System (TERIS) Albation of Squamous Neoplasia BARRX and Esophegeal Squamous Cell $43,364.00 $69,826.00 MEDICAL INC. Carcinoma Albation of Intestinal Metaplasia BARRX (AIM) Dysplasia Extension of $218,622.50 $25,856.75 MEDICAL INC. follow-up to 5 years BARRX Halo Patient Registry- Ablation of $244,479.25 MEDICAL INC. Barrett's Esophagus Micro-Layer Ablation of Barrett's BARRX Metaplasia- Extension of Follow- $52,077.00 MEDICAL INC. Up to 5 years Bayhill BHT - 3021 $244,479.25 Therapeutics Bayhill BHT - 3034 $244,479.25 Therapeutics Bebaas Inc Cyprem $242,500.00 $1,979.25 Bebaas Inc Cobacan $242,500.00 $1,979.25 BeneChill, Inc RhinoChill $244,479.24 Beyond Lucid MEDIVIEW DX by Beyond Technologies, $9,477.83 $157,022.86 Lucid Technologies, Inc. Incorporated BFIONOVO, MENERBA $244,479.25 Inc. Induced Pluripotent Stem Cell Bio Time Inc $112,580.75 $131,898.50 Technologies Bio3 Research HMGB1 for accelerated wound $20,439.00 $32,032.00 Inc. healing BioAssay Development of $244,479.24 Systems LLC Pharmacodynamic and Diagnostic Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Assays for Cancer Drug Targets Development of a High Affinity BioAtla, LLC Antibody for nonHodgkin's $28,500.00 $37,350.00 Lymphomas Helical Infusion System for Heart BioCardia, Inc $244,479.25 Failure CEE Cell Enrichment and Biocept, Inc. $244,479.25 Extraction Platform Technology Discovery of a highly specific and Biodesy LLC potent therapeutic for Parkinson's $71,058.50 $39,996.50 disease Development and BioDx Partners Commercialization of a Blood $3,450.50 $138,599.50 LLC Test for Non-Small Cell Lung Cancer Bioenergenix, BioEnergenix $244,479.25 LLC Develop fully automated tools for BioGenex quantitative gene expression $244,479.25 Laboratories profiling in situ for cancer. Biological Point of Care Cancer Diagnostic $244,479.25 Dynamics, Inc. Device Development of Molecular Biomatrica Inc Diagnostic Tools for High- $244,479.25 Sensitivity Cancer Detection Developing Cancer Vaccines to BioMedicure Prevent and Treat Cancer $196,047.50 $48,431.74 LLC including Melanoma Enzyme-Linked Immunosorbent Biomerica Inc $172,890.28 $71,588.97 Assays (ELISA) Biomerica, Inc Microalbumin Project $44,185.60 $68,811.41 BIONOVO, INC BEZIELLE $244,479.25 BioTechPlex SUPRAER:High Dose-Rate $19,271.00 $36,681.50 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Corporation Aerosol Delivery of Biotherapeutics ACTCellerate Embryonic BioTime Inc $244,479.25 Progenitor Cells BioTime, Inc Chondrocyte Progenitor Cells $119,663.74 $124,815.51 Anagrelide Control Release for BioVascular Inc $244,479.24 Cardiovascular Risk Reduction Development of Saratin to BioVascular Inc. $244,479.24 increase vascular graft survival Development of Novel and New Bioxiness Class of Antimicrobial $18,780.00 $225,699.25 Pharmaceuticals Therapeutics BN Immuno MVA-BN-HER2 $244,479.25 Therapeutics Inc BN Immuno PROSTVAC $244,479.25 Therapeutics Inc BrainCells Inc BCI-632 $244,479.25 BrainCells Inc. BCI-540 $244,479.25 BrainCells Inc. BCI-952 $244,479.25 BrainCells Inc. BCI-224 $244,479.25 Broncus LungPoint Planning and Technologies, $244,479.25 Navigation Systems Inc Broncus Airway Bypass with Drug-Eluting Technologies, $244,479.25 Stents Inc. Broncus FleXNeedle Tissue Sampler (18 Technologies, $244,479.24 Gauge) Inc. Bruin Sub-epidermal moisture scanning $244,479.25 Biometrics, LLC device C2 Therapeutics, Cryoballon Ablation System for $176,887.51 $67,591.74 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Barrett's Esophagus Specifically-targeted C3 Jian, Inc. antimicrobial peptides $244,479.25 ("STAMPs) C8 MediSensors, HG-1c Noninvasive Glucose $244,479.25 Inc. Monitor OFIRMEV, A NEW Cadence INTRAVENOUS TREATMENT Pharmaceuticals, $244,479.25 FOR ACUTE PAIN AND Inc. FEVER Caerus Low-Cost Diagnostic Platform Molecular $150,000.00 using Millikan Sequencing Diagnostics Inc. Novel therapies for autoimmune CalciMedica, Inc $244,479.24 diseases Caldera Medical, POP SI $117,025.76 $127,453.49 Inc Caldera Medical, Desara Mini $140,691.80 $103,787.44 Inc. Calibra Medical, Finesse Personal Insulin Delivery $244,479.24 Inc. System Discovery of Novel Therapeutics Califia Bio, Inc. for the Treatment of HIV- $128,113.00 $116,366.25 associated Neurological Disease California Stem MotorGraft $244,479.25 Cell Inc Calithera Caspase Activator Program $244,479.25 Biosciences Inc S-ICD System, Subcutaneous Cameron Health, Implantable Defibrillator to Treat $244,479.25 Inc Sudden Cardia Death Cantimer Osmo Point-of-Care Dehydration $244,479.25 Incorporated Diagnostic System Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 A Novel Therapeutic Product for Capnia, Inc. $244,479.24 Treating Migraine A Novel Therapeutic Product for Capnia, Inc. $244,479.24 Allergic Rhinitis A Novel Diagnostic Device for Capnia, Inc. $3,915.00 $240,564.24 Detecting Hemolysis Cardiosphere-derived stem cell Capricor, Inc. $129,094.00 $115,385.25 therapy for advanced heart failure CapsoCam Colon Capsule Capso Vision Inc $244,479.25 Endoscope Carbylan Hydros TA $244,479.25 Biosurgery Inc. Mitochondrial Protection and Cardero Stimulation (MIPS) Drug $95,437.50 $149,041.75 Therapeutics, Inc Development Program Cardigant Project Nautilus $60,200.00 $110,550.00 Medical Inc Cardima, Inc. Catheter ablation technology $244,479.24 Corus SCA (sudden cardiac CARDIODX arrest)genetic test for the $244,479.24 INC detection of cardiac arrhythmia risk Corus CAD gene expression test CardioDx, Inc. for obstructive coronary disease $244,479.24 (CAD) Cardiogenesis Corporation and Phoenix Project $195,528.76 $48,950.49 Subsidiaries CT Flow: Non-Invasive Cardiovascular Assessment of Coronary Artery $119,606.00 $124,873.25 Simulation Inc Disease Cardium Therapeutics, Generx ® ("Generx") $244,479.24 Inc. Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Carmot Identification of novel anticancer $244,479.24 Therapeutics, Inc drugs Carolus Peptide Therapeutic-CT-2008 $244,479.25 Therapeutics, Inc Catalyst Improved recombinant human $244,479.24 Biosciences, Inc. Factor Vlla Catalyst Anti-complement Alterase TM $244,479.24 Biosciences, Inc. therapeutic program Catalyst Improved recombinant human $244,479.24 Biosciences, Inc. Factor IX CEBIX C-Peptide Replacement Therapy $244,479.24 Incorporated Cell Biosciences, Nanoimmunoassay for Biomarker $244,479.24 Inc Detection Small Molecule to treat Cell Viable Corp Neurodegenerative Disease such $17,250.00 as Alzheimers MYDICAR (AAV1/SERCA2a) Celladon for treatment of NYHA Class $244,479.24 Corporation III/IV symptoms of heart failure CellScape CellScape NIPD System $244,479.24 Corporation Imaging cell trafficking to CellSight advance clinical translation of cell $105,795.00 Technologies Inc and gene therapeutics Therapeutic agents for the Celprogen Inc. treatment of Breast Cancer triple $107,500.00 $136,979.24 negative patients High-Capacity Single-Cell Celula Inc Molecular Diagnostics for Non- $244,479.25 Invasive Prenatal Genetic Testing Cenna Peptide Drugs to Treat $16,248.50 $228,230.75 Biosciences Inc Alzheimer's Disease Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Ceregene, Inc Ceregene, Inc $244,479.25 Neurotrophic Factor Therapy Ceregene, Inc (AAV-NGF) for the Treatment of $244,479.25 Alzheimer's Disease (CERE-110) Delivery of NT-4 for the Ceregene, Inc. Treatment of Degenerative Ocular $244,479.25 Diseases (CERE-140) Diclofenac sodium topical patch Cerimon for treatment of acute $244,479.24 Pharmaceuticals musculoskeletal pain Cerus INTERCEPT Pathoogen $244,479.25 Corporation Inactivation for Platelets Cerus INTERCEPT Pathogen $244,479.25 Corporation Inactivation for Red Blood Cells Charisela Charisela Technologies: $213,581.03 Technologies Inc Advanced Reagent Technologies NOVEL SMALL MOLECULE HEDGEHOG PATHWAY CHEM DIV INC $73,690.00 $65,481.00 INHIBITORS AS ANTICANCER AGENTS ChemGenex Pharmaceuticals, Omacetaxine Mepesuccinate $244,479.24 Inc. ChemoCentryx Treating Chronic Hepatitis with $244,479.25 Inc C0334578 ChemoCentryx, Treating Glioblastoma Cancers $244,479.24 Inc with CCX662 ChemoCentryx, Treating Vasculitis with CCX168 $244,479.24 Inc ChemoCentryx, Treating Rheumatoid Arthritis $244,479.24 Inc with CCX354 ChemoCentryx, Treating Inflammatory Bowel $244,479.25 Inc. Disease (IBD) with CCX282 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ChemoCentryx, Treating Type 2 Diabetes with $244,479.24 Inc. CCX140 ChemoCentryx, Treating Atopic Dermatitis with $125,808.00 $118,671.25 Inc. C0333158 ChemoCentryx, Treating Inflammatory Bowel $244,479.24 Inc. Disease (IBD) with CCx025 New Stem Cell Therapies for ChemRegen, Inc. $244,479.25 Heart Disease CHF PliCath HF System $244,479.24 Technologies Inc ChromoLogic Occular Radiation Dosimeter $244,479.25 LLC (OCDOS) ChromoLogic Rapid brain injury dosimeter $29,394.00 LLC (RAPIDOS) ChromoLogic Amplified Refractometric $48,256.00 $20,344.00 LLC interference Analysis System ChromoLogic Debridement and Vitality $6,429.00 $29,587.00 LLC Assessment System (DAVANIS) ChromoLogic Reactie Chest Seal (ReSEAL) $7,842.00 $14,863.50 LLC ChromoLogic Fluid preservation system (FPS) $28,191.00 LLC ChromoLogic Label free integrated biofilm $16,109.00 $16,385.00 LLC analysis (LIBA) system ChromoLogic, Occular Hydration Monitor $110,770.50 $120,380.00 LLC (OCHYMO) Apoptosis Blood DNA Test to Chronix Guide Therapeutic Decisions in $244,479.25 Biomedical, Inc. Cancer Management Cianna Medical, SAVI Applicator System $244,479.25 Inc Claremont Rapid Sample Preparation and $234,671.10 $9,808.15 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Biosolutions Detection of C. diff. and Other LLC Pathogens Claret Medical, Dual Filter Embolic Stroke $77,166.00 $154,500.00 Inc Prevention Catheter Holos, a unique, high resolution, Clarity Medical real time optical measurement $192,231.50 $52,247.75 Systems, Inc technology for opthalmology Advanced Next Generation Clarity Medical System for Diagnostic Ocular $244,479.25 Systems, Inc Imaging Clincial Micro K-ras mulation cancer treatment $8,188.50 $236,290.75 Sensors, Inc Clinical Micro AD-8 DNA System $171,256.00 $73,223.25 Sensors Inc Clinical Micro Plavix Sensitivity Drug $60,588.00 $183,891.25 Sensors, Inc Clinical Micro Warfarin Sensitivity Test $110,390.50 $68,026.00 Sensors, Inc Clinical Micro Thrombophilia Risk Test (TRT) $244,479.25 Sensors, Inc. Clinical Micro Respiratory Viral Panel (RVP) $244,479.25 Sensors, Inc. Clinical Micro Cystic Fibrosis Genotyping (CF) $244,479.25 Sensors, Inc. CoaguSense Coagulometer CoaguSense, Inc $244,479.25 Project Hemophilia Therapeutic CoaguSense, Inc. $220,220.50 Monitoring Project Coda Nexagon ® For the Treatment of $244,479.25 Therapeutics, Inc Venous Leg Ulcers Colby Development of a New Chemical Pharmaceutical Entity Inhibiting JunD Activation $244,479.25 Company of the Androgen Receptor Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Colby Clinical Development of CPC-100 Pharmaceutical $51,500.00 $192,979.25 for Recurrent Prostrate Cancer Company Colby Androgen Receptor DNA Vaccine Pharmaceutical for Prostate Cancer Patient in $244,479.25 Company Vivo Immunization Colby Tempol-based Radioprotective Pharmaceutical Solid State Oral Drug Formation $244,479.25 Company for US stockpile COMBIMATRI COMPREHENSIVE CANCER X $244,479.24 ARRAY, OR "CCA" CORPORATION Combimatrix Array Comparative Genomic Molecular $244,479.24 Hybridization, or "aCGH" Diagnostics, Inc CoMentis Inc BACEi $244,479.25 Complete Complete Human Genome $244,479.24 Genomics, Inc. Sequencing for Personal Medicine CONATUS PHARMACEUT CTS-1027 $244,479.24 ICALS INC. The Trevo system provides rapid CONCENTRIC clot integration and removal in $244,479.25 MEDICAL, INC patients experiencing acute ischemic stroke. Conkwest Inc. NK-92 $17,594.05 $179,775.00 Selective GR-II Antagonist- Corcept CORT 108297- Treatment of Therapeutics $244,479.25 Antipsychotic Induced Weight Incorporated Gain Corcept CORLUX for Treatment of Therapeutics $244,479.25 Endogenous Cushing's Syndrome Incorporated Corcept CORLUX for the treatment of $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Therapeutics, Psychotic Depression Incorporated Corium MicroCor PTH(1-34) transdermal $244,479.25 International Inc delivery system for osteoporosis Cortene Inc Hercules $244,479.24 Cortex CX1739 A novel Ampakine Pharmaceuticals Molecule for Neurologicial and $244,479.24 Inc Psychiatric Disorders Crescendo Vectra ™ DA (Disease Activity $244,479.25 Bioscience, Inc Test) Crescendo Crescendo Structural Damage $244,479.25 Bioscience, Inc. Test CRISI Medical Advanced Cardiac Life Support $1,938.05 $242,541.20 Systems, Inc (ACLS) Drug Delivery System Cura Medical Range Compensator and Aperture Technologies Development for Proton Beam $244,479.24 LLC Radiation Therapy CuraSeal Inc PICS therapeutics delivery system $244,479.24 Customized Biomarker for prediciting Therapeutics response to chemotherapy in $31,666.67 $60,000.00 LLC prostate cance patients Biomarker for predicting respons Customized to chemotherapy in breast cancer $36,666.67 $105,000.00 Therapeutis LLc patients CX-7000 next generation CK2 Cylene inhibtor as a personalized Pharmaceuticals $244,479.24 anticancer agent with Inc accompanying diagnostic kit FiRST-IN-CLASS CX-6258 PAN-PIM KINASE INHIBITOR Cylene AS A PERSONALIZED Pharmaceuticals $244,479.24 ANTICANCER AGENT WITH Inc ACCOMPANYING DIAGNOSTIC KIT Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 FIRST-IN-CLASS RNA CYLENE POLYMERASE I INHIBITORS PHARMACEUT $244,479.24 AS PERSONALIZED ICALS, INC ANTICANCER AGENTS FIRST-IN-CLASS CX-4945 Cylene INHIBITORS AS Pharmaceuticals, PERSONALIZED $244,479.24 Inc ANTICANCER AGENTS with accompanying diagnostic kit Liquid Biopsy: Oncogenetic Cynvenio analysis of Cancerous Circulating $229,743.50 $14,735.74 Biosystems, Inc. Tumor Cells CytoDesign Inc Homogeneous Assay Platform for $23,288.00 (CDI) Clinical Diagnostics CytoDesign, Inc Engineering Proteolytic $45,637.50 (CDI) Therapeutics for Biodefense CytoDesign, Inc. Engineering Proteolytic $80,099.00 $78,151.50 (CDI) Therapeutics for Psoriasis Cardiac Muscle Activators for Cytokinetics, Inc $244,479.24 Heart Failure Cytokinetics, Inc Skeletal Muscle Activators $244,479.24 Cytokinetics, Smooth Muscle Myosin Inhibitors $244,479.24 Incorporated CytomX Armed Probodies for the Therapeutics, Treatment of Colon and Head & $175,983.50 $68,495.74 LLC Neck Cancer and GBM CytomX Probodies for the Treatment of Therapeutics, Triple Negative Breast Cancer $171,354.00 $73,125.24 LLC and Pancreatic Cancer The Celution System for the Cytori delivery of adipose derived stem $244,479.25 Therapeutics Inc and regenerative cells CytoScale New-Generation CTC Cancer $244,479.24 Diagnostics , Diagnostic Devices Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC Cytotech Labs Cytotech Labs, Api 31510 $244,479.24 LLC INNO-206 a prodrug of CytRx doxorubicin, which selectively $244,479.25 Corporation becomes active in tumors. Tamibarotene, a novel retinoid CytRx drug for treatment of a rare form $244,479.25 Corporation of leukemia CytRx Clinical trials with Bafetinib $146,172.50 $98,306.75 Corporation DataPhysics CaseReader: Healthcare Image $173,150.00 $71,329.24 Research, Inc Processing System Dean Allgeyer, Simplified Vital Signs Acquisition $3,252.50 $5,397.50 M.D for the Medical Home DM-1992 for the Treatment of Depomed, Inc $244,479.24 Parkinson's Disease Serada for the Treatment of Depomed, Inc $244,479.25 Menopausal Hot Flashes DermTech Epidermal Genetic Information $244,479.24 International Retrieval Cough analyzer of airborne Deton Corp bacteria for tuberculosis and $66,463.50 pulmonary disease diagnosis Axxess Drug Eluting Bifurcation Devax, Inc $244,479.24 Stent StabiliT therapeutic delivery Dfine, Inc $244,479.24 system Chemically Induced DNAmicroarray, Reprogrammed Human Somatic $244,479.25 Inc. Stem Cells for Treatment of Human Medi DOSE Medical DOSE Medical Drug Delivery $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Corporation Platform Duke Taheri LaDuca Endograft $161,302.23 $83,177.02 Vascular,In. Durect ORADUR $244,479.25 Corporation DURECT POSIDUR PROGRAM $244,479.25 CORPORATION DURECT BIOBETTERS PROGRAM $244,479.25 CORPORATION DxTerity Rapid Point of Care Genetic Diagnostics Testing Platform for Complex $177,025.00 $67,454.24 Incorporated Gene Expression Assays Dynavax Technologies HEPLISAV, Hepatitis B Vaccine $244,479.25 Corporation Dynavax DV1179 for the Treatment of Technologies $244,479.25 Systemic Lupus Erythematosis Corporation Dynavax Universal Flu Vaccine Technologies $244,479.25 N8295/llVSA Corporation Edison Pharmaceuticals, EPI-743 $244,479.25 Inc. Edison Pharmaceuticals, CNTO-530 $244,479.25 Inc. Eiger Biopharmaceutic EBP921 $138,813.50 $105,665.75 als, Inc EIGER BIOPHARMAC CLEMIZOLE AND BACK UPS $244,479.25 EUTICALS, INC Elcelyx Targeting Gut Chemosensory $62,465.50 $182,013.75 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Therapeutics Inc Receptors to Treat Obesity and Diabetes Elevation Pharmaceuticals, EP-101(LAMA) $244,479.24 Inc Elixir Medical Drug Eluting Stent (DES) $244,479.25 Corporation Elixir Medical Fully Bioresorbable Drug Eluting $244,479.25 Corporation Stent (BDES) ELIXIR MEDICAL Oncology Platforms $199,084.50 $45,394.75 CORPORATION Elixir Medical Ophthalmis Drug Eluting $199,094.00 $45,385.25 Corporation Implants Drug Eluting Stent (DES) with Elixir Medical Bioabsorbable Coating $244,479.25 Corporation (DESyneBD) Ellipse Ellipse MAGEC Technology $244,479.24 Technologies Inc Translational Development of a Emiliem, Inc Novel mTOR Pathway inhibitor $244,479.25 for Unmet Medical Needs An Electromagnetic EMKinetics Inc. neurostimulator for treatment of $244,479.25 overactive bladder (OAB) Endothelin Antagonist in Non- EndogenX Inc. $52,778.00 $191,701.25 Opiate Analgesia ENDOLOGIX, PEVAR $58,092.00 $186,387.25 INC. Endoscopic Treatment of Atrial Fibrillation Technologies, Utilizing Temperature Controlled $244,479.24 Inc DBA Estech Radio Frequency Surgery EndoSphere Inc. SatiSphere Duodenal Insert $221,690.50 $22,788.75 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Recombinant Human Albumin EnGen Bio, Inc. from an Optimized Expression $244,479.24 Sstem Hematopiesis Compound Entelos Inc $88,712.50 Evaluation Rheumatoid Arthritis Entelos, Inc $65,750.00 $27,387.50 Inflammatory Evaluation Project Rheumatoid Arthritis Entelos, Inc $58,118.00 Inflammatory Targets Evaluatuion development of a diagnostic test EntroGen Inc to aid in therapeutic decisions for $244,479.24 colorectal cancer patients Novel oligopeptides for the ENVY treatment and prevention of $68,250.00 $139,190.00 MEDICAL INC melanoma Eos Development of EOS-013, a Neuroscience Therapy to Restore Vision to $53,377.13 $191,102.12 Inc. Blind RP and AMD Patients EPEIUS REXIN-G, TARGETED BIOTECHNOLO MOLECULAR GENE $244,479.25 GIES THERAPY FOR CANCER CORPORATION CTC-HRP, predicting the Epic Sciences, response to anti-hormone receptor $226,377.50 $18,101.75 Inc. drugs in cancer patients Epicardial Epicardial Treatment and Technologies $244,479.24 Diagnosis of Cardiac Arrhythmias Inc. Epicenter Biologist Oriented Workbench for $108,042.00 $108,500.00 Software Genomic Integration. Discovery and development of Epigen novel agents for the treatment of $716.40 Biosciences Inc. pruritis Epigen Discovery and development of $3,023.16 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Biosciences, Inc. novel agents for the treatment of renal fibrosis Epinex G1A Rapid Diabetes Monitoring $244,479.24 Diagnostics, Inc Index Test Epiphany Phase 2 Clinical Development of $244,479.25 Biosciences, Inc. Valomaciclovir EPITOGENESIS VACCINE FORMULATION $244,479.25 INC Development of Therapeutic Epitomics, Inc. Monoclonal Antibodies Against $135,139.00 $109,340.25 Her3 Development of an immune Escape tolerant hESC source for Therapeutics, $242,668.26 $1,810.98 allogeneic cell therapy Inc. applications Diazoxide Choline Controlled Essentialis, Inc. Release Tablets in the treatment $244,479.24 of hypertriglyceridemia Eureka MAGE 101: A Next-Generation Therapeutics, anti-Her2 Antibody for Metastatic $244,479.25 Inc. Breast Cancer Treatment EVOKE EVK-001 $244,479.25 PHARMA, INC Excaliard Pharmaceuticals, Anti-Fibrosis Skin Scarring $244,479.24 Inc. Fully integrated and dynamic Existence genetic testing, analysis, and $87,449.20 $157,030.05 Genetics, LLC reporting system Expression Drug Biologic antagonism of S1P3 for $45,866.49 $54,844.39 Designs the treatment of breast cancer Drug-Mediated Cell Therapy For EyeCyte, Inc. $244,479.24 Diabetic Retinopathy Eye-Predict LLC Assessing brain disorders based $42,139.00 $202,340.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 on natural gaze features Anti-Angiogenic DLL4 Antibody Fabrus LLC $244,479.25 Therapy for Cancer Fallbrook Advanced Cord Blood Collection $108,145.50 $95,902.00 Engineering Inc System Novel bone Regenerative Therapy Fate to Improve Healing and Reduce $244,479.25 Therapeutics, Inc Healthcare Costs Novel Regenerative Therapeutic Fate to Restore Pancreatic Function to $244,479.25 Therapeutics, Inc Cure Diabetes Fate Patient-matched Cell Therapy to Therapeutics, $244,479.25 Cure Parkinson's Disease Inc. Fate Novel therapy Targeting Cancer Therapeutics, Stem Cells to Treat Highly $244,479.25 Inc. Aggressive Cancers FT1050 to Improve Fate Hematopoietic Stem Cell Therapeutics, $244,479.25 Transplants to Cure Inc. Leukemia/Lymphoma FEMTA FM101:Anti human IL-6 PHARMACEUT $244,479.24 Monoclonal Antibody ICALS, INC Ferrokin FBS0701:A novel iron chelator $244,479.25 BioSciences, Inc. for the treatment of iron overload FFA Sciences Diagnosing Acute Coronary $44,864.50 $158,370.50 LLC Syndromes FG-65155 for treatment of Fibrogen Inc ischemia reperfusion injury post- $244,479.25 myocardial infarction Development of FG-3019 for FIBROGEN INC treatment of locally advanced and $244,479.25 metastatic pancreatic cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 FG-6874 Development for the Fibrogen Inc. $244,479.25 Treatment of Oncologic Anemias FG-4592 Development for the FIBROGEN treatment of Anemia of Chronic $244,479.25 INC. Kidney Disease FP-1039 (FGFR1c:Fc), a Novel Anti-Cancer Agent Acting as an Five Prime Antagonist of Multiple Fibroblast $244,479.24 Therapeutics Inc Growth Factor Ligands, for the Treatment of patients of with Advance CancerMalignancies. FP-1069 (CSF1Rc), a Novel Antagonist of CSC-1 and IL-34 Five Prime for the Treatment of patients with $244,479.24 Therapeutics, Inc Inflammatory Disease and Cancer. Micro Fluidics Therapeutic Flex Partners, Inc $65,559.00 $178,920.24 Delivery Pump Flow Pharma Microencapsulation for Next $244,479.25 Inc. Generation HIV Vaccine Flow Pharma, Implantable, Microencapsulated $244,479.25 Inc. Antibiotic Fluidigm Non-invasive prenatal diagnostic $244,479.25 Corporation development Development of a Handheld Fluigence, LLC Bilirubin Bionsensor for Rapid $21,897.00 $23,758.50 Diagnosis of Neonatal Jaundice Fluxion The IsoFlux cancer diagnostic $244,479.25 Biosciences, Inc. system Rechargeable drug delivery ForSight device for treatment of ocular $244,479.25 VISION4, Inc disease OCT-Based Non-Invasive FP Technology $137,617.50 $106,861.75 Glucose Monitor Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 fqubed's Development Project of FQUBED Inc NRI-1013 as a topical ibuprofen $90,155.16 $132,480.47 gel NRI-1018: Topical Etoricoxib for FQUBED Inc $139,127.99 $105,351.26 Treatment of Osteoarthitis NRI-ANA: Topical Lidocaine for FQUBED, Inc the Treatment of Acute Herpes $63,888.97 $133,330.84 Zoster NuPro and OxoFoam for FQUBED, Inc Improved Treatment of Chronic $89,938.86 $97,309.69 Wounds Effective Topical Treatment of FQUBED, Inc. $110,959.88 $109,943.72 Nail Fungal Infection Topical Diclofenac for Relief of FQUBED, Inc. $244,479.25 Osteoarthritis FREEDOM NON-INVASIVE MEDITECH OPHTHALMIC GLUCOSE $53,896.16 $74,430.37 INC MONITORING DEVICE Freedom Non-Invasive Ophthalmic $31,180.54 $74,031.12 Meditech Inc Diabetes Screening Device. FZIOMED, INC. OXIPLEX SPINE GEL $244,479.24 Humanized monoclonal antibody Galaxy Biotech, to FGF receptor 2 for treatment of $78,034.50 $55,497.50 LLC gastric and other cancers Humanized monoclonal antibody Galaxy Biotech, to Sonic Hedgehog protein (SHH) $106,162.50 $95,657.50 LLC for treatment of cancer Humanized monoclonal antibody Galaxy Biotech, to FGF2 for treatment of $61,817.50 $40,705.50 LLC hepatoma and other cancers Humanized monoclonal antibody Galaxy Biotech, to Wnt co-receptor LRP6 for $13,123.50 $92,915.00 LLC treatment of cancer Gamma Medica - SPECT-MRI Hybirid Molecular $84,754.00 $158,494.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Ideas (USA) Inc Imaging Gamma Medica- Molecular Breast Imaging $244,479.25 Ideas (USA) Inc Gamma Medica- Translational Molecular Imaging $244,479.25 Ideas (USA), Inc. Prevention and Treatment of GangaGen Inc. Staphylococcus aureus (MRSA) $244,479.24 infection Gemmus Pharma Novel treatment for influenza $20,508.50 $141,689.50 Inc infections Silicon photonic sensor system for Genalyte Inc highly multiplexed diagnosis of $244,479.24 multiple diseases Development of inexpensive, ultra-high throughput micro- GenapSys Inc $244,479.25 electronic medical DNA sequencer. GENE ARRAY INFORMATICS TO SECURITY UNDERSTAND PLOIDY $196,010.00 $48,469.25 NETWORK INC CONCORDANCE Gene Therapy Creation & testing of a novel gene $84,060.99 $84,643.75 Systems Inc targeting vector for gene therapy Gene Therapy apid serodiagnostic test for active $46,072.63 $45,612.74 Systems Inc tuberculosis Rapid phenotypic antibiotic susceptibility testing for evidence- Genefluidics Inc $244,479.25 based treatment for infection diseases. Genelux GL-ONC1 $244,479.24 Corporation GRNIC1: hESC-derived Geron pancreatic islet cells for the $244,479.24 Corporation treatment of diabetes Geron GRNCM1: Human Embryonic $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Corporation Stem Cell-Derived Cardiomyocytes for Heart Disease GRNOPC1: hESC-derived Geron oligodendrocyte progenitors for $244,479.24 Corporation SCI & neurodegenerative disease Geron GRNVAC1, autologous $244,479.24 Corporation therapeutic cancer vaccine Geron Imetelstat (GRN163L) $244,479.24 Corporation Personalized Companion GigaGen Inc. Diagnostics for Myelodysplastic $7,500.00 $236,979.25 Syndrome Glaukos The iStent® Trabecular Micro- $244,479.24 Corporation Bypass Stent GluCath Intravascular Continuous Glumetrics, Inc. $244,479.24 Glucose Monitoring System Implantable Glucose Monitor for GlySens Inc $244,479.25 Therapeutic Furtherance GT LIFE SYSTEMS BIOLOGY BASED SCIENCES, BIOTHERAPEUTIC $244,479.25 INC. PRODUCTION Guided Delivery Subcutaneous Mitral Valve Repair $244,479.25 Systems, Inc High-throughput single-molcule HALCYON quantitative transcriptional $244,479.25 Molecular Inc profiling by EM Halcyon DNA sequencing using electron $244,479.25 Molecular, Inc microscopy Recombinant human Halozyme, Inc. hyaluronidase (rHuPH20) for $244,479.25 & Subsidiary subcutaneous drug delivery Recombinant Human Cathepsin L Halozyme, Inc. for the treatment of collegan $244,479.25 & Subsidiary deposition disorders Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 PEGPH20, a novel treatment for Halozyme, Inc. solid tumors such as pancreatic $244,479.25 and Subsidiary cancer Insulin-PH20-Ultrafast insulin for Halozyme, Inc. superior glycemic control in the $244,479.25 and Subsidiary treatment of diabetes Hana MARQIBO Cancer Therapeutic $244,479.25 Biosciences Inc HANA BIOSCIENCES Alocrest Cancer Therapeutic $148,327.67 $67,373.84 INC. HANA BIOSCIENCES Menadione Topical Lotion $244,479.25 INC. Hansen Medical VASCULAR CATHETER $244,479.25 Inc CONTROL SYSTEM Harbor Triolex $244,479.25 BioSciences Inc Harbor Apoptone $244,479.25 BioSciences Inc Harbor Medical Sprizz hand hygiene system $68,547.18 Inc DBA Sprixx HEMO THERAPEUTIC AQUAPHERESIS $118,362.50 S HOTSPUR TECHNOLOGIE PTA-PLUS $239,697.11 $4,782.14 S INC HOTSPUR TECHNOLOGIE MACERATOR-ASPIRATOR $244,479.25 S, INC Hotspur Technologies, EMBO-PLUS $178,946.39 $65,532.86 Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Hotspur Technologies, PTA DUO $56,404.83 $155,193.88 Inc. HourGlass Transoral Restrictive Intra Gastric Technologies, Mesh Incisionless Gastric $244,479.25 Inc Banding system for weight loss Hunter HunterHeart $199,634.00 $44,845.25 Laboratories Inc Hunter HPV OncoTect Cancer Detection $244,479.25 Laboratories Inc Diagnostic Huya Bioscience Development of HBI-8000: A International Novel HDAC Inhibitor for $244,479.24 LLC Treatment of Cancer Importance of HydraDx Dehydration Diagnostic For HydraDx Inc $244,479.25 Diagnosis and Monitoring State of Hydration Hyperion HPN-100 (GPB) in Urea Cycle Therapeutics, Disorders and Hepatic $244,479.25 Inc. Encephalopathy ICB International Diagnosis and treatment of $244,479.24 Inc Alzheimer's disease (AD) Ichor Medical Novel Delivery Platform for DNA $49,356.09 $100,233.07 Systems Inc Vaccine Delivery in Skin Ichor Medical A xenogeneic DNA Vaccine for $53,672.80 $91,831.78 Systems, Inc Melanoma IND-Enabling Biodistribution and Ichor Medical Integration GLP Assays for DNA $13,022.30 $42,151.33 Systems, Inc Drugs DNA Drugs Delivered with Novel Ichor Medical Intramuscular Electroporation $117,452.35 $117,648.59 Systems, Inc Technology Ichor Medical Therapeutic HBV DNA Vaccine $106,663.02 $137,816.23 Systems, Inc. Delivered withIchor's TDS Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Electroporation Technology Icon Bioscience, Versiome Ophthalmic Drug $244,479.25 Inc Delivery System Icon Bioscience, IBI-10090 for Intraocular $187,126.84 $57,352.41 Inc. Injection Icon Bioscience, IBI-20089 for Intravitreal $244,479.25 Inc. Injection ID FISH Fluorescent in site hybridization Technologies, $226,876.00 $17,603.25 assay kits (FISH kits) Inc. Idolo Biotechnology Idolo $35,000.00 $57,933.50 LLC IGeneX, Inc Bartonella FISH Diagnostic $211,861.57 $32,617.68 Novel Therapeutic Monoclonal Igenica, Inc $244,479.25 Antibodies for Cancer Novel Monoclonal Antibody for Igenica, Inc. Treating Acute Myelogenous $244,479.25 Leukemia IGT LLC dba Apollo: Robotic Needle Guidance $244,479.24 Eigen System IGT, LLC dba Artemis:3D Imaging Workstation $244,479.24 Eigen Contract Manufacturing of an in Imaginab, Inc. vivo Molecular Diagnostic for $12,244.30 $232,234.95 Imaging Agent of Prostate Cancer Contract Manufacturing of an in Imaginab, Inc. vivo Molecular Diagnostic for $111,251.62 $133,227.63 Imaging Autoimmune Disease System for Health Monitoring in iMetrikus, Inc $244,479.25 Populations ImmPORT Novel non-invasive diagnostics $94,750.00 $149,729.25 Therapeutics Inc. for liver diseases Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 dba Antigen Discovery Inc ImmPORT Therapeutics, Inc Safe and efficacious vaccine $244,479.25 (dba) Antigen against Chlymedia Discovery, Inc ImmPORT Accurate and robust Therapeutics,Inc. serodiagnostic test for Lyme $130,404.50 $114,074.75 (dba).Antigen Disease Discovery. Inc. Development for the treatment of ImmunGene Inc. non-Hodgkins's lymphoma $200,326.57 $44,152.68 patients with genetic resistance. ImmunoCellular Development of a Cancer Vaccine $244,479.25 Therapeutics Ltd for Glioblastoma (Brain Cancer) ImmunoScience, Salivax $244,479.25 Inc. IMTEC IMTEC VasConnect and VasPort $48,114.00 $115,540.00 Biomedical Inc System for Vascular Access Imthera Medical THN Sleep Therapy for $244,479.24 Inc Obstructive Sleep Apnea (OSA) E6, E7 mRNA Cervical and Anal IncellDx, Inc. $39,857.50 $204,621.75 Cancer Diagnostic Incline Therapeutics, IT101 $244,479.25 Inc. InCode BioPharmaceutic C3 Complement Depletor Project $229,735.50 $14,743.75 s, Inc. Drug Respositioning, Biomarker Ingenuity and Therapeutic Target Discovery $244,479.25 Systems Inc Program Development of a therapeutic Inhibrx, Inc $244,479.25 antibody for the treatment of Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 vascularized tumors Developing Clinical Grade Cell Innovative Cell Dissociation Reagent for Technologies, $6,250.00 $61,375.00 Embryonic Stem Cell Inc. Manufacturing Early cancer detection : A Innovative Micro MEMS-based cell sorter for CTC $244,479.25 Technology Inc enumeration and functional testing Novel clot-retrieval and clot- Insera filtering device for Stroke Therapeutics, $125,000.00 $119,479.25 treatment including intra-arterial Inc. thrombolsys InSite Medical Technologies, Epiphany Epidural Access System $136,117.00 $108,362.25 Inc. ISV-303 Ocular Anti- InSite Vision, Inc $244,479.25 Inflammatory Therapeutic ISV-502 Therapeutic for InSite Vision, Blepharitis and Lid Margin $244,479.25 Inc. Disease Inspiration Recombinant Factor IX for the Biopharmaceutic $244,479.25 treatment of Hemophilia B als, Inc Inspiration Recombinant Porcine Factor VIII Biopharmaceutic (OBI-1) for the Treatment of $244,479.25 als, Inc. Acquired Hemophilia Continuous, Subcutaneous Intarcia Delivery of an Incretin Mimetic to $244,479.25 Therapeutics, Inc Treat Type 2 Diabetes IntegenX Inc Apollo 200 $244,479.25 IntegenX Inc Apollo 396 $244,479.25 IntegenX Inc Apollo 324 $244,479.25 IntegenX, Inc Apollo 100 $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Integrated Single use HD Endoscope $21,783.33 $25,000.00 Endoscopy, Inc Integrated Life Support for trauma and Medical Systems $71,707.00 transport commercialization Inc InteKrin INT131 A Safe Insulin Sensitizer $244,479.25 Therapeutics Inc for Treatment of Type 2 Diabetes Development of INK1117 for Intellikine, Inc. treatment of hematologic $132,457.00 $112,022.25 malignancies Development of INK1117 for Intellikine, Inc. $244,479.25 treatment of solid tumors Development of INK1117 for Intellikine, Inc. treatment of solid tumors and $244,479.25 hematologic malignancies Development of INK1117 for Intellikine, Inc. $244,479.25 treatment of rheumatoid arthritis PIRFENIDONE FOR THE Intermune Inc. TREATMENT OF IDIOPATHIC $244,479.25 PULMONARY FIBROSIS INTERMUNE, Danoprevir Development $244,479.25 INC Program Next Generation HCV Intermune, Inc. $244,479.25 Therapeutic Discovery Program International Stem Cell hPSC $244,479.25 Corporation and Subsidiaries Intersect ENT, SpiderRX $244,479.25 Inc Intersect ENT, CrownRX $244,479.25 Inc Interventional Percudyn System ("PDS") $244,479.25 Spine Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Intradigm Corporation Silence Therapeutics: Novel (Silence $244,479.24 RNAi Therapeutics Therapeutics, plc) IntraOp Medical Mobetron IOERT and Etanidazole $244,479.24 Corporation Radiation Sensitizing Drug Intrinsic Development of FDA-approved LifeSciences, Hepcidin Diagnostic Devices for $75,420.73 $169,058.51 LLC Clinical Medicine Intuity Medical, POGO™ $244,479.25 Inc. Development of Next Generation Ion Torrent Sequencing Platform for $244,479.25 Systems, Inc Molecular Diagnostic Applications New Drugs for Amyotrophic iPierian Inc Lateral Sclerosis (ALS) $236,827.00 $7,652.25 Discovered using iPS Cells New Drugs for Spinal Muscular iPierian, Inc. Atrophy Discovered using $244,479.25 Induced Pluripotent Stem Cells Physician Office Metabolic IR2DX Inc $37,500.00 Assessment Laboratory Panel - Metabolic and IR2Dx, Inc $111,500.00 Atherosclerlerosis Assessment iRhythm The Zio [tm] Patch and ZEUS Technologies $244,479.24 Project. Inc. Premixed, Sterile Single Dose Gas IRIDEX (Eye Gas) for Treatment of $58,853.87 Corporation Retinal Detachments Iris Optimizing Personalized and BioTechnologies, Targeted Medical Treatment $34,808.50 $209,670.75 Inc. Using Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 iScience iScience Microcatheter, for $244,479.25 Interventional treatment of Macular Edema iScience iSceince Canaloplasty Project $244,479.25 Interventional Islet Sheet Novel Islet Sheets Method for $53,746.57 $148,946.96 Medical LLC Treating Diabetes Itero A newly formulated and Biopharmaceutic differentiated recombinant follicle $244,479.25 als Inc stimulating hormone, or rFSH. Itherx Development of Novel Entry $244,479.25 Pharmaceuticals Inhibitors for Hepatitis C IVANTIS INC. Hydrus Aqueous Implant $244,479.25 Jaden BioScience Ultrasensitive cell surface Inc AKA Jade detection of B-cell chronic $26,089.00 $57,115.50 BioScience inc lymphocytic leukemia(B-CLL) Jan Medical Inc. Jan Medical DCX Project $228,658.50 $15,820.74 Jazz JZP-6 Sodium Oxybate for the Pharmaceuticals, $244,479.25 Treatment of Fibromyalgia Inc. Jazz PLE-1 Twice-Nightly Immediate Pharmaceuticals, Release Solid Oral Dosage Form $203,019.50 $41,459.75 Inc. of Sodium Oxybate Jazz JZP-8 Intranasal Clonazepam for Pharmaceuticals, the Treatment of Acute Repetitive $218,133.00 $26,346.25 Inc. Seizures Jazz PLE-2 Once-Nightly Controlled- Pharmaceuticals, Release Solid Oral Dosage Form $147,883.00 $96,596.25 Inc. of Sodium Oxybate Intravenous Treatment of Jennerex Inc Advanced Metastic Colorectal $244,479.24 Cancer with JX-594 JX-2011: A Novel Product for Jennerex Inc. Advanced Metastatic Prostate $244,479.25 Cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 JX-594: A Novel Therapeutic for Jennerex, Inc $244,479.25 Direct Injection into Liver Tumor Development of an JN Biosciences, immunosuppressive therapeutic $109,300.00 $135,179.24 LLC antibody Juvaris Bio Use of JVRS-100 to protect Therapeutics, $244,479.25 against ionizing radiation Inc. Juvaris Use of JVRS-100 as an BioTherapeutics immunotherapeutic to treat Acute $244,479.25 Inc Myelogenous Leukemia Juvaris Combination of JVRS-100 with BioTherapeutics, Francisella tularensis membrane $244,479.25 Inc fraction Juvaris Use of JVRS-100 to protect BioTherapeutics, $244,479.25 against reperfusion injury Inc. KAI Pharmaceuticals, KAI-1678 for Neurpathic Pain $244,479.25 Inc KAI KAI-9803 for Acute Myocardial Pharmaceuticals, $244,479.25 Infarction Inc. KAI KAI-4169 for Secondary Pharmaceuticals, $244,479.25 Hyperparathyroidism (SHPT) Inc. Humaneered Monoclonal KaloBios Antibody (KB003) for the Pharmaceuticals, $244,479.24 Treatment of Rheumatoid Inc. Arthritis KaloBios Therapeutic Antibody (KB004) Pharmaceuticals, FOR THE Treatment of $244,479.24 Inc. Hematological Malignancies KaloBios KB001-A for Treatment of $244,479.24 Pharmaceuticals, Pseudomonas Aeruginosea in Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc. Cystic Fibrosis Patients KaloBios KB001- A for Treatment of Pharmaceuticals, $244,479.24 Mechanically Ventilated Patients Inc. Kalos Kalos Therapeutics, Inc. $66,633.00 $177,846.25 Therapeutics, Inc Development of KT-220 Kalypsys, Inc. H4R Antagonist Project $244,479.25 KenHealth LLC Percutaneous Closure Device $244,479.25 New Artificial Cornea and KeraMed Inc Implantation Method for $152,044.12 Treatment of Blindness Keren Development of External Guide Parmaceutical, Sequence (EGS) therapeutics for $9,970.50 $12,612.50 Inc. inflammatory lung disease Automated Hight Throughput KI cRBC Stem Cell Hematopoietic $244,479.24 Biotechnologies Processing System GM602 for treatment of Stroke KM Biotech, Inc. and Parkinson's Disease $244,479.25 indications Noninvasive Device Based Kona Medical $244,479.25 Treatment for Hypertension Konan Medical Bionocular Analytic Dynamic $115,000.00 USA, Inc Pupillometer Kythera Nanoencapsulation of Therapeutic Biopharmaceutic $196,473.00 Proteins als Inc Kythera Biopharmaceutic ATX-101 $244,479.24 als Inc Kythera Biopharmaceutic ATX-104 $244,479.25 als, Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Kythera Biopharmaceutic ATX-202 $244,479.24 als, Inc LAAX, INC STROKE- LAAX PROJECT $244,479.25 Development of a Novel Recombinant Protein For The LakePharma, Inc $40,850.00 $118,915.00 Treatment Of Diabetes And Cancer Lasmed Limited Infrared diode-laser tools for pain Liability $117,426.24 $127,053.01 diagnostics and management Company LENR Solutions, LENR LipoSector $76,631.00 $167,848.25 Inc. Lerner Medical Targeted Phototherapeutic $244,479.25 Devices, Inc Treatment of Psoriasis at Home CLINICAL STUDIES OF THE Leuchemix Inc NOVEL ANTI-CANCER $240,189.50 $4,289.74 AGENT LC-1 CytoPaint Extreme Analysis Leukobyte, Inc. $2,730.50 $241,748.75 Software for Flow Cytometry Ligand Selective Androgen Receptor Pharmaceuticals $244,479.25 Modulators (SARM), LGD-4033 Inc LIGAND Thrombopoietin (TPO) LGD- PHARMACEUT $244,479.25 4665 ICALS INC Ligand Pharmaceuticals DARA $244,479.25 Inc LIGAND PHARMACEUT Organon Collaboration $244,479.25 ICALS INC Ligand Erythropoietin (EPO) Research $244,479.25 Pharmaceuticals Program Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc LIM-075 ATP-binding cassette Limerick activator for safer $244,479.25 BioPharma Inc immunosuppressant therapy in transplants Limerick Limerick's Lipid Chaperones for $244,479.25 BioPharma, Inc treating metabolic disorders $ Livermore BioAerosol Mass Spectrometry

Instruments Inc for Tuberculosis Diagnosis 146,001.50 Loma Vista Mulit-Layer Medical Balloons $244,479.24 Medical, Inc Lonestar Heart Cardiogenic Stem Cell $244,479.25 Inc Modulators Development of ASONEP™ for Lpath, Inc. $244,479.24 the treatment of Cancer Development of iSONEP(TM) for Lpath, Inc. the treatment of Age-related $244,479.24 Macular Degeneration Lumen Nona-L-Arginine for Prevention Therapeutics, $53,472.49 $82,801.38 of Saphenous Vein Graft Disease LLC Luminous Luminous Blod Glucose Monitor $244,479.25 Medical Inc. (LBGM) Lutran Industries DRH12 Acute Viral $244,479.25 Inc. Nasopharyngitis Lutran Industries DRH12 Chronic Bronchitis $244,479.25 Inc. Lutran Industries DRH12 Mother to Child $244,479.25 Inc. Transmission of Gonorrhea Lutran Industries DRH12 Mother to Child $244,479.25 Inc. Transmission of Chlamydia Lutran Industries DRH12 Mother to Child $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc. Transmission of Hepatitis Lutran Industries DRH12 Mother to Child $244,479.25 Inc. Transmission of HPV Lypro Nano Disks $220,262.84 $24,216.40 Biosciences Inc Brain penetrating BMP-4 as a MabPrex, Inc. cancer stem cell differentiation $22,494.00 $221,985.24 therapy against glioblastoma Human Monoclonial Antibodies Mabvax from Immunized patient $244,479.24 Threapeutics Inc Lymphocytes Phase II Clinical Trial to determine efficacy of a vaccine to prevent recurrent sarcoma Mabvax carbohydrate antigens in stage IV $244,479.24 Threapeutics, Inc patients rendered disease free with the objective of preventing recurrent sarcoma Madera Small molecule angiogenesis $1,481.13 $8,500.00 Biosciences, Inc. inhibitors for cancer therapy Magnetic Nanoparticle MagArray, Inc Immunoassay System for Cancer $189,439.67 $55,039.57 Diagnostics Magellan Spine Technologies, Magellan DART Technology $244,479.24 Inc Optimized magnetic nanoparticle Magnesensors, labels for ultra-sensitive magnetic $48,995.00 Inc detection of pathogens Magnesensors, Ultra-sensitive magnetic rare cell $201,707.50 $42,771.75 Inc assays for leukemia Quantitive detection of nucleic Magnesensors, acids without amplification for $38,479.00 Inc sepsis diagnostics Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Magnetecs Catheter guidance control & $244,479.25 Corporation imging appartatus(CGCI) Galectin-3C for treatment of MandalMed, Inc. cancer and prevention of $30,264.00 $4,486.00 metastasis MAP Pharmaceuticals LEVADEX ™ $244,479.25 Inc Mapp Biopharmaceutic Vaginal Microbicide Antibodies $102,274.34 $9,063.39 al Inc Mapp Biodefense Monoclonal Biopharmaceutic $244,479.25 Antibodies al, Inc Mapp Clostridium Difficile Monoclonal Biopharmaceutic $244,479.25 Antibodies al, Inc Mapp Alzheimer's Monoclonal Biopharmaceutic $151,031.76 $93,447.49 Antibodies al, Inc Mapp Respiratory Synctial Virus Biopharmaceutic $14,598.24 Antibodies al, Inc. Mariposa Automated osmolaltiy control for Biotechnology $244,479.25 cryogenic freezing or thawing Inc Masimo Improved Glucose Strip Reader $244,479.25 Laboratories, Inc Masimo Glucose 1 Non-Invasive Glucose $244,479.25 Laboratories, Inc. Diagnostic Device Matrix Sensors, Matrix Sensors, Inc. $244,479.25 Inc. Maven LFIRE $197,015.00 $47,464.25 Technologies Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC Maya Medical Maya System $244,479.25 Inc Selective tumor vascular Medbiocom $244,479.24 thrombogen Anti cancer prodrug activated by Medbiocom proteases of the coagulation $244,479.25 cascade Cancer immune therapy targeting Medbiocom $244,479.25 tumor associated macrophage Medical Tactile SureTouch breast cancer detection $95,483.73 $148,995.51 Inc and diagnostics MEDIVATION Dimebon for the treatment of NEUROLOGY, $244,479.25 Huntington Disease INC MEDIVATION Dimebon for the treatment of NEUROLOGY, $244,479.25 Alzheimer's Disease INC Medivation MDV3100 for the treatment of Prostate $244,479.25 advanced prostate cancer Therapeutics Inc MedSolve Low Cost Micro Infusion Pump Technologies, for the Treatment of Diabetes $35,412.50 Inc (Type 1 and Type 2) Mercator Catheter-directed renal MedSystems, sympathectomy to reduce $45,642.09 $198,837.16 Inc. hypertension MERITAGE ORAL VISCOUS $244,479.24 PHARMA, INC BUDESONIDE Metabasis Thyroid Receptor-beta Agonist $244,479.25 Therapeutics Inc METABASIS Glucagon Receptor Agonist THERAPEUTIC $244,479.25 Program S INC Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of MBX-3254 a Metabolex Inc GPR119 receptor agonist for the $185,654.00 treatment of Type 2 Diabetes Development of MBX-2982 a Metabolex Inc GPR119 agonist for the treatment $244,479.24 of Type 2 Diabetes Small molecule agonists of the Metabolex Inc bile acid receptor GPR131 for the $125,300.00 $119,179.24 treatment of type 2 diabetes Development of MBX-102 for the Metabolex Inc $244,479.24 treatment of gout. Agonists of the anti-lipolytic Metabolex Inc receptor GPR81 for the treatment $43,000.00 of Coronary Artery Disease Agonists of the fatty acid receptor Metabolex Inc GPR 120 for the treatment of type $244,479.24 2 diabetes Development of TRPM5 Metabolex, Inc. Activators for the treatment of $229,396.00 Type 2 Diabetes MBX-8025 is a potential first-in- Metabolex, Inc. class therapy to treat mixed $244,479.24 dyslipidemia Continuous Glucose Monitoring Metronom System with Hypoglycemic $244,479.25 Health, Inc. Detection MiCardia MiCardia Encor Dynamic Heart $244,479.24 Corporation Valve Repair Technology A Novel device("Wrist") for MicroCube LLC precise delivery of $147,000.00 $97,479.25 therapeutics/devices Novel Office-based Menorrhagia MicroCube LLC $244,479.25 Treatment Micropoint Developing POC In-Vitro $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Bioscience, Inc Diagnostic Rapid Tests of Chronic and Acute Diseases Mindframe Interventional MINDFRAME, Recanalization is Ischemic Stroke $244,479.25 INC (IRIIS) System Minerva Aurora System $244,479.25 Surgical, Inc MS-553, A Novel Oral Therapy MingSight For the Treatment of Diabetic Eye $61,901.00 Pharmaceuticals Diseases and Uveitis Minnow Medical Peripheral Vascular System (PVS) $244,479.24 Inc Mitos Use of Tempol to improve Pharmaceuticals, radiation treatments in head, neck, $244,479.24 Inc breast, and brain cancer. DNA sequencing based MLC Dx Inc recurrence test for Non-Hodgkin $92,909.48 $151,569.77 lymphoma Modulated Advanced Medical Camera for $69,673.50 $154,201.00 Imaging Inc Tissue Health Assessment Molecular GPS Molecular GPS Technologies' Technologies and $231,861.17 $12,618.08 Influenza Vaccine 1230 Project Subsidiaries Molecular GPS Molecular GPS Technologies' Technologies and $170,310.90 $42,500.00 Aspergillus Program Subsidiaries Molecular GPS Technologies and Minisurf™ and Minisurf-R™ $136,453.51 $108,025.74 Subsidiaries Molecular GPS Development Project of a New Technologies and HSV2 Vaccine for Herpes $146,616.47 $97,862.78 Subsidiaries genitalis (GH) Molecular Development of single chain $244,479.25 Imaging and antibody conjugates against a Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Therapeutics, unique prostate cancer antigen Incorporated Tumor Anatomy Characterization Molecular - Developing a Validated Test for $244,479.25 Response, LLC EGFRi Therapies Gene Expression Tests for Molecular Pedicting Lung Cancer Patient to $244,479.25 Response,LLC EGFRi and HSP90i Therapy Mountain View PharmaPEG Technology for PEG- Pharmaceuticals, protein Drug Conjugates with $122,810.00 $121,669.25 Inc. Decreased Immunoreactivity Moximed, Inc Kinespring Knee implant system $244,479.25 Mpex AEROQUIN TM (MP-376: Phamaceuticals, $244,479.25 Levofloxacin Inhalation Solution) Inc. Multimeric Precision immunization vaccine Biotherapeutics, for nicotine and other drugs of $3,518.68 $77,251.04 Inc. abuse Development of a triptolide MyeloRx LLC derivative for acute myeloid $32,748.00 $211,731.24 leukemia and other cancers Mynosys Surgical Device For The Cellular Devices Treatment Of Childhood $80,050.00 $164,429.24 Inc Blindness Due to Lens Cataract Hollow Porous Silica NanoComposix, Nanoparticles (HOPS $24,617.32 $82,257.18 Inc Nanoparticles) Gold Nanoparticle Matrices for NanoComposix, MALDI-MS Diagnostic $120,956.26 $101,819.19 Inc. Applications Nanotechnology-based Cancer NanoIVD, Inc IVD Platform and Point-of-care $244,479.24 Test NANOMIX, Cardiac early detection biosensor $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 INC. NanoPacific Nanodevice Cancer Drug $244,479.25 Holdings, Inc Delivery Nanostim's Leadless Cardiac Nanostim Inc $244,479.25 Pacemaker NANOVASC NANOVASC DRUG-ELUTING $244,479.24 INC VASCULAR GRAFT Napo Development of crofelemer for Pharmaceuticals, $244,479.25 treatment of secretory diarrhea Inc Digitax Therapeutic Treatment for Nativis Inc $244,479.25 Brain Cancer a-PCSK9s Therapeutic Treatment Nativis, Inc $244,479.25 for Hypercholesterolemia Navigenics pharmacogenomics Navigenics, Inc. panel to predict medication $244,479.25 response and risk of side effects POSITRON EMISSION NAVISCAN,IN MAMMOGRAPHY SCANNER $244,479.25 C FOR BREAST CANCER DIAGNOSIS Neodyne Neodyne Device for Improved $244,479.25 Biosciences, Inc Healing and Scar Reduction PURIFIED SECRETORY IMMUNOGLOBIN TO NEOLAC, INC. PREVENT & TREAT $11,350.09 $233,129.16 NECROTIZING ENTERCOLITIS Neonc Development of Intranasal Technologies, $49,029.00 $195,450.25 Delivery to the Brain Inc T15 monoclonal antibody for the Neostasis Inc treatment of audioimmune $244,479.25 disease. Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Neuro-EEG Synchronization NeoSync Inc $244,479.25 Therapy NeoVista, Inc. CABERNET $244,479.24 Nereus Pharmaceuticals, Marizomib (NPI-0052 $244,479.25 Inc NEREUS PHARMACEUT PLINABULIN $244,479.25 ICALS, INC. Development of a Recombinant Neugenesis Influenza Virus-Like Particle $244,479.25 Corporation Pandemic(H5N1)Vaccine Development of a cost effective NEUGENESIS polyclonal therapeutic against $55,398.00 $189,081.25 CORPORATION MRSA Develop Recombinant Virus-Like Neugenesis Particle Trivalent Seasonal $244,479.25 Corporation Influenza Vaccine Neumedicines NM-Gene Therapy $85,975.29 $43,947.23 Inc HHS1: Characterization and Neumedicines, Manufacturing Development of a $23,414.67 $114,553.90 Inc Novel Anti-Tumor Therapeutic HemaMax Advancement for Neumedicines, Multiple Unmet Medical Needs in $244,479.24 Inc. hematology/Oncology Single pulse transcranial magnetic stimulation device for Neuralieve, Inc. $244,479.25 treatment/management of migraine. Neuraltus Neuraltus NP003 - Developing a Pharmaceutical, treatment for Lysosomal Storage $176,543.50 $67,935.74 Inc Disorders Neuraltus Neuraltus NP001 - Developing a $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceuticals, treatment for ALS and other Inc. neurodegenerative diseases Neuraltus Neuratus NP002 - A treatment for Pharmaceuticals, dyskinesias caused by l-dopa $244,479.24 Inc. treatment of Parkinson's Development of GnRH Neurocine antagonists (Elagolix) for $244,479.24 Biosciences, Inc endometriosis related pain Development of G protein- Neurocrine coupled receptor agonists or $244,479.24 Biosciences Inc antagonists Development of Selective Neurocrine GPR119 Receptor Agonists for $244,479.24 Biosciences, Inc. the Treatment of Type 2 Diabetes Development of VMAT 2 Neurocrine inhibitors for hyperkinetic $244,479.24 Biosciences, Inc. movement disorders NEUROGEN Aplindore $244,479.25 CORPORATION Neurogenetic Novel therapeutics for the Pharmaceuticals, $169,963.00 $74,516.24 prevention of Alzheimer's disease Inc. NeurogesX Inc Quetenza (capsaicin)8% patch $244,479.25 NGX-1998-LIQUID HIGH NEUROGESX, CONCENTRATION TOPICAL $156,101.50 $88,377.75 INC CAPSAICIN NeurogesX, Inc. Acetaminophen Prodrugs $6,408.00 $137,913.00 Responsive Neurostimulator NeuroPace,Inc. Systems for Treating Neurological $244,479.25 Diseases Nevro Senza SCS $244,479.25 Corporation NewLife Final Phase Full-Scale US Launch $244,479.25 Sciences LLC, of TMR Technology Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 dba Scientific Imaginetics PREVONCO FOR THE NEXMED TREATMENT OF LIVER $244,479.25 CANCER Femprox for female sexual NEXMED $244,479.25 arousal disorder VITAROS FOR REYNAUD'S NEXMED Inc $244,479.25 PHENOMENON NextWave Methylphenidate HCI Extended- Pharmaceuticals Release Powder for Oral $244,479.25 Inc Suspension NextWave Mexocopm XR Tablet - clonidine Pharmaceuticals $244,479.25 extended release tablet Inc NextWave Methylphenidate Extended Pharmaceuticals $25,766.50 $218,712.75 Release Chewable Tablet Inc NextWave Nexiclon XR Liquid - clonidine Pharmaceuticals $244,479.25 extended release liquid suspension Inc NextWave Dexmethylphenidate Extended Pharmaceuticals, $57,486.00 $186,993.25 Release Formulation Inc. Nexus Dx Inc High Sensitivity cardiac panel $244,479.25 Nexus Dx Inc Flu-ID $244,479.25 NGM NPT1162 for Type 2 Diabetes Biopharmaceutic $244,479.25 Mellitus als NGM Disease Modifying Therapeutics Biopharmaceutic $244,479.25 for Type 2 Diabetes Mellitus als, Inc. NGM Therapeutics to Enhance $244,479.25 Biopharmaceutic Compromised Muscle Function Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 als, Inc. Nile CD-NP-Acute Heart Failure $244,479.24 Therapeutics, Inc NOCISCAN-MR Spectroscopy NOCIMED LLC for Molecular Diagnosis of $233,732.16 $10,747.09 Discogenic Low Back Pain Development of Molecular Nodality Inc Diagnostics for Prediction of $244,479.24 Treatment Response in AML Molecular Diagnostics for Patient- Nodality Inc Specific Characterization of $74,491.00 $169,988.24 Immune Dysfunction Molecular Diagnostics for Drug Nodality Inc Pathway Profiling in Hematologic $244,479.24 Malignancies Development of Molecule Nodality Inc Diagnostics for Prediction of $244,479.24 Treatment Response in MDS Molecular Diagnostics for Nodality Inc Prediction of Disease Progression $244,479.24 and Treatment Response in CLL NovaBay Pharmaceuticals, Treatment of Impetigo $244,479.24 Inc. Pivotal phase III clinical trial of NovaRx Lucanix for non-small cell lung $244,479.24 Corporation cancer Novelix Pharmaceuticals, NVX-207 $16,741.00 $227,738.25 Inc. Empirical Codon Optimization Novici Biotech, Technology for $36,662.00 LLC Biopharmaceutical & DNA Vaccine Improvement Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 NovoMedix , Treatment of Triple Negative $5,060.50 $95,729.00 LLC Breast Cancer NovoMedix, Treatment of Type II Diabetes $155,828.00 $26,264.50 LLC NuCardia Inc HeartFlow $244,479.24 NuMask IntraOral Mask and NuMask, Inc. Oropharyngeal Airway Research $71,187.50 and Development NuMask IntraOral Mask and NuMask, Inc. Oropharyngeal Airway, Clinical $142,829.50 Research using computational drug Numedii repositioning to develop novel $4,150.00 $240,329.25 lung cancer therapeutics Novel drug products for treating Numerate Inc latent and drug-resistant $170,689.46 $73,789.78 tuberculosis A novel drug for treating celiac Numerate, Inc $159,084.28 $85,394.97 sprue A novel drug for treating Numerate, Inc. $189,658.15 $54,821.09 hepatitis C virus infections Nuon NU3450 (tranilast) for the $244,479.25 Therapeutics Inc treatment of rheumatoid arthritis Nuon NU1618 for the treatment of $244,479.25 Therapeutics Inc. chronic gout Nuveta, Inc IVF Technology $96,446.81 $21,883.50 OCR-002 for Hyperammonemia Ocera & Resultant Hepatic $244,479.25 Therapeutics Inc Encephalopathy in Chronic Liver Disease OCR-002 for Hyperammonemia Ocera & Resulant Hepatic $244,479.25 Therapeutics Inc Encephalopathy in Acute Liver Failure Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 AST-120 for the Treatment of Ocera Non-Constipating Irritable Bowel $244,479.25 Therapeutics Inc Syndrome (nc-IBS) miRNA Oncology Target Odyssey Thera, Validation and Therapeutic $244,479.25 Inc Development Odyssey Thera, Development of Multi-Targeted $244,479.25 Inc. Oncology Therapeurics Olema Oral Complete Anti-estrogens for Pharmaceuticals, the Treatment of Metastatic $144,092.60 $100,386.65 Inc. Breast cancer A breakthrough technology for pharmaceuticals: Validating and commercializing an enabling Oligasis, LLC $244,479.24 platform and manufacturing technology in collaboration with multiple pharmaceutical partners. Overcoming Tumor Hypoxia with Omniox, Inc. OMX-0004 to Revolutionize $230,794.86 $13,684.38 Chemo/Radiation Outcomes Therapeutic Technology for Real Omnueron Inc $244,479.25 Time Functional MRI OMP, Inc Treatment for Melasma, NuDerm $244,479.25 Laser activated, opthhalmic drug On Demand delivery implant for treating $244,479.25 Therapeutics, Inc retinal diseases Oncolytics Biotech (U.S..) Reolysin $244,479.24 Inc. OncoMed OMP-21M18: Targeting DLL4 in Pharmaceuticals Cancer Stem Cells for the $244,479.24 Inc. treatment of cancer. OncoMed OMP-59R5: Targeting Notch Pharmaceuticals, Receptors in Cancer Stem Cells $244,479.24 Inc for the treatment of Cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 OncoMed Antibodies Targeting Notch Pharmaceuticals, Pathway Ligands for the $244,479.24 Inc Treatment of Cancer OncoMed Inhibiting the Wnt Pathway for Pharmaceuticals, $244,479.24 the Treatment of Cancer Inc OncoMed OMP-18R5 Targeting the Wnt Pharmaceuticals, Pathway in Cancer Stem Cells for $244,479.24 Inc. the Treatment of Cancer Isoforms of gene transcription OncoTx Inc proteins: Development of novel $107,777.00 $136,702.25 tools for cancer diagnosis Onset Medical Onset Controlled Deployment $244,479.25 Corporation Technology Opal Opal HIV - An Immunotherapy $11,469.50 $64,335.00 Therapeutics Inc for HIV Open Monoclonal Antibody Cocktail Monoclonal $244,479.25 Therapy Technology Inc Novel Cholinergic Therapeutics Ophidion, Inc. $111,568.50 $97,650.00 for Cognitive Enhancement Optimedica Image-guided femtosecond laser $244,479.25 Corporation cataract surgery Optimer Fidaxomicin, a novel therapy for Pharmaceutical, Clostridium difficile infections $244,479.25 nc. (CDI) OptiScan Closed Loop Insulin delivery with Biomedical an ICU Continuous Glucose $244,479.24 Corporation Monitor Optovue Inc iVue $244,479.25 OPTOVUE, Inc ACVUE $85,382.00 $159,097.25 Opus L-FABP drugs as novel Pharmaceuticals, therapeutics for fatty liver disease, $49,880.50 $44,768.00 Inc elevated lipids and obesity Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Electro-Fluidic Thrombolysis Oramic, LLC microcatherter for the clearing of $20,138.50 $109,700.00 vascular occlusions O-Ray Sustained Release Inner Ear $22,500.00 $101,966.67 Pharmaceuticals Delivery of Corticosteroid Orexigen Contrave $244,479.24 Therapeutics, Inc Orexigen Therapeutics, Empatic $244,479.24 Inc. Biological 3D Bioprinted Blood Organovo Inc $152,808.68 Vessel NovoGen 3D Bioprinter Organovo Inc $184,735.50 $59,743.75 Development Novel Small Molecule Drug Class Orphagen for the Treatment of Retinal $88,752.50 $57,265.00 Pharmaceuticals Degeneration Novel Small Molecule Drug Class Orphagen for the Treatment of Autoimmune $176,533.50 $67,945.75 Pharmaceuticals Disease A novel drug class for treating Orphagen adrenocortical cancer, prostate $29,494.00 $202,980.50 Pharmaceuticals cancer and endometriosis. ORTHALIGN, KneeAlign $244,479.25 INC. LACTIN-V-Preventing Osel, Inc. Recurrence of Female Urinary $162,466.00 $33,378.00 Tract Infections MucoCept-Development of a Osel, Inc. $244,479.24 Novel Anti-HIV Microbicide Osseon Therapeutics, Osseoflex Balloon Tamp $142,500.00 Inc. Otonomy, Inc OTO-203: Ciprofloxation + $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Dexamethasone Gel for Use During Tympanostomy Tube Surgery OTO-104: Sustained Release Otonomy, Inc. Dexamethasone Gel for Treatment $244,479.24 of Meniere's Disease Creation of a Cell Line System for OvaGene Companion Diagnostic $125,000.00 Oncology Development Validation of STMN1 as a OvaGene Predictor of Endometrial Cancer $147,500.00 Oncology Recurrence OvaGene Molecular Definition of Atypical $244,479.24 Oncology Endometrial Hyperplasia Development of CA4P as a OXiGENE, Inc Topical Treatment for Abnormal $244,479.24 Vascular Ophthalmic Diseases Development of CA4P for the OXiGENE, Inc Treatment of Solid Tumor $244,479.24 Cancers Development of CA1P (OXi4503) OXIGENE, Inc. for the Treatment of Solid Tumor $244,479.24 and Hemotologic Cancers Pacira DepoNSAID - sustained release Pharmaceuticals drug for improved treatment of $35,796.71 $46,464.93 Inc pain and inflammation Pacira EXPAREL™ -sustained release Pharmaceuticals, drug for postoperative pain relief $244,479.25 Inc and reduced opiod usage Pacira DepoMTX - sustained release Pharmaceuticals, $124,187.58 $61,706.39 drug for rheumatoid arthritis Inc. Pain PTI-721 $111,513.00 $132,966.24 Therapeutics Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pain PTI-421 $116,870.00 $127,609.24 Therapeutics Inc Pain PTI-320 $244,479.24 Therapeutics, Inc Pain Remoxy $244,479.24 Therapeutics, Inc Pain Alzheimer's Treatment $11,745.00 $31,918.50 Therapeutics, Inc Pain Therapeutics, PTI-301 $244,479.24 Inc. Pain Therapeutics, PTI-221 $117,643.00 $126,836.24 Inc. Pain Therapeutics, PTI-DX304 $38,630.00 $21,335.00 Inc. Pain Therapeutics, PTI-609 $244,479.24 Inc. Pain Therapeutics, PTI-303 $244,479.24 Inc. Panorama Inotropic Antibodies $40,293.65 $59,329.81 Research, Inc Novel Multiplex Assay for Panorama Biomarkers of Alzheimer's $5,988.08 $72,399.00 Research, Inc Disease Novel Therapy for Pemphigus Panorama Vulgaris by Treatment with a $7,193.96 $77,883.00 Research, Inc Cholinergic Agonist Panorama Novel TACE Inhibitors for Breast $61,536.98 $24,611.43 Research, Inc Cancer Therapy Panorama Novel Therapy for Diabetic $168,624.62 $69,362.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Research, Inc Complications Using RAGE-Fc Panorama Kinetic Assembly of Bispecific $76,103.69 Research, Inc Antibodies Panorama Myocardial Repair by Targeted $244,479.25 Research, Inc Stem Cells Panorama Multiplex Biomarkers for Prostate $49,054.35 $38,586.50 Research, Inc Cancer Anti-inflammatory Nicotinic Panorama Agonists for Therapy of $34,111.23 $147,003.00 Research, Inc. Ulcerative Colitis Paracor Medical, HeartNet System $244,479.24 Inc. Parallel Multiplex Serodiagnostic Test for Synthesis $244,479.25 Chagas Disease Technologies Inc Pathologica, LLC Pathologica $244,479.25 Pathwork Tissue of Origin Test $244,479.24 Diagnostics, Inc Corneal Epithelial Transplant Paul H Chen $244,479.25 Device-Jet Contact Lens Pavilion Medical Pavilion Reversible Vena Cava $64,964.50 $179,514.74 Innovations LLC Filter PaxVax Inc PaxVax - Cholera Vaccine $93,760.50 $150,718.75 PaxVax, Inc PaxVax - influenza vaccines $244,479.25 PaxVax, Inc PaxVax - HIV Vaccine $83,323.00 $161,156.25 PaxVax, Inc. PaxVax - anthrax vaccine $244,479.25 PEAK Surgical, PEAK Plasmablade Improving $244,479.25 Inc. Patient Treatment Outcomes Pearl PT003 - formoterol- Therapeutics, glycopyrrolate combination HFA- $244,479.25 Inc. MDI for COPD Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pearl PT001- glycopyrrolate HFA-MDI Therapeutics, $244,479.25 for treatment of COPD Inc. PT010 - Pearl formoterol/glycopyrrolate/momet Therapeutics, $96,654.00 $147,825.25 asone combination HFA-MDI for Inc. COPD PENUMBRA THE PENUMBRA $244,479.25 INC EMBOLIZATION SYSTEM PENUMBRA, THE PENUMBRA SYSTEM $244,479.25 INC. Peregrine Bavituximab for the treatment of Phamaceuticals Refractory of Non-small Cell $244,479.25 Inc Lung Cancer Peregrine Bavituximab for the treatment of Pharmaceuticals Non-Small Lung Cancer (Front- $244,479.25 Inc line Therapy) Peregrine Bavituximab for the treatment of Pharmaceuticals patients Co-infected with HCV- $238,783.50 $5,695.75 Inc HIV Peregrine Cotara for the treatment of Pharmaceuticals, $244,479.25 Glioblastoma Multiforme (GBM) Inc Perseid Therapeutics BA $96,183.50 $148,295.74 LLC Perseid Therapeutics PTLA $37,850.50 $206,628.74 LLC Perseid Therapeutics Maxy-4 $244,479.24 LLC Therapuetic treatment of chronic Phage tympanic membrane perforation $244,479.25 Pharmeceuticals by fibroblast growth factor. Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 PharmacoFore, Tamper-and-Abuse-Resistant $244,479.25 Inc. Hydromorphone Prodrug PharmacoFore, PF0713: Safer IV Sedative- $244,479.25 Inc. Hypnotic Agent PF03 MPAD: Multi-Pill Abuse- PharmacoFore, Deterrent (MPAD) $213,354.73 $31,124.52 Inc. Hydromorphone Prodrug Pharmaco- Metronomic Biofeedback Pump Kinesis $244,479.25 (MBP) Corporation Pharmacyclics Factor Vlla Inhibitor PCI-27483 $244,479.25 Inc Pharmacyclics HDAC Inhibitor PCI-24781 $244,479.25 Inc Pharmacyclics, Btk Inhibitor PCI-32765 $244,479.25 Inc. Pherin Pharmaceuticals, PH80 $102,708.25 Inc. Pherin Pharmaceuticals, PH94B $131,068.25 Inc. VENOUS STASIS ULCER PHILOMETRO THERAPY MANAGEMENT $68,413.00 $28,590.00 N INC SYSTEM PhiloMetron, Inc Weight Management System $60,216.00 $106,989.00 Integrated Vascular Access PhiloMetron, Inc. $27,258.50 $74,813.50 stenosis Mitigation System Phoenix Rapid POC STD Molecular $143,760.00 $100,719.25 Biosystem Inc Diagnostics NeuroThera Laser System and PhotoThera, Inc. TLT for the Treatment of Acute $244,479.25 Ischemic Stroke Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development and PIKAMAB Inc Commercialization of ADCC $244,479.25 Therasight™. Development and PIKAMAB, Inc. Commercialization of Lupus $244,479.25 Therasight Piper Medical Portable, battery operated, low dba Odyssey cost (<$500), Tactical CO2 $22,262.00 $11,975.00 Medical Asthma and COPD Respiratory Technologies Therapy Device Piper Medical dba Odyssey Quixie Cancer Drug Inhalation $8,415.50 $9,547.50 Medical Therapy Technologies Planet TEM-8Fc, An Anti-Cancer Biotechnology $13,948.50 $16,850.00 Immunoadhesin Made in Plants Inc Planet PBI-220 A Novel Therapy for Biotechnology $244,479.24 Inhalational Anthrax Inc Planet PBI-230, a therapy for treatment Biotechnology $135,834.50 $108,644.74 of botulism Inc Digestible Balloon Obesity PlenSat, Inc. $216,951.50 $27,527.74 Treatment Small molecule inhibitors of Plexxikon Inc CRAF kinase for the treatment of $244,479.25 polycystic kidney disease Small molecule inhibitors of Fms Plexxikon Inc. receptor tyrosine kinase for the $244,479.25 treatment of cancers Small molecule inhibitors of Plexxikon Inc. BRAF kinase for treatment of $244,479.25 cancers PneumRx, Inc. RePneu ® Lung Volume $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Reduction Coil (LVRC) System Poincare Systems AccuSwept MIS Surgical Device $97,673.50 Inc Trans-Thoracic Wall Assisted Portaero, Inc. Therapeutic Drug Administration $244,479.25 for Emphysema Portola Elinogrel - Novel direct-acting Pharmaceuticals competitive reversible P2Y12 $244,479.25 Inc inhilitor Portola Pharmaceuticals PRT061103 $244,479.25 Inc Portola PRT062607-Novel, oral Syk- Pharmaceuticals, $244,479.25 specific inhibitor Inc Portola Betrixaban-Novel, oral, direct, Pharmaceuticals, $244,479.25 Factor Xa inhibitor Inc Portola PRT062070 - Novel, oral Syk-Jak Pharmaceuticals, $36,720.50 $207,758.75 kinase inhibitor Inc Portola PRT064445 - Universal Factor Xa Pharmaceuticals, $244,479.25 Antidote Inc. Posit Science Plasticity-based Adaptive $244,479.25 Corporation Cognitive Remedation (PACR) Ultra-High Speed and Ultra- Praevium broadband Sources for Optical $148,096.50 $71,230.50 Research Inc Coherence Tomography Precise Light Acute Ischemic Stroke treatment $29,710.00 $214,769.25 Surgical with localized tPA delivery Prediction Theranostic for ischemic stroke $244,479.24 Sciences LLC PRESIDIO NS5B $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 PHARMACEUT ICALS, INC PRESIDIO PHARMACEUT NS5A $244,479.25 ICALS,INC Proacta HSMKI development program $244,479.24 Proacta, Inc. PR104 development program $244,479.24 Antibody targeted Liposomal Probactive Etoposide (provisionally referred $242,539.52 $1,939.72 Biotech, Inc as "ATLE") Radioimmunotherapy (RIT) Probactive Iodine - 131 Antinuclear $244,479.24 Biotech, Inc. Antibody (ANA) Prodo Human Islet Expansion $141,723.83 $102,755.42 Laboratories Inc. Prodo Human Islets For Research $134,137.63 $110,341.62 Laboratories Inc. Resourcing & Distribution Progentech-USA, Progentech Integrated Molecular $244,479.25 Inc. Diagnostic System Prognosys Technology for Mapping Protease $16,693.50 $68,236.50 Biosciences Inc Activity Across the Proteome Prognosys Technology for Multiplexed $103,875.50 Biosciences, Inc. Profiling of Protease Activity Technology for Mapping Protein Prognosys Kinase Activity Across the $66,428.50 Biosciences, Inc. Proteome Macromolecule-Drug Conjugate Prolynx LLC $65,330.00 $179,149.24 Delivery Platform ProSci Inc Novel HIV/AIDS Vaccine Project $244,479.25 Prosetta Bioconformatics BioConformatics $149,267.91 $95,211.34 Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Prosetta Bioconformatics, Anti-Virals $244,479.25 Inc A universal bioinformatics based PROTELIX, Antibody Mimic Platform for the INC. d/b/a $244,479.25 Discovery and Development of PROTELICA Novel Therapeutics Proteus Chipskin Technology $244,479.25 Biomedical, Inc. Proteus The Raisin system $244,479.25 Biomedical, Inc. Development of Nephrilin for the Protigen Inc treatment of diabetic $126,311.00 $118,168.24 complications and cancer Prostate Cancer Diagnostics and Proveri Inc. $74,967.50 $169,511.74 Prognostics Providence Medical DTRAX Delivery System $244,479.24 Technology, Inc Psylin Peptid Therapeutics for the Neurosciences $244,479.25 treatment of Schizophrenia Inc PSYLIN Peptide therapeutics for the NEUROSCIENC $244,479.24 treatment of depression ES, INC. Chartis Pulmonary Assessment System and Zephyr PULMONX INC $244,479.25 Endobronchial Valve for Emphysema Novel Punctal Plug Sustained QLT Plug Release Drug Delivery System - $244,479.24 Delivery Inc Opthalmics QUALIGEN ALPHA GST $31,531.00 $182,238.50 INC Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Rapid low-cost MRSA QuantaLife, Inc. $244,479.25 diagnostics Quark QPI-1007 for non-arteritic Pharmaceuticals, ischemic optic neuropathy $244,479.24 Inc (NAION) Quark QPI-1002 (I5NP) for Delayed Pharmaceuticals, Graft Function (DGF) in Kidney $244,479.24 Inc Transplant Quark QPI-1002 (I5NP) for Acute Pharmaceuticals, $244,479.24 Kidney Injury (AKI) Inc. Low inventory, low cost Quexta, Inc $80,950.50 $93,750.00 eyeglasses Quiescence Pharyngeal Stent to Treat Sleep $53,200.00 $191,279.25 Medical, Inc Apnea RadioRx, Inc RRx-001 $244,479.25 Raptor WntTide, a peptide targeting $83,078.00 $137,450.00 Discoveries Inc LRP6 positive breast cancers HepTide, a drug targeting peptide Raptor for the potential treatment of liver $111,027.00 $7,500.00 Discoveries Inc. disease Raptor DR Cysteamine for the potenial $220,167.50 $24,311.75 Therapeutics Inc treatment of Huntington's Disease DR Cysteamine for the potenial Raptor treatment of non-alocholic $215,299.50 $29,179.75 Therapeutics Inc steatohepatitis (NASH) Raptor DR Cysteamine for the potenial $244,479.25 Therapeutics Inc treatment of Cystinosis Inhibition of lung inflammation Receptos Inc associated with influenza viral $160,570.00 $83,909.25 infection Small Molecule GLP1R Agonist Receptos Inc $103,397.00 $141,082.25 Program Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Reduction Novel Therapy for the Non- Technologies Fusion Treatment of Adolescent $210,119.36 $34,359.89 Inc. Idiopathic Scoliosis Redwood Universal Carrier Scaffolds for $58,352.96 $186,126.28 Bioscience Inc Drug Delivery Novel microRNA therapeutics for Regulus treatment of hepatitis C viral $244,479.25 Therapeutics Inc infection Regulus Novel microRNA therapeutics for $244,479.25 Therapeutics, Inc treatment of fibrosis Relevare Combination therapy for the Pharmaceuticals treatment of chronic neuropathic $244,479.25 Inc pain conditions Relia Diagnostic Relia Diagnostic Systems, Inc $244,479.25 Systems, Inc RLY 106 polymer bile acid Relypsa, Inc. sequestrant ("BAS") for lowering $244,479.24 cholesterol and glucose levels RLY 5016 Potassimum Relypsa, Inc. $244,479.24 Management Renova Gene Therapy Transfer for $119,388.50 $125,090.75 Therapeutics, Inc Clinical Congestive Heart Failure An Endovascular Catheter for Renovorx Targeted Delivery of Drug/Cells $6,250.00 $22,750.00 to the Pancreas Implantable Anterior MicroPump Replenish Inc $244,479.25 System for Glaucoma Implantable Ophthalmic Replenish Inc MicroPump for Retina Drug $244,479.25 injections Resolution ClearPrep Cytology Solution and $25,106.07 $219,373.18 Biomedical Inc. Test Kit Response Genetic Profile Product $244,479.25 Genetics Inc Development Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 To develop an Anti -Angiogenic Retina Pharma Therapeutic for Wet Age related $244,479.25 Inc Macular Degeneration (AMD). Novel therapies for the treatment RetroVirox, Inc $35,914.69 $171,794.75 of HIV infection REVA Medical Peripheral Biodegradabe Drug $244,479.25 Inc Delivery Stent REVA Medical, REVA's Bioresorbable Drug- $244,479.25 Inc Eluting Stent REVA Medical, Structural Alloplastic Bone Graft $127,415.50 $29,161.00 Inc. (SABG) REVA Medical, Bioresorbable, Radiopaque $60,250.00 $8,357.50 Inc. Embolic Microspheres (BREMS) Revance RT001 Topical Botulinum Toxin Therapeutics, $244,479.25 A for Plantar Fasciitis Inc. Revascular Revascular Chronic Total $244,479.25 Therapeutics Inc Occulusion System ACUTE STROKE INFUSION Reverse Medical THROMBECTOMY $244,479.24 Corporation CATHETER PROJECT Development of Fenretinide for ReVision the Treatment of age-related $244,479.24 Therapeutics Inc macular Degeneration RP5000 PROGRAM FOR REVIVA SCHIZOPHRENIA AND PHARMACEUT $146,982.00 $97,497.25 SCHIZOAFFECTIVE ICALS INC DISORDERS Blood-based tests for the Ridge diagnosis and monitoring of $211,457.00 $33,022.24 Diagnostics, Inc. Neuropsychiatric disorders Rigel Syk Inhibitors with Improved Pharmaceuticals Specificity for the Treatment of $244,479.25 Inc Rheumatoid Arthritis Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Rigel Janus Kinase 2(JAK2) Inhibitor Pharmaceuticals for the Treatment of $165,761.00 $65,927.00 Inc Myeloproliferative Neoplasms Rigel PKC-theta inhibitors for the Pharmaceuticals $244,479.25 Treatment of Multiple Sclerosis Inc RIGEL Adiponectin Mimetics for the PHARMACEUT $244,479.25 Treatment of Type 2 Diabetes ICALS INC Rigel Spleen tyrosine kinase (Syk) Pharmaceuticals, Inhibitors for Treating Non- $244,479.25 Inc Hodgkins Lymphoma Rigel JanUS Kinase 1/3 inhibitors for Pharmaceuticals, the Treatment and Prevention of $244,479.25 Inc Organ Transplant Rejection Rigel Inhibitors of Axl Kinase for the Pharmaceuticals, $164,647.00 $8,356.50 Treatment of Metastatic Disease Inc. Rigel Novel Treatments for Muscle Pharmaceuticals, $244,479.25 Wasting Inc. Rigel Fostamatinib disodium (FosD), an Pharmaceuticals, oral syk inhibitor for treating $244,479.25 Inc. Rheumatiod Arthritis (RA) Rigel Topical JAK 1/3 Inhibitors for the Pharmaceuticals, $91,784.00 $152,695.25 Treatment of Psoriasis Inc. Ritter RP-G28 A Novel Treatment of Pharmaceuticals, $244,479.25 Lactose Intolerance Inc. Roxro Pharma, SPRIX $244,479.24 Inc Ruga Targeted Cancer drug for Multiple $108,990.00 Corporation Myeloma Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 RUGA Cancer treatment targeting $244,479.25 Corporation glucose metabolism LotusTM Valve System for Sadra Medical transcutaneous aortic valve $244,479.25 Inc. replacement therapy SafeLife Corp Antimicrobial Catheters $194,891.50 $49,587.75 SafeLife Corp. Antimicrobial Respirator $244,479.25 SB623 Cell Therapy for the Recovery of Function from SanBio, Inc. $244,479.25 Disability Caused by Ischemic Stroke SB-313-xTZ for Recurrent or Sangamo Refractory Glioblastoma $244,479.25 BioScience, Inc. Multiforme (GBM) SB-728-T for Human Immunodeficiency Sangamo Virus/Acquired $244,479.25 BioSciences, Inc immunodeficiency Syndrome (HIV/AIDS) Sangamo SB-509 for Diabetic Peripheral $244,479.25 BioSciences, Inc. Neuropathy(DPN) Sangamo SB-509 for Amyotrophic Lateral $244,479.25 BioSciences, Inc. Sclerosis (ALS) Sanovas Interventional Drug Sanovas, Inc. $244,479.25 Therapy SanRx Dipterinyl Calcium Pentahydrate Pharmaceuticals $14,847.50 $229,631.74 (DCP) Inc Sapheon Inc Sapheon Closure System $244,479.24 SARCODE SARcode SAR 1118 Ophthalmic $244,479.25 CORPORATION Solution Satiety, Inc TOGA $244,479.25 Satiogen Colon/Rectum targeted GPBAR1 $51,039.00 $50,829.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceuticals agonists for the treatment of Inc obesity AN ORAL, SMALL SATIOGEN MOLECULE INHIBITOR OF PHARMACEUT $114,216.00 $71,488.00 THE ASBT FOR THE ICALS, INC TREATMENT OF OBESITY SBIO SB1518 JAK2/FLK3 SBIO Inc. $244,479.24 Inhibitor Scharp Burn and Wound Dressing Technologies, $244,479.25 Treatment Inc SciClone Pharmaceuticals, SciClone Oral Mucositis $244,479.25 Inc SciClone Pharmaceuticals, SciClone Hepatitis C $244,479.25 Inc SciClone Pharmaceuticals, SciClone Vaccine Enhancer $221,306.50 $23,172.75 Inc. SciClone Pharmaceuticals, SciClone Oncology $244,479.25 Inc. SCIGENE Automated genetic analysis $216,842.50 $27,636.74 CORPORATION system for human disease SCRIPPS DIABETES - LOW COST LABORATORIE HEMOGLOBIN A1C METER $244,479.24 S, INC. AND TEST SeaChange Drug Repurposing using Pharmaceuticals, $48,051.61 Chemoinformatic Links Inc Sechrist Technological Advancements $172,045.00 $72,434.25 Industries Inc Sechrist Utility of Large Hyperbaric $203,864.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Industries Inc Chamber Pro-Apoptotic DNA Vaccination SEKRIS for the treatment of type 1 $244,479.25 Corporation diabetes Antiangiogenic Surrobodies ™ Selby Life for the treatment of multiple $208,891.58 $35,587.67 Science LP cancers Selby Life Surrobodies [tm] for the treatment $219,832.84 $24,646.41 Sciences LP of Multiple Solid Tumor Cancers Selby Life Surrobodies TM for the Treatment $244,479.25 Sciences, LP of Breast and Other Cancer Passive Immunity and Selby Life Therapeutic Treatment of $106,735.67 $137,743.58 Sciences, LP Seasonal Influenza Selby Life Proapoptotic Surrobodies™ for $222,872.70 $21,606.54 Sciences, LP the Treatment of Multiple Cancers Selby Life Surrobodies ™ for the Treatment $196,036.18 $48,443.07 Sciences, LP of Diabetes and Obesity Selexagen Hedgehog Pathway Inhibitor for $27,108.48 $217,370.77 Therapeutics, Inc the Treatment of Cancer Selexagen Oncogenic BRAF Kinase Therapeutics, (V600E) Inhibitor for the $2,087.29 $242,391.96 Inc. treatment of cancer Senomyx, Inc. Sweet Enhancer Program $244,479.25 Sensor Improved diabetes therapeutics Innovations, administration via novel self- $244,479.24 Incorporated calibrating glucose sensor (DBA Sensorin) PLACE: Permanent Left SentreHEART, Auricular Closure & Exclusion in $244,479.24 Inc Patients with Atrial Fibrillation Sequel K201: a novel treatment for Atrial Pharmaceuticals, $244,479.25 fibrillation Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Age-related macular degeneration Sequenom, Inc $244,479.25 test PRENATAL TESTING FOR SEQUENOM, TRISOMY 21 $244,479.25 INC. (DOWNSYNDROME) Woven EndoBridge Cerebral Sequent Medical Aneurysm Embolization Device $244,479.25 Inc (WEB) Sialix Inc N-glycolyneuraminic Acid in the (formerly Gc- Pathogenesis and Progression of $6,376.00 $59,123.50 Free Inc) Rheumatoid Arthritis Sialix Inc Detection of Non-Human Sialic (formerly Gc- Acid in Biotherapeutic $52,127.50 $42,714.50 Free Inc) Applications Sialix, Inc Neu5Gc-Glycan Arrays for (formerly Gc- Discovery and Validation of $28,370.50 $86,694.50 Free,Inc.) Human Cancer Biomarkers Sierra Surgical Technologies Minimally Invasive System $244,479.24 Inc. FAST-CAS(Flow Altered Short Silk Road Transcervical Carotid Artery $244,479.24 Medical Inc Stenting) Research/Development Silver Lake Rapid Diagnostic Test Kit for Research $73,817.51 $145,222.90 Urinary Tract Infections Corporation Silver Lake Development of Rapid Diagnostic Research test Kit for Methicillin-Resistant $53,665.12 Corporation Staph. Aureus Silver Lake EAP-Derived Monoclonal Research Antibodies for Cancer Diagnostics $23,802.44 $31,071.09 Corporation by Immunohistochemistry Intra-operative monitoring of Silver Medical, stroke in high-risk patient $10,868.50 $135,500.00 Inc. populations Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Highly multiplexed cancer Solulink, Inc $41,622.00 $155,749.50 biomarker assays. An RNA-based therapeutic for SomaGenics, Inc $244,479.25 hepatitis C miR-ID, a novel diagnostic SomaGenics, Inc. platform for microRNAs and $76,535.82 $25,904.69 other small RNAs Somaxon Silenor (doxepin hydrochloride), a Pharmaceuticals, pharmaceutical treatment for $244,479.25 Inc. insomnia Sonexa ST101 Compound for Alzheimer's Therapeutics, $244,479.24 Disease Inc. Sorbent CLP(Cross Linked $244,479.24 Therapeutics Inc Polyelectorlyte) Sorrento STI-MRSV $150,000.00 Therapeutics, Inc Sorrento Therapeutics, STI-MRSA $195,089.50 $49,389.74 Inc. Sotera Wireless, ViSiMobile System $244,479.24 Inc. Specialized Vascular EndoCoat Drug-Eluting Stent $244,479.24 Technologies, Inc Spectral Early Melanoma Detection Molecular Device Using Hyperspectral $32,622.00 $157,550.00 Imaging, Inc Imaging WavSTAT Optical Biopsy SpectraScience System-Inflammatory Bowel $202,308.50 Inc Disease-Cancer SpectraScience, WavSTAT optical Biopsy System $244,479.24 Inc - Esophageal Cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 SpectraScience, LUMA Cervical Imaging System $73,480.00 $41,731.00 Inc. - FDA Post Approval Study NON-INVASIVE, TRANS- SPECTROS ABDOMINAL BROADBAND $79,006.00 $108,375.00 CORPORATION OXIMETER FOR EARLY- STAGE NEC DIAGNOSIS Real-Time Detection of Colon Spectros Ischemia During Abdominal $76,988.00 $55,908.50 Corporation Aortic Aneurysm Surgery ProstaFluor FDA Trail for Real- Spectros Time Margin Detection During $39,409.00 $205,070.24 Corporation Protatectomy Spectros Broadband Spectroscopic $244,479.24 Corporation Localization of Breast Cancer Spectrum Pharmaceuticals Renazorb $244,479.25 Inc Spectrum Pharmaceuticals Zevalin $244,479.25 Inc Spectrum Pharmaceuticals, Apaziquone $244,479.25 Inc. Spectrum Belinostat, a novel anti-cancer Pharmaceuticals, $244,479.25 agent Inc. Artificial Spinal Discs to Treat SpinalMotion, Back Pain More Effectively at $244,479.24 Inc Lower Cost that Spinal Fusion SpineAlign VerteLift $244,479.25 Medical Inc Spiracur Inc SNaP $244,479.24 Small molecule erythropoietin Stategics, Inc $28,629.82 $23,433.34 mimetics for the treatment of Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 neurological disorders Stellar Diagnostic Immune Status Biotechnologies, Monitoring in Patients with $244,479.24 Inc Immunodeficiency ENABLING ICH-S8 STELLAR IMMUNOTOXICITY TESTING BIOTECHNOLO $244,479.25 WITH KEYHOLE LIMPET GIES, INC. HEMOCYANIN Stem CentRx, Identification and Therapeutic of $244,479.25 LLC Solid Tumor Cancer Stem Cells StemCells HuCNS-SC Eye $244,479.25 California Inc StemCells HuCNS-SC Spinal Cord Injury $244,479.25 California, Inc. StemCells hLEC Project $244,479.25 California, Inc. StemCells HuCNS-SC Brain $244,479.25 California, Inc. Chronic Spinal Cord Injury Stemcyte Inc $244,479.25 Treatment Stemcyte, Inc. Chronic Stroke $157,177.50 $87,301.75 Stemedica Cell Allogenic Mesenchymal Stem Technologies, $244,479.25 Cell Therapy Stroke in the USA Inc. Stephen J Opioid Dose Reduction Taper Peroutka MD $4,805.00 $120,100.10 Pack Device PhD STKR, Inc. STKR QwikJect $143,516.50 $100,962.75 Creation of safe and effective String PAP for development of $175,000.00 Therapeutics Inc immunotoxin for lupus String Direct Intracranial administration $220,000.00 Therapeutics Inc of BMP-4 as Therapy Against Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Giloblastoma Stroma Medical Iris Stroma Retraction and $106,917.10 $137,562.15 Corporation Depigmentation Sunesis Development of voreloxin for the Pharmaceuticals, treatment of patients with acute $244,479.24 Inc myeloid leukemia Suneva Medical, Artefill for the Treatment of HIV- $2,000.00 $242,479.25 Inc. Associated Lipoatropy SGI-1776-PIM Kinase Inhibitor SuperGen Inc $244,479.25 (an anti-cancer compound) Commercial Scale Cell-Free Sutro Biopharma, Production Enabling Novel $244,479.25 Inc Neutropenia Therapies Lead optimization and biomarker SuviCa Inc. identification for novel anti- $102,500.00 cancer therapies Symthetic TGF-beta ligands for Symor, Inc $244,479.24 bone repair and diseases Novel Therapeutics to Treat Synedgen, Inc Bacterial Infections including $218,735.00 $25,744.24 Drug Resistant Bacteria Synergenesis Inc MNC-1000 $20,964.71 $81,703.77 Clinical development of SYN115: Synosia a new chemical entity for treating $244,479.25 Therapeutics, Inc Parkinson's Disease (PD) Synosia Clinical development of SYN120: Therapeutics, a new treatment for Alzheimer's $244,479.25 Inc. disease (AD) Therapeutic Delivery for Tendon Synthasome Inc $244,479.25 Repair T F Instruments Phase X-ray Diagnostic Imaging $222,000.00 Tacere Ocular (SMK-01/03) $244,479.25 Therapeutics, Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc. Tacere Therapeutics, Hepatitis C (TT-034) $244,479.25 Inc. TaiMed Tamiphosphor for influenza $28,738.00 $54,213.50 Biologics USA infections TaiMed Ibalizumab for HIV-1 infections $244,479.24 Biologics USA Talima Terbinafine Micro Implant (TMI- $244,479.25 Therapeutics, Inc 358) Tandem Diabetes T-Slim Infusion Pump - Diabetes $244,479.24 Care Inc. Tandem Non-invasive prenatal diagnosis $111,484.38 $132,994.86 Diagnostics, Inc of fetal genetic abnormalities Novel Topical Analgesic for Taraxos, Inc. $39,623.11 $57,500.00 Peripheral Neuropathy Diagnostic Test for Crohn's Targeson Inc. $112,793.00 $131,686.25 Disease TARGETED Novel Treatment for Sleep MEDICAL $244,479.25 Disorders in the Elderly PHARMA, INC TARGETED NEW THERAPY TO REDUCE MEDICAL SIDE EFFECTS OF PAIN $244,479.25 PHARMA, INC DRUGS TARGETED A safe and effective treatment for MEDICAL $244,479.25 Gulf War illness PHARMA, INC. Phase 2 Randomized Clinical Telik, Inc Trial of Telintra for Treatment of $208,368.00 $36,111.24 Severe Chronic Neutropenia. Phase 2 Clinical trial of Telcyta Telik, Inc for the treatment of Refractory $244,479.24 Lymphoma & Multiple Myeloma Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Phase2 Clinical Trial of Telintra Telik, Inc. ® in Low to Intermediate-1 Risk $244,479.24 Myelodysplastic Syndrome Clinical Trial of Telintra® & Telik, Inc. Revlimid® in Patients with $213,536.50 $30,942.74 Myelodysplastic Sydrome (MDS). Development of a Novel Inhibitor Telik, Inc. of Aurora and VEGFR Kinases $244,479.24 for the Treatment of Cancer. Tethys Cardiovascular Event Prevention $244,479.25 Bioscience Inc Tethys PreDx Diabetes Risk Score $244,479.25 Bioscience, Inc. Diagnostics for the Prevention Tethys and Management of $142,933.00 Bioscience, Inc. Cardiometabolic Disease Stem Cell Separation and Gene TheraCell Inc. $137,527.00 $106,952.25 Transfection Device' THERACOS THR-1442 $244,479.24 INC Theracos, Inc THR-4450 $244,479.24 Therapeutics Clinical Research, A Carbazole $11,551.92 $175,760.76 Medical Corporation Therapeutics Clinical Super-Potent Corticosteroid Research, A $49,392.00 $195,087.25 Lotion Medical Corporation Therapheresis, TheraSystem I $130,545.00 $113,934.25 Inc Theravance Inc A novel approach to the $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 management of congestive heart failure Improving the quality of life for Theravance Inc patients with opioid-induced $244,479.24 constipation A novel approach to the Theravance Inc management of uncontrolled $244,479.24 hyper tension Novel symptomatic and disease Theravance Inv approach to the treatment of $244,479.24 Alzheimer's Disease A novel treatment designed to Theravance, Inc cure Hepatitis C and prevent $244,479.24 hepatocellular carcinoma Novel bifunctional muscarinic Theravance, Inc antagaonist-beta2 agonist for $219,000.00 $25,479.24 respiratory disorders A novel oral therapy for the Theravance, Inc treatment of pulmonary arterial $244,479.24 hypertension A novel lung-selective muscarinic Theravance, Inc antagonist for chronic obstructive $244,479.24 pulmonary disease A Novel analgesic optimized to Theravance, Inc reduce or replace opioid-based $244,479.24 therapies for chronic pain Novel approach to the treatment Theravance, Inc. of resistant Gram-positive $244,479.24 bacterial infections Novel approaches for the tratment Theravance, Inc. of Gram-negative bacterial $244,479.24 infections THERAVIDA THVD-102 $244,479.25 INC Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Clinical development of Theregen Inc. Anginera™ for the Treatment of $244,479.25 Refractory Angina/Ischemia Sustained Release Anti-Cancer Therinject LLC Immuno-therapeutic Formulation $32,596.00 $7,664.00 Development Thermogenesis Res-Q 60 BMA $244,479.25 Corp. SSO2 Therapy for the Treatment TherOx, Inc. $244,479.24 of Heart Attack Threshold Hypoxia-Activated prodrug Pharmaceuticals technology plaform for cancer $244,479.25 Inc drug discovery and development Threshold Clinical Development of Hypoxia Pharmaceuticals, Activated Prodrug TH-302 for the $244,479.24 Inc. Treatment of Cancer Tioga Asimadoline for the Treatment of Pharmaceuticals, $244,479.24 Irritable Bowel Syndrome Inc TLC Lipotecan® TLC388 Anti-Tumor Biopharmaceutic $241,979.50 $2,499.74 Therapeutic als, Inc. TM3 A novel method of generating Therapeutics $39,844.50 $204,634.75 Therapeutic HIV vaccines LLC TM3 Therapeutics A respiratory prophylactic vaccine $29,883.50 $195,422.00 LLC TM3 A novel method of generating Therapeutics fully human monoclonal antibody $29,883.50 $158,500.00 LLC therapeutics Toca 511 with 5-FC to Significantly Improve Tocagen Inc. $244,479.24 Glioblastoma Multiforme Camcer Patient Survival Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Topica Development of a Novel Pharmaceuticals, Antifungal, Luliconazole, for $244,479.25 Inc Onychomycosis TK-112690 for the Prevention of Tosk, Inc Cancer Chemotherapy Induced $244,479.24 Mucositis TK-115339 for the Prevention of Tosk, Inc. Chemotherapy Induced $95,220.35 $149,258.90 Cardiotoxicity Tragara Capoxigem (apricoxib, TG01) an Pharmaceuticals Oral COX-2 Inhibitor for the $244,479.24 Inc Treatment of Cancer Tragara TG02, an Oral Multi-kinase Pharmaceuticals, Inhibitor for the Treatment of $244,479.24 Inc Cancer Transcend Drug-Eluting Microstent for $244,479.25 Medical Inc Glaucoma Treatment Transcept INTERMEZZO $244,479.25 Pharma, Inc Transdel Efficacy and Safety of Ketoprofen Pharmaceuticals, Cream in the Treatment of Acute $244,479.25 Inc. Pain Transpose UGIB Therapy $147,550.00 Medical LLC Transvivo, Inc. OMNI-OA $244,479.25 Development of the PTD-DRBD Traversa delivery technology for siRNA $244,479.25 Therapeutics, Inc drug therapies Development of RNA Traversa interference-based drug $243,868.00 $611.25 Therapeutics, Inc candidates for human brain cancer Development of a human-derived Trellis antobody to prevent maternal-fetal $244,479.25 Bioscience, LLC transmission of CMV Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of a human-derived Trellis antibody for pandemic influenza $244,479.25 Bioscience, LLC with broad strain efficacy TriAct Therapeutics, TT-100 $222,500.00 Inc. Image-guided Liver Tumor Trillium Ablation using Internal Energy $34,517.50 $82,500.00 Engineering Inc (Vapor) Trius Torezolid research & Therapeutics, $244,479.24 Development Inc. TriVascular's Ovation™ TriVascular, Inc Abdominal Stent Graft $244,479.25 System(Ovation ™ /ASGS) TriVascular's Thoracic Stent- TriVascular, Inc. $244,479.25 Graft System Ultrawave Labs UltraWave Imaging Technology $62,747.49 $181,731.75 Universal Thermostable Rabies Vaccines for Stabilization $61,365.00 $131,694.00 Oral Delivery Technologies Inc Universal Stabilization Thermostable Measles Vaccines $28,750.00 Technologies for Pulmonary Delivery Inc. US Biotest, Inc Progenitor Cell Engrafment $129,384.10 $115,095.14 Treatment of Multiple-Cytopenias US Biotest, Inc $244,479.24 with TXA127 Treatment of Acute Respiratory US Biotest, Inc $214,005.55 Distress Syndrome with TXA127. Development of Incisionless USGI Medical, Operating Platform and procedure $244,479.25 Inc for the treatment of obesity Valent VAL-083 $12,579.50 $231,899.74 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Technologies LLC Valentx, Inc ENDO BYPASS SYSTEM $244,479.25 Vascular CAR Peptide for Targeted Drug $66,876.00 $115,000.00 Biosciences Delivery Vascular IsoFlow Ainfusion Catheter $158,850.50 $85,628.75 Designs, Inc. Vascular Intravascular ultrasound steerable Imaging $244,479.24 imaging guidewire Corporation VasoNova, Inc. VasoNova-VPS $244,479.25 Pediatric formulation for oral Vaxart Inc $38,704.50 $88,505.00 vaccines Vaccine for Venezeulan equine Vaxart Inc $157,061.00 $87,418.25 encephalitis Vaccine for Herpes Simplex Virus Vaxart Inc $16,366.00 type 2 Vaccine to prevent pandemic Vaxart Inc $92,701.50 $151,777.75 avian influenza Oral-delivery vaccine for seasonal Vaxart Inc $42,823.00 $41,095.00 influenza Commercialization of a novel, Vaxiion minicell-based, nano-sized Therapeutics, $117,783.00 $126,696.24 targeted drug and RNAi delivery Inc. platform technology Novel Automated Peritoneal Lavage System for Controlled Velomedix Inc $244,479.25 Induction of Therapeutic Hypothermia VentiRx TLR8 Agonist (VTX-2337): Pharmaceuticals Targeted Novel Immunotherapy $244,479.24 Inc for Multiple Oncology Indications VentiRx TLR8 Agonist (VTX-1463): $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceuticals, Novel Immunomodulatory Agent Inc. for Allergic Rhinitis and Asthma Molecular profiling of thyroid Veracyte, Inc nodules to determine benign or $244,479.25 malignant cancer Lung Nodule Genomic Marker Veracyte, Inc. $24,810.00 $122,442.00 Panel Test A novel diagnostic test for the Vermillion Inc diagnosis of early stage ovarian $244,479.25 cnacer (OVA2) A novel diagnostic test for the Vermillion Inc diagnosis of peripheral artery $244,479.25 disease (PAD) Vertos Medical, Vertos mild for Lumbar Spinal $244,479.25 Inc Stenosis VIA PHARMACEUT VIA-2291 $244,479.25 ICLALS, Inc ViaCyte, Inc Cell Therapy for Diabetes $244,479.25 Vical Allovectin-7 $244,479.24 Incorporated Vical TransVax $244,479.24 Incorporated Preclinical and Clinical Virobay Inc Development of Cathepsin S $244,479.25 inhibitor VBY-8911 Clinical Development of VIROBAY, INC. Cathepsin B Inhibirot VBY-376 $244,479.25 for Liver Fibrosis A novel Immune Virogenics Inc Modulator/Adjuvant for HIV $85,080.50 $16,544.50 Vaccines FIV Vectors for Treatment of Virogenics, Inc $191,188.50 Hemophilia A Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 VisionCare Ophthalmic IMT Project #002 $244,479.25 Technologies Inc Vital Therapies ELAD Bioartificial Liver $244,479.24 Inc A finger-prick medical diagnostic Vitalea Science for vitamin B12 malabsorption: $219,682.44 $24,796.80 Inc An early intervention tool VITAPATH SPINA BIFIDA PREVENTION $244,479.24 GENETICS, INC ASSAY VitaPath Cleft Palate Prevention Assay $244,479.24 Genetics, Inc. VIVUS, INC. Qnexa $244,479.25 Preclinical Development of VM Discovery, VMD-902 for Chronic $225,743.84 $18,735.40 Inc Neuropathic Pain Voyage Medical, Cardiac Ablation Under Direct $244,479.25 Inc. Visualization Direct Visualization Cardiac Voyage Medical, Catheter for Transseptal Puncture $244,479.25 Inc. and Drug Delivery IRIS ™ SmartChip Genetic Analysis for WaferGen Molecular Identification of $244,479.25 Biosystems Inc. Disease States & Therapy Selection Molecular Diagnostic Assays and Wave 80 Instrumentation for HIV Viral $244,479.25 Biosciences, Inc. Load Measurement Wnt pathway inhibitor drug for Wintherix, LLC $244,479.24 epithelial and leukemic cancers Wiseman SV-BR-1-GM, a Whole-Cell Research Vaccine to Treat Various Types of $40,378.50 $20,189.50 Initiatives LLC Advanced Cancer XDX, Inc XDx Lupus Molecular $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Diagnostics XDx AlloMap: Molecular XDX, Inc. Diagnostic for Heart Transplant $244,479.25 Acute Cellular Rejection Development of biosuperior Xencor Inc $244,479.25 antibodies with extended half-life Clinial development of XENCOR INC XmAb5574 an antibody treating $244,479.25 Chronic Lymphocytic Leukemia Clinical development of XmAb2513, a therapeutic XENCOR, INC $244,479.25 antibody treating Hodgkin Lymphoma Clinical development of XENCOR, INC. XmAb5871, an antibody treating $244,479.25 Lupus and other diseases XP21279 - A Transported XenoPort, Inc Prodrug of L-Dopa for the $244,479.25 treatment of Parkinson's Disease Arbaclofen Placarbil, or AP - A XenoPort, Inc. Transported Prodrug of R- $244,479.25 baclofen Electronic brachytherapy for the Xoft Inc treatment of Gynecological $244,479.25 Cancers Electronic Brachytherapy for the Xoft, Inc $244,479.25 Treatment of Breast Cancer XOMA Monoclonal Antibody XOMA Ltd Therapeutics for the Treatment of $244,479.24 Oncologic Diseases XOMA's Heptavalent Anti- Xoma Ltd Botulinum Toxin Monoclonal $244,479.24 Antibody Program XOMA Ltd XOMA Monocional Antibody $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Therapeutics for the Treatment of Metabolic Diseases XOMA 052, Gevokizumab, Anti- Xoma Ltd IL 1Beta, Anti-inflammatory $244,479.24 therapeutic moncolonal anitbody Zacharon Sensi-Pro Diagnosic for the Pharmaceuticals, $219,911.00 $24,568.24 Mucopolysaccharidoses ( MPS) Inc Zacharon Development of ZP2571: The first Pharmaceuticals, inhibitor of 6-O sulfation of $244,479.24 Inc herparan sulfate for cancer Zacharon Development of AP10295: A Pharmaceuticals, novel ganglioside inhibitor for the $244,479.24 Inc. treatment of cancer Zacharon ZP2345: The First inhibitor of 2- Pharmaceuticals, O sulfation of heparan sulfate for $181,546.50 $62,932.74 Inc. the Mucopolysaccharidoses Discovery of inhibitors of Zenobia G2019S LRRK2 kinase for the $31,630.00 Therapeutic, Inc treatment of Parkinson's disease Zenobia Discovery of inhibitors of caspase Therapeutics, 6 kinase for the treatment of $12,500.00 Inc. Huntington's disease Zogenix Inc DosePro $244,479.25 Zogenix, Inc. ZX002 $244,479.25 ZOGENIX, INC. Sumavel DosePro $244,479.25 Novel PTH Microprojection Zosano Pharma, System for improved treatment of $244,479.25 Inc. severe osteoporosis Prostate Cancer Multi-Analyte ZYDX. Inc $46,100.00 Diagnostic Test A novel CD4 point-of-care Zyomyx,Inc diagnostic test for HIV $244,479.24 monitoring Colorado $22,418,899.79

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Accelr8 Technology BACcel Rapid Diagnostic $244,479.24 Corporation Electromagnetic radio frequency Actium Biosystems, excitation of nanoparticles for the $244,479.25 LLC external, non-invasive treatment of cancer via physical means. Pralatrexate for the Treatment of Allos Therapeutics, Relapsed/Refractory Cutaneous T- $244,479.24 Inc cell Lyphoma (CTCL) Pralatrexate for the Treatment of Allos Therapeutics, Relapsed/Refractory B-cell Non- $244,479.24 Inc Hodgkin's Lymphoma (NHL) Pralatrexate as treatment for Allos Therapeutics, urinary bladder trasitional cell $244,479.24 Inc carcinomas (TCCs). Pralatrexate for the Treatment of Allos Therapeutics, Advanced Non-small Cell lung $244,479.24 Inc Cancer (NSCLC) Pralatrexate for the Treatment of Allos Therapeutics, Advanced/Metastatic Breast $244,479.24 Inc Cancer Pralatrexate for the Treatment of Allos Therapeutics, Relapsed/Refractory Peripheral T- $244,479.24 Inc. cell Lymphoma ApopLogic AP-300 to treat superficial bladder $105,313.00 Pharmaceuticals, Inc cancer ApopLogic B201-acetate to treat small lung Pharmaceuticals, cancer and other hard to treat $201,419.00 $3,032.50 Inc. cancers Aqueous Oculieve glaucoma shunt $70,736.52 $155,000.00 Biomedical Inc. development ARCA Biopharma Gencaro (Bucindolol) CHF $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Therapeutic ARCA biopharma, NU172 Short-acting anticoagulant $244,479.25 Inc for cardiac procedures. ArcScan, Inc. Artemis 3 $244,479.25 AspenBio Pharma AppyScore™ $244,479.25 Inc Beacon BrightSPOT diagnostic $180,126.83 $64,352.42 Biotechnology LLC technology Novel Therapeutics for the BioAMPS Treatment of Drug-resistant $70,773.50 International, Inc Bacterial Infections Mass Spectrometry for Prostate Biodesix Inc $155,268.50 $89,210.75 Cancer Detection Researching Immunosuppressive BIODESIX INC Agents for Improved EGFR-I $97,831.00 $146,648.25 Therapy Effectiveness Mass Spectrometry for Diagnosis Biodesix, Inc $83,601.00 $118,757.50 of Inflammatory Colitis VeriStrat® : For Guiding Epidermal Growth Factor BIODESIX, INC $244,479.25 Receptor inhibitor Therapy in Cancer Mass Spectrometry for Biodesix, Inc Autoimmune Liver Disease $101,018.50 $118,757.50 Diagnosis CancerDetect: For early Biodesix, Inc. $162,120.00 $82,359.25 diagnostic of lung cancer (LC) BiOptix BiOptix Accolade Project $227,575.00 $16,904.25 Diagnostics, Inc. Novel Erythropoiesis-Stimulating Bolder Protein for Chronic Kidney $41,763.53 $202,715.72 Biotechnology Inc. Disease and Cancer Bolder Novel, Long-Acting Growth $125,951.74 $118,527.51 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Biotechnology Inc. Hormane Analog for Treatment Short Stature and Lipodystrophy Novel long-acting G-CSF analog Bolder for treating acute radiation $17,523.68 $196,704.31 Biotechnology Inc. syndrome and cancer Novel long-acting beta interferon Bolder analog for treating multiple $119,991.28 $124,487.97 Biotechnology Inc. sclerosis and cancer Novel, long-acting GM-CSF Bolder analog for treating acute radiation $21,682.98 $222,796.27 Biotechnology Inc. exposure and cancer-associated neutropenia. Cell Point EC Technology $244,479.24 Molecular Diagnostic Project for CeMines Inc $197,725.50 Lung Cancer Peptide Enhancement Anorganic Cerapedics Inc Bone Mineral for Cervical Spinal $244,479.24 Fusion Surgery Optimized Delivery Matrices for Cerapedics Inc Augmenting Pluipotent {Stem} $244,479.24 Cell Repair of Hard Tissue Lyophilized Peptide Enhanced Cerapedics Inc Bone Graft Conjugates For $244,479.24 Trauma Applications Development of tools to diagnose CereScan Corp diseases and conditions of the $244,479.25 brain Chata Biosystems, A Stronger, Broad Spectrum, $67,799.50 $176,679.75 Inc Environmentally safe Disinfectant Development of CO-1.01 and Clovis Oncology Inc companion diagnostic test for $244,479.25 treatment of pancreatic cancer Clovis Oncology, Development of EMSI and $244,479.25 Inc. companion diagnostic for Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 treatment of non-small cell lung cancer Determination of predictive value Corgenix Medical of AtherOx for atherosclerotic $26,250.00 $72,500.00 Corporation cardiovascular disease. PoIC Inhibitors as Novel herapeutics for Antibiotic- Crestone, Inc $8,900.00 $138,840.00 Resistant Gram-Positive Infections REP3123 as a Novel Therapeutic Crestone, Inc. for Treatment of Clostridium $37,233.00 $60,885.00 difficile Infection A nonmetalic, Shape Memory EndoShape, Inc Polymer AAA Endograft to $130,608.00 $109,080.50 expand patient applicability, etc An SMP fallopian tube occlusion EndoShape, Inc device for non-surgical, $61,230.00 $99,954.00 permanent female sterilization, etc Development of a Coagulation Eveia Medical,Inc $244,479.25 Test for Clinic and Home Use GI-6207 as active immunotherapy GlobeImmune, Inc. for the treatment of CEA over- $241,869.50 $2,609.74 expressing cancers. GI-4000 as active immunotherapy GlobeImmune, Inc. for the treatment of mutated-Ras $244,479.24 cancers. GI-5005 as active immunotherapy Globelmmune, Inc. for the treatment of chronic $244,479.24 hepatitis C virus infection Fully Deleted Helper-Virus Greffex, Inc Independent Vectors as Vaccine $244,479.24 Carriers Hiberna Corporation Python Project $63,550.50 $33,591.50 ICVRX LLC CNS Site Specific Medication $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Delivery to Improve Outcomes for Refractory Epilepsy Patients Recombinant attenuated Inviragen, Inc $113,013.50 $131,465.75 chikungunya vaccine A recombinant, tetravalent Inviragen, Inc $244,479.25 vaccine to prevent dengue fever Protection of Tissue & Organ Isogenis, Inc $244,479.24 Transplants by Engineered Veto Noninvasive CO-Oximeter for Kestrel Labs, Inc Measuring Multiple Hemoglobin $244,479.25 Species Biomimetic Approach for the Lanx, Inc. Delivery of Bone Morphogenic $119,000.00 $125,479.25 Proteins Frogg Dynamic Compression Leap Frogg, LLC $189,969.50 $54,509.75 system (FDCS) Novel bone-targeted therapeutics MBC Pharma Inc $244,479.24 for cancer-induced bone disease Rigid and Articulating-tipped Micro-Imaging (flexible), disposable CMOS- $244,479.24 Solutions LLC based endoscopes Deveolpment of a Novel Rapid MicroPhage Inc $244,479.24 MRSA/MSSA Blood Culture Test Development of a Novel and MicroPhage, Inc Rapid Skin Tissue Antobiotic $244,479.24 Susceptibility Test Developing microRNA based Miragen therapies to transform the course $244,479.25 Therapeutics, Inc. of Cardiovascular Disease Myocept, Inc Myocept Project $78,224.16 $166,255.09 N30 Inhibitors of S-nitrosoglutathione Pharmaceuticals, $244,479.24 reductase (GSNOR) LLC Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Ocutronics, LLC OC100 $76,411.00 $168,068.25 Otologics, LLC Carina Project $244,479.25 Parascript, LLC AccuDetect $244,479.25 PARE Surgical, Inc. Flexible Endoscopic Instruments $127,457.00 $117,022.24 Pathogen Systems, Pathogenic Microbe Detection $244,479.25 Inc. Device Novel Delivery of Drugs and PharmaJet Inc Vaccines Enabled by Intradermal $91,876.26 $152,602.99 Jet Injection Technology Point-of-care(POC) diagnostic Precision Photonics device for critical infectious $244,479.24 Corp disease panel testing High Pressure Refolding of ProFoldRx, Inc dba protein Aggregates for Novel $244,479.25 BaroFold, Inc Therapeutics and Biosimilars Protectstyle Preventative Therapeutic $244,479.24 Corporation Antimicrobial Textiles LC/MSMS Bioassay for Pyxant Labs Inc $27,703.45 Physiologic Iron Biomarkers Trastuzumab Bioanalytical Assay Pyxant Labs, Inc for Regulatory Development $71,029.59 Studies Quest Product Cardiac Sync Technology for Development $244,479.25 Improved CPR Therapy Corporation Quest Product MicroFlex Endescopes for Development $244,479.25 Improved Diagnosis and Surgery Corportaion Rocky Mountain Adtivated Thermoset Adhesive $244,479.25 Biosystems, Inc. for Wound Closure Skin Patch for Drug Delivery after Rocky Mountain Controlled Stratum Corneum $29,281.00 $73,049.00 Biosystems, Inc. Ablation. Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 A Simple Blood Test for the Early Somalogic Inc $130,028.00 $114,451.25 Detection of Mesothelioma A Simple and inexpensive Blood SomaLogic, Inc Test for the Early Detection of $244,479.25 Non-Small Cell Lung Cancer Novel Therapeutics for the SomaLogic, Inc $244,479.25 Treatment of Cancer A Simple and inexpensive Blood SomaLogic, Inc Test for the Early Detection of $244,479.25 Ovarian Cancer A Simple Blood Test for the Early SomaLogic, Inc. $875.00 $193,137.00 Detection of Pancreatic Cancer Novel Neuroprotective and SomaLogic, Inc. Neuroregenerative Therapeutics $244,479.25 for Neurodegenerative Diseases Aggregation of Blood Test for Multiple Diseases into an SomaLogic,Inc. $244,479.25 Inexpensive Multiplexed Diagnostic A Simple and Inexpensive Blood SomaLogic. Inc Test for the Early Detection of $86,685.50 $157,793.75 Chronic Kidney Disease Sophono Alpha 1 magnetic Sophono Inc $82,120.82 $162,358.43 hearing prosthesis Source Precision Develop & Validate a Breast Medicine Inc dba Cancer Early Detection Molecular $38,836.00 $205,643.25 Source MDx Diagnostic Test Source Precision Develop & Validate a Molecular Medicine Inc dba Diagnostic Test Predictive of $244,479.25 Source MDx Prostate Biopsy Outcomes Source Precision Develop & Validate a Lung Medicine Inc dba Cancer Early Detectin Molecular $244,479.25 Source MDx Diagnostic Test St Cardio Z6 Cardiac Stimulator $186,138.50 $58,340.75 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Technologies St. Renatus LLC Nasal Mist Dental Anesthetic $244,479.25 Whole Genome Sequencing for Sundance Diagnostic Test for Suicidal $244,479.25 Diagnostics, Inc Ideation Surefire Medical, Paladin Embolization Infusion $12,576.00 $231,903.25 Inc System Vitality ™ and Vanguard ™ heart ValveXchange, Inc $244,479.24 valve systems Development of an oral delivery Ventria Bioscience $111,500.00 $71,000.00 platform biologics Prevention of Antibiotic Ventria Bioscience $33,938.50 $210,540.75 Associated Diarrhea Treatment for spontaneous Ventria Bioscience $244,479.25 bacterial peritonitis HELP- Human Ex-Vivo Lung Vitrolife Inc $244,479.24 Preservation and Reconditioning

Connecticut $13,847,706.16

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Achillion Pharmaceuticals, ACH-2881 $166,432.50 $78,046.75 Inc. Achillion Pharmaceuticals, ACH-1625 $244,479.25 Inc. Achillion Pharmaceuticals, ACH-2684 $244,479.25 Inc. Achillion Pharmaceuticals, Elvucitabine $131,052.00 $113,427.25 Inc. Achillion Pharmaceuticals, ACH-2928 $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc. Achillion Pharmaceuticals, ACH-1095 $244,479.25 Inc. Achillion Pharmaceuticals, ACH-702 $244,479.25 Inc. Achillion Pharmaceutics, ACH-2892 $244,479.25 Inc. Penicillin Minor AllerQuest, LLC $244,479.24 Determinants (PMD) AllerQuest, LLC PrePen $51,598.50 AMARIN PHARMACEUTICALS, AMR101 $244,479.25 INC. Applied Spine Stabilimax Spine $244,479.24 Technologies, Inc Stabilization System Nanoparticulate Vaccine Artificial Cell Against Respiratory $244,479.25 Technologies Syncytial Virus Nogo receptor (NgR)protein Axerion Therapeutics therapy to treat chronic $244,479.25 spinal cord injury Cellular Prion Protein (PrP) Axerion Therapeutics as a treatment for $122,818.50 Alzheimer's Disease Icotinib, a novel drug for the Beta Pharma, Inc treatment of EGFR-mutated $87,192.09 $157,287.16 cancer diseases. Biodel Inc Smart Basal $244,479.25 Biodel, Inc VIAject $244,479.25 Biodel, Inc. Improved Glargine $244,479.25 Biodel, Inc. Glucagon $244,479.25 Biodel, Inc. VIAtab $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Huperzine for the Treatment Biomedisyn Corporation $21,405.80 $137,070.98 of Schizophrenia Novel riboswitch-targeting treatments for multi-drug BioRelix, Inc. $244,479.24 resistanr and hypervirulent bacteria Prescription Peripheral Biowave Corporation Neuromodulation Pain $48,055.00 $95,700.00 System Discovery of the Brain Temperature Tunnel ( BTT) Brain Tunnelgenix and the world's first non- $244,479.24 Technologies Corp invasive brain temperature monitoring device Development of A Novel Cara Therapeutics Inc $244,479.24 Analgesic, CR845 Non-Invasive CAS Medical Systems Inc $244,479.25 Cerebral/Tissue Oximetry MEK Inhibitor for Cheminpharma LLC $59,362.50 Treatment of Cancer Cytogel Pharma, LLC Cyt-1010 $244,479.24 CyVek, Inc (FKA CyVek, CyVek: Enabling $21,281.00 $223,198.25 LLC) Proteomics PhyzioType System:Improve Treatment Genomas, Inc Outcome of Drugs for $156,399.00 $88,080.24 Mental Illness & Heart Disease AQUA technology HistoRx Inc Dianostics Enabling Better $244,479.25 Treatment Decision Ikonisys Inc OncoFISH cervical test $244,479.24 IVFonline.com DBA Develop and make liver $81,500.00 $63,000.00 Zenith Biotech, LLC biomatrix for extended Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 hepatocyte functionality for drug discovery Novel Predictive Model for IVFonline.com DBA Hepatocytes Toxicity in $95,000.00 $107,500.00 Zenith Biotech, LLC Preclinical Drug Screening Scalable Human Neural IVFonline.com DBA Stem Cells for High $122,500.00 $118,000.00 Zenith Biotech, LLC. Throughput Screening Kolltan Pharmaceuticals, RTK Project No. 5 $244,479.25 Inc Kolltan Pharmaceuticals, RTK Project No.4 $244,479.25 Inc Kolltan Pharmaceuticals, RTK Project No.3 $244,479.25 Inc Kolltan Pharmaceuticals, RTK Project No. 1 $244,479.25 Inc. Kolltan Pharmaceuticals, RTK Project No. 2 $244,479.25 Inc. Kolltan Pharmaceuticals, RTK Project No. 6 $244,479.25 Inc. Development of Tigapotide Kotinos Pharmaceuticals (PCK3145) as novel therapy $196,017.00 $48,462.24 Inc for prostate cancer Ganaxolone for Adjunctive Marinus Pharmaceuticals Treatment of Partial Onset $244,479.25 Inc. Seizures Ganaxolone for Treatment Marinus Pharmaceuticals of Posttraumatic Stress $244,479.25 Inc. Disorder (PTSD) DIABETES REMOTE MEDADHERENCE LLC $244,479.25 MANAGEMENT SYSTEM Biomarkers for the Molecular Neuroimaging Diagnosis of Parkinson's $222,854.00 $21,625.25 LLC Disease Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Biomarkers for the Molecular Neuroimaging Diagnosis of Alzheimer $202,974.50 $41,504.75 LLC Disease A small molecule agonist for enhancing alvelolar bone Myometrics, LLC $10,043.50 $1,230.50 regeneration in toothextraction rhCFHp - Recombinant Optherion, Inc $244,479.24 Human Factor H Protein Sciences FluBlok $244,479.25 Corporation Protein Sciences PanBlok $244,479.25 Corporation RIB-X RX-04 Completely New PHARMACEUTICALS Antibiotics to Treat Multi- $244,479.25 INC drug Resistant Infections Delafloxacin: a broad RIB-X spectrum antibiotic for the PHARMACEUTICALS, $244,479.25 treatment of multi-drug INC. resistant infections RX-02: Enhanced RIB-X Marcrolides for Treating PHARMACEUTICALS, $244,479.25 Drug-Resistant Community INC. Infections Radezolid: A Novel RIB-X Oxazolidinone Antibiotic PHARMACEUTICALS, $244,479.25 for Resistant Gram-positive INC. Infections Guiding Cancer Therapy by Sibtech Inc $244,479.25 imaging VEGF Receptors AirSeal ® Trocar & SurgiQuest, Inc. $244,479.25 Cannula System The Bronx Project Inc The Bronx Project $26,739.00 $217,740.25 The Institutes for Arginase Inhibitor Program $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceutical Discovery LLC The Institutes for Pharmaceutical Discovery Urinary Peptide Assay $244,479.24 LLV

Delaware $1,907,078.03

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of INCB24360 as Incyte Corporation a treatment for cancerous solid $244,479.25 tumors. Development of INCB7839 as a Incyte Corporation treatment for metastatic breast $244,479.25 cancer. Development of INCB18424 as Incyte Corporation $244,479.25 a treatment for myelofibrosis Lake Biosciences Nerve Stimulation for the $217,500.00 LLC Treatment of Stroke Haptoglobin Type as a Lake Biosciences Prognostic Test for Vasospasm $102,500.00 LLC After Subarachnoid Hemorrhage OrPro ORP100 Inhaled Mucolytic $24,000.00 Therapeutics, Inc Octreotide Phytate for QPS Holdings LLC $129,669.47 $104,738.52 Injectable Suspension (OPIS) QPS Holdings, Leuprolide Mesylate for $81,053.15 $110,893.23 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC Injectable Suspension (LMIS) Design, synthesis and QPS Holdings, development of highly selective $96,431.23 $62,375.43 LLC matrix metalloprotease inhibitors Respiratory Management Aerosol-Dispersion $6,747.22 $237,732.03 Technology, Inc

District of Columbia $518,667.34

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Clinical Trial of Liver Health Bionutrigen Inc. Formulation of Ingredients Derived $43,055.25 From Edible Plant Sources Branched-chained aminotransferase- 1 (Bcat-1) inhibitors as therapeutic Ergon products for the treatment of $6,494.84 $15,015.00 Pharmaceuticals metastatic cancer and rheumatiod arthritis Foligo Foligo 002 & OvaDetect $57,364.50 Therapeutics Inc Onconon LLC Onconon LLC $12,132.50 $12,000.00 Aloe Therapeutic Protein Production Thegreencell Inc $57,126.00 $71,000.00 Platform and Delivery System Warner OB/GYN Green Pregnancy $244,479.25 Associates, PC Florida $26,057,929.04

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development and .Decimal Inc. Commercialization of Electron $144,260.68 $77,112.17 Conformal Therapy Bolos Accentia Revimmune ReBOOT for the $75,187.50 $169,291.75 Biopharmaceuticals Inc treatment of Multiple Sclerosis Accu-Break Pharmaceuticals Inc Accu-Break Wafarin $244,479.25 and Subsidiaries Novel therapeutic strategies for Adhaere preserving vascular access graft $45,390.00 Pharmaceuticals Inc in hemodialysis patients Altor QTD Project #5 - Altor Bioscience Development of IL-15 $1,631.65 $132,923.11 Corporation Superagonists for Cancer Altor QTD Project #2 - Altor Bioscience Development of ALT-802 for $163,352.23 $81,127.01 Corporation Cancer Altor QTD Project #1- Altor Bioscience Development of ALT-801 for $244,479.24 Corporation Cancer Altor QTD Project #6 - Altor Bioscience Development of DPC-1528, an $171,144.86 $19,428.32 Corporation Antisense Drug for Acne ALtor QTD Project #3 - Altor Bioscience Development of ALT-836 for $60,512.03 Corporation ALI/ARDS AOI Medical Inc Ascendx Spine Technology $244,479.25 Applied Genetic Alpha One Trial $244,479.25 Technologies Corp Applied Genetic Achromatopsia Project $244,479.25 Technologies Corp Applied Genetic XLRS Project $7,446.74 $237,032.51 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Technologies Corporation Applied Genetic Technologies LCA Trial $188,664.43 $55,814.82 Corporation Novel stratefies for the treatment Aquatrove Biosciences of vaginal dryness in trying to $33,506.00 $95,000.00 Inc conceive patients Aspiration Medical FoodDivurzn (FD) Weight $244,479.24 Technology LLC Management System Atlas Spine, Inc. APELO $244,479.24 Biomarkers of Brain Injury: Banyan Biomarkers, Magnitude, Secondary Insults $244,479.25 Inc. and Outcome Bioheart, Inc. MARVEL Trial REGEN Trial $244,479.24 Novel Peptidomimetic for Bio-Nucleonics Inc Unstable Atherosclertic Plague $244,479.24 detection and differentiation. Bio-Nucleonics Inc Rubidium $244,479.25 Gallium-68/Germanium-68 Bio-Nucleonics, Inc. $244,479.25 Radionuclide Generator Bio-Nucleonics, Inc. Gynocyte $244,479.25 BiovaxID - a patient-specific Biovest International vaccine for B-cell Non- $244,479.25 Inc. Hodgkin's Lymphoma Catalyst CPP-109 For The Treatment Of Pharmaceutical $244,479.24 Stimulant Dependence Partners, Inc Catalyst CPP-115 for the treatment of Pharmaceutical various forms of Epilepsy and $110,454.66 $134,024.58 Partners, Inc stimulant dependence CHS RESOURCES, TOPICAL TREATMENT FOR $60,442.50 $184,036.75 LLC SKIN CANCER AND OTHER Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 PRE-CANCEROUS CONDITIONS. SpectraWave Blood and Blood Claro Scientific, LLC $244,479.25 Culture Diagnostic System Concordia Salirasib $244,479.24 Pharmaceuticals, Inc. Biohybrid Device for Treatment Converge Biotech Inc $94,570.00 $84,932.00 of Diabetes Convergent eToco Maternal Fetal $25,162.00 $9,564.50 Engineering Monitoring Convergent ID-Cap $28,385.50 Engineering Inc. CORD:USE Cord Allogeneic Cord Blood Banking $244,479.25 Blood Bank, Inc Cytorex Biosciences, Cytoreg® $244,479.25 Inc. Isolation and Synthesis of Dharma Biomedical, Bioactive Molecules from $48,612.54 $52,025.56 LLC Commiphora wightii Bark Oleoresin Electrostim Medical Iglucotouch $244,479.24 Services Inc. dba EMSI Development of diagnostic EnCor Biotechnology biomarkers of CNS damage and $85,303.50 $159,175.75 Inc. disease states A New Oral Therapy for Envoy Therapeutics, Treating Cognitive Deficts $10,827.50 $233,651.75 Inc Associated with Schizophrenia A Novel, Non Dopamine-Based Envoy Therapeutics, oral Therapy for Parkinson's $20,437.50 $224,041.75 Inc. Disease An Oral Therapy for Parkinson's Envoy Therapeutics, Disease designed to mimic Deep $20,437.50 $224,041.75 Inc. Brain Stimulation Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 eTect LLC ID Cap $21,539.06 $173,403.94 Eyetech Inc The Macugen ER Project $141,639.50 $102,839.74 Florida Cancer Care Radiation Therapy Oncology $244,479.25 Network, LLC management Program A Rapid Point-of-Care GeneEx, Inc Diagnostic for Active $244,479.25 Periodontal Disease A Rapid Point-of-Care GeneEx, Inc Diagnostic for Active Group A $244,479.25 Streptococcal Pharyngitis A ultra-pure inhalede Nitric Oxide drug for chronic treatment GeNO LLC $244,479.24 of mutiple pulmonary diseases for unmet medical needs GLG-202 Manufacturing and GlG Pharma LLC IND-Enabling Pre-Clinical $244,479.25 Toxicology Studies GLG-401 Manufacturing and GLG Pharma LLC IND-Enabling Pre-clinical $244,479.25 Toxicology Studies GLG-302 Manufacturing and GLG Pharma, LLC IND-Enabling Pre-Clincal $244,479.24 Toxicology Studies Heat Biologics Inc HS-System $82,044.68 $162,434.56 High Clinical Relevancy Point of Imigene Inc Care Blood Borne Bacteria $91,800.00 $152,679.25 Detection a Novel Drug/Medical Device InnFocus $244,479.24 Treatment for Glaucoma Intezyne Technologies, Polymer Polyplex $52,231.88 $43,059.02 Inc Intezyne Technologies, Ivect Technology $244,479.24 Inc Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Colorimetric Breath Analyzer iSense, LLC $156,605.83 $87,873.42 for Lung Cancer Diagnosis Mago4S and diagnostic ELISA Ivax Diagnostics, Inc. $244,479.25 and IFA assays LifeSync Corporation WECGII $244,479.25 LINGUAFLEX TONGUE LINGUAFLEX, INC $244,479.24 RETRACTOR (LTR) HiFLO HFT with Airway Mergenet Medical, Inc $200,174.50 $44,304.74 Pressure Monitoring Combining inhibitors of Metabogenix glycolysis with cancer $244,479.25 Technologies, Inc chemotherapy to increase treatment efficacy Fenofibrate induces endoplasmic Metabogenix reticulum stress leading to $244,479.25 Technologies, Inc. selective toxicity in multiple myeloma cells ImmuneFx ™ Cancer Morphogenesis, Inc $161,560.50 $82,918.74 immunotherapy NanoDOX 1% Doxycycline Nanotherapeutics Inc Monohydrate Hydrogel for the $91,995.13 $98,718.24 treatment of Chronic Wounds NanoBUP Buprenorphine/Naloxone Nanotherapeutics, Inc. $74,617.68 $169,861.57 Capsule for the Treatment of Opiod Addiction NanoFOVIRTM Inhaled Nanotherapeutics, Inc. Cidofovir Dry-Powder $244,479.25 Formulation for Postexposure NonoGENT™ Gentamicin Sulfate Inhalation Powder for Nanotherapeutics, Inc. post-exposure prophylaxix of $244,479.25 pneumonic plague (Yersinia pestis) Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 NeoGenomics Inc Melanoma FISH Test $244,479.24 NeoGenomics Barrett's esophagus FISH Test $130,000.00 Laboratories Inc NTMD for treatment of Neuro Assisted Comorbid Substance abuse $234,715.00 $9,764.25 Recovery Inc disorders Nutra Pharma Development of Recet for the $244,479.25 Corporation treatment of pain Serum MicroRNAs as Ocean Ridge Prognostic Markers of $34,873.00 $34,562.00 Biosciences, LLC Emphysema OPKO Instrumentation, LLC a Aquashunt $244,479.25 single member LLC of OPKO Health, Inc OPKO Pharmaceuticals Rolapitant $244,479.25 LLC OPKO Pharmaceuticals LLC a single member Bevasiranib $244,479.25 LLC of OPKO Health, Inc Optima Neuroscience, High Performance Automated $244,479.25 Inc. Seizure Detection Novel Antibiotics for the Oragenics Inc Treatment of Healthcare $132,041.27 $112,437.97 Associated Infections Rapid and Sensitive Id. Of Novel Diagnostic Biomarkers for Oragenics, Inc $186,971.87 $57,507.37 Cancer for Cancer and Infectious Diseases Prevention of Tooth Decay using Oragenics, Inc $52,206.00 $192,273.24 SMaRT Replacement Therapy Orbus Neich Medical, Combo Bio-engineered $244,479.24 Inc Sirolimus-eluting Stent (Combo Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Stent) Development of Oxabact(R) for OxThera, Inc the Treatment of Primary $244,479.24 Hyperoxaluria Prevention of heparin-induced ParinGenix, Inc. thrombocytopenia and associated $26,693.00 $125,648.00 thrombosis Development of a treatment of ParinGenix, Inc. pediatric protein-losing $19,938.50 $204,564.50 enteropathy TAME-DX: A blood based Pioma Inc diagnostic for evidence-based $63,885.00 $180,594.25 treatment of brain cancer. Precision Medical Flow Control Device $105,038.00 $139,441.25 Devices, Inc Development of Oncofetal Antigen/immature Laminin Quantum Receptor Protein (OFA/iLRP) $66,922.72 $137,628.09 Immunologics Inc peptides for the treatment of cancer A Phase I/II Study with Autologous Dendritic Cells Quantum Loaded with Oncofetal $244,479.25 Immunologics Inc Antigen/iL RP in Patients with Metastatic Breast Cancer Quantum Developmental of Monoclonal $59,506.57 $137,628.09 Immunologics, Inc Antibodies against OFA/ILRP Quick-Med NIMBUS Wound $244,479.25 Technologies, Inc Dressings/Drain (DWD) AMID Stapler for Simplified SafeStitch Medical, Stapled Lichtenstein Procedure $244,479.25 Inc. and Subsidiaries (SSLP) Ketogenic diet in a pill with Seraph antioxidant activity for control of $10,750.00 $35,000.00 Pharmaceuticals epileptic seizures Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 IV Methamphetamine for Stroke Sinapis Pharma Inc and other acute ischemic $186,112.00 $58,367.24 conditions INTERNAL JOINT SKELETAL STABILIZER FOR THE $134,395.88 $110,083.36 DYNAMICS LLC ELBOW Skeletal Dynamics Align Radial Head Arthroplasty $152,094.98 $92,384.26 LLC System Syntheon LLC Milwaukee Project $244,479.25 Evaluation of the kinase inhibitor TTT-3002 for TauTaTis, Inc $109,391.50 $135,087.74 neurodegenerative diseases and cancer Tele Home Care The Tele Home Care Solution $152,410.83 Solutions Company Project Tigris Pharmaceuticals, AFP-464 $244,479.25 Inc Tigris Pharmaceuticals, GGTI-2418 $244,479.25 Inc. Treatment for Demodex Tissue Tech, Inc Infestation by Active Ingredient $31,783.50 $162,450.50 from Tea Tree Oil Novel Therapeutics based on Tissue Tech, Inc Amniotic Membrane Extract and $164,862.00 $79,617.25 its Purified Component development of a Novel Device Tissue Tech,Inc to deliver Therapeutics to Ocular $51,019.50 $90,106.00 Surface Novel Ex Vivo Expansion of Tissuetech,Inc $189,002.50 $55,476.75 Limbal stem Cells X-82 VEGFR/PDGFR small Tyrogenex Inc $155,311.00 $89,168.25 molecule kinase inhibitor Device Strategies for the Venx LLC $39,549.00 $165,950.50 management of Venous Stasis Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Winprobe Corporation The Ultravision Research Project $244,479.25 Xcelience SKL-10406 $61,698.47 $17,564.24 Xcelience Holdings PX-866 $39,831.05 $27,468.85 LLC Xcelience Holdings CTO $18,562.47 $7,738.27 LLC Xcelience Holdings, DAS-181 $21,073.91 $54,300.04 LLC Xcelience Holdings, AM-152 $53,076.00 LLC Xcelience Holdings, CC-930 $156,629.47 $87,849.78 LLC Xcelience Holdings, AT-406 $26,236.82 $13,418.48 LLC Xcelience Holdings, OSI-296 $50,273.75 $28,662.85 LLC Xcelience Holdings, Acuracet $165,781.99 $78,697.26 LLC Xcelience Holdings, Duodopa $22,118.87 LLC Xcelience Holdings, AP24534 $52,264.27 $192,214.98 LLC Xcelience Holdings, Alpha-tocherolquinone $60,602.00 $183,877.25 LLC Xcelience Holdings, Loperamide $69,003.32 $54,202.23 LLC Xcellience Holdings, PN-3602 $89,974.23 $143,487.74 LLC Xcovery Holding X-379 c-Met small molecule $35,661.50 $208,817.75 Company LLC kinase inhibitor Xcovery Holding x-387 mTor (TORC1/TORC2) $177,961.50 $66,517.75 Company LLC small molecule kinase inhibitor Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Xcovery Holding X-396 (ALK) small molecule $41,638.00 $202,841.25 Company LLC kinase inhibitor One Breath: a non-invasive Xhale diagnostics, Inc glucose self-monitoring system $244,479.25 using exhaled breath Next generation evidential Xhale, Inc. breath-based ethanol sensor to $69,604.00 $108,888.00 diagnose and treat alcohol abuse

Foreign $733,437.74

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Enobia Pharma, ENB-0040 $244,479.25 Inc. mtm laboratories Clinical evaluation of the CINtec $244,479.24 AG Histology Kit Placenta derived cells (PLX) for Pluristem the treatment of patients suffering $244,479.25 Therapeutics Inc. from PAD and CLI

Georgia $15,165,946.20

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Discovery of monocional Abeome Corporation antibodies for cancer therapeutic $244,479.24 and biomarker development Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Project APM01050 - Patient Access Product friendly delivery of glucagon for $207,410.00 $37,069.25 Marketing, LLC emergency treatment of severe hypoglycemia AerovectRx disposable drug AerovectRx cartridge (DDC) compatibility and $32,200.00 $90,800.00 Corporation stability CALM-UC Clinical Assessment of Alaven Low Dose Mesalamine in $244,479.25 Pharmaceutical LLC Uncerative Colitis Alimera Sciences Iluvien for the Treatment of $244,479.25 Inc. Diabetic Macular Edema ALTEA ENOXPARIN SODIUM $244,479.25 THERAPEUTICS PASSPORT ® SYSTEM ALTEA EXENATIDE THERAPEUTICS $244,479.25 PASSPORT(R)STEM CORP Altiris Therapeutics, ALT-118 $244,479.25 Inc. Apeliotus Vision Diagnostic for Age-Related $96,546.00 $147,933.25 Science, Inc. Macular Degeneration Argent Diagnostics High Sensitivity Nano-Optical $6,222.00 $28,904.50 Inc Method to Detect Measles Virus Atlanta Catheter Prototype development and Pre- Therapies, Inc Clinical testing of Occlusion $160,112.00 $84,367.24 (ACT) Perfusion Catheter Axona Inc. (dba Calpain inhibitors for Cancer $64,939.50 $87,500.00 AxoTect, Inc.) Related Neuropathies Cardiac regeneration CardioGold Project $174,527.00 $69,952.25 Technologies, LLC CardioMEMS Heart Failure CardioMEMS Inc System (CardioMEMS HF- $244,479.25 system) Carticept Medical, Navigator™ Delivery System $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Autologous Stem Cell Therapy Cell Constructs Inc $15,787.50 $108,808.00 Dressing for Chronic Wounds Safety and Efficacy of Embozene CeloNova Microspheres for Uterine Artery $244,479.25 BioSciences, Inc. Embolization for SUF Safety and Efficacy of a Newly CeloNova Designed Coronary Stent Coated $244,479.25 BioSciences, Inc. with Polyzene-F Target Drug Delivery Device: CeloNova OncoZene Drug Eluting $244,479.25 BioSciences, Inc. Microspheres Celtaxsys Inc Chemorepulsion Project $244,479.24 CorMatrix ECM Emulsion Injection Therapy $244,479.24 Cardiovascular Inc to Treat Myocardial Ischemia CorMatrix Reduction of Postoperative Atrial $170,526.57 $73,952.67 Cardiovascular Inc Fibrillation using Co-Matrix ECM CorMatrix Tissue Regenerating ECM for $108,602.13 $135,877.11 Cardiovascular Inc Vascular Applications New method to decellularize and CorMatrix sterlize Xenografts for optimized $220,709.83 Cardiovascular Inc host integration CorMatrix Drug-eluting ECM for Pericardial $213,668.94 Cardiovascular Inc Reconstruction Effcon Laboratories Alcohol Abuse Treatment $2,730.00 $167,775.00 Inc Effcon Laboratories, Glaucoma Project $76,540.00 $167,939.25 Inc. Effcon Laboratories, Lice Project $8,190.00 $236,289.25 Inc. Effcon Laboratories, Dystonia Project $22,800.50 $221,678.75 Inc. Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Envisionier Medical endogo®HD, endoscopic imaging $159,992.00 $48,504.50 Technologies, Inc system Femasys Inc. FemVue Systems $244,479.25 FemBloc Permanent Contraceptive Femasys Inc. $244,479.25 System Development of therapeutic HIV GeneCure LLC $244,479.24 vaccines GeoVax, Inc HIV/AIDS Vaccine $244,479.24 High-specificity affinity reagents Glycosensors and for N-glycosylation site mapping $33,307.98 $84,709.16 Diagnostics, LLC and glycomics Guided Cost Effective Noninvasive $244,479.24 Therapeutics, Inc. Cervical Cancer Detection System Health Discovery Health Discovery Corporation's $109,323.02 $135,156.23 Corporation SVM and RFE-SVM Technology ICON Interventional ICON® NULOY® Drug Eluting $244,479.25 Systems, Inc. Stent (DES) Platform Iconic Therapeutics, Iconic Therapeutics, Inc.: $244,479.25 Inc. Development of I-con1 Inhibikase Host-targeted antiviral for seasonal $76,207.50 $168,271.74 Therapeutics Inc and pandemic influenza Inhibikase Antiviral treatment for progressive $61,799.50 $182,679.74 Therapeutics Inc multifocal leukoencephalopathy Antiviral treatment for Inhibikase polyomavirus-associated $61,799.50 $182,679.74 Therapeutics Inc nephropathy INHIBITEX, INC FV-100 $244,479.24 INHIBITEX, INC INX-189 $244,479.24 InVasc Therapeutics, INV-140 Series $137,557.00 $106,922.25 Inc LEXICOR NEBA- $244,479.25 MEDICAL M(NEUROPSYCHIATRIC EEG- Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 TECHNOLOGY, BASED ASSESSMENT AID- LLC Major Depressive Disorder) Lexicor Medical NEBA (neuropsychiatric eeg- $244,479.24 Techonology LLC based ADHD assessment Aid Degenerative Disease models in Luminomics Inc $184,394.18 $60,085.07 zebrafish PneumoniaCheck-A Therapeutic MD Innovate, Inc $244,479.25 Discovery Project Metabolic Testing for Early Metabolic Testing Detection & Treatment of Heart $244,479.24 Services, Inc. Disease MiMedx Group, Inc. CollaFix Therapeutic Delivery $244,479.25 Neuroprotection by pH Sensitive NeurOp, Inc Antagonists to the NMDA NR2B $198,809.00 $45,670.25 Receptor RVX-108 (CDP-CB) IND 105,579 Revogenex, Inc. $244,479.25 Chlorideazepoxide Hydrochloride RVX-100 (L-HS) IND 105,364 Revogenex, Inc. $244,479.25 Hysocyamine Sulfate RVX-109 (TRML) Tramadol Revogenex, Inc. $204,277.25 $40,202.00 Hydrochloride for Injection (IV) Salutria Development of Succinobucol to Pharmaceuticals Reduce Cardiovascular Risk in $244,479.24 LLC Type 2 Diabetes Patients dermaPace FDA IDE study for Sanuwave Inc treating chrinic diabetic Foot $244,479.24 ulcers Sebacia, Inc Sebacia Acne Therapy $244,479.24 Serrg Savannah Inc CB-01-02/01 (Cosmo) $5,241.50 Serrg Savannah Inc PTK 0796-CSSSI-0804 $26,206.50 Serrg Savannah Inc NXL 103/2002 (Novexel) $20,965.00 Serrg Savannah Inc GSK TOC110978 $7,748.50 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 SoloHealth Health and Wellness SoloHealth, Inc $244,479.25 Kiosk Southeast Regional CB-01-02/01(Cosmo) $2,305.00 Research Group Inc Southeast Regional PTK 0796-CSSSI-0804 $13,825.00 Research Group Inc Southeast Regional GSK TOC110978 $4,608.50 Research Group Inc Southeast Regional CE06-300(Cempra ABSSSI) $9,216.50 Research Group, Inc Southeast Regional CVRX $18,433.00 Research Group, Inc. Tissue Regeneration Software $126,172.00 $118,307.25 Technologies, LLC Transfusion & Transplantation Aegis Automated Blood Analyzer $198,769.50 $45,709.75 Technologies INC. Velocity Medical Imaging for Treatment Assessment $244,479.25 Solutions, LLc and Response to Cancer Therapies Development of a Novel Visioneering Therapeutic to Treat and Prevent $244,479.25 Technologies, Inc Myopia DETECT - an immersive solution Zenda Technologies, for neuropsychological testing in a $167,354.00 $77,125.25 Inc. primary care setting The Development of Broadly Zirus Inc Active and Orally Bioavailable $244,479.24 Antiviral Drugs

Hawaii $4,494,694.93

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 CDX-085 A novel drug from Cardax Cardax Pharmaceuticals, for $244,479.25 Pharmaceuticals, Inc. inflammatory Disease Cellular Bioengineered Artificial Cornea $244,479.24 Bioengineering Inc for Restoration of Vision Cellular Technology for Secure and Bioengineering Inc. Accurate Delivery of $244,479.24 (CBI) Therapeutics and Dosage Treatment and Removal of Cellular Absorbed Radioactive and $244,479.24 Bioengineering, Inc. Carcinogenic Chemicals Dengue Recombinant Subunit Hawaii Biotech, Inc $244,479.24 Vaccine West Nile Recombinant Subunit Hawaii Biotech, Inc $244,479.24 Vaccine Lifebed/Lifegurney Patient Hoana Medical Inc $244,479.25 Vigilance System Implementation of novel Nanopoint Inc. microfluidics platform for $244,479.24 infertility treatment Oceanit Laboratories Nanovector Drug Delivery $13,150.00 $74,808.50 Inc System Oceanit Laboratories, Laser Actuated Transcranial $59,566.50 $30,865.00 Inc Hemostasis (LATCH) OCEANIT RAPID ADVERSE LABORATORIES, IDENTIFIER FOR DRUG AND $244,479.25 INC. EVALUATION RESOURCE Identification and evaluation of a Pacific Biotech, LLC $148,891.50 $95,587.74 potent angiogensis inhibitor Discovery & Development of Panthera Biopharma Anti-Viral small molecule $152,793.50 $41,360.50 LLC therapeutics for flaviral infections. Panthera Biopharma Development of a Multi-Valent $138,685.00 $22,898.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC recumbinant subunit for filovirus infections Discovery & Development of Panthera Biopharma small molecule Anti-Toxin $244,479.25 LLC Therapeutics for Anthrax DISCOVERY AND DEVELOPMENT OF SMALL PANTHERA MOLECULE ANTI-TOXIN $193,647.50 $50,831.75 BIOPHARMA, LLC THERAPEUTICS FOR BOTULISM Skai Technologies Development of Bioengineered $48,900.00 LLC Soft Tissue Graft Technology STI Medical System, Colon Cancer (Colonocad) $175,582.50 $68,896.75 LLC Program ULTRASIGHTHD® COLPOSCOPY SYSTEM w/ STI Medical IMAGESENSE™ $244,479.25 Systems, LLC DIAGNOSTIC ENHANCEMENT TECHNOLOGIES Poplulation Health Management TEAMPRAXIS, (PHM) Module of Allscripts $100,313.50 $144,165.75 LLC Clinical Quality Solution (CQS) Tissue Genesis / Adipose derived Tissue Genesis, Inc. cell therapy and regenerative $244,479.25 medicine

Illinois $13,953,940.11

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ABS-21: Schizophrenia AbaStar MDx Inc Diagnostic Product $52,600.00 $191,879.25 Development Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Early, Accurate Detection and Abiant Inc. Measurement of Therapeutic $38,826.50 $59,270.00 Response for Dementias Academic Development of an Intravenous $4,500.00 $131,500.00 Pharmaceuticals Inc Formulation of Metolazone Aqueous Amiodarone for Academic Treatment & Prevention of $76,848.00 $85,300.00 Pharmaceuticals LP Ventricular Tachycardia & Fibrillation Acura AveRox $50,000.00 $194,479.25 Pharmaceuticals, Inc. Acura Prazatrex $51,650.00 $19,450.00 Pharmaceuticals, Inc. ADVANCED Development of an Esophageal COOLING Temperature Management $10,000.00 $27,500.00 THERAPY, LLC Product Advanced Life Cethromycin for Respiratory $244,479.25 Sciences Inc Tract Infections Rapid Screening Device for Advanced Scanning Young Adults to Prevent $34,188.00 $149,000.00 Inc. Sudden Death AJ Medical Devices Implanted Cardiac Arrest Alarm $244,479.24 Inc Oral Brush Cytology RNA Arphion LTD $12,038.50 Screening for Oral Cancer Treatment of Patients with AtCor Medical Inc Heart Failure through $109,240.00 $26,397.00 USA Aggressive Cardiac Load Reduction Nano-Flare Platform for AuraSense, LLC $4,455.00 $240,024.24 Intracellular Assays AURORA LIFE AutoImmune Diagnostic Array $244,479.25 SCIENCES LLC (ADA) B&G Partners Novel Mucin-Directed TGF-B $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ALK5 Inhibitors Targeted for Muc4 A drug candidate for prevention B&H Biotechnologies and treatment of serious $38,940.00 $61,000.00 LLC influenza infections Phase II Development of BioSante LibiGel for Low Sexual Desire, $244,479.25 Pharmaceuticals, Inc. A Significant Unmet Medical Need CDG Therapeutics, Novel therapy for advanced $244,479.25 Inc refractory tumors Corpak Medsystems, Project Triangle - Cortrak 11 $244,479.25 Inc. Reducing the Heart Failure Cost Endotronix Inc Burden: Anytime, Anywhere $244,479.25 Pulmonary Pressure Monitoring Gastrointestinal allergy Entopy Research LLC $43,750.00 diagnostic device and method Thalagen, a Novel Gene Errant Gene Therapy for the treatment of B $244,479.25 Therapeutics, LLC Thalassemia Major and Sickle Cell Anemia Next-Generation Microarray Genomics USA, Inc. Technology, For Low-Cost $244,479.24 HLA-Typing Horizon Therapeutics, HZT-501, Ibuprofen/famotidine $244,479.25 Inc Proprietary Combination Tablet Immune Cell Therapy's Immune Cell Therapy $29,955.00 Autologous Cancer Vaccines Innovative Visual Discovery $128,122.50 $116,356.75 Systems LLC Development of Endoxifen: A Jina Pharmaceuticals New Cornerstone for Breast $244,479.25 Inc. Cancer Prevention and Therapy Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Disinfectant and Diagnostic Kim Laboratories, Inc $170,817.50 $73,661.75 tests for Norovirus Infant Formula Blocks HIV Lavax, Inc. $95,346.50 Transmission Via Breastfeeding Lenticular Research Management of the growth of $244,479.25 Group LLC the human cystalline lens Novel Markers for Alcohol Lohocla Research Intake and Alcohol-Induced $141,389.57 $103,089.68 Corporation Organ Damage Automated Free Hand Breast Metritrack LLC Ultrasound Screening and $11,861.19 $33,791.69 Diagnosic system Nanoink Inc NanoEncryption $244,479.24 Nanoink, Inc. NanoStemCell $244,479.24 Diagnostic tests for the early NANOSPHERE, INC $244,479.25 detection of cancer Diagnostic tests for the NANOSPHERE, INC $244,479.25 detection of infectious diseases Diagnostic tests for the early NANOSPHERE, detection of immune system $244,479.25 INC. disorders Diagnostic tests for the NANOSPHERE, detection and prevention of $244,479.25 INC. cardiac and vascular diseases. Peptide-Amphiphile Nanofiber Nanotope, Inc. $244,479.25 Matrix Improved CNS Therapies Through Development of Novel Naurex, Inc $244,479.24 Drugs to Modulate NMDA Receptor Clinical Evaluation of LEP- NeoPharm Inc $244,479.25 ETU in Cancer Patients NeoPharm Inc IL 13-PE as a novel, targeted $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 therapy for Idopathic Pulmonary Fibrosis Nerve Access, Inc The Alzheimer Project $244,479.25 Enabling Wireless Delivery of NeuRDS Inc. $22,053.00 $105,842.00 Electrical Stimulation Therapy Neuro Therpeutics NTP-2014 $244,479.24 Pharma Inc NeuroTherapeutics NTP-6009 $9,692.50 $234,786.74 Pharm, Inc Development of novel anti- NovaDrug, LLC $244,479.25 hepatitis C virus (HCV) drugs Novilase Interstitial Laser Novian Health Inc. $244,479.24 Therapy Versatile, cost-effective point- OHMX Corporation of-care medical diagnostic $244,479.25 device for chronic diseases Controlled coronary reperfusion Rhoextech. LLC $2,379.50 $233,750.00 during PCI for acute ischemia Treatment of adverse complications of diabetes Siwa Corporation $65,125.00 through enhanced clearance of AGE-modifie SNAP Diagnostics SNAP Model 8 $104,115.50 $109,079.50 SteadySleepRx Obstructive Sleep Apnea Drug $244,479.24 Company Program Improve immunoassay SWORD sensitivity & accuracy in DIAGNOSTICS, $244,479.25 disease ID & quantitation of INC. biomarkers. Synergenz Respiragene Lung Cancer risk $20,095.00 $74,741.50 BioScience, Inc. Predictive test Tactic Pharma, LLC ATN-161 $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Tactic Pharma, LLC huATN-658 $244,479.24 Use of a Bispecific Antibody Tolerogenics Inc $29,042.51 $51,364.31 for Treating Type I Diabetes Development of TOL-463: a Toltec vaginal biofilm disruptor for the $229,946.50 Pharmaceuticals LLC treatment of vaginitis NOVA toolkit for quantitative VASSOL, Inc Magnetic Resonance $242,287.50 $2,191.75 Angiography (qMRA) VesselTek Drug-eluting, elastomer-coated $40,554.16 $40,548.16 BioMedical LLC vascular graft Identification of biomarkers for VidaGene $96,685.50 $117,064.50 VDR activation Novel VDR Modulators with Expanded Therapeutic Index Vidasym $46,779.00 $81,987.00 and Cardio-Renal Protective Effects ViMedicus, LLC. ViMedicus HER 301 $244,479.25 Winston Laboratories, Civamide Capsule $221,647.38 $22,831.86 Inc Winston Laboratories, Civamide Nasal Spray $12,545.81 $231,933.43 Inc. Winston Laboratories, Civamide Cream $244,479.24 Inc. Winston Laboratories, Civamide Patch $151,319.33 $93,159.91 Inc. zuChem inc Xylitol $107,207.21 $38,583.28 Therapeutic Oligosaccharides zuChem Inc and Glycosylated Small $98,427.25 $86,651.26 Molecules

Indiana $10,293,530.56 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of Novel Drugs Aarden Targeting Key Protein Tyrosine $86,772.79 $157,706.45 Pharmaceuticals Inc Phospatase Disease Targets Admiral Medical Qualifying Therapeutic $180,750.00 Supply, Inc Discovery Project Credit Development of Low Dose Levetiracteam Therapy for AgeneBio Inc $28,750.00 $50,750.00 Amnestic Mild Cognitive Impairment Development of GABAA a5 agonists for treatment of amnestic Mild Cognitive AgeneBio Inc Impairment (aMCI); these $30,387.50 $206,500.00 compounds may also modify or slow progression to Alzheimer's Disease. Akina, Inc. Microfabrication $144,623.50 Development of APE1 ApeX Therapeutics, Inc Inhibitors for Treatment of $14,842.52 $164,063.04 Cancers and Retinal Diseases Ash Access Zuragen Catheter Lock Solution $244,479.25 Technology, Inc Ash Access ZuraPrep Preoperative Skin $164,370.59 $64,472.88 Technology,Inc Preparation BIOSCIENCE The Development of Improved $44,692.50 $199,786.74 VACCINES INC Vaccines for Human Use Chemigen, LLC CC100 Project ALS $92,371.50 $152,107.75 Definitive cancer diagnosis with CS-Keys, Inc a conserved biomarker of $244,479.24 malignacy Proton/Photon flexible Dunigan Medical Inc dosimetry and organ $75,000.00 $65,000.00 displacement catheters Elona Biotechnologies USP Insulin $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc EndGenitor Neovascular Cell Therapeutic $199,566.00 $44,913.25 Technologies, Inc for Cardiovascular Disease Endocyte Inc EC20 $244,479.25 Endocyte Inc PSMA $244,479.25 Endocyte Inc EC0489 $244,479.25 Endocyte Inc EC145 $244,479.25 Endocyte, Inc EC0531 $185,000.50 $59,478.75 Endocyte, Inc Inflammation $244,479.25 Development of Laparoscopic Focus Surgery inc Probe to treat of metastatic $244,479.25 cancers {prostate pancreas, ect} Therapeutic Angiogenesis by General Bio Universal Donor Endometrial $24,523.99 $70,145.27 Technology, LLC Regenerative Cells A Novel Approach to GMP General Bio Production of Tooth Derived $115,913.17 $128,566.07 Technology, LLC Stem Cells Automated Closed System for General Bio DMSO Removal from $244,479.24 Technology, LLC Peripheral Blood Stem Cells A public umbilical cord blood General bank to facilitate allogenic cord $85,639.72 $148,771.26 BioTechnology, LLC blood transplantation Innovative Delivery Device For Glucago LLC a Wide Rangeof Lyophilized $11,800.51 $232,678.74 Drugs Reversible Gastric Sleeve GRest Inc Implant for Substantial Weight $110,178.50 $134,300.75 Loss with Preserved Anatomy Horizon AVN316 $244,479.25 Biotechnologies, LLC Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Magnetic Sorter Channels for IKOTECH LLC $70,242.45 $89,760.96 Stem Cells. IVDiagnostics LLC IVD Onco Dx - CTC Platform $106,021.00 $138,458.24 KT-105 a pRNA nanoparticle Kylin Therapeutics Inc $244,479.24 for cancer treatment GIP/GLP - 1 Dual Agonist for Marcadia Biotech, Inc. Treatment of Diabetes and $244,479.25 Obesity Metabolite Profiling Matrix Bio, Inc. $100,284.50 $84,000.00 Technology Femoral Introducer Sheath and Morris Innovative Inc. $244,479.25 Hemostasis Device Oral arNOX inhibitors for NOX Technologies, Atherogensis Prevention and $93,954.50 $150,524.74 Inc. Skin Health Park Funding, LLC SF1126-Dual mTOR-P13K d/b/a Semafore Inhibition For Next Generation $244,479.25 Pharmaceuticals Cancer Treatment DEVELOPMENT OF PDS POTENT, SAFE AND COST BIOTECHNOLOGY EFFECTIVE THERAPEUTIC $244,479.24 CORPORATION (CURATIVE) CANCER VACCINES Rapid, Safe, Controlled Access Pericardial Access, Inc to the Pericardial Space for Left $152,888.50 $91,590.75 Ventricle Lead Delivery Pharmacophotonics, FAST GFR System $244,479.24 Inc Fatzo mouse, obese diabetic Preclinomics, Inc (type II) mouse model without $64,308.00 $54,050.00 leptin/leptin-receptor defects ZDSD rat, an obese diabetic Preclinomics, Inc (typeII) rat model without $227,381.50 $17,097.74 leptin/leptin-receptor defects Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ProCure Treatment Negative Pressure Breast $158,700.00 $85,779.24 Centers, Inc. Stabilization Device (BSD) Solstice Medical,LLC RFSuite System $244,479.25 SonarMed Airway Monitoring SonarMed, Inc $244,479.25 System (AMS) GOPump Rapid Recovery Symbios Holdings, Inc $244,479.25 System Therapeutic Compounds for the SynTherix Inc $164,725.00 $79,754.25 treatment of Cancer

Iowa $1,744,960.41

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Advanced Analytical DNA Profiler for Rapid $244,479.25 Technologies Inc Pathogen identification Development of regenerative Cellular Engineering medicine tools for preclinical $68,982.50 $68,982.50 Technologies, Inc drug development Innovative Medical Device for Safe Effective Delivery & J & J Solutions Inc $136,086.00 $108,393.25 Administration of Chemotherapeutics KP106: A Treatment for KemPharm, Inc Attention Deficit/Hyperactivity $244,479.25 Disorder (ADHD) KP303: A Treatment for KemPharm, Inc. Schizophrenia and Bipolar $175,678.00 $68,801.25 Disorder MedCara WartPEEL $57,079.78 $41,561.13 Pharmaceuticals, Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC MTI BIOTECH 3MH BIOMARKER $11,997.00 $29,482.00 INCORPORATED NewLink Genetics HyperAcute Vaccines for $244,479.25 Corp Cancer Terpenoid Developing Terpenes as Anti- Therapeutics $244,479.25 cancer Therapeutics Incorporated

Kansas $3,818,255.68

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Nanotax®: sustained drug release CritiTech, Inc from pure drug nanoparticles to $150,954.50 $93,524.74 treat ovarian cancer Nanothecin™: sustained drug release from pure drug CritiTech, Inc. $133,544.50 $110,934.74 nanoparticles to treat peritoneal cancer CyDex Melphalan HC1 for Pharmaceuticals $244,479.24 Injection(Propylene Glycol Free) Inc CyDex New Dosage Form of Pharmaceuticals Clopidogrel-Rapid Onset $133,059.00 $111,420.24 Inc Injectable An oral Therapeutic Agent for Edenspace Systems Ischemic, Inflammatory and $3,316.00 $68,826.00 Corporation Immune Disorders GeneProTM (4SHIVku2)- a ImmunoGenetix DNA vaccine therapeutic for $57,552.08 $15,420.00 Therapeutics, Inc HIV patients KC BioMedix, Inc Ntrainer System ® $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Madeira Novel Analgesic Oral Solution to $154,500.00 Therapeutics LLC Treat Pain in Children. Novel Simvastatian Oral Solution Maderia to Treat High Cholesterol in $198,050.00 $46,429.24 Therapeutics, LLC Children Functionalized Core/Shell NanoScale Fe/Fe304 Stealth Nanoparticles $78,000.00 Corporation for Cancer Diagnosis & Treatment Intelligent Low-Toxicity NanoScale Materials for Cancer Diagnosis $66,869.00 $54,807.46 Corporation and Treatment. Nexus Medical, Nexus TKO $187,678.50 $56,800.75 LLC EarlyCDT-Lung-a novel blood Oncimmune (USA) test to aid in the early detection $244,479.24 LLC of cancer Precision Particle Fabrication Orbis Biosciences, Technology for improving $149,637.14 $94,842.10 Inc Therapeutics through API Control Pulse NeedleFree Multi-Use Needle-Free Injection $53,817.50 $86,917.50 Systems, Inc. Device Minuteman & Scarab Spinal Simplicity, Interspinous Process Fusion Cage $120,187.78 $124,291.47 LLC Devices TVAX Biomedical, TVI-Brain-1 as a Treatment for $9,183.50 $235,295.74 LLC Malignant Cancer VasoGenix Novel Sustained Treatment of Pharmaceuticals $244,479.24 Heart Failure Inc Verrow Development of a new kidney Pharmaceuticals $235,199.50 $9,279.74 protective x-ray contrast dye Inc Kentucky $4,292,588.43

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Circulating RNA diagnostic for Advanced Genomic metastatic ovarian $244,479.25 Technology, LLC carcinoma:an animal model study Abuse Deterrent Transdermal ALLTranz Inc Buprenorphine for Treatment of $79,584.13 $68,561.57 Pain and Opiate Addiction Transdermal Cannabinoid ALLTRANZ Inc $90,303.08 $154,176.16 Prodrug Treatment Transdermal Cannabidiol for Treatment of Osteoarthritis, Alltranz Inc $114,288.70 $85,744.68 Alcoholism, And Other Diseases ALT BioScience Periodonatl diagnostic strip $244,479.25 LLC Apellis Complement Inhibitors as a $244,479.25 Pharmaceuticals, Inc. Therapeutic for Asthma ApoVax104 as a Novel Vaccine ApoImmue, Inc $244,479.25 Platform Technology IOP and Therapeutic Assenti LLC Monitoring System for $54,310.50 Glaucoma Patients Burn Treatment Adjuvant CeeLA Naturals $60,503.50 $114,405.00 Therapies CTI Science Inc NBMI Drug Approval $230,691.00 $13,788.24 Novel Therapy to improve EndoProtech, Inc. outcomes in cardiac $166,515.50 $77,963.74 transplantation Inflammation-Targeting Kentucky theragnostic nanocomposite $244,479.25 Pharmacecuticals Inc system for the eye NeoCytex Novel Neuroregenerative Drug $115,894.93 $38,209.84 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Biopharma Inc. Therapy for Stroke Diagnostic improvements in OrthoData, Inc $244,479.25 spinal fusion Potentia POT-4 $244,479.25 Pharmaceuticals, Inc Bone-targeted Vancomycin for Pradama, Inc. the Treatment of Osteomyelitis $43,771.50 $133,681.00 (Bone Infection) Re-Borne Inc Re-Borne Prosperity Project $73,500.00 FCRx for Safe Bone Marrow Regenerex. LLC $167,516.00 $76,963.25 Transplantation The use of olfactory of stem RhinoCyte, Inc. $244,479.24 cells for neurodegeneration Summit Biosciences THC-nasal spray $138,247.00 Inc. Summit Biosciences THC- nasal spray $9,639.00 LLC Vindico NanoBio Polymersomes, a nonoparticle- $40,291.27 $188,204.85 Technology, Inc. based delivery platform

Louisiana $1,955,833.96

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Autoimmune Flufirvitide-3: A Broad-Spectrum Entry- Technologies, $216,310.35 $28,168.90 inhibiting Seasonal and Pandemic Influenza Drug LLC The Clinical Development of 4- Demethylcholesterloxycarbonylpenclomedine.The Clinical Development of 4- DEKK-Tec, Inc. $126,990.50 $117,488.74 Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) for the Treatment of Cancers Involving the Central Nervous System Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Embera Neuro EMB-001: A novel pharmaceutical product for Therapeutics, $244,479.24 the treatment of addictive disorders Inc. Esperance The Development of a Cationic Lytic Peptide Pharmaceuticals, $244,479.24 (CLYPTM) Technology Platform Inc Trace-level biosensing for early detection, and Meta Logos Inc $137,500.00 $106,979.24 treatment, of cancer and other diseases. A new Approach to Regenerative Medicine NuPotential,Inc. $244,479.25 Development TCA Cellular TCA Cellular Therapies for treatment of $168,075.93 $76,403.32 Therapy LLC cardiovascular and neurological disease. TRANSGENRX, Engineered glycosylated interferons for the $244,479.25 INC. treatment of viral diseases, Melanoma and MS

Maine $275,654.24

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 AIKO 150: Drug Therapy for AIKO Treatment Constipation $43,867.74 Biotechnology Inc associated with Opioid USE Bar Harbor Bar Harbor BioTechnology- $77,770.50 $82,018.50 BioTechnology Diagnostic Initiative Sea Run Holdings Salmon Fibrin for inflammation $71,997.50 Inc and pain

Maryland $48,745,215.69

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 20/20 GeneSystems Inc Diagnostic for the Early $165,935.50 $78,543.74 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Detection of Lung Cancer 20/20 GeneSystems Inc PredicTOR cancer diagnostic $244,479.24 Development of Anti-GP88 Drug & Diagnostic: Novel A&G Pharmaceuticals, Inc $244,479.25 Therapy for Chemoresistant Cancer Adlyfe Alzheimer's Adlyfe, Inc. $244,479.25 Diagnostic Assay Development of an Accurate, Advanced Biomimetic Pain-free and Reagent-free $73,757.09 $32,007.02 Sensors, Inc Blood Glucose Monitoring Device Simultaneous PCR & Akonni Biosystems, Inc. Microarray Detection, $244,479.25 TruArray Test The Multiplexed Respiratory Akonni Biosystems, Inc. Infection POC Testing in 15 $244,479.25 Minutes CAD system to improve Alan Penn & Associates, sensitivity of breast MRI $25,376.24 $7,511.99 Inc. using diffusion weighted imaging Biomarker Platform Alper Biotech LLC Technology for Breast Cancer $116,052.70 $128,426.55 Diagnosis and Treatment Immune Sensor for Early Ambay Immune Sensors Detection of Breast Cancer in $8,082.50 and Controls LLC Blood Safe Lentiviral Delivery of American Gene Technology Multiple Therapeutic $140,816.50 $103,662.75 International Inc. Molecules for the Treatment of Cancer AMP-224 A novel Drug for Amplimmune, Inc the Treatment of Cancer and $244,479.24 Infectious Disease Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 AMP-110: A Novel Product Amplimmune, Inc Candidate for the Treatment $244,479.24 of Autoimmune Disease Therapeutic angiogenesis with AnGes, Inc HGF plasmid (collategene)in $244,479.25 critical limb ischemia (CLI) Ligand-Targeted Lentiviral Aparna Biosciences Vectors for Systemic Gene $161,029.00 $83,450.25 Corporation Therapy Antifungal therapeutic for Aparna Biosciences life-threatening invasive $68,282.00 $27,592.00 Corporation fungal infections Aparna Biosciences Nanoparticle Based Dual- $52,457.50 $152,753.50 Corporation antigen Anthrax Vaccine In vivo targeted siRNA Aparna Biosciences nanoparticles for non-small $177,183.00 $67,296.25 Corporation cell lung cancer Acoustic array biosensor for Applied Sensor Research & multiplexed point of care $51,340.23 $80,350.34 Development Corporation diagnosis of infectious agents Arcion Therapeutics, Inc ARC-2022 $244,479.25 Arcion Therapeutics, Inc ARC-4558 $244,479.25 Discovery of prophylactic antimalarials, oral delivery cutaneous antileishmanial and Astha Consultancy, Inc blood-brain barrier crossing $36,501.50 $50,616.00 Acetylcholine estrase- Organophate reactivator drugs for the war fighter Development of Rapid, Point of Care) Diagnostics for HIV BioAssay Works, LLC $16,338.00 $6,319.50 & Methicillin-Resistant Staph. Development of rapid, BioAssay Works, LLC $31,967.50 $26,555.50 Lateral-Flow and ELISA Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Research Assays for Kidney Injury Molecule Development of rapid, Lateral-Flow Diagnostic BioAssay Works, LLC $7,583.00 $9,674.50 Assays for Various Infectious Diseases Modification/Conjugation of Antibodies to Thyroid BioAssay Works, LLC $2,795.00 $7,909.00 Stimulating Hormone & Cardiac Troponin Development of rapid, Lateral-Flow Diagnostic BioAssay Works, LLC $12,189.50 $16,592.00 Assay to Detect PROM in pregnant women BioElectronics Corporation Third Molar Extraction Pain $128,270.00 SMALLPOX BIODEFENSE BIOFACTURA, INC. $204,793.72 $39,685.52 THERAPEUTIC Immune Refocusing Biological Mimetics, Inc $232,631.50 $11,847.75 Technology SnapPath™ Biomarker BioMarker Strategies $244,479.25 Testing System for Cancer Development of D-tagatose Biospheric Incorporated for treatment of $225,000.00 hypertriglyceridemia Development of D-tagatose Biospherics, Inc oral prescription medicine for $244,479.24 treatment of Type 2 diabetes BioSurface Engineering BioSET F2A Reparative $36,325.50 $31,310.00 Technologies Inc Mesh BioSurface Engineering BioSET Amplex with B2A $244,479.25 Technologies Inc BioSurface Engineering BioSET PreFix with B2A $244,479.25 Technologies, Inc Biosynexus Incorporated Pagibaximab $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Vitruvian Robotic Diagnostics Blue Torch Medical Platform for Cancer Surgery $213,900.00 Technologies Inc Advancement BrainScope Company Inc BrainScope Ahead M-100 $244,479.24 Pharmacodiagnostic Molecular Test Panels to CCC Diagnostics, LLC $244,479.25 Optimize Chemotherapy Selection Molecular Diagnostics for Celadon Laboratories Inc. Tuberculosis and African- $151,820.50 $92,658.74 American Public Health. Development of CEL-031, a targeted therapeutic for non- Celek Pharmaceuticals LLC $38,783.80 muscle invasive bladder cancer. Development of CEL-021 for the treatment of interstitial Celek Pharmaceuticals LLC $500.00 $19,592.50 cystis/painful bladder syndrome Development of CEL-011, an Celek Pharmaceuticals LLC innovative bladder cancer $18,281.98 $17,294.89 therapy Qflu Influenza Diagnostic and Cellex, Inc $114,051.38 $130,427.87 Drug Resistance Combo Tes A Quantitative Bacterial Cellex, Inc. Vaginosis Test for Point-of- $139,396.13 $105,083.12 Care Use CT-10, a new class of Cellona Therapeutics, Inc compound and targeted $244,479.24 cancer drug Cellphire platelet Stabilization Cellphire, Inc. $244,479.25 Therapeutic ThermoDox®-A heat Celsion Corporation activated Liposomal $244,479.24 Encapsulation of Doxorubicin Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 to treat HCC A Novel Approach to Treat Centegen, Inc Staphylococcus Aureus $65,541.67 $178,937.58 Infections (Including MRSA) A Novel Vaccine to Prevent Centegen, Inc. Staphylococcus Aureus $8,583.34 $42,375.00 Infections (Including MRSA) Development of Single Chain CHAMPIONS Antibody Fragment Targeting $140,927.00 $103,552.25 BIOTECHNOLOGY INC Mutant p53 for the Treatment of Cancer Development of Personalized Tumorgraft Models to Champions Biotechnology, Identify Biomarkers and $118,653.50 $124,142.00 Inc Guide Personalized Cancer Therapies Development of Small Champions Biotechnology, Molecule Autotaxin Inhibitor $147,870.00 $96,609.25 Inc. Bithionol for the Treatment of Cancer Development of a Novel Predictive Preclinical Champions Biotechnology, Tumorgraft Platform to $244,479.25 Inc. Enhance and Accelerate Oncology Drug Development Development of Irinophore- Champions Biotechnology, C™ a Novel Nanoparticle $118,803.50 $125,675.75 Inc. Formulation of Irinotecan as an Anti-Cancer Therapy Development of Small Champions Biotechnology, Molecule Tubulin Inhibitor $190,057.50 $54,421.75 Inc. SG410 for the Treatment of Cancer Recombinant human CC10 Clarassance, Inc. protein for prevention of $77,769.00 $166,710.24 neonatal BPD Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Point-of-Care Diagnostics of Infectious Diseases Using Columbia Biosystems Inc $131,580.00 $105,044.00 Molecularly Imprinted Polymers Development of the Cordex Cordex Systems, LLC $222,606.00 Cardiovascular Device Development of diagnostic Correlogic Systems Inc Multi-variate Assays for $244,479.24 Ovarian and Breast Cancers The therapeutic application of Corridor Pharmaceuticals, C-122 in Pulmonary Arterial $244,479.24 Inc Hypertension (PAH) Therapeutic application of Corridor Pharmaceuticals, Arginase inhibitors for the $244,479.24 Inc treatment of endothelial dysfunction TruFreeze Spray Cryotherapy CSA Medical, Inc. Therapeutic Agent Delivery $244,479.24 Platform Pegylated Colloidal Gold Nanoparticles: The Core of a Cytlmmune Sciences, Inc $244,479.25 Family of Novel Nanomedicines Development of a Blood Test DioGenix Inc for the Early Detection of $244,479.24 Multiple Sclerosis Entremed Inc. ENMD-2076 $244,479.24 ExonHit Dx21 $244,479.25 ExonHit Therapeutics, Inc. Program 107 $3,253.50 $79,222.00 Treatment of Recurrent FASgen, Inc. $244,479.25 Ovarian Cancer FLAVORx, Inc. & Medicinal Compliance $71,098.00 $76,925.50 Subsidiary Functional Genetics, Inc Development of a Broad $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Spectrum Antiviral Antibody Therapeutic Targeting TSG 101 Development of a Broad Spectrum Small Molecule Functional Genetics, Inc $244,479.24 Antiviral Therapeutic Targeting TSG-101 Fyodor Biotechnologies Inc Urine Malaria Test (UMT) $94,584.27 $149,894.98 Development of Biomarkers GenArraytion Inc for Clinical Assessment of $93,159.50 Occult Infections Plasmepsin V Inhibitor GeneCopoeia, Inc. Therapeutics for Malaria $223,750.00 Infection p53 Fusion Protein GeneCopoeia, Inc. Therapeutics for Pancreatic $244,479.25 Liver Cancer Mutant MicroPlasmin GeneCopoeia, Inc. $244,479.25 Therapeutics Recombinant alpha 1- GeneCopoeia, Inc. $244,479.25 Antitryspin Therapeutics GenVec, Inc. TNFerade™ Biologic $244,479.25 GL-2045, A stradomer for the treatment of ITP, RA other Gliknik Inc $244,479.24 Chronic Autoimmune diseases Clinical stage immunonmodulators GL- Gliknik Inc $8,574.00 $235,905.24 0810 and GL-0817 for the treatment of cancer GB-2542, a stradobody for Gliknik, Inc the treatment of breast cancer $236,068.50 $8,410.74 and other cancers Glycomimetics, Inc GMI-1070 $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 GLYC-101 Gel investigational product for Glycotex, Inc. $132,917.50 $111,561.74 treatment of acute and chronic wounds Prognostic Test Development Hitech Analytical and for Recurrent Spontaneous $10,700.00 Diagnostic Solutions LLC Abortions and Viable Pregnancy Dev. Of novel tumor-targeted antibody-based fusion Iatrica, Inc $195,392.00 $49,087.25 proteins for immunotherapy of cancer Development of Universal ILSbio, LLC. $190,293.80 $54,185.44 Research Specimen Sets Novel aproach to treat autoimmune hemolytic Imagilin Technology LLC $110,000.00 $134,479.25 anemia {AIHA}, an autoimmune disease. Speckle Free C-scan Ultrasound Video Imaging Imperium, Inc. $141,524.00 $102,955.25 Camera for Clinical Diagnostics Carbendazim/Benzamidazoles ImQuest BioSciences, Inc Broad Based Anti-Tumor $50,000.00 $194,479.25 Agent Project Novel Carbamate-based HIV ImQuest BioSciences, Inc $50,000.00 $194,479.25 Replication InhibitorProject Novel DNA Oligonucleotide development as a Topical ImQuest BioSciences, Inc $244,479.25 Microbicide (ISIS 5320) Project Novel Pyrimidinedione Small ImQuest BioSciences, Inc Molecule as a Topical $244,479.25 Microbicide Project PG 301029 Anti-HCV ImQuest BioSciences, Inc $64,794.50 $179,684.75 Program Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 ImQuest Pharmaceuticals Novel Piperazine Project $70,525.00 $173,954.25 Inc ImQuest Pharmaceuticals, Novel Pyrimidinedione $244,479.25 Inc. Project-IQP0410 EEG headband for Automated Infinite Biomedical Seizure Detection with $208,417.84 $36,061.41 Technoliogies, LLC. Telemedicine Review Infinite Biomedical Cortical Health Index Monitor $143,724.63 $79,462.56 Technologies - Regulatory Approval Laser Speckle Imaging to Infinite Biomedical Study Brain Tumor $72,586.82 $14,467.76 Technologies, LLC Vasculature A dexterous prosthetic Infinite Biomedical controller for multi-fingered $165,848.70 $78,630.55 Technologies, LLC hands Neonatal Neurological Infinite Biomedical Monitor - Regulatory $244,479.25 Technologies, LLC. Approval Protecting the Intergrity of the InfraTrac, Inc Drug Supply with $19,062.50 $33,650.00 Spectroscopic Verification Development of a CANARY® - based rapid Innovative Biosensors, Inc $244,479.25 clinical diagnostic test for MRSA. Integrated Biotherapeutics, Therapeutics for Staph aureus $244,479.24 Inc. and related toxic shock Integrated Biotherapeutics, Staphylococcus aureus $74,250.77 $100,000.00 Inc. Vaccine Program In vitro-diagnostic grade an Kirkegaard & Perry tibodies for whole bacteria $90,899.15 $153,580.09 Laboratories, Inc capture and detection LG1041 Breakthrough Lentigen Corporation $132,289.85 Therapy/Cure for Hunter's Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Syndrome LG911 Novel Broad- Lentigen Corporation Spectrum Cancer Therapy for $5,833.05 $57,088.32 Solid Tumors LG912 Novel Hepatitis Lentigen Corporation C/Liver Cancer Therapeutic $11,988.24 $82,594.26 Vaccine Advanced Bioproduction Lentigen Corporation $138,997.66 $79,624.52 Platform for US Military LG611 High Potential Lentigen Corporation $244,479.25 Pandemic Influenza Vaccine LG723 Novel Anticancer Lentigen Corporation $4,601.27 $223,730.34 Melanoma Therapy LG631 Novel Therapy for Lentigen Corporation $142,487.08 Glioblastoma LG970 Next Generation Lentigen Corporation Preventative Vacine for $1,655.14 $109,936.87 HIV/AIDS Development of Fully Luminescent MD, LLC Automated Chemiluminescent $10,643.85 $4,930.09 Enzyme Immunoassay Systen MacroGenics Inc MGAH22 $244,479.25 MacroGenics Inc mAb Pipeline $244,479.25 MacroGenics, Inc T-Dart $244,479.25 MacroGenics, Inc MGAWN1 $244,479.25 MacroGenics, Inc. Cancer Stem Cells $244,479.25 MacroGenics, Inc. Teplizumab $244,479.25 MacroGenics, Inc. MGA271 $244,479.25 Effect of chitosan gum on Mastix Medica LLC serum phosphate in ESRD $19,371.00 patients Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 MaxCyte Cell Modification Technology Platform for MaxCyte Inc. $244,479.25 Therapeutic Development and Discovery Myostatin Inhibitors to MetaMorphix, Inc. $113,923.50 $39,353.50 Accelerate Tissue Growth NABI DEVELOPMENT OF $244,479.24 BIOPHARMACEUTICALS NICVAX Development of an allogeneic NEURALSTEM INC human neural stem cell $244,479.25 product for treatment of ALS Development of an IGF1- expressing human neural stem Neuralstem, Inc $165,463.00 $79,016.25 cell product for treatment of ALS Neurogenic Compound to Neuralstem, Inc. $165,463.50 $79,015.75 Treat Major Depression Novel Small-Molecule Neurogenic Preclinical Neuronascent Inc Candidates as Therapeutics $43,081.00 $63,025.00 for Chronic Neurodegenerative Disorders A simple and Rapid NEW HORIZONS Diagnostic Test for DIAGNOSTICS $66,053.50 $137,000.00 Pancreactic Cancer Using CORPORATION Novel Serum Biomarkers The use of phage lytic New Horizons Diagnostics enzymes as non-resistant anti- $99,080.50 $145,398.74 Corporation microbials Northwest Biotherapeutics Clinical Development of $244,479.25 Inc DCVaz Northwest Biotherapeutics Development of DCVax- $244,479.25 Inc Direct Respiratory Syncytial Virus Novavax, Inc. $244,479.25 Vaccine Development Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Varicella-Zoster Virus Novavax, Inc. $69,000.00 $175,479.25 Vaccine Development Pandemic Influenza Vaccine Novavax, Inc. $244,479.25 Development Seasonal Influenza Vaccine Novavax, Inc. $244,479.25 Development Ocular Proteomics LLC The Vitreous Proteome $244,479.24 Rapid Microbial Infection OpGen,Inc $244,479.25 Identification OriGene Autoantibodies Early OriGene Technologies, Inc Screening Test for Ovarian $244,479.25 Cancer Osiris Therapeutics, Inc. Prochymal $244,479.25 Induction of Hypoxia Paragon Bioservices,Inc Tolerance at the Cellular $244,479.25 Level Bioengineering host cells to Pearl Lifescience Partners, produce superior vaccines $87,630.92 $156,848.32 LLC against envelop viruses recombinant BChE Alternate PharmAthene Inc Expression System $1,040.00 $114,705.65 Development Program Protexia Drug Development PharmAthene Inc $244,479.25 Program rPA Drug Development PharmAthene, Inc $7,500.00 $235,580.41 Program Valortim Biologic PharmAthene, Inc. $244,479.25 Development Program PlantVax Inc BChE $45,902.00 $58,324.00 PlantVax, Inc MA b $61,936.50 $45,893.50 NF-kB Rel inhibitors for the Profectus BioSciences Inc $244,479.25 treatment of Cancer Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Therapeutic and prophylactic Profectus BioSciences, Inc $244,479.25 vaccines against HIV Psyadon Pharmaceuticals, Ecopipam for the Treatment $244,479.24 Inc of Lesch-Nyhan Disease Phase-contrast enhanced X- Quantum Medical Metrics ray imaging system for small $4,000.00 $80,500.00 LLC joint of hand Development of cancer- selective replication- RAFAGEN, Inc. $118,375.82 $126,103.42 competent retrovirus therapy for neuroblastoma RxFusion Infusion Switch Raland Technologies LLC $25,500.00 $218,979.25 Device Chemokine Receptor RAPID LABORATORIES, Antagonists That Treat HIV $244,479.24 INC. Viral Reservoirs & Chronic Inflamm. Disease RegeneRx RGN-352 for Cardiac and $244,479.25 Biopharmaceuticals Inc Neuronal Tissue Regeneration RegenexRx RGN-137 for Dermal Tissue $244,479.25 Biopharmaceuticals Inc Regeneration RGN-259 for Corneal Tissue RegenRx Regeneration and Other $244,479.25 Biopharmaceuticals Inc Anterior Eye Pathologies Reprograming gene RetroTherapy LLC $114,605.54 $129,873.71 expression in stem cells Rexahn Pharmaceuticals, Zoraxel $154,426.35 $90,052.89 Inc Rexahn Pharmaceuticals, Anti-Cancer Drugs $244,479.24 Inc. Rexahn Pharmaceuticals, Poly HPMA System for Drug $33,239.23 $55,460.59 Inc. Delivery Rexahn Pharmaceuticals, Serdaxin $244,479.24 Inc. Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Live Attenuated Plasmodium Sanaria, Inc. Falciparum Sporozoite $244,479.24 (malaria) Vaccine Post Operative Adhesion Seguro Surgical Inc. $20,163.50 $118,310.50 reduction SQ641: A Novel Translocase- Sequella Inc 1 Inhibitor for Treatment of $244,479.25 Mycobacterial Infections B-SMART: a novel rapid Sequella, Inc platform technology to detect $83,717.50 $103,915.00 bacterial drug resistance SQ109: A Potential Foundation Drug for a New Sequella, Inc. $244,479.25 Regimen to Cure Tuberculosis SQ609:A Potent New Drug Sequella,Inc for Treatment of multidrug- $162,295.50 $25,927.50 resistant Tuberculosis Sequoia Pharmaceuticals Development of Novel HCV $244,479.24 Inc Protease Inhibitors Development of Pharmacokinetically Sequoia Pharmaceuticals, Enhanced Fixed Dose $244,479.24 Inc. Combinations for HIV and Cancer Sequoia Pharmaceuticals, Clinical Development of a $244,479.24 Inc. Pharmacokinetic Enhancer The Cythotron-a novel, stand- alone therapeutic device utilizing non-ionizing Shreis Scalene Sciences, RFQMR to treat cancer and $244,479.25 LLC improve drug targeting & delivery through nano- permeabilization Obstructive Sleep Apnea SLEEP METHODS, INC. $108,553.00 $135,926.25 Therapeutic System Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Sleep Solutions Inc NovaSom II $75,705.00 $168,774.25 A Study of the Efficacy and Sucampo Pharma Americas, Safety of Lubiprostone in $244,479.25 inc Patients with OBD A STUDY OF SUCAMPO PHARMA COBIPROSTONE FOR THE $244,479.25 AMERICAS, INC PREVENTION OF NSAID- INDUCED ULCERS UNOPROSTONE SUCAMPO PHARMA ISOPROPYL FOR DRY $244,479.25 AMERICAS, INC. AMD RETINITIS PIGMENTOSA Zalvari™ A new therapy to Supemus Pharmaceuticals, treat persistent conduct $244,479.25 Inc problems in children with ADHD Supernus Pharmaceuticals A Novel Non-Stimulant $244,479.25 Inc Treatment for ADHD XL647 RTK Cancer Symphony Evolution Inc $244,479.24 Therapeutics XL784 for Abominal Aortic Symphony Evolution, Inc $157,998.50 $86,480.74 Aneurysm Development of Clostridial toxin based therapies for Synaptic Research, LLC $63,349.27 $123,191.53 Botulism, Cancer, AKS, and Stem Cells A Novel Tumor-targeting SynerGene Therapeutics, Cancer Nanomedicine $140,177.93 $104,301.32 Inc Eliminates, and Prevents Recurrence of, Solid Tumors Product Development for Synergy America Inc Invasive Pneumoccal $244,479.25 Diseases YK-4-279 as a Novel Therapy TDP Biotechnology $159,070.00 for Cancer Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Tetracore, Inc FAS- Detect ELISA Test $181,204.18 $63,275.06 Novel Diagnostic Test for Directing Molecular Targeted Theranostics Health Inc. $151,670.50 $92,808.75 Therapies in Metastatic Cancer Brain Disease Treatment Therataxis LLC $14,150.00 Simulator Noninvasive regenerative TissueGene, Inc therapy for the treatment of $244,479.24 osteoarthritis Trevigen Inc Knockdown Cell Lines $134,640.52 $88,851.69 PARP in vivo Trevigen Inc $58,906.64 $5,227.27 pharmacodynamic Assay II Development of TSH Superagonist Analogs for Trophogen Inc $244,479.24 Diagnosis and Treatment of Thyroid Cancer Development of FSH TROPHOGEN, INC. Superagonist Analogs for $6,969.22 $196,483.90 Infertility and Ovarian Cancer Development of VBP15 for Validus Biopharma, Inc. the treatment of Duchenne $81,728.23 $162,751.02 Muscular Dystrophy VNX-4975 for the treatment Vallinex Inc of severe knee osteoarthritis $244,479.25 and Morton's neuroms Development VZP-758 Vanda Pharmaceuticals Inc. compound to treat Raynaud's $244,479.25 Phenomenon Development of tasimelteon to treat Non-24-Hou Vanda Pharmaceuticals Inc. $244,479.25 Sleep/Wake Disorder in blind individuals. Vapotherm Inc. Adaptive Oxygen Control $3,664.54 $63,540.52 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Vapotherm Inc. Nasal Drug Delivery $18,358.20 $62,554.29 VectorLogics, Inc Cancer Virotherapeutics $244,479.24 Grafting Strategies for Liver Vesta Therapeutics $225,856.25 $18,623.00 Cell Therapies Allogeneic Hepatic Progenitor Vesta Therapeutics Cell Therapy for Liver $244,479.25 Diseases Viracine Therapeutics NoVR $50,575.10 $193,904.15 Corporation AntiViral Drug for ViroDefense Inc Enterovirus 71 Neurologic $244,479.24 Infections Antiviral drug Essential for ViroDefense Inc $244,479.25 Polio Eradication VIRxSYS Corporation Lexgenleucel-T $244,479.25 VIRxSYS Corporation VRX1273 $244,479.24 VIRXsys Corporation VRX1243 $211,840.00 $32,639.25 Weinberg Medical Physics, Ultra Fast Magnetic Field $202,673.22 $41,806.02 LLC Generator Weinberg Medical Physics, MRI-Compatible PEM $109,350.06 LLC Scanner Real-Time Guidance System Weinberg Medical Physics, for Monitoring Proton $51,756.97 $87,316.04 LLC Therapy Wellstat Biologics PV701 Oncolytic Virus for $244,479.24 Corporation the Treatment of Cancer Electrochemiluminescent WELLSTAT based RNA detection $244,479.24 DIAGNOSTICS LLC platform for POC diagnosis of cancers and pathogens WELLSTAT Rapid POC blood-based $80,232.00 $164,247.24 DIAGNOSTICS LLC diagnostic test for Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 nonalcoholic fatty liver disease and steatohepatitis Rapid point-of-care Lyme Wellstat Diagnostics LLC disease blood-based $85,974.50 diagnostic test A novel antibiotic combination to treat WellStat Diagnostics, LLC $82,262.00 $162,217.24 infections of drug resistant Staphylococcus aureus. WELLSTAT IMMUNO WIT-301 for prevention and $79,667.00 $87,203.00 THERAPEUTICS LLC treatment of Type 1 Diabetes WIT-201: Tolerogenic protein Wellstat Immuno for treatment of multiple $66,653.00 Therapeutics LLC sclerosis ZPS pllysaccharide for WELLSTAT IMMUNO treatment of inflammatory $244,043.50 $435.74 THERAPEUTICS LLC diseases Sustained Delivery of Novel Wellstat Ophthalmics Therapeutics for the $244,479.24 Corporation Treatment of Ocular Diseases pn2107 FOR THE WELLSTAT TREATMENT OF $244,479.25 THERAPEUTICS CORP HYPERURICEMIA AND GOUT Invitro-generated T- progenitor cells for T-cell Wellstat Therapeutics reconstitution in $42,781.50 $178,795.00 Corporation hematopoietic stem cell transplantation WELLSTAT PN403 for the treatment of THERAPEUTICS mitochondrial disease and $244,479.25 CORPORATION Alzheimer's disease Wellstat Therapeutics pn401 FOR THE Treatment $244,479.25 Corporation of Cancer Patients WELLSTAT PN951 for ex vivo expansion $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 THERAPEUTICS of cord blood stem cells for CORPORATION transplants A novel Neisseria meningitidis Group B Wellstat Vaccines LLC $156,919.50 $87,559.74 polysaccharide Conjugate vaccine Neisseria meningitidis Groups WELLSTAT VACCINES C and Y/Haemophilus $176,142.50 $68,336.74 LLC influenzae type b conjugate vaccine Method and Equipment for Xcision Medical Systems, Image-Guided Stereotactic $244,479.24 LLC Radiosurgery of Breast Cancer Single protein, multi-specific Zyngenia, Inc $244,479.24 therapeutics for Cancer Single, protein, multispecific therapeutics in Chronic Zyngenia, Inc. $244,479.24 Autoimmune and Inflammatory Diseases

Massachusetts $124,271,278.13

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Use of Zinc Chelators to inhibit 3G Biotech, LLC $244,479.24 Biofilm Formation Multiparameter Screening Method and Multicomponent 3W Consulting Co $240,250.00 $4,229.24 Drug for Cardiovascular Disease Intravenous Protein Therapy by 4s3 Bioscience, Inc $189,538.00 $54,941.24 Myotonic Dystrophy Type 1 Acceleron Pharma, Inc ACE-031 $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Acceleron Pharma, Inc. ACE-536 $244,479.25 Acceleron Pharma, Inc. ACE-435 $244,479.24 Acceleron Pharma, Inc. ACE-011 Anemia $244,479.24 Acceleron Pharma, Inc. ACE-041 $244,479.24 Acetylon Development of novel cancer $244,479.25 Pharmaceuticals Inc drug candidate ACY-1215 ACY-257 A NOVEL HDAC6 ACETYLON INHIBITOR DRUG PHARMACEUTICALS, CANDIDATE FOR $152,965.50 $91,513.75 INC. INFLAMMATORY DISEASES AC-100 Treatmenty for Signs Aciex Therapeutics, Inc and Symptoms of Dry Eye $244,479.24 Syndrome AC-120 TREATMENT FOR Aciex Therapeutics, Inc. $244,479.24 CHRONIC EYELID EDEMA AC-200- Treatment for Aciex Therapeutics, Inc. $244,479.24 Meibomian Gland Disease AC-150- TREATMENT FOR ACIEX COMPREHENSIVE $244,479.24 THERAPEUTICS, INC. ALLERGIC CONJUNCTIVITIS Acton Pharmaceuticals, Aerospan (flunisolide hfa 80 $244,479.25 Inc. mcg) Inhalation Aerosol AI-700- (perflubutane polymer Acusphere, Inc microspheres) for Injectable $244,479.25 Suspension AdvanDx Inc. PNA FISH $244,479.24 Development of PancAtak for Advantagene Inc $20,290.00 $124,128.00 Panceatic Cancer Development of GliAtak for Advantagene, Inc. $244,479.25 malignant brain tumors Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of ProstAtak™ Advantagene, Inc. $101,602.00 $142,877.25 for Prostate Cancer AES-103: A new targeted AesRX, LLC $173,806.92 $70,672.33 treatment of Sickle Cell Disease Developing novel cancer Agios Pharmaceuticals therapies targeting the key $244,479.25 metabolic enzyme PKM2 Developing novel targeted therapies for gliomas & AML Agios Pharmaceuticals $244,479.25 harboring IDH2 & IDH2 mutations Aileron Therapeutics, Inc BIM Mimetic for Oncology $244,479.24 Aileron Therapeutics, Stapled Peptide Therapeutic $244,479.24 Inc. Pipeline Development of a novel drug to Alfama, Inc. treat acetaminophen-induced $244,479.24 acute liver failure (ALF) Synthesis of improved CORMs Alfama, Inc. to treat acute liver failure and $244,479.24 post-operative ileus Development of a novel drug to Alfama, Inc. prevent to treat post-operative $63,658.34 $47,794.70 ileus (POI). Assessment of ALK001 for the Alkeus Pharmaceuticals prevention of vision loss in dry $129,437.00 $115,042.25 Inc macular degeneration Product Development for Allegro Diagnostics $244,479.25 BronchoGen (AEGIS Trial) Alnylam Pharmaceuticals Single Strand RNAi $244,479.24 Inc Technology Platform Alnylam Pharmaceuticals Alnylam Biotherapeutics $244,479.24 Inc Alnylam Pharmaceuticals ALN-VSP for Liver Cancer $244,479.24 Inc. Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Alnylam RNAi Therapeutic Delivery $244,479.24 Pharmaceuticals, Inc Platform Alnylam ALN-HTT for Huntington's $244,479.24 Pharmaceuticals, Inc Disease Alnylam ALN-PCS for the treatment of $244,479.24 Pharmaceuticals, Inc Hypercholesterolemia Alnylam ALN-RSV for Respiratory $244,479.24 Pharmaceuticals, Inc. Syncytial Virus (RSV) infection ALN-TTR for the Treatment of Alnylam Transthyrein-mediated $244,479.24 Pharmaceuticals, Inc. Amyloidosis (ATTR) Modulators of Amyloid Alzcor Pharmaceuticals Precursor $2,000.00 Inc protein(APP)Processing Development of Diagnostic and AmberGen, Inc. Prognostic Cancer Assays For $244,479.25 Personalized Medicine Minimally Invasive Targeted Therapeutic Hypothermia for AmelioMed, LLC $4,755.93 the Treatment of Spinal Cord Injury Novel long-lived peptide Anchor Therapeutics, allosteric G protein coupled $244,479.25 Inc. receptor modulators Synthetic Carbohydrate-Based Ancora Pharmaceuticals Staphylococcal Vaccine $244,479.25 Inc Program Ancora Pharmaceuticals, Synthetic Carbohydrate-Based $220,853.50 $23,625.75 Inc Malaria Vaccine Program ANX-042 treatment of acute Anexon Inc decompensated haert failure $244,479.25 (ADHF) Ii-Key Her-2/neu Peptide Antigen Express Inc $244,479.25 Vaccine, AE37, for the Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 treatment of breast cancer. li-Key Her-2/neu Peptide Antigen Express, Inc Vaccine, AE37, for the $244,479.25 treatment of prostate cancer AG-707, Inveestigational Antigenics Inc. therapeutic vaccine for $59,891.00 $120,350.00 treatment of genital herpes Antigenics Inc.(a QS-21, Vaccine adjuvant under Massachusetts development to treat infections, $244,479.25 corporation) cancers, and Alzheimers Amonafide: evading drug Antisoma Inc $244,479.24 resistance in leukemia Development of Zindol, a Novel Aphios Corporation $80,968.50 $106,759.00 Anti-Nausea Drug Phospholipid Nanosomes Drug Aphios Corporation $82,652.50 $51,873.50 Delivery Pathogen Inactivation of Human Aphios Corporation $83,801.00 $160,678.25 Plasma AQUILUS Development of AQU-010 for PHARMACEUTICALS $5,460.00 $11,714.50 Neuropathic Pain INC Archemix Corp Hemophilia-ARC19499 $244,479.25 ARIAD PHARMACEUTICALS, mTOR Inhibitor-Ridaforolimus $244,479.24 INC ARIAD PHARMACEUTICALS, ALK Inhibitor-AP26113 $244,479.24 INC ARIAD Pan BCR-ABL Inhibitor- PHARMACEUTICALS, $244,479.24 AP24534 INC Antifungal therapies for the ARIETIS treatment of recalcitrant and $76,354.91 $168,124.34 CORPORATION recurrent Candida albicans Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 infection Arisaph Pharmaceuticals Niacin Mimetics $244,479.25 Inc Arisaph Pharmaceuticals APO A1 Mimetics $102,759.50 $132,924.00 Inc Arisaph Pharmaceuticals GLP-1 $120,236.00 $117,636.00 Inc Arisaph Pharmaceuticals Endothelial Lipase Inhibitors $148,986.00 $95,493.25 Inc. Arisaph Pharmaceuticals, Small Molecule Enhancers for $179,287.50 $65,191.75 Inc Cancer Vaccines Arisaph Pharmaceuticals, Stabilized Peptide Hormones $111,473.50 $67,985.50 Inc Arisaph Pharmaceuticals, Tumor-Activated Prodrugs $244,479.25 Inc ARISAPH OBESITY/METABOLIC PHARMACEUTICALS, DISORDERS- $198,579.00 $45,900.25 INC MULTIMEDIATORS Arisaph Pharmaceuticals, Tumor Diagnotics $150,059.50 $94,419.75 Inc Arisaph Pharmaceuticals, DPP-4 Inhibitors $244,479.25 Inc. Arisaph Pharmaceuticals, Kinetically Dosed Tumor $181,868.50 $62,610.75 Inc. Selective Proteosome Inhibitors Arisaph Pharmaceuticals, Stable NPY Analogs $111,046.50 $67,610.50 Inc. Inhibitors of Mutant BRAF Arqule Inc $244,479.24 Kinase in Cancer Arqule Inc ARQ 621 Cancer Drug Project $244,479.24 ARQ-197 Cencer Drug Arqule, Inc. $244,479.24 Development Project Arqule, Inc. ARQ -087 Fibroblast Growth $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Factor Receptor (FGFR) inhibitor Project Therapeutic Drug Delivery Arsenal Medical, Inc. $244,479.25 Bioabsorbable Vascular Stent Artisan Pharma Inc ART-123 $244,479.25 Magnetic Hanoportide Aspen Medisys LLC Thermathempy for treating $244,479.25 cancer Development of Attention Attention Therapeutics, Therapeutic System for $173,371.50 Inc. regulatory clearance/commercialization. Twin-base linker (TBL) bone Audax Medical, Inc $206,885.00 augmentation Augmenix, Inc SpaceOAR $244,479.25 Development of a topical self- Aura Biosciences Inc administered treatment for $244,479.24 cervical and anal dysplasia Light-activated Soft Tissue Aura Medsystems, Inc. $206,804.50 $37,674.75 Repair (laSTR) Co - Transplanation of Auxocell laboratories, Wharton's Jellly Stem Cells and $244,479.24 Inc. Cord Blood Stem Cells Auxocell Laboratories, Medical Device to Process $200,000.00 $44,479.24 Inc. Wharton's Jelly Stem Cells Development of AVX-470 for Avaxia Biologics, Inc the treatment of Gastrointestinal $24,168.78 $220,310.46 Inflammatory Disorders Novel Therapy Using Microwave and Ultraviolet Avedro, Inc. $244,479.25 Energy to Treat Degenerative Corneal Disease AVEO Pharmaceuticals, Tivozanib-A Potent and $244,479.25 Inc Selective Triple VEGF-R Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inhibitor AVEO Pharmaceuticals, AV-299- A Novel HGF/c-Met $244,479.25 Inc Inhibitor AVEO Pharmaceuticals, Human Response Platform™ $244,479.25 Inc. and Antibody Programs Inhibition of Bruton's tyrosine kinase [Btk} to treat blood Avila Therapeutics Inc. $244,479.24 cancers and autoimmune diseases. Development of novel therapies, Avila Therapeutics, Inc AVL-181 and AVL-192 to treat $244,479.24 Hepatitis C Virus infection Bach Pharma, Inc a novel neuroprotective agent $244,479.24 The BGM Galectin-3 blood test BG Medicine Inc for predicting development and $244,479.25 progression of heart failure AMIPredict™ : A novel BG Medicine, Inc. molecular diagnostic for near- $244,479.25 term heart attack or stroke Pharmacotherapeutics for the Bikam Pharmaceuticals Treatment of Retinitis $244,479.24 Pigmentosa Development of targeted nanoparticle therapeutics Bind Biosciences, Inc $244,479.24 containing highly potent cytonixic agents Development of BIND-014--a solid tumor-targeted BIND Biosciences, Inc $244,479.24 nanoparticle containing docetaxel Develop a Medicinal Nanoengineering ™ platform BIND Biosciences, Inc $244,479.24 for polymer-based targeted nanoparticle Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Surface Active Tissue BIO2 Technologies, Inc. $18,614.00 $225,865.24 Engineering Scaffold Resorbable Tissue Engineering BIO2 Technologies, Inc. $55,445.50 $189,033.74 Scaffold Development of a TNF Inhibitor BioAssets Development Drug for the Treaments of $244,479.24 Corp Sciatica. BioBehavioral Expansion of Use of the $230,018.50 $14,460.75 Diagnostics Company Quotient ADHD System Transdermal Diabetic BioChemics Inc Neuropathy Treatment (BC- $147,004.66 $97,474.59 DN-01) Arresting progression of BioNevia diabetic Neuropathy with $162,689.50 $81,789.74 Pharmaceuticals Inc Epalrestat (BNV-222) ViBe platform and AMMP assay for biomarker BioScale, Inc $244,479.25 measurement in therapeutics and Dx Sensor-based Auto- BioSensics LLC BioFeedback and Health $9,250.00 $104,230.00 Monitoring System Bio-Tree Systems, Inc OncoTree discovery $244,479.25 Novel Therapeutics for the Biousian Biosystems Inc treatment of Chronic Pain and $61,464.50 $73,113.00 Diabetes The OPTiHaN Trial: A Phase 3 BioVex, Inc. Trial to Evaluate OncoVEX in $2,962.50 $241,516.74 Head and Neck Cancer The OPTiM Trial: A BioVex, Inc. Randomized Phase 3 Clinical $244,479.24 Trial to Evaluate OncoVEX Use of longterm patient- Birch Tree Medical, Inc. $206,000.00 controlled heat to relieve Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Restless leg Syndrome BB15600 Anti-Cancer Stem Boston Biomedical, Inc Cell Drug Discovery and $7,673.39 $236,805.85 Deveopment Program BBI8000 Anti-Cancer Drug Boston Biomedical, Inc. Discovery and Development $4,024.94 $240,454.31 Program BB16000 Anti-Cancer Stem Boston Biomedical, Inc. Cell Drug Discovery and $244,479.24 Development Program Therapeutic Gastrointestinal Boston Endoscopic Delivery Platform for EUS fine $185,052.50 $59,426.74 Engineering Corporation needle aspiration Rapid Point-of-Care Test Boston Microfluidics Inc $244,479.24 Platform Braintree Laboratories, BLI801- SULFATE $64,956.50 $146,603.50 Inc LAXATIVE Braintree Laboratories, BLI1100-MEDIDERMIS $152,698.50 $91,780.75 Inc. Braintree Laboratories, PCD03 - METRONIDAZOLE $244,479.25 Inc. 10% Ointment BetterMilk with Cambrooke Foods, LLC Glycomacropeptide for $80,095.50 Phenylketonuria(PKU) Articulated Robotic Medprobe Cardiorobotics, Inc. $244,479.25 (ARM) Robotic System Fatty Acid Salicylate Catabasis Conjugates as Novel $244,479.24 Pharmaceuticals, Inc Therapeutics for the Treatment of Type 2 Diabetes Isolation of Therapeutic Binders Celexion LLC $78,118.00 $166,361.24 to Oncogenic Targets New Method for Cancer Cellay, Inc. $244,479.24 Diagnosis Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 KM-133 for Treatment of Cellceutix Corporation $141,984.50 $102,494.75 Psoriasis Cellceutix Corporation Kevetrin for Cancer Treatment $244,479.25 KM-391 For Treatment of Cellceutix Corporation $142,830.00 $101,649.25 Autism Celldex Therapeutics Inc CDX-301 $244,479.24 Celldex Therapeutics Inc CDX-1307 $244,479.24 Celldex Therapeutics Inc CDX-011 $244,479.24 Celldex Therapeutics Inc CDX-1127 $244,479.24 Celldex Therapeutics, Rindopepimut (CDX-110) $244,479.24 Inc. Celldex Therapeutics, CDX-1135 $133,360.50 $111,118.74 Inc. Celldex Therapeutics, CDX-1401 $244,479.24 Inc. Functional restoration of a large-scale skeletal muscle CellThera, Inc. $219,093.50 $25,385.74 defect using dedifferentiated cells Celthera, Inc. Regenerative Platform $25,716.54 $4,803.25 high-Density Diffuse Optical Tomography for Real-Time Cephalogics LLC $67,612.00 $93,531.70 Neurological Assessment in Infants Cequent Pharmaceuticals, CEQ508 $244,479.25 Inc. Cequent Pharmaceuticals, CEQ626 $244,479.25 Inc. CeQur Insulin Delivery Device CeQur Corporation $244,479.24 for Use in Type 2 Diabetes Neurostimulation for Cerenova, Inc $244,479.25 neurotrauma rehabilitation Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 CRLX101 (formerly IT-101)A Cerulean Pharma Inc Novel Nanopharmaceutical $244,479.25 Oncology Agent in Phase 2 Nanopharmaceutical Docetaxel- Cerulean Pharma Inc A Promising Next Generation $244,479.25 Oncology Agent Nanopharmaceutical Drug Cerulean Pharma Inc. Delivery Patform Enabling $244,479.25 RNA Interference Therapy Point-of-Care Diagnostic Claros Diagnostics, Inc. $244,479.24 System for Urologist Office Use CombinatoRX ,Inc Synavive Project $244,479.24 Combinent Biomedical CBMS-10 $221,188.93 $23,290.31 Systems, Inc. Concert Medical, LLC Concert Conductor Guidewire $35,650.50 Concert Medical, LLC "Concert N2009 Guidewire $24,927.00 Novel HIV protease inhibitor Concert Pharmaceuticals, not requiring co-dosing with a $244,479.24 Inc pharmacokinetic boosting agent Concert Pharmaceuticals, Novel Treatment for Diabetic $244,479.24 Inc Nephropathy New Therapeutics That Target Constellation Epigenetic Regulatory Proteins $244,479.25 Pharmaceuticals, Inc in Cancer CorNova Inc The FiberHalo Catheter $244,479.25 Correx 18-mm Aortic Valve Correx Inc $244,479.25 Bypass Kit Anticancer agents based on a Creagen Biosciences, Inc $205,841.50 $38,637.74 dual function structures Curaxis Pharmaceutical ALADDIN Clinical trials $39,154.00 Corporation CuriRx Inc Novel anti-cancer drug $15,410.00 $109,750.00 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 candidate Multi-targeted network inhibitor Curis Inc $244,479.25 platform for cancer CUDC-101, a Phase 1 cancer Curis, Inc $244,479.25 agent Novel Combination Immunotherapy of Cancer: CYTOCURE LLC $120,224.00 $124,255.25 Drugs that Enhance Tumor Antigens Therapeutic Cell Sorter for Cytonome/ST, LLC $244,479.25 Blood Cancers High Potency Cord Blood Stem Cells as Therapeutics for CytoVera Inc $7,926.50 $125,000.00 Treatment for Treating Blood Cancers in Adults. Development of a Handheld CD4 Cell Counter for Point-of- Daktari Diagnostics Inc. $244,479.24 Care Monitoring of HIV Patients A Novel Castration Restitant Dicerna Pharmaceuticals Prostate Cancer Treatment $244,479.24 Inc Targeting Androgen Receptor Dicer Substrate Technology ™, Dicerna Pharmaceuticals a new and novel RNAi-based $244,479.24 Inc drug development platform Antibody Repertoire Profiling Differential Proteomics, for Enabling Detection, $132,836.84 $111,642.41 Inc. Diagnosis and Treatment of Diseases DNA Medicine Institute, Universal Blood Sensor $54,048.50 $168,950.00 Inc. Dragonfly Sciences, Inc Etanercept Biosimilar $244,479.25 Dune Medical Devices MarginProbe System $244,479.25 Inc Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Dyax Corp FcRn (DX-2500) $220,011.50 $24,467.75 Dyax Corp DX-88 HAE KALBITOR $244,479.25 Dyax Corp DX-2400 $244,479.25 ACE inhibitor Induced Dyax Corp $179,610.00 $64,869.25 Angioedema Dyax Corp. MMP-9 (DX-2802) $244,479.25 Dyax Corp. Plasma Kallikrein Inhibitor $244,479.25 Antibiotic Drug Discovery from EarthGenes Environmental DNA Expression $69,882.50 $166,689.50 Pharmaceuticals LLC Libraries Symphony Transdermal Echo Therapeutics, Inc Continuous Glucose Monitoring $244,479.25 System Adults & Neonatal Stem Cell ECW Therapeutics, Inc $80,000.00 Seperation Device EDI200, a recombinant protein for treatment of X-linked Edimer Pharmaceuticals $244,479.24 hypohidrotic ectodermal dysplasia. Protein based drug discovery Eleven Biotherapeutics project Myostatin for Muscle $244,479.25 Inc wasting Protein-based drug discovery Eleven Biotherapeutics, project: T helper cell, 17 in $244,479.25 Inc. inflammatory diseases Protein-based drug discovery Eleven Biotherapeutics, project: Factor VIII for the $244,479.25 Inc. treatment of Hemophilla A Development of a Small Elixir Pharmaceuticals, Molecule Ghrelin Antagonist, $244,479.25 Inc EX-1832, for the Treatment of Metabolic Disorders Enanta Pharmaceuticals Novel Oral Antibiotic for the $211,295.50 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc treatment of MRSA, VRE and Resistant Strep Infections Novel NS5A Inhibitors for the Enanta Pharmaceuticals treatment of Hepatitis C $244,479.24 Inc Infection Novel I.V. Antibiotic for the Enanta Pharmaceuticals treatment of MRSA, VRE and $49,673.00 Inc. resistant Strep Infections Novel Cyclophilin inhibitors for Enanta Pharmaceuticals, the Treatment of Hepatitis C $244,479.24 Inc Infection Thermoacoustic imaging device Endra Inc for point of care $129,189.02 $115,290.23 diagnosticapplications Energesis Discovery of Novel Brown Fat $244,479.24 Pharmaceuticals Inc Targeting Drugs for Obesity Enlight Biosciences, LLC Enigma Liver Toxicity $41,214.64 $79,990.33 Enlight Biosciences, LLC Ensof Biomarker Discovery $27,992.37 $216,486.88 Enlight Biosciences, LLC Entrega Drug Delivery $118,888.34 $125,590.91 DNA-Programmed Chemistry Ensemble Therapeutics and its Application for the $244,479.24 Corporation Discovery of Novel Oncology Drugs. New Personalized Medicine Ensemble Therapeutics Diagnostics for Predicting Drug $244,479.24 Corporation Resistance in Breast Cancer Oral Macrocycle Drugs for Ensemble Therapeutics Treatment of Rheumatiod $244,479.24 Corporation Arthritis & Other Inflammatory Diseases. Entra Pharmaceuticals Novel Biopharmaceuticals Drug $244,479.25 Inc Delivery System Epizyme Inc WHSC1 Therapeutic Project $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Epizyme Inc DOT1L Therapeutic Project $244,479.24 Epizyme Inc EZH2 Therapeutic Project $244,479.24 ETEX Corporation Bone Regenerating Biomaterial $244,479.24 EB-1020: A novel treatment for Euthymics Bioscience, adult Attention Deficit $5,802.50 $238,676.75 Inc Hyperactivity Disorder (ADHD) EB-1010: A NOVEL ANTIDEPRESSANT TO Euthymics Bioscience, PATIENTS NOT $52,224.00 $192,255.25 Inc. RESPONDING ADEQUATELY TO SSRIs Developing BH3 profiling as a Eutropics predictive diagnostic test for $32,910.50 $105,652.50 Pharmaceuticals multiple myeloma Developing Small molecule Eutropics inhibitor of Mcl-1to treat blood $78,719.00 $165,760.25 Pharmaceuticals cancer Development and Manufacture Excelimmune Inc. of Human Recombinant $244,479.24 Polyclonal Antibodies (HRPA) Eyegate Pharmaceuticals Biologics $56,500.00 $173,500.00 Inc EyeGate Pharmaceuticals Nanoparticles $174,500.00 $69,979.25 Inc Eyegate Pharmaceuticals EGP 437 $244,479.25 Inc Eyegate Pharmaceuticals, EyeGate III $244,479.25 Inc Prevention of Tumor Fifth Base, LLC Recurrence via Flexible $55,799.14 $22,539.94 Chemotherapy-Eluting Strips Novel low-cost automated First Light Biosciences, platform for rapid and sensative $244,479.25 Inc detection of resistant bacteria Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 FX005 Intra-articular Injection Flexion Therapeutics Inc for Treatment of Pain in $244,479.25 Osteoarthritis of the Knee Flexion Therapeutics, FX004- Acamprosate for the $137,784.50 $106,694.75 Inc. Treatment of Tinnitus Tafamidis for the treatment of FoldRx Pharmaceuticals $244,479.25 TTR Amyloidosis Unduggable Targets Important Forma Therapeutics, Inc for Cancer Treatment $244,479.25 (Protein/Protein Interactions) Forma Therapeutics, Inc NAMPT $244,479.25 Diversity-Oriented Synthesis Forma Therapeutics, Inc $244,479.25 (DOS) Chemistry Formatech Inc Miradocetaxel Development $15,635.50 $113,901.50 Foundation Medicine, Molecular Cancer Diagnostics $244,479.25 Inc. 5-HT6 Antagonists for Galenea Corp. cognitive improvement in $65,651.00 $178,828.25 schizophrenia 5-HT2C Agonists for Appetite GALENEA CORP. $244,479.25 Suppression in Obesity Discovery of novel mechanism- Galenea Corp. based therapies for $244,479.25 Schizophrenia Gelesis Inc Gelesis Novel Hydrogels $244,479.25 Gene Network Sciences, Collaboration with Biogen Idec $28,457.50 Inc Phase I Genetix Pharmaceuticals Lentiglobin $244,479.24 Inc Genetix Pharmaceuticals Lenti-D $244,479.24 Inc Genocea Biosciences, Inc Development of a Chlamydia $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Vaccine Based on Natural Immunity in Humans Development of Vaccines for Genocea Biosciences, Genital Herpes Based on $244,479.24 Inc. Natural Immunity in Humans The EndoBarrier for treatment GI Dynamics, Inc. $244,479.25 of type 2 diabetes and obesity Hybrid Molecules Designed to GLSynthesis Inc $244,479.24 Enhance Antibiotic Activity Novel drugs to treat Urinary GLSynthesis Inc. $244,479.24 Incontinence Preclinical development of a GLSynthesis Inc. novel antibacterial for $219,164.00 Clostridium difficile disease Novel Antithrombotic GLSynthesis Inc. Diadenosine Tetraphosphate $151,747.00 $92,732.24 Analogs Rapid in vitro Substrate Assay GLSynthesis, Inc. for the multi-drug Resistant P- $107,992.00 $132,649.50 glycoprotein Oligosaccharides to Prevent Glycosyn, Inc. $155,208.00 $89,271.24 Infectious Diarrhea GSG Molecular Genetic Screen Good Start Genetics $145,925.39 $98,553.86 Platform Nonivasive glucose monitor for Grove Instruments Inc $244,479.25 diabetic patients SmartHealth: Hypertension Healthrageous, Inc. $244,479.25 Self-Management Non-invasive detection of Helicos BioSciences genetic disorders for prenatal $138,671.50 $93,884.50 Corporation diagnostics Identification of disease-specific Helicos BioSciences mutations and polymorphisms $244,479.25 Corporation in affected individuals Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Detection of pathogen nucleic Helicos BioSciences acid contamination in body $88,828.50 $155,650.75 Corporation fluids & in biological therapeutics Novel Device to Diagnose Conditions of Compromised Hemedex, Inc. $244,479.25 Blood Flow and to Quantify Edema Electrosonic Stimulation for Highland Instruments Noninvasive deep Brain $47,534.00 $68,890.00 Stimulation NeoCart (Cultured Autologous Histogenics Corporation $244,479.24 Neo-Cartilage) Multimodal Silica Nanoparticles Hybrid Silica as Cancer Targeted Probes for $228,130.00 $16,349.25 Technologies Inc Clinical Translation TRPA1 Antagonists as a Broad Medical Countermeasure to Hydra Biosciences, Inc $200,753.50 $43,725.74 Biological and Chemical Threats TRPA1 Antagonists as New Hydra Biosciences, Inc. Treatments for Pain due to $244,479.24 injury or inflamation TRPV3 Antagonists as New Hydra Biosciences, Inc. Treatments for Chronic and $244,479.24 Acute Pain A unique Herceptin conjugate ImmuneXcite, Inc directs neutrophils to fight $42,352.50 $68,737.50 breast cancer Jak2/Hexim1 kinase inhibitors ImmunoDiagnostics, Inc as therapeutics for the treatment $107,730.00 $136,749.25 of viral (HIV) disorders IMGN009- Antibody-drug ImmunoGen Inc $244,479.24 conjugate to fight cancer ImmunoGen Inc. IMGN007 Antibody-drug $153,250.00 $91,229.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 conjugate to fight cancer. IMGN529 Antibody-drug ImmunoGen Inc. $244,479.24 conjugate. IMGN388 antibody-drug ImmunoGen Inc. $244,479.24 conjugate Lorvotuzumab mertansine - ImmunoGen, Inc. IMGN901 - antibody-drug $244,479.24 conjugate Development of a low-cost, Inanovate Inc accurate cancer diagnostic $227,192.05 $17,287.19 platform. Office-based Varicose Vein InaVein, LLC Treatment with Local $38,494.50 Anesthesia Hsp90 Chaperone Inhibitor Infinity Discovery, Inc $244,479.24 Program IPI 926 Hedgehog Pathway Infinity Discovery, Inc $244,479.25 Inhibitor Program IPI-940 Fatty acid Amide Infinity Discovery, Inc $244,479.25 Hydrolase Inhibitor Program Clinical validation of near- infrared spectoscopy for InfraReDx, Inc $244,479.25 diagnosing high risk coronary plaques LipiScan ™ IVUS Diagnostic InfraReDx, Inc $244,479.25 System Early Warning System for InnerSea Technology Inc Spinal Cord injured at Risk for $103,489.50 $106,677.00 Autonomic Dysreflexia Inotek Pharmaceuticals INO-8875 $244,479.24 Corporation Inotek Pharmaceuticals Development of PARPs for use $178,152.67 $66,326.58 Corporation in oncology treatment Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inotek Pharmaceuticals INO-4885 $182,507.61 $27,493.59 Corporation Intact Medical Corp Breast Lesion Excision System $244,479.24 Novel Programming Device to Intelect Medical, Inc. Further the Delivery of Deep $244,479.25 Brain Stimulation Devices DNA Sequence Based Cancer Intelligent Bio-Systems $244,479.25 Diagnostic System Intelligent Medical XMRV and other molecular $11,214.00 $96,384.50 Devices Inc factors to assess prostate cancer Low Cost Screening for Intelligent Medical Healthcare Associated $209,418.00 $35,061.25 Devices Inc infections Intelligent Medical Detection and Resistance $244,479.25 Devices Inc Screening for Influenza Intelligent Medical Monitoring Viruses Associated $117,346.50 $73,475.50 Devices, Inc with Transplant Rejection Comprehensive Test to Guide Intelligent Medical Treatment and Prevent $97,308.50 $147,170.75 Devices, Inc. Outbreaks of Whooping Cough MyoSure Rod Lens Interlace Medical, Inc Hysteroscope Development $244,479.25 Project Interleukin Genetics Osteoarthritis $128,071.00 $100,843.50 Interleukin Genetics Inc Perilipin $227,377.00 $17,102.25 Safety and Efficacy of an InVivo Therapeutics Implanted Biodegradable $244,479.25 Corporation Polymeric Scaffold to Treat Spinal Cord injury Rapid Point of Care Molecular Diagnostics for Influenza; IQuum, Inc $244,479.25 Seasonal & Pandemic H1N1 Assays Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Rapid, Point of Care Molecular Iquum, Inc. Diagnostic Assay for Detection $76,541.00 $167,938.25 of Fungemia Development of Novel CRTH2 Ironwood Inhibitor, IW-1221, for $244,479.25 Pharmaceuticals Inc Treatment of Asthma Ironwood FAAH Inhibitor, IW-6118 to $244,479.25 Pharmaceuticals Inc Treat Pain and Inflammation Ironwood Linaclotide, A Novel Guanylate $244,479.25 Pharmaceuticals, Inc Cycase C Agonist IW-9179, for Treatment of Ironwood Gastroparesis and Functional $180,000.00 $64,479.25 Pharmaceuticals, Inc. Dyspepsia. Ischemix LLC CMX-2043 $244,479.24 Jasco Pharmaceuticals, The Pim Inhibitor Project $244,479.24 LLC Clinical Development of an oral, non-psychotropic JB Therapeutics Inc $19,587.50 $224,891.75 CB1/CB2 Cannabinoid Agonist for the treat Chronic Pain Development of a Lead Based JEF Core, Incorporated System for Respiratory $41,392.00 $160,749.50 Variation Monitoring Development of KALA617, a Kala Pharmaceuticals, once-daily inhalable b-lactam to $12,500.00 $231,979.24 Inc. treat Cystic Fibrosis infections NOVEL CRM1 INHIBITORS KARYOPHAM FOR THE TREATMENT OF $92,500.00 $151,979.25 THERAPEUTICS CANCER Development of HIF inhibitors Ligon Discovery Inc $244,479.25 for Renal Cell Carcinoma LNK-3248: Treating Link Medicine Alzheimer's Disease by $63,348.00 $181,131.25 Corporation Clearing Toxic Proteins Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 LNK-754 Enhancing Link Medicine Autophagy and Mitochondrial $244,479.25 Corporation Function to Treat Alzheimer's Disease LNK-3186: Developing Novel Link Medicine Treatments for Alzheimer's $166,439.00 $78,040.25 Corporation Disease LOGICAL LT-NS001 (NAXPROXEN $244,479.25 THERAPEUTICS, INC ETEMESIL) Prevention and Treatment of Lubris LLC $23,550.00 Osteoarthritis Development of Novel Marine Polymer Biomaterial for Trauma $201,000.50 $43,478.75 Technologies Inc Hemorrhage, Diabetic, & Infected Wound Care Development of IL-15 Protein Marine Polymer Complex as a Therapy for $79,633.00 $45,878.00 Technologies Inc Lymphopenia & Cancer Conformal Electronics for MC10, Inc. Diagnosing and Treating Heart $204,079.79 $40,399.46 Disease Medical Discovery A Blood Test for the Early $60,887.00 $163,617.50 Partners LLC Detection of Cancer Medwell 1-2-3 Molecular Medwell Foods, Inc $244,479.25 Baking Mercator Therapeutics, The Tumor Targeting Project $244,479.25 Inc. Development of Direct AMP Mercury Therapeutics, Kinase Activators for Type 2 $184,696.97 $59,782.28 Inc Diabetes Merrimack MM-151 $244,479.24 Pharmaceuticals Inc Merrimack MM-141 $244,479.24 Pharmaceuticals Inc Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Merrimack MM-121 $244,479.24 Pharmaceuticals Inc Merrimack MM-302 $244,479.24 Pharmaceuticals Inc Merrimack MM-111 $244,479.24 Pharmaceuticals Inc Merrimack MM-POD2 $184,931.50 $59,547.74 Pharmaceuticals Inc. Merrimack MM-POD3 $86,698.50 $157,780.74 Pharmaceuticals, Inc Merrimack MM-131 $244,479.24 Pharmaceuticals, Inc Merrimack MM-POD1 $193,380.50 $51,098.74 Pharmaceuticals, Inc. Merrimack MM-398 $9,228.50 $235,250.74 Pharmaceuticals, Inc. Mersana Therapeutics Inc XMT-1001 $244,479.25 Mersana Therapeutics Inc siRNA $244,479.25 Mersana Therapeutics, XMT-1107 $244,479.25 Inc Development of function-based Metamark Genetics Inc prognostic assays to optimize $244,479.24 and personalize cancer care Preclinical development of Microbiotix $9,586.88 $10,187.29 antagonists of host immunity Preclinical development of Microbiotix, Inc $244,479.24 bacterial replication inhibitors Preclinical Inhibitors of Microbiotix, Inc $244,479.24 Botulinum Neurotoxin A Preclinical development of Microbiotix, Inc novel anti-biofilm coatings for $15,526.04 $64,817.83 implanted medical devices Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Preclinical development of novel broad-spectrum Microbiotix, Inc $118,957.83 $125,521.41 hemorrhagic fever virus inhibitors Clinical development of MBX400: a novel inhibitor of Microbiotix, Inc. $244,479.24 human cytomegalovirus infection Preclinical inhibitors of non- Microbiotix, Inc. replication essential bacterial $244,479.24 targets Preclinical Inhibitors of Microbiotix, Inc. $160,378.98 $84,100.26 bacterial virulence factors Development of an implantable MicroCHIPS Inc one year Continuous Glucose $244,479.25 Monitoring System Development of an implantable MicroCHIPS Inc drug delivery device controlled $244,479.25 release of PTH for one year MindChild Medical Inc Meridian Monitor $111,795.00 $132,684.24 THERAPEUTIC DISABLES MINERVA PRIMAL GROWTH BIOTECHNOLOGIES $244,479.24 MECHANISM ON CANCER CORP STEM CELLS Mobius Imaging LLC SurgiTom $244,479.25 Biosynthetic Meridamycin Modular Genetics, Inc. Analogs for Neurological $170,718.50 $73,760.75 Disorders MOLECULAR INSIGHT ZEMIVA $244,479.25 PHARMACEUTICALS INC Molecular Insight Trofex $244,479.25 Pharmaceuticals Inc Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 MOLECULAR INSIGHT SOLAZED $211,316.50 $33,162.75 PHARMACEUTICALS INC Molecular Insight Azedra - Neuroblastoma $244,479.25 Pharmaceuticals, Inc Molecular Insight Azendra - Pheochromocytoma $244,479.25 Pharmaceuticals, Inc. Molecular Insight Onalta $244,479.25 Pharmaceuticals, Inc. M118, a novel antigoagulant to Momenta treat patients diagnosed with $244,479.25 Pharmaceuticals, Inc Acute Coronary Platform for Momenta Glycosaminoglycan $244,479.25 Pharmaceuticals, Inc Therapeutics-Novel Multimodal Drugs for Multifaceted diseases Momenta M402- A novel multimodal $244,479.25 Pharmaceuticals, Inc inhibitor of tumor metastasis Development of a biologics Momenta platform utilizing through $244,479.25 Pharmaceuticals, Inc characterization to ensure purity Nano Surfaces, Inc. Drug Delivery Micelles $244,479.25 Gene-RADAR for Medical Nanobiosym Diagnostics $72,164.00 $172,315.24 Molecular Diagnostics Single Molecule Drug Nanobiosym, Inc $244,479.24 Discovery Rapid Nucleic Acid-Based NetBio, Inc Diagnosis of STDs at the Point- $244,479.24 of -Care NXN-462 for chronic daily NeurAxon (USA) Inc. headache and post-herpetic $42,011.00 $202,468.24 neuralgia NeurAxon (USA), Inc. NXN-188 for acute migraine $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 NeuroHealing NH001 $180,467.50 $64,011.75 Pharmaceuticals, Inc. Precision Targeted Therapeutic Neurometrix Inc Delivery System for Peripheral $244,479.24 Nerve Indications Development of a definitive Neuron Systems, Inc treatment for dry amd and $244,479.25 stargardt's diesease NPT001, a novel disease- NeuroPhage modifying treatment for $244,479.25 Pharmaceuticals, Inc. Alzheimer's Disease Ocular Diagnostic Test for Neuroptix Corporation $244,479.24 Alzheimer's Disease Diagnosis and Therapy of Drug- Nextcea, Inc Induced Phospholipidosis and $66,107.24 of Niemann-Pick Diseases Development of Novel Nikan Pharmaceuticals, Compounds for Treatment of $6,333.50 $2,855.00 LLC Inflammatory Disorders in Humans Preclinical R&D to advance Nimbus Apollo, Inc. lead molecules targeting ACC $196,019.50 for obesity and diabetes R&D to advance programs targeting PFKFB3 and ZAP70 Nimbus Discovery Inc $71,412.50 $173,066.75 kinases for cancer & inflammation Preclinical R&E to advance lead Nimbus Iris Inc molecules targeting IRAK4 for $244,479.25 inflammatory disease N-lighten Optical Diagnostic NinePoint Medical, Inc. $244,479.25 and Therapeutic System Development of Antibodies NKT Therapeutics INC $244,479.24 Directed Towards NKT Cells Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of OXY111A for NormOxys, Inc the Treatment of Cancer and $244,479.25 Cardiovascular Disease Novelos Therapeutics, NOV-002 Development $244,479.25 Inc. Therapeutic Nuclea Biotechnologies Diagnostic/Prognostic Assay $244,479.25 LLC Development Program Research Methodology for Nuclea Biotechnologies, Therapeutic/Diagnostic $228,990.00 $15,489.25 LLC Discovery Nuclea Biotechnologies, Humanized Anti-Cancer $79,104.00 $165,375.25 LLC Monoclonal Antibodies Ocular Therapeutix, Inc Epi-Coat $132,373.00 $112,106.24 ReSure Adherent Ocular Ocular Therapeutix, Inc. $244,479.25 Bandage Ocular Therapeutix, Inc. Punctum Drug Depot $244,479.25 Breast Biopsy Tumor Tissure On-Q-ity Inc. test to predict response to $244,479.25 anthracycline treatment Lung Biomarker Tumor Tissue On-Q-ity Inc. test to predict cisplatin response $200,422.50 $44,056.75 in lung cancer patients HER-2 Circulating Tumor Cell On-Q-ity Inc. test to inform therapeurtic $93,187.00 $151,292.25 choice for breast cancer patients EGFR circulating tumor cell test On-Q-ity Inc. to inform therapeutic choice for $86,661.50 $157,817.75 lung cancer patients HBOC-201/cGMP OPK Biotech LLC $244,479.25 Manufacturing Facility Novel Immunotherapy ORA, Inc $99,743.00 $144,736.25 Treatment for Dry AMD Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 ORA, Inc Novel Cerumenolytic $31,599.50 $18,486.00 ORA, Inc Novel Anti-Allergic $191,293.50 $53,185.75 Novel Nasal Treatment for ORA, Inc $90,844.50 $142,004.50 MRSA Insulin B Chain to Treat Type 1 Orban Biotech LLC $244,479.25 Diabetes Mellitus Self-shielding radiotherapy Orbital Therapy, LLC $244,479.24 device Ore Pharmaceutical ORE1001 $244,479.25 Holdings Inc PAKA Pulmonary SP-B-Polymyxin Conjugate For $34,230.00 Pharmaceuticals Inc Lung Infection Palomid 529, a First -in-Class Paloma Pharmaceuticals, Dual TORC 1/2 Inhibitor of the $244,479.24 Inc P13k/Akt/m TOR Pathway Development of Oral Therapies Paratek Pharmaceuticals for Major Chronic AutoImmune $244,479.25 Inc Diseases: MS, RA, IBD Gram-Negative Hospital Paratek Pharmaceuticals, Bacterial Infections; Treatment $244,479.25 Inc and Prophylaxis PTK 0796- A First-in-Class Paratek Pharmaceuticals, Oral & IV antiboiotic in Phase 3 $244,479.25 Inc for Serious Infections, incl. MRSA Treatment of Moderate to Pear Tree Severe Vulvar and Vaginal $152,775.40 $91,703.85 Pharmaceuticals, Inc Atrophy in Menopausal Patients PI-2301 for thre ftreatment of Peptimmune, Inc. Relapsing and Remitting $244,479.25 Multiple Sclerosis (RRMS) Pervasis Therapeutics, Development of PVS-10200 for $244,479.25 Inc Peripheral Artery Disease Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of Vascugel® to Pervasis Therapeutics, Sustain Arteriovenous Access $244,479.25 Inc. for Hemodialysis Development of Tissue- Pervasis Therapeutics, Engineered Endothelial Cell $30,307.90 $161,113.04 Inc. Therapy for Brain and Prostate Cancer Devel. Of Tissue-Engineered Pervasis Therapeutics, Endothelial Cell Therapy to $35,022.33 $209,456.92 Inc. Supplement Orthopedic Procedures Vilazodone: A novel treatment PGxHealth LLC $244,479.25 for major depressive disorder Apadenoson: A novel PGxHealth LLC pharmacologic stress agent for $244,479.25 myocardial perfusion imaging Lymph Node Localization by Pharmalucence, Inc $85,732.00 $158,747.24 Tc-99m Sulfur Colloid Injection CNS penetrating anti- Phase Design Research inflammatory/metal chelators $29,921.79 $37,500.00 for treating neuroinflammation Continuous Automated Physical Sciences Inc $71,626.00 $166,094.50 Mandibular Distractor Physical Sciences Inc. Breath Test for Cancer Therapy $106,900.50 $137,578.75 Dosimeters for Photodynamic Physical Sciences Inc. $242,635.00 $1,844.24 Cancer Therapy (PDT) Image-Guided Intervention for Physical Sciences Inc. $128,383.00 $116,096.25 Pancreatic Cysts Retinal Imaging for Disease Physical Sciences, Inc $244,479.24 Detection RenalGuard: A Novel Therapy PLC Medical Systems to Prevent Contrast Induced $244,479.25 Inc Nephropathy Predictive Biosciences, Bladder Cancer Recurrence $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc. Monitoring Triage Test Predictive Biosciences, Test for Prognosis of Bladder $244,479.25 Inc. Cancer Pressure BioSciences, Pressure Cycling Technology $244,479.25 Inc. ViraQuant: Automated PrimeraDx, Inc. Quantitative Multi-Plex Viral $244,479.25 Load Assay System Privo Technologies Insulin Chewing Gum $4,000.00 Treatment and reversal of liver Pro-Pharmaceuticals, Inc. fibrosis using galectin blockers $10,083.67 $234,395.57 GRGs Anticancer treatments using Pro-Pharmaceuticals, Inc. galectin blockers combined with $244,479.24 chemotherapies or biologics. Proteon Therapeutics, PRT-201 for Vascular Access in $244,479.24 Inc. Chronic Hemodialysis Patients Modified SDF-1 for the Provasculon, Inc treatment of myocardial infarct $244,479.25 and ischemic tissue Provenance DI-Leu16-IL2 Anti-cancer $33,421.77 $211,057.48 Biopharmaceuticals Corp Therapeutic Veterinary immunocytokines to Provenance aid development of therapies for $29,117.77 $131,895.54 Biopharmaceuticals Corp treatment of human cancers pSivida US Inc Sustained Release Brimonidine $110,062.00 Antibodies for Treatment of pSivida US, Inc. Wet-Acute Macular $98,087.00 Degeneration (Wet-AMD) Inhaled Cationic Lining Modulators for Treatment and Pulmatrix Inc. $244,479.25 Prevention of Pulmonary Disease Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Pulsar Clinical Multiplex Microarray for Pre- $65,183.30 $54,437.03 Technologies Type 1 Diabetes Autoantibodies Inflammatory Bowel Disease PureTech Ventures, LLC $76,490.76 $164,028.87 (IBD) PureTech Ventures, LLC Autism $60,835.08 $86,590.68 PureTech Ventures, LLC Karuna $109,573.80 $134,905.45 Development of the First Blood- Quanterix Corporation based Diagnostic test for $244,479.24 Alzheimer's Disease A TNF-alpha Companion Quanterix Corporation Diagnostic to Predict Response $127,716.00 $116,763.24 to Therapy in Crohn's Disease Development of a Single Molecule Array Test for Quanterix Corporation $244,479.24 Prostate Cancer Recurrence Monitoring Radius Health Inc RAD1901 $244,479.25 Radius Health Inc BA058 $244,479.25 Radius Health, Inc SARM/RAD140 $244,479.25 Enhanced Robustness of Rapid, Rapid Micro Biosystems, Automated Microbial $244,479.25 Inc Enumeration Non-Invasive Tissue Perfusion Reflectance Medical Inc $101,592.50 $142,886.74 for Therapeutic Admin. RG3039-DcpS inhibitor for Repligen Corporation treatment of patients with Spinal $201,583.50 $42,895.75 Muscular Atrophy (SMA) RG2833, an inhibitor of HDAC- Repligen Corporation 3 for the treatment of $244,479.25 Friedreich's ataxia RG1068 - Synthetic Human Repligen Corporation $244,479.24 Secretin for Pancreatic Imaging Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 DEVELOPMENT OF Resolvyx RESOLVINS TO TREAT $244,479.24 Pharmaceuticals Inc Chronic Inflammatory Disease DEVELOPMENT OF RESOLVYX RESOLVINS TO TREAT PHARMACEUTICALS, $244,479.24 SIGHT-THREATENING INC DISEASE RFE-007 CAI injectable for treating diabetic retinopathy & RFE Pharma Corp $38,561.00 $92,144.00 age-related macular degeneration Rhythm Pharmaceuticals Rm-493 $244,479.25 Inc Rhythm Pharmaceuticals, RM-131 $244,479.25 Inc Development of self-delivering Rxi Pharmaceuticals RNA Interference (RNAi) $244,479.25 Corporation therapeutic for the fibrotic disease Oral Delivery of Glucose Rxi Pharmaceuticals Encapsulated siRNAs for $244,479.25 Corporation Rheumatoid Arthritis (RA) Self-Delivering RNA Rxi Pharmaceuticals Interference Therapeutic for $66,002.17 $178,477.08 Corporation Age-Related Macular Degeneration (AMD) Self-Delivering RNA Rxi Pharmaceuticals Interference Therapeutic for $237,273.92 $7,205.33 Corporation ALS (Lou Gehrig's Disease) Gamma-Secretase Modulators Satori Pharmaceutcals for the treatment of Alzheimer's $244,479.24 Incorated Disease Development of a Therapy for SBH Sciences Inc Liver Fibrosis by Specific $98,932.50 $112,000.00 Targeting of Galectin-3 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Developing Therapy for SBH Sciences, Inc Pancreatic Cancer Targeting $44,600.00 $140,100.00 Nuclear Export by CRM-1 Sci Dose LLC Ulcerative Colitis $188,828.00 $55,651.25 SciDose, LLC Docetaxel $244,479.25 Prevention and treatment of Seahorse Bioscience, Inc age-related diseases by targeting $244,479.25 defects in mitochondria. Diagnosis of Metabolic and Seahorse Bioscience, Inc. $244,479.25 Age-Related Diseases Development of Arbaclofen Seaside Therapeutics Inc (STX209) for the Treatment of $244,479.25 Fragile X Syndrome Development of Novel M1 Seaside Therapeutics Inc, Modulators for the Treatment of $244,479.25 Austism and Fragil X syndrome Discovery Project to identify Seaside Therapeutics Inc. biomarkers related Austism $244,479.25 Spectrum Disorders(ASD) Development of mGluR5 Seaside Therapeutics, Modulators for the Treatment of $244,479.25 Inc. Autism and Fragile X Syndrome Development of STX107 for the Seaside Therapeutics, Treatment of Fragile X $244,479.25 Inc. Syndrome Development of Arbaclofen Seaside Therapeutics, (STX209) for the Treatment of $244,479.25 Inc. Autism Spectrum disorders (ASD) Nicotine Vaccine for Smoking Selecta Biosciences, Inc Cessation and Relapse $244,479.25 Prevention A synthetic Nanoparticle Selecta Biosciences, Inc $244,479.24 Vaccine Platform to induce a Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Cytolytic T-Cell Response Development of a Synthetic Selecta Biosciences, Inc. Nanoparticle Vaccine Platform $244,479.25 to Induce Protective Antibodies SelectX Pharmaceuticals SXP2554: A Novel Inhaled $244,479.25 Inc Antibiotic SXP2523: A Novel Antibiotic SelectX Pharmaceuticals, for Serious Gram-Negative $244,479.25 Inc. Infections Targeting Telomere-Associated Semaco Inc. Werner Protein to Treat $156,500.00 $87,979.24 Hematologic Malignancy Semprus PICC (Peripherally Semprus BioSciences $244,479.25 Inserted Central Catheter) Sentien Biotechnologies, Stem Cell Therapeutic Devices $244,479.25 Inc. for Critical Care SetPoint Medical Immune System Regulator $244,479.25 Corporation Therapy On Vivo, A Fully Integrated Seventh Sense Blood Collection and $244,479.24 Biosystems, Inc. Diagnostic Test Device SHP-141 for the treatment of Shape Pharmaceuticals, Cutaneous T-Cell $244,479.25 Inc. Lymphoma(CTCL) SimuConsult Diagnostic SimulConsult, Inc $244,479.25 Decision Support Software SmartInsulin-The First Glucose- SmartCells, Inc regulated insulin for Treating $244,479.24 Diabetes Soteira Shield Kyphoplasty Soteira, Inc $244,479.25 System Objective Acoustic Speech Speech Technology and Analysis for Post Concussional $626.50 $15,329.50 Applied Research Corp Blast Effects Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 System for DBS Programming Speech Technology and for Speech Functionality in $146,055.50 $98,423.75 Applied Research Corp Parkinson's Disease Spring Bank SB 9000 $244,479.24 Pharmaceuticals, Inc Proton Beam Radiotherapy Still River Systems, Inc. $244,479.25 System (PBRT) Strohl Medical SEP-RAD Stroke Detection $34,975.00 Technologies Inc Device Development of STX-100 as a Stromedix, Inc. novel therapeutic for the $244,479.24 treatment of fibrotic diseases Interactive feeding system for Sunshine Medical LLC $244,479.25 the premature infant SLx-2119, a small molecule inhibitor of Rho kinase 2 Surface Logix, Inc $244,479.24 (ROCK2) for oncology and fibrosis Intestinally selective small Surface Logix, Inc $244,479.24 molecule activators of satiety SLx-2101, a small molecule Surface Logix, Inc PDES inhibitor targeting $244,479.24 cardiovascular disease SLx-4090 Microsomal Surface Logix, Inc Triglyceride Transfer Protein $244,479.24 (MTP) Surface Logix, Inc 50 Soldiers Field Place $244,479.24 Intestinally selective small Surface Logix, Inc. molecule inhibitors of DGAT $232,867.49 $11,611.75 for obesity and diabetes Enhancement of the Synageva BioPharma glycosylation machinery of the $16,995.76 $107,290.28 Corp Synageva Expression Platform Synageva BioPharma SBC-101 $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Corp Synageva BioPharma SBC-091 $244,479.24 Corp Synageva BioPharma SBC-014 $244,479.24 Corp Synageva BioPharma SBC-055 $244,479.24 Corp Synageva BioPharma SBC-103 $24,026.32 $105,693.33 Corp Synageva BioPharma SBC-105 $91,706.28 Corp Synageva BioPharma SBC-104 $244,479.25 Corp. Synageva BioPharma SBC-102 $244,479.24 Corp. Synageva BioPharma SBC-201 $182,911.81 $55,148.08 Corp. Synageva BioPharma SBC-202 $89,388.76 $47,469.53 Corp. Synageva BioPharma PTR-302 $101,394.51 Corp. Retrospective Study and Prospective Trial to Develop SynapDx Corporation $244,479.25 Autism Spectrum Disorder Diagnostic Syndax Pharmaceuticals Syndax Pharmaceuticals Entinostat for the Treatment of $244,479.24 Inc Breast Cancer and HL High potency polymer/metAP2 SynDevRX, Inc inhibitors for the treatment of $216,825.00 $27,654.24 cancer Syndexa Pharmaceuticals ISR Modulators as Novel Drugs $244,479.24 Corp for the Treatment of Type 2 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Diabetes and Metabolic Diseases Novel Bivalent JNK Modulators Syndexa Pharmaceuticals for the Treatment of Obesity $244,479.24 Corp. and Type 2 Diabetes SDP051 is a Cad-11 antagonist Synovex Corporation antibody for the treatment of $244,479.25 rheumatoid arthritis Synta Pharmaceuticals Development of elesclomol as a $244,479.24 Corp cancer therapeutic Development of a novel, small Synta Pharmaceuticals molecule Hsp90 inhibitor, STA- $244,479.24 Corp 9090, as a cancer therapeutic Oral CRAC channel inhibitor Synta Pharmaceuticals therapeutics for inflammatory $244,479.25 Corp. diseases and cancer Oral Hsp90 inhibitor therapies Synta Pharmaceuticals for cancer, inflammatory and $244,479.24 Corp. neurodegenerative diseases. Tacrolimus and Creatinine T2 Biosystems, Inc $244,479.25 Project T2 Biosystems, Inc Dx Platform Project $244,479.25 T2 Biosystems, Inc. Candida Project $244,479.25 TT30 therapeutic recombinant Taligen Therapeutics, fusion protein to modulate $244,479.24 Inc. Complement system Development of a Novel Oral Targeted Cell Therapies, Delivery Technology or Large $73,440.50 $131,500.00 LLC Molecule Therapeutics A novel drug-device combination prod. To improve TARIS Biomedical Inc $244,479.25 the treatment of superficial bladder cancer Taris Biomedical, Inc LiRIS: A novel local therapy for $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 the management of discomfort associated with ureteral stent LiRIS: A novel drug-device TARIS Biomedical, Inc combination product for the $244,479.25 treatment of Interstitial Cystitis New Therapies for Cancer using Temple Therapeutics, Mesenchymal Stem Cells $244,479.25 LLC (MSC's) expressing TRAIL Hernia Mesh with Therapeutic Tepha Inc $244,479.24 Coating TP-834:A Promising New Oral Tetraphase Antibiotic for Community $244,479.25 Pharmaceuticals Inc Acquired Pneumonia(CABP) TP-434: A Potent New Antibiotic To Treat a Broad Range of Multi-Drug Resistant Tetraphase "Superbugs" 834:A $244,479.25 Pharmaceuticals, Inc. Promising New Oral Antibiotic for Community Acquired Pneumonia(CABP) TP-2758: A Novel and Exciting Tetraphase Oral Antibiotic for Complicated $244,479.25 Pharmaceuticals, Inc. Urinary Tract Infections (cUTI) Monoclonal antibodies targeting Theracrine Inc cancer-specific osteopontin $244,479.24 (vOPN) Dual CXCR/1CXCR2 Inhibitor Theracrine, Inc for the Treatment of Metastatic $244,479.25 Cancer Fascin inhibitor for the Theracrine, Inc $244,479.24 Treatment of metastatic Cancer Tokai Pharmaceuticals, TOK-001 $244,479.25 Inc. Development of a Targeted Tolerx, Inc. $244,479.24 Immunotherapeutic for the Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Treatment of Type 1 Diabetes. Development of Novel Anti- Tolerx, Inc. ILT Immunotherapeutics for the $110,144.11 $134,335.13 Treatment of Cancer Development of a Novel Anti- Tolerx, Inc. GITR Monoclonal Antibody as $244,479.24 an Immunotherapy for Cancer. Optical Coherence Tomophase Corporation Tomographic Imaging System $242,476.00 $2,003.24 (OCTIS ™ ) Translational Cancer Therapeutics System $55,532.00 $188,947.25 Therapeutics Inc. Highly Multiplexed Infectious U.S. Genomics Inc Disease Diagnostics Based on $244,479.25 Single Molecule DNA Analysis VANAS ONCOLOGY, BCP-21, A Novel Anti-Cancer $136,512.91 $107,966.33 INC Molecule Variation Biotechnologies (US), Thermostable Vaccine $244,479.25 Inc c/o Variation Biotechnologies Inc Variation Biotechnologies (US), Oral Shigella Vaccine $244,479.25 Inc, c/o Variation Biotechnologies Inc. Variation Biotechnologies (US), Variosite Technology $235,077.50 $9,401.75 Inc. Variation Biotechnologies (US), Oral Vaccine $244,479.25 Inc. c/o Variation Biotechnologies Inc. A Novel Drug-Eluting Stent -- VasoTech, Inc. Power Stent ® -- for Coronary $110,119.50 $134,359.75 Arterial Disease Treatment Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Velico Medical, INC Refrigerated Platelets $7,500.00 $59,733.00 VELICO MEDICAL, SPRAY DRIED PLASMA $244,479.25 INC. Verax Biomedical PGD Platelet Test Device $244,479.24 Incorporated Information Technology Veritas Health Solutions Management of Adolescent $53,427.50 $11,455.50 LLC Depression (iTAD) sFc-Recombinant Sialylated Virdante Immunoglobulin G (lgG) Fc $244,479.24 Pharmaceuticals, Inc fragments Virdante Svig - Siaylated Intravenous $244,479.24 Pharmaceuticals, Inc Immunoglobulin PAR401: A Potent, Selective Visterra, Inc (f/k/a Anti-Influenza Therapeutic and $244,479.24 Parasol Therapeutics, Inc Prophylactic Development of an engineered ViThera LLC bacterial therapy of $5,739.16 $216,250.00 Inflammatory Bowel Disease Vortex Medical Inc AngioVac $244,479.24 Wadsworth Medical Novel Device to Reduce $71,683.00 $172,796.24 Technologies, Inc. Surgical Site Infection XB-387, a PDGFRB Antibody X-BODY, Inc Therapeutic for Non-Small Cell $244,479.24 Lung Cancer XRX-001 Inactivated Yellow Xcellerex Inc $244,479.24 Fever Vaccine Zafgen Inc T2D Program $244,479.25 Zafgen, Inc. ZGN-440 $244,479.25 ZIOPHARM Oncology, Indibulin $244,479.25 Inc. ZIOPHARM Oncology, Palifosfamide $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc. ZIOPHARM Oncology, Darinaparsin $244,479.25 Inc.

Michigan $18,138,110.55

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 A Phase III Stage Expanded, Aastrom Biosciences, Autologous Stem Cell Product $244,479.24 Inc. to Treat Severe CV Disease Improved central venous and Accord Biomaterials Inc hemodialysis catheters to $211,615.81 $32,863.44 minimize infection and clotting Coronary stent with passivated Accord Biomaterials, Inc. surfaces to address restenosis $178,815.24 $65,664.01 and late-stage thrombosis Point-of-Care Diagnostic and Therapy Management Tool for Accord Biomaterials, Inc. $20,493.75 $189,918.09 Pulmonary Arterial Hypertension Development of the Accuri CS Accuri Cytometers Inc Clinical Flow Cytometry $244,479.25 System Adeona Pharmaceuticals, Estriol (Trimesta) $35,493.50 $208,985.75 Inc. Adeona Pharmaceuticals, Zinthionein and $133,439.00 $111,040.25 Inc. ZincMonoCysteine Treatment of Acute Coronary AlphaCore Pharma, LLC Syndromes with Recombinant $244,479.25 LCAT Infusion Angott Medical Products, Multi-modality Breast Cancer $19,157.00 $225,322.25 LLC Tester Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Secretary IgA for orally applied therapy for treatment ApoLife, Inc $57,509.66 $143,400.00 of Clostridium difficile infection. Molecular Diagnostics for Armune BioScience Inc $244,479.24 Early Detection of Cancer Art Optical Contact Lens, Therapeutic treatment of $39,571.00 $44,847.50 Inc. irregular corneas A novel antibiotic for the AureoGen Bioscience treatment of drug resistant $136,897.60 $107,581.64 Inc. bacterial infections Aursos BB for primary & secondary osteoporosis and Aursos, Inc. $36,335.00 $4,618.00 bone-building (anabolic) activity Development of CARD-024 Cardiavent Inc. for the treatment of $66,868.50 $177,610.75 hypertension and heart failure Cayman Chemical EP4 Project $172,016.50 Company Inc Cayman Chemical H-PGDS Inhibition Project $96,509.00 $31,848.00 Company Inc Cayman Chemical Tetranor Prostaglandin E $11,769.00 $11,557.50 Company, Inc Metabolite ELISA Project HDL-Mimetic Cerenis Therapeutics Inc Peptide/Phospholipid complex $165,319.49 $79,159.76 (CER-522) Cerenis Therapeutics Inc. CER-627 Low Flushing Niacin $117,626.86 $63,100.93 Cerenis Therapeutics, CER-002 $43,428.26 $95,307.06 Inc. Compendia Bioscience, Oncopredictor $122,116.50 $122,362.74 Inc. CytoPherx, Inc Selective CytoPheretic Device $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Commercialization of SoftVue Delphinus Medical for early detection of Breast $238,705.00 $5,774.25 Technologies, inc. cancer Esperion Therapeutics, ETC-1002 $244,479.24 Inc Commercialization of a Stage I and II colorectal Cancer Genetics Squared, Inc. $244,479.24 Recurrence Prognostic Technology Noninvasive cortical Great Lakes BioSciences stimulation treatment of pain in $118,246.00 $126,233.25 fibromyalgia Novel Inhibitors for the Housey Pharmaceutical Treatment of Highly Drug- Research Laboratories, $62,210.50 $182,268.75 Resistant Chronic LLC Myelogenous Leukemia HOUSEY DISCOVERY AND PHARMACEUTICAL DEVELOPMENT OF ANTI $201,356.00 $43,123.25 RESEARCH DIABETIC DRUGS LABORATORIES, LLC Hygieia Inc PRIVATE-DOC $80,761.72 $163,717.53 Bioengineered Cellular/ Innovative BioTherapies, Biomimetic-based Therapeutic $244,479.24 Inc System for treatment of SIRS Wireless Pressure Monitoring Integrated Sensing Implant for Tailored $244,479.24 Systems Medication of Cardiovascular Diseases A Microfluidic-Based Integrated Sensing Therapeutic Drug Infusion $244,479.25 Systems System Determining an infectious process prior to syndromic IPGDx LLC $244,479.25 findings as a biosurveillance tool Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Detection of Disease Severity & Progression, Treatment IPGDx, LLC $244,479.24 Effectiveness & Survival in Cancer Sensitive, Rapid Diagnostic Life Magnetics, Inc device for Antibiotic $162,127.08 Susceptibility Testing TRACKCORE SOFTWARE LPIT SOLUTIONS, INC FOR OR IMPLANT $210,295.33 $34,183.92 MANAGEMENT Via-Derm-2, a novel long-term LVAD Technology Inc. $85,079.32 $159,399.93 percutaneous access device Lycera Corp ATPase Oral Therapeutic $244,479.24 Lycera Corp. RoR Gamma Therapeutic $244,479.24 Meditrina MPI-676 $12,860.00 $99,477.63 Pharmaceuticals Inc. Novel Insulin Sensitizing Metabolic Solutions Agents for Therapy in Type 2 $244,479.24 Development Company Diabetes Michigan Critical Care Hyperthermia device for Consultants Inc DBA $36,179.85 $98,601.27 cancer treatment MC3 Inc Michigan Critical Care Catheter Enterogenesis Device Consultants Inc DBA $40,746.68 Development MC3 Inc Michigan Critical Care Pediatric blood pump Consultants, Inc. DBA $93,822.77 $150,656.47 development MC3, Inc. Michigan Critical Care Consultants, Inc. DBA Artificial Lung Development $93,587.07 $150,892.17 MC3, Inc. Michigan Critical Care Bidirectional Arterial Cannula Consultants, Inc., DBA $80,991.20 $163,488.04 Development MC3, Inc. Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Michigan Critical Care Annuloplasty Ring for Heart Consultants, Inc., DBA $17,393.01 $46,276.11 Valve Disease MC3, Inc. Michigan Critical Care Automatic Perfusion System Consultants, Inc., DBA $13,314.69 $70,696.82 Development MC3, Inc. Michigan Critical Care Simple Ventricular Assist Consultants, Inc., DBA $53,422.38 Device Development MC3, Inc. GENETIC CHARACTERIZATION OF MICHIGAN FIBROSIS & TECHNOLOGY & INFLAMMATORY $22,191.00 $8,518.71 RESEARCH SUSCEPTIBILITY IN INSTITUTE, LLC CHRONIC KIDNEY DISEASE Novel Nebulized Therapy for NanoBio Corporation $244,479.25 Cystic Fibrosis Novel Topical Therapy for NanoBio Corporation $244,479.25 Herpes Labialis Novel Intranasal Vaccine NanoBio Corporation $244,479.25 Adjuvant Novel Intranasal 23- Valent NanoBio Corporation $244,479.25 Pneumococcal Vaccine Novel Topical Anti-fungal NanoBio Corporation Therapy for Tinea Capitis and $244,479.25 Onychomycosis Therapeutic Development of Antiviral Compounds that NanoVir, L.L.C. $244,479.24 Target Human Papillomaviruses (HPV) NX001 Treatment of Acute Nephrx Corporation $244,479.24 Kidney injury NS002 Treatment of Oral NEPHRX Corporation $91,845.50 $152,633.74 Mucositis Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 NeuroNexus Deep Brain Stimulation $162,088.50 $47,855.50 Technologies, Inc. Development of pump for use Novalung, Inc. $226,495.16 $17,984.08 with artificial lung Metabolic Cost of Recumbent Nustep, Inc Exercise in Overweight $24,330.00 Individuals Nymirum Inc Alzheimer's Project $17,248.00 $227,231.25 Nymirum Inc Hepatitis C Project $9,764.50 $234,714.75 Nymirum, Inc Myotonic Dystrophy Project $30,283.50 $214,195.75 Prevention of Drug Induced OtoMedicine Inc Hearing Loss (DIHL) by $98,011.00 $146,468.25 AuraQuell Phrixus Pharmaceuticals, Heart Failure $168,430.00 $76,049.24 Inc Phrixus Pharmaceuticals, Duchenne Muscular Dystrophy $168,430.00 $76,049.24 Inc A Phase 1 Study of PNT2258 ProNAI Therapeutics, Inc in Patients with Advanced $30,965.00 $213,514.24 Solid Tumors QuatRx Pharmaceuticals Ospemifene $244,479.25 Company Biorealistic Tissue models for RealBio Technology, Inc. $93,800.00 $150,679.24 Drug Discovery and Testing RetroSene Therapeutics Gene therapy for vision LLC aka RetroSense $1,750.00 $161,094.43 restoration Therapeutics LLC Soluble Ferric Pyrophosphate Rockwell Medical (SFP) indicated for the $244,479.24 Technologies, Inc. treatment of iron deficiency anemia Development of PicoPlex - Rubicon Genomics, Inc $85,674.50 $99,166.50 NGS Kits Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of MethylPlex ™ Rubicon Genomics, Inc. $80,501.00 $129,187.00 -NGS Kits Fully-sampled 2D/planar Sonetics Ultrasound, Inc. ultrasound transducer $185,276.47 $59,202.78 technology Development of High Sensitivity Genetic Tests for Swift Biosciences Inc $244,479.24 Detection and Assessment of Cancer Tangent Medical Peripheral intravenous $244,479.25 Technologies therapeutic delivery device TCH Pharmaceuticals, Imidazoline-based Inhibitors $17,519.50 $26,431.62 Inc Therapeutic System Research Laboratories, Anti-Influenza Therapeutic $53,603.56 $43,987.62 Inc. (TSRL) Therapeutic Systems Cidofovir, Nucleoside Prodrug Research Laboratories, $244,479.25 for Antiviral Treatment Inc (TSRL) Therapeutic Systems Research Laboratories, Bile Acid Carrier $85,919.29 $24,184.42 Inc. (TSRL) Therapeutic Systems Inflammatory Bowel Disease Research Laboratories, $45,127.53 $75,793.37 Therapeutic Inc. (TSRL) TOL 101 in Phase 2 short course immune induction Tolera Therapeutics, Inc $244,479.24 therapy for chronic immune disease imaging of cardiovascular Ultrasound Medical mechanical function for $221,258.00 $23,221.25 Devices Inc assessment diagnosis and therapy guidance Velcura Therapeutics, VEL-0230 an Orally $194,016.10 Inc. Available, Disease Modifying Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Anti-Rheumatic Drug (DMARD) Xoran Technologies Inc Xoran xCAT $244,479.25 Xoran Technologies, Inc. Xoran MiniCAT $244,479.25 Development of Novel zuSyn, Inc. Taxanes for the Treatment of $3,280.20 $1,704.58 Cancer

Minnesota $22,469,564.39

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Redesign of AHS Wound Data Advanced Healing Reporting Electronic Medical $195,000.00 Systems Record Alwyn Company, Inc Alwextin $86,952.70 $157,526.55 American Telecare Advanced American Telecare Inc. $244,479.25 Care Management Expansion VIBEX Methotrexate Subcutaneous Auto-injector Antares Pharma Inc. $184,415.00 $60,064.25 (VIBEX MTX) to treat Rheumatoid Arthritis Anturol oxybutynin Advanced Antares Pharma, Inc. Transdermal Delivery gel for $244,479.25 treatment of overactive bladder Anulex Technologies Versaclose Tissue Repair $231,323.50 $13,155.75 Inc Anulex Technologies Large Defect Tissue Repair $45,075.00 $49,702.50 Inc Anulex Technologies, Xclose Tissue Repair $244,479.25 Inc. Apnex Medical, Inc. Hypoglossal Nerve $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Stimulation(HGNS™ System Ativa Medical Inc Point of Care Testing Module $244,479.25 WATCHMAN Left Atrial Atritech Inc $244,479.25 Appendage System AUM Cardiovascular, CADence $20,500.00 $98,516.99 LLC PREPACYTE REAGENT BIOE LLC $67,018.50 $177,460.74 TECHNOLOGY Multi-Lineage Progenitor Cell BIOE LLC $21,475.00 $180,049.00 (MLPC) Multi-Lineage progenitor cell Bioe, Inc. $188,626.50 (MLPC) I.V. Ribose for the Enhancement of Recovery of Bioenergy Inc $173,037.50 $71,441.75 Myocardial Function after CABG Surgery Imprime PGG Cancer Drug Biothera, Inc. $244,479.25 Development Implantable Soft Tissue Marker Breast-Med Inc. for Multimodal Breast Imaging $14,663.00 $229,816.25 with Positive MRI Contrast Interventional Treatment of BridgePoint Medical. Advanced Vascular Disease- $244,479.25 Inc. Alternative to Bypass Surgery EGG antibodies as Camas Incorporated immunoprophylactic agents for $27,820.00 $120,471.50 the prevention of influenza. Utilization of avian antibodies Camas Incorporated in an oral application to $37,281.00 $207,198.25 ceutralize gut bacterial toxins. Cardious Inc Aortic Valve Delivery graft $73,045.00 $110,724.50 Cardiovascular Coronary Clinical Trial $244,479.25 Systems Inc Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Cardiovascular Diamondback 360 to Prepare $244,479.25 Systems Inc Vessels for drug therapy Pain Reduction Following Aesthetic Procedures- A Study Celleration Inc $46,500.00 Conducted at Northwestern University Using Therapeutic Low Celleration, Inc. Frequency Ultrasound to $55,000.00 $127,500.00 Recruite Stem Cells Drug Discovery of Novel Chi's Research Antimicrobial and Antimalarial $5,224.00 Corporation Agents Novel Compounds for Chi's Research Treatment of Neuropathic and $10,562.50 Corporation Inflammatory Pain Novel Compounds for Chi's Research Treatment of Alzheimer's $17,447.50 Corporation Disease High Concentration Intrathecal CNS Therapeutics, Inc. Baclofen for the Treatment of $244,479.25 Spasticity NeuroFloTM Cerebral CoAxia Inc Perfusion Augmentation $244,479.24 Catheter Baroreflex Activation Therapy- CVRx, Inc. $244,479.24 Diastolic Heart Failure Baroreflex Activation Therapy - CVRx, Inc. $244,479.24 Hypertension DISTALOCK™ Intramedullary DGIMED Ortho, Inc. $244,479.25 (IM) Nail and Drill System Dymedix Corporation Dymedix NM System $244,479.24 EnteroMedics Inc Entero-Medics Maestro System $244,479.25 Thermoformable Bracing Exos Corporation $244,479.24 Devices Using Tri-laminate Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Technology ExoStat Medical, Oral Mucosa Carbon Dioxide $50,059.17 $194,420.08 Incorporated (CO2) Monitor Novel Therapeutic Device for FourSquare Medical, the Preatment of Pulmonary $244,479.25 LLC Hypertension Medium Voltage Therapy to Galvani Ltd Provide Coronary and Cerebral $169,479.25 Perfusion during Cardiac Arrest Gel-Del Technologies VasoGraft Therapeutic System $120,835.50 $123,643.75 Inc Tumor-targeted MRI nanoparticles for detecting and GeneSegues Inc $35,086.50 $15,301.00 diagnosing microscopic metastasis Tissue-targeted sub-50 nanometer particles for GeneSegues Inc $23,611.00 $77,017.50 subcutaneous delivery of nucleic acid drugs Genii, Inc ( a MN C Genii GI Development and $244,479.24 Corporation) Submission The use of D-Ribose for the Heartland Biosciences, treatment of cardiovascular $170,000.00 $62,500.00 Inc disease HEMERUS LEUKOSEP® SOLX® $244,479.24 MEDICAL, LLC HeRO Vascular Access Device- Patency, Access & Hemosphere, Inc $145,716.00 Development Improvement Project Development of NICS-15 for Humanetics Treatment of Alzheimer's $50,359.00 $194,120.24 Corporation Disease Humanetics Development of 7-oxo $24,400.00 $64,900.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Corporation Dehydroepiandrosterone for the Treatment of PTSD IGF-Methotrexate Conjugate to IGF Oncology, LLC $4,730.00 $86,552.50 Treat Cancer MRI of Apoptosis Using New Immunochemistry Tracers Specific for Caspase $29,255.00 $82,131.50 Technologies LLC Activity Immunochemistry Near Infrared Tracers For $66,810.24 $176,221.06 Technologies, LLC Imaging Apoptosis in Vivo IMPRES MEDICAL ELATE SYSTEM $244,479.25 INC Imricor Medical MRI Compatible Catheter $244,479.24 Systems Inc Ablation System Inspire therapeutic delivery Inspire Medical system for Obstructive Sleep $244,479.25 Systems, Inc Apnea (OSA) (the "inspire system") Non-Invasive Technology to International Cardio Diagnose and Treat Arterial $46,175.00 $198,304.25 Corporation Plaque in Cardiovascular Disease Subcutaneous Catheter Interrad Medical, Inc $244,479.24 Securement System Ionix Medical, Inc. Prostate Cancer System $140,888.64 $103,590.61 Ionix Medical, Inc. Neuflo System $244,479.25 Kinexum Metabolics, INGAP PEPTIDE FOR ISLET Inc (dba Exsulin REGENERATION IN TYPE 1 $244,479.25 Corporation ) DIABETES Lexion Medical LLC DewHeart CO2 Blower/Mister $30,385.00 $43,989.50 LEXION MEDICAL, INSUFFLATION GAS $26,377.00 $39,530.50 LLC CONDITIONING TROCAR Lutonix, Inc. Drug Coated Balloon Catheter $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 A New Blood Test to Detect, Martell Biosystems, Manage, and Monitor Women $40,000.00 Inc. with Her-2 Breast Cance Medinvent Nasal Drug Delivery Catheter $120,218.01 Medinvent NasoNeb Nasal Nebulizer $12,376.78 $232,102.47 Medisyn technologies, MT103 Project $8,845.37 $9,057.51 Inc Medisyn Technologies, Alzheimer's Program $46,436.48 $52,761.45 Inc. Medisyn Technologies, MT477 Program $55,617.62 $48,911.95 Inc. Medisyn Technologies, Protease Inhibitor Program $32,117.94 $15,502.85 Inc. Novel Transdermal Delivery of Nanocopoeia, Inc. Therapeutic Nanoparticles for $224,034.00 $20,445.25 Systemic Treatment of Pain Neochord, Inc NeoChord Model DS 1000 $244,479.25 NeuroVasx, Inc cPax $244,479.25 New Breath Medical, Sleep Apnea Treatment system $27,032.03 LLC NxThera Therapeutic Vapor NxThera Inc. Ablation and Drug Delivery $244,479.25 System Uterine Electrical Stimulation Obstetric Solutions and for Treating Postpartum $85,975.00 $158,504.24 Interventions, LLC Hemorrhage (PPH) Alzheimer's disease progression ORASI MEDICAL, and severity biomarker using $244,479.25 INC. magneoenchelography Ultrasound Blood Parsus Medical, LLC Filtration/Autotransfusion $225,000.00 Project Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Integrated Dispensing PDAP LLC $55,000.00 Aspirating Device Amnion Stent-graft (Asg) Peytant Solutions Inc $27,134.00 $44,392.50 System Phraxis, Inc InterGraft $244,479.25 ClearGuard Therapeutic Pursuit Vascular, Inc. $83,835.36 $160,643.89 Delivery Device Low-Cost Retinal Imaging Quantum Catch, LLC $49,872.50 $194,606.74 System Neuromodulation for the ScyFix , LLc treatment of low vision $244,479.24 blindness causing diseases Shape Medical Detection and classification of Systems, Inc. (a severity of pulmonary $244,479.24 Minnesota for profit C hypertension Corp) Softscope Medical Propulsive Assist Device $244,479.24 Technologies Inc Vertebral Compression Fracture Spineology Inc $169,552.00 $74,927.25 & Down-Sized Mesh Nucleus replacement and Spineology Inc. $201,349.50 $43,129.75 printed mesh Steady State Imaging, SWIFT $71,076.74 $91,233.83 LLC Electromagnetic Navigation SuperDimension, Inc $244,479.25 Bronchoscopy (ENB) Development of Technology for SURMODICS INC Controlled Delivery of $175,737.00 $59,448.50 Therapeutic Proteins DEVELOPMENT OF DRUG SURMODICS, INC $171,312.00 $73,167.25 DELIVERY BALLOON Development of sustained Surmodics, Inc. $130,790.50 $113,688.75 release injectable drug delivery Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 system for ocular administration Development of Systems for SURMODICS, INC. $133,857.00 $110,622.25 Delivery of Therapeutic siRNA DEVELOPMENT OF MALTODEXTRIN-BASED SURMODICS, INC. $107,037.50 DRUG DELIVERY POLYMERS Development of SynBiosys SURMODICS,INC. Biodegradable Polymer Drug $185,084.00 Delivery System Bacterial Vaccine & Synitron LLC Therapeutic Platform $244,479.24 Technology Multi Center Clinical Wound Tactile Systems Study for the Treatment of $126,159.50 $65,540.50 Technology, Inc. Venous Stasis Ulcers LINX Reflux Management System for treating Torax Medical, Inc. $244,479.24 gastroesophageal reflux disease (GERD) Tumor Biology Development of sHer Investment Group, Inc $4,658.76 $23,420.83 Theragnostics (TBIG, Inc) Twin Star Medical, Inc. Compartment Syndrome $244,479.24 Twin Star Medical, Inc. Drug Delivery Catheter $56,737.94 $105,455.00 VASAMED PADIQ $59,644.35 $184,834.90 Incorporated Diagnosis and Treatment of Vatrix Medical, Inc Abdominal Aortic Aneurysms $71,560.81 $172,918.44 (AAAs) Computed Tomography 3D Vital Images Inc $23,575.50 $159,373.50 Body Perfusion Myocardial Analysis and Vital Images Inc $167,390.00 $77,089.25 Perfusion Imaging Software Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 CT Brain Analysis Imaging Vital Images Inc $68,347.50 $115,913.00 Software Anatomical visualization with Vital Images, Inc Multi-region segmentation $165,749.00 $58,887.00 (MRS) Automated airways Vital Images, Inc quanification for diagnosis & $15,937.00 $40,515.00 treatment planning Fully Volumetric, CT-MRI Vital Images, Inc Comprehensive Tumor $20,147.00 $35,603.00 Response Analysis Endovascular Stent Planning Vital Images, Inc. $104,083.50 $76,467.50 Imaging Software CT De-noising Image Vital Images, Inc. $5,729.50 $83,645.00 Enhancement Multi-Chamber Cardiac Vital Images. Inc $56,687.00 $183,903.00 Function Imaging Software Development and validation of VivaQuant, LLC a novel algorithm for highly $20,162.50 $128,000.00 accurate ECG analysis Wilson Wolf Superior cell culture devices for Manufacturing effective delivery of adoptive $153,918.50 $90,560.74 Corporation cell therapeutics Zoltan Laboratories Treatment of Obesity and $79,878.00 LLC Diabetes Zyga Technology, Inc. Glyder facet resurfacing system $244,479.25

Mississippi $924,818.96

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 EDWARDS ANTISPASMODIC $55,187.50 $189,291.75 PHARMACEUTICAL, ORALLY Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 INC DISINTEGRATING TABLET Edwards Pharmaceutical, Urninary Antispasmodic $191,245.97 $53,233.28 Inc. and Antiseptic Artemisinin Dimer Analogs ElSohly Laboratories, Inc $32,156.17 $33,025.00 as Anti-cancer Agents Delta-9- ElSohly Laboratories, Inc. Tetrahydrocannabinol $162,395.06 $82,084.19 Transmucosal Matrix Patch Poison Ivy Allergic Contact ElSohly Laboratories, Inc. Dermatitis Treatment $22,810.84 $103,389.20 Products

Missouri $7,695,336.29

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Antigen Sublingual CAT Hair Allergenic $244,479.25 Laboratories, Inc Extract APT Therapeutics, Therapeutic Use of Human $244,479.25 Inc. Apyrase BioMed Valley Combination Bacteriolytic $6,403.00 $178,957.50 Discoveries Inc Therapy {COLBALT} Project BioMed Valley Phenix Inflammation Project $244,479.25 Discoveries, Inc BioMed Valley In Vivo FIAU Project $69,601.00 $174,878.25 Discoveries, Inc. BioMed Valley Phenix Chagas Project $43,688.50 $72,998.00 Discoveries, Inc. BioMed Valley Phenix Diabetes Project $116,561.50 $127,917.75 Discoveries, Inc. CardiaLen, Inc. Low-Energy Atrial Cardioverter $42,532.00 $188,481.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Novel Serotonin Daya Drug Agonists/Antagonists for the $83,759.00 $102,600.00 Discoveries Inc Treatment of Neurological Disorders Small Molecule Steriod Mimics Daya Drug for Molecular Imaging and $20,000.00 Discoveries Inc Therapy of Breast Cancers ENDOSTIM ENDOSTIM INC $152,091.15 $92,388.10 MICROSTIMULATOR Fully automated point of care Evogen, Inc platform for the diagnosis of $244,479.25 infectious disease and genotyping Foundation Care Cystic Fibrosis Health $110,000.00 $134,479.24 LLC Management Program Development of a Drug to Galera Therapeutics Prevent Oral Mucositis in Cancer $244,479.25 LLC Patients Automated Video Vision Gerhard W. Cibis, Development Assessment $46,300.50 $44,000.00 M.D., P.C. (AVVDA) Immunophotonics, Laser-Assisted Immunotherapy $7,821.54 $236,657.71 Inc ISTO Technologies Cell-based technology platform $244,479.25 Inc Molecularly Targeted Kereos, Inc Nanostructures for Anticancer $88,108.50 $66,696.50 Therapy with Cytologic Peptides Development of a F-19 Imaging Agent for Early Diagnosis of Kereos, Inc $162,045.00 $82,434.24 Cancer and Cardiovascular Disease Multi-Dimensional Mass LipoSpectrum LLC Spectrometry-based Shotgun $90,860.00 $95,111.00 Lipidomics (MDMS-SL) Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular PINCER-based Mediomics LLC biosensors for point of care $244,479.24 diagnosis Mobius Optomycin $230,779.50 $13,699.74 Therapeutics, LLC Composite Conductive Monofilament (CCM) Biosensor Pepex Biomedical $244,479.25 Technology- Therapeutic Applications Sequoia Sciences, Novel therapeutic vaccine for $159,106.63 $85,372.61 Inc. urinary tract infections Novel Small Molecule Sequoia Sciences, Therapeutic for the Treatment of $244,479.25 Inc. Recalcitrant Bacterial Infections Shear Kershman A Tamper Resistant Delivery $16,408.50 $95,420.10 Laboratories System for Opiods Stereotaxis, Inc V-Drive $244,479.25 Stereotaxis, Inc TOTAR $40,750.00 $74,000.00 Stereotaxis, Inc STOP-VT $20,580.00 $101,804.00 Stereotaxis, Inc. Navigant 3.2 $244,479.25 Vascular Remote Advancement Stereotaxis, Inc. Systems (VRAS) and Next Gen $209,745.50 $34,733.75 Radiofrequency Generator Stereotaxis, Inc. Odyssey $244,479.25 Stererotaxis, Inc Next Generation Catheters $120,134.00 $124,345.25 Biomarkers for Diagnosis and Traxxsson, LLC $21,947.00 $41,950.00 Prognosis of Cancer Veran Medical SPiN Drive $244,479.25 Technologies, Inc Cancer Therapy with Oncolytic VirRx Inc $244,479.25 Adenovirus VRX-007 ZeaVision LLC Macular Pigment Reflectometer $55,852.50 $188,626.74 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 (MPR)

Montana $1,296,971.19

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Organophosphate poisoning Ateris detection and diagnostic $244,479.25 Technologies, LLC systems Bacterin Antimicrobial Orthopedic $7,500.00 $236,979.25 International, Inc Surgical Fixation Devices New therapy for metastatic Genectar Com LLC melanoma through expanded $7,836.53 $13,343.30 comparative genomics. LigoCyte Development of a Vaccine for Pharmaceuticals, the Prevention of Human $244,479.25 Inc Norovirus Acute Gastroenteritis LigoCyte Development of a Novel Virus- Pharmaceuticals, like Particle Based Respiratory $244,479.25 Inc. Syncytial Virus Vaccine A Novel, Broad-Spectrum Microbin Antimicrobial Therapeutic for $113,575.50 $130,903.75 Corporation Treatment of infectious Diseases NanoValent Drug delivery system to treat Pharmaceuticals, $9,712.11 $13,500.00 cancer Inc. Targeted Two-photon SensoPath Photodynamic Therapy Drugs $13,730.50 $16,452.50 Technologies, Inc for Treatment of cancer

Nebraska $2,379,064.05 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Advanced Adjuplex, A Novel Vaccine $244,479.24 BioAdjuvants, LLC Adjuvant Discovery Rapid Intervention of Acute JN Medical Stroke Using NMDAR R-Peptides $244,479.24 Corporation to prevent Neurotoxicity NATURE NON-VIRAL GENE TECHNOLOGY THERAPY/VACCINATION $70,468.00 $174,011.25 CORPORATION VECTOR PLATFORM Development of a vertically SpineX Tec LLC expandable spinal fusion device $125,359.50 for IBF applicants 2D Analysis for Transgenomic, Inc Neurodegenerative Disease $244,060.76 $418.49 Diagnosis Transgenomic, Inc COLD-PCR $193,647.31 $50,831.94 Transgenomic, Inc. SURVEYOR Scan Kits $178,016.85 $66,462.40 Transgenomic, Inc. mtDNA Damage Assays $128,304.87 $116,174.38 Transgenomic,Inc. Mitochondrial Genetics Analysis $42,252.39 $50,283.93 Miniature In Vivo Robotic System Virtual Incision for the Surgical Treatment of $205,334.25 Corporation Diverticular Disease Reversal of diabeties with pig Ximerex, Inc. islets by inducing immune $244,479.25 tolerance in the donor pig

Nevada $3,068,649.00

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 NATRIUTRETIC PEPTIDE AKI Bioscience, RECEPTOR AGONISTS FOR $31,903.50 $30,000.00 Incorporated THE TREATMENT OF HEART FAILURE AND Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 HYPERTENSION CardioVascular Human FGF1 (CVBT-141C) to BioTherapeutics $40,365.00 Treat Peripheral Artery Disease Inc CardioVascular Human FGF-1 (CVBT-141A) to BioTherapeutics $244,479.25 Treat Coronary Heart Disease Inc Deuteria Scale-up of tetradeuterio p- Pharmaceuticals, $18,921.50 $148,647.50 flurobenzaldehyde LLC Deuteria Deuterium-enriched atorvastatin Pharmaceuticals, $12,500.00 Derivatives LLC Deuteria Deuterium-enriched oxybutynin Pharmaceuticals, $51,420.00 $110,750.00 derivatives LLC LANCO Neridronate $244,479.25 Biosciences Inc NEXGEN DEVICES FOR THERAPEUTIC MEDICAL DRUG DELIVERY TO BRAIN $45,851.00 $34,506.50 SYSTEMS, INC TUMORS NexGen Medical Devices for Therapeutic Drug $91,562.50 $67,512.50 Systems, Inc Delivery NexGen Medical Devices for Blood Clot Removal $228,906.00 $15,573.25 Systems, Inc Development of a Pulsed Electro- PEMF SYSTEMS Magnetic Field generator to treat $196,000.00 INC Osteoarthritis Redlabs, U.S.A. Sandwhich ELISA for XMRV $232,875.00 Inc. Detection Samaritan SP-233, A New and Novel Pharmaceuticals, Mechanism of Action for the $244,479.25 Inc. Treatment of Alzheimer Disease Samaritan SP1000, A Novel Therapy for the $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceuticals, Removal of Excessive Cholesterol Inc. Directly from the Blood Samaritan SP-6310, As a Treatment of HIV- Pharmaceuticals, infected Patients with Abnormal $244,479.25 Inc. Cortisol Levels Sierra Sciences, hTERt $244,479.25 LLC Soar BioDynamics Early Detection of High-Risk $244,479.25 Inc. Prostate Cancer Project

New Hampshire $2,241,711.25

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of Adimab's fully Adimab, Inc human antibody discovery and $244,479.25 optimization platform Commercialization of a fully- Allyon Solutions, implantable anti-biofouling $10,635.00 $14,887.00 LLC intraperitoneal glucose monitor Allyon Solutions, Commercial Development of a $10,635.00 $14,887.00 LLC novel Radio-mitigant Alternative System C-Hub: Low-Power Cancer $13,670.00 $230,809.24 Concepts, Inc. Therapy Control Device Balch Hill Medical, Precision Thread IV Catheter $45,000.00 $199,479.24 Inc Celdara Medical, Myocardial Infarction (MI) $13,423.26 $53,027.24 LLC Therapeutic Development Celdara Medical, OnCyte: Cellular Therapy for $1,400.00 $164,645.46 LLC Cancer Celdara Medical, Scleroderma Diagnostic Services $35,665.48 $126,121.09 LLC Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Design Mentor Inc Ventriflo $6,398.42 $62,841.91 An Immunotherapy Drug ImmuRX Product for Cancer and Chronic $120,725.00 $123,754.24 Infectious Disease Ultrasound Signal Processing Kaonyx Labs, LLC Algorithms for Improved $244,479.25 Anatomical Definition ThermoRetractor for Mantis Enterprises Prophylactic Treatment of $45,090.59 LLC Retractor Ischemia/Edema Mantis Enterprises ThermoPad for Traumatic Brain $41,629.79 LLC Injury Microwave Alternative Breast Imaging Imaging System $80,034.00 $68,519.50 Program Technologies Inc. Fully Implantable Chronic Novoculi Inc Intraperitoneal Glucose $10,045.93 $14,949.11 Monitoring for CGLCS Hyperpolarized noble gas MRI Xemed LLC of pulmonary function and $244,479.25 microstructure

New Jersey $51,109,445.09

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Bioabsorbable drug-eluting 3D Biotek, LLC $14,397.32 $117,737.43 stents Actinium Alpha Particle Immunotherapy $244,479.24 Pharmaceuticals, Inc (APIT) drugs development STABILIZATION OF EGFR AD4-PHARMA CLOSED FORM USING $238,708.50 $5,770.75 SMALL MOLECULE Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 COMPOUNDS Small molecule compounds that AD4-Pharma $238,708.50 $5,770.75 mimic ERBITUX binding MDM2 INHIBITORS IN AD4-PHARMA COMBINATION WITH EGFR $119,353.50 $108,498.00 KINASE INHIBITORS Resplmmune™ for the ADMA Biologics treatment of Respiratory $244,479.25 Syncytial Virus Advanced Technologies Preclinical and clinical for Novel Therapeutics, development of a novel and $191,650.00 $52,829.25 LLC potent anti-cancer therapeutics ADXS11-001, a live attenuated Advaxis Inc bacterial vaccine for the $244,479.24 treatment of cancer Aegerion Pharaceuticals, Inc Aegerion Iomitapide development $244,479.25 Pharmaceuticals, Inc program Aerie Pharmaceuticals AR-12286 $244,479.24 Inc Treating neuropathic pain by Aestus Therapeutics, Inc $244,479.24 means of novel mechanisms Agennix USA, Inc RGB-286638 $244,479.25 Agile Therapeutics' Skinfusion - Agile Therapeutics, Inc. $244,479.25 Low Dose Contraceptive Patch Alitair Pharmaceuticals Method for reducing or Inc DBA The cough preventing overdose events with $244,479.24 Company pharmaceuticals Amicus Early Onset Familial $175,445.00 $69,034.25 Therapeutics,Inc. Alzheimers Disease Amicus Therapeutics Inc Sporadic Alzheimer's Disease $244,479.25 Amicus Therapeutics, Inc AT1001 for Fabry Disease $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 AT1001 in Combination with Amicus Therapeutics, Inc Enzyme Replacement Therapy $244,479.25 for Fabry Disease Alpha-One Antitrypsin Amicus Therapeutics, Inc $244,479.25 Deficiency Pharmacological Chaperones for Amicus Therapeutics,Inc. $244,479.25 Parkinson's Disease AMORCYTE INC AMR-001 Phase 2 Trial $244,479.25 Angel Medical Systems Nextgen R & D Project $244,479.24 Inc Angel Medical Systems, Alerts R&D Project $244,479.24 Inc Treatment of Cancer with a Antyra Inc novel IGF-1R antagonist, ANT- $204,273.00 $40,206.24 429 Dev of AR-67: A Novel, Third- generation Comptothecin Arno Therapeutics Inc $244,479.24 Analogue for the Treatment of Cancer Development of AR-42: A Arno Therapeutics Inc Novel, pan-DAC Inhibitor for $244,479.24 the Treatment of Cancer Dev. Of AR-12: A Novel and Arno Therapeutics, Inc. Potentially First-in-class Agent $244,479.24 for the Treatment of Cancer BeFree! LLC BeFree! $1,453.43 $26,782.00 Bioscience Development Diagnostic Test for Lyme & $244,479.24 Inc Tick-borne Diseases Bioscience Development Vaccines and diagnostic tests $57,899.00 $186,580.24 Inc for Burkholderia Infections Arm Motor Rehabilitation, Bright Cloud Entertainment and Cognition $32,143.00 International System for the Elderly Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Cahaba Pharmaceuticals, TCN-P (triciribine phosphate) $244,479.25 Inc. Cancer Treatment Cahaba Pharmaceuticals, 1UO (.1% uracil topical) DPD $244,479.25 Inc. Inhibitor Cancer Genetics, Inc. MatBA $244,479.25 FISH-based HPV-associated Cancer Genetics, Inc. $209,466.50 $35,012.75 Cancer Test (FHACT) FISH-based Renal Cancer Cancer Genetics, Inc. $125,680.50 $118,798.75 Diagnostics (FReCAD) CPX-351 Celator Pharmaceuticals, (Cytarabine:Daunorubicin) $244,479.25 Inc Liposome Injection A Drug Discovery Program Chemo Dynamics Inc Based on Metalloporphyrin with $42,222.00 $46,250.00 Peptide end links Development of novel, selective Chromocell Corporation NaV1.7 antagonists for $244,479.25 treatment of chronic pain Novel PAP assay with ChromoDynamics automated hyperspectral $177,631.12 $66,848.12 imaging slide reader Circulite Synergy Endovascular Circulite Inc. $244,479.25 System Circulite Synergy Surgical Circulite Inc. $244,479.25 System Circuport Vacsular Access Circuport, Inc $98,515.43 $145,963.82 Systems for Hemodialysis Evaluate CRINONE ®/ Columbia Laboratories, PROCHIEVE ® for Reduction $244,479.24 Inc of Preterm Births in Women CorMedix Inc Deferiprone $244,479.25 CorMedix Inc Neutrolin $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Cornerstone Development project of $121,668.91 $122,810.34 Pharmaceuticals Inc Emulsiphan Platform (EmPA) Cornerstone AEMD $244,479.25 Pharmaceuticals, Inc. EntericSorb Anti-inflammatory CytoSorbents Inc therapy for life-threatening $244,479.25 disease CytoSorb Autologous Blood CytoSorbents Inc $244,479.25 Transfusion DSC 127 Clinical Development Derma Sciences Inc $244,479.25 Program Development of ASDmiR, molecular test for early DiamiR, LLC $156,600.00 detection and monitoring of Alzheimer's Disease. Drais Pharmaceuticals, DTS-108 anti-cancer $244,479.24 Inc. chemotherapy drug The EndoTube Duodenal Drug E2 $25,000.00 $35,000.00 Delivery Reservoir E2, LLC The EndoSleeve Project $244,479.25 Eagle Pharmaceuticals, Ready-to-Use Oncology Product $20,500.00 $114,501.00 Inc. "P" Eagle Pharmaceuticals, Diluent for Oncology Product $244,479.25 Inc. "A" Eagle Pharmaceuticals, Nanosuspension for Treatment $244,479.25 Inc. of Malignant Hyperthermia Eagle Pharmaceuticals, Diluent for Oncology Product $244,479.25 Inc. "D" Eagle Pharmaceuticals, Ready-to-use Oncology Product $244,479.25 Inc. "B" New Drugs to treat EDG Therapeutics, Inc. $50,000.00 Angiogenesis in Cancer Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 NimoGel to prevent secondary stroke (vasospasm) and improve Edge Therapeutics, Inc $42,203.50 $202,275.75 outcome after sudden brain injury. Edusa Pharmaceuticals, Pumosetrag Clinical Trials $108,798.50 $135,680.75 Inc. Resolve System for treating ElectroCore LLC $244,479.25 acute Bronchoconstriction Rejuvenation System for ElectroCore LLC Treating Chronic Obstructive $244,479.25 Pulmonary Disease (COPD) Revive System for treating ElectroCore LLC $244,479.25 Sepsis and Septic Shock Resolution System for Treating ElectroCore LLC $244,479.25 Post-Operative Ileus Inhaled Liposomal Cisplatin for Eleison Pharmaceuticals, Treatment of Recurrent $244,479.25 Inc. Pulmonary Pediatric Osteosarcoma Development of Glufosfamide Eleison Pharmaceuticals, for the Treatment of Second-line $29,112.50 $215,366.75 Inc. Pancreatic Cancer Development of a Monoclonal Elusys Therapeutics Inc. Antibody for Prevention and $244,479.25 Treatment of Anthrax Emisphere Technologies, Eligen Oral B12 $244,479.24 Inc Delivery System Development Endovalve, Inc. for Foldable Suture-free Mitral $244,479.24 Valve Prosthesis Enzon Pharmaceuticals Androgen Receptor (AR) $244,479.24 Inc Antagonist (EZN-4176) Enzon Pharmaceuticals, HER3 Antagonist (EZN-39200) $78,521.50 $165,957.74 Inc Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Enzon Pharmaceuticals, PEG-SN38 $244,479.24 Inc Enzon Pharmaceuticals, Survivin Antagonist (EZN- $244,479.24 Inc. 3042) Enzon Pharmaceuticals, HIF-1alpha Antagonist (EZN- $244,479.24 Inc. 2968) EnzymeRx, LLC Pegsiticase $244,479.25 Peripheral Vascular Self Flexible Stenting Expanding (SE) Stenting $244,479.24 Solutions, Inc System (the "FlexStent") Drug Delivery Program for Follica Incorporated inducing Follicular Neogenesis $237,563.01 $6,916.23 for Scarless Wound Healing Clinical Program for Inducing Follica Incorporated Follicular Neogenesis for $244,147.19 $332.05 Scarless Wound Healing Development of NAL 1606 as a Galaxy Bio Inc New Delivery System for $146,928.00 $97,551.24 Migraine Genta Incorporated Tesetaxel $244,479.24 Genta Incorporated Oblimersen $244,479.24 Selective HDL Delipdation HDL Therapeutics LLC $104,429.50 Therapy (Delipidation Therapy) Pressure Ulcer Prevention and Healthy Functions, LLC $15,058.00 $229,421.24 Treatment Mattress Pressure Ulcer Prevention and Healthy Functions, LLC $4,078.50 $194,000.00 Treatment Wheelchair Cushion HiLin Life Products, Inc KNOWHEN ® $87,739.50 $79,842.00 Development of Adiptin as a HMGene Inc $188,500.00 $55,979.25 Biotherapeutic to treat Obesity Humigen IBD1:Use of the IL- Humigen, LLC $146,003.00 $98,476.24 32R "Delta-9" variant to Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 monitor prognosis and progression. hLL1 Dox for multiple Immunomedics Inc $244,479.25 myeloma Immunomedics Inc TF4 for NHL $244,479.25 F-18 labeling technique for Immunomedics Inc $244,479.25 imaging hRS7-SN-38 for lung and breast Immunomedics Inc $244,479.24 cancers. Veltuzumab as a subcutaneous Immunomedics Inc $244,479.25 formulation for NHL Immunomedics, Inc 20-2b for NHL $138,342.50 $106,136.75 Immunomedics, Inc 22-20 for NHL $157,091.50 $87,387.75 hLL1 for multiple myeloma and Immunomedics, Inc $244,479.25 NHL/CLL Immunomedics, Inc. TF2 for colorectal cancer $244,479.25 hPAM4 for early diagnois, Immunomedics, Inc. imaging and therapy of $244,479.24 pancreatic cancer Immunomedics, Inc. hMN14-SN-38 $244,479.25 IMMU-114 for B-cell Immunomedics, Inc. $41,460.50 $157,955.50 lymphoma IntelliSante Corporation Psytracker $102,500.00 X Chromosome Abnormality JS Genetics, Inc. $22,480.53 $118,702.53 Test-Fragil X (XCAT-FX) X Chromosomal Abnormality JS Genetics, Inc. Test-Turner Syndrome Test $101,275.94 $60,182.91 (XCAT-TS) Novel Therapeutic for Priventricular White Matter JS Genetics, Inc. $30,157.94 $134,739.08 (Brain White Matter) Injury PWMI Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Life Recovery Systems The ThermoSuit System $194,228.80 $50,250.45 HD, LLC Linkwireless LLC RXManager $34,500.00 LX214-Voclosporin as a topical Lux Biosciences Inc solution for the treatment of dry $244,479.24 eye syndrome. LX211-Voclosporin for the Lux Biosciences Inc treatment of Non-infectious $244,479.25 Uveitis LX212 Treatment of severe dry Lux Biosciences, Inc. eye syndrome with a $219,361.50 $25,117.75 voclosporin implant PROMETRA II MRI SAFE MEDASYS PROGRAMMABLE DRUG $244,479.24 INCORPORATED INFUSION PUMP Prometra Programmable Drug Medasys Incorporated $244,479.24 Infusion System Medical Nutrition USA, Katz Study $23,791.50 $18,627.45 Inc Medical Nutrition USA, EVANS STUDY $64,698.04 $64,698.04 Inc Health E-Dose Medication Med-In-Touch LLC Adherence System for Improved $185,000.00 $59,479.24 Outcomes and Reducing Costs MicroDose Therapeutx MUDI-Multi Use Dry Powder $244,479.25 Inc Inhaler MicroDose Therapeutx, MDT-637 - Respiratory $244,479.24 Inc Syncytial Virus (RSV) MicroDose Therapeutx, MDT-011 - Breath for Life! $244,479.25 Inc. MicroDose Therapeutx, MDT 006 - Treatment for $244,479.25 Inc. Gastrointestinal Diseases Moerae Matrix, Inc. Pre-Clinical Development of $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Novel Peptide Therapeutics Fast Dissolving Film Drug Monosol Rx, LLC $244,479.24 Delivery Nanoparticle Technology- Monosol Rx, LLC $51,449.00 $193,030.24 Insulin Film Delivery SUBLINGUAL AND BUCCAL MONOSOL RX, LLC $244,479.24 FILM DRUG DELIVERY Nephrogenex Inc. Pyridorin Clinical Trials $244,479.25 Neurologix, Inc NLX-P101 $244,479.24 Leptin as a Therapy for Neurotez Inc. $244,479.24 Alzheimer's disease Niiki Pharma, Inc. NKP-46 $244,479.24 Niiki Pharma, Inc. NKP-1339 $244,479.24 Duromist--Sildenafil Oral Spray NovaDel Pharma Inc for the treatment of Erectile $244,479.24 Dysfunction NPS Pharmaceuticals Inc Teduglutide $244,479.24 NPS Pharmaceuticals, NPSP558 $244,479.24 Inc NX-1207 for the Treatment of Nymox Corporation $244,479.25 Benign Prostatic Hyperplasia Solesta: novel product to treat Oceana Therapeutics Inc $244,479.24 fecal incontinence Omthera Epanova $182,843.50 $61,635.75 Pharmaceuticals, Inc Novel immuno-oncology biopharmaceutical drug Oncobiologics, Inc $125,000.00 $119,479.25 development for treatment of cancer Ophthotech Corporation Volociximab $244,479.24 Ophthotech Corporation E10030 $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Ophthotech Corporation ARC1905 $244,479.24 Lucassin (terlipressin) for Orphan Therapeutics, Hepatorenal Syndrome (HRS) $244,479.25 LLC Type 1 ANTI-MICROBIAL ORTHOBOND SURFACES FOR $244,479.25 CORPORATION IMPLANTABLE MEDICAL DEVICES OSTEOCONDUCTIVE ORTHOBOND SURFACES FOR $202,421.64 $42,057.61 CORPORATION IMPLANTABLE MEDICAL DEVICES Improved Cost Effective Dental Orthogen LLC $123,479.24 and Orthopaedic Bone Grafts MELANOCORTIN AGONIST PALATIN FOR OBESITY AND $244,479.25 TECHNOLOGIES, INC RELATED METABOLIC SYNDROME PALATIN Melanocortin Agonists for $244,479.25 TECHNOLOGIES, INC Sexual Dysfunction PL-3994 NATRIURETIC PALATIN PEPTIDE MMETIC FOR $113,330.00 $131,149.25 TECHNOLOGIES INC ACUTE ASTHMA Subcutaneous Natriuretic PALATIN Peptide Mimetic for $244,479.25 TECHNOLOGIES, INC Cardiovascular Disease Panoptica inc PAN-90716-DES $85,755.50 $158,723.75 Panoptica Inc PAN-90806 $104,577.00 $139,902.25 Panoptica Inc PAN-90716-2 $85,755.50 $158,723.75 Pestka Biomedical Synferon $191,859.59 $52,619.66 Laboratories, Inc. Pestka Biomedical Human Interferon Beta Elisa Kit $180,733.27 $63,745.98 Laboratories, Inc. Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Pharmalead Therapeutics Breast Cancer Drug $42,500.00 Inc Use of Silver Nanostructures on PharmaSeq, Inc Mirotransponders in Ultra- $48,727.56 $95,142.25 sensitive Assay Microtransponder-based PharmaSeq, Inc Prostate Cancer Multiplex $61,475.69 Assay Cystic Fibrosis DNA-based PharmaSeq, Inc $244,479.25 Assay on Microtransponders Pharmasset, Inc PSI-7977 $244,479.25 Pharmasset, Inc. PSI-938 and PSI-661 $244,479.25 Dextofisopam to treat Irritable Pharmos Corporation $244,479.24 Bowel Syndrome PMI-001 for Treatment of Phytomedics, Inc. $244,479.25 Rheumatoid Arthritis (RA) Innovative therapy for nasal Piasek Biotech, Inc $74,340.01 $169,439.50 allegies and related discorders SeraFILE {TM}: Conformational Variants ProFACT Proteomics Inc $61,831.50 $120,260.50 {Conformers} for Drug and Biomarker Discovery Prolong Pharmaceuticals, Sanguinate - A broad based $244,479.25 LLC Oxygen Therapeutic FIRBERGRAFT Anti- mircobial, Ultra-porous, Prosidyan, Inc. $119,005.00 $125,474.25 Bioactive, Osteostimulative, bone graft substitute PROVID Development of PV-267 A DR2 PHARMACEUTICALS, inhibitor for the treatment of $6,696.50 $159,000.00 INC Multiple Sclerosis Development of small PTC Therapeutics Inc molecules to treat spinal $62,136.00 $18,224.50 mucular atrophy via modulation Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 of Novel Broad Spectrum PTC Therapeutics Inc $244,479.25 Antibacterials Development of small molecules to treat spinal PTC Therapeutics Inc muscular atrophy via $244,479.24 modulation of alternative splicing Discovery & Development of PTC Therapeutics Inc Novel Small Molecule Antiviral $244,479.25 Agents against Hepatitis C Upregulation of the muscle specific form of insulin like PTC Therapeutics Inc $219,521.50 growth factor (mlGF-1) to treat muscular dystrophies Identification of Compounds PTC Therapeutics, Inc that Increase Utrophin Protein to $219,521.50 $24,957.75 delay progression of DBMD Inhibition of Myostatin to slow PTC Therapeutics, Inc the Progression of Muscular $219,521.50 Dystrophies Discovery & Development of PTC Therapeutics, Inc. Small Molecules that Increase $162,655.00 $81,824.24 the Translation of Tumor Development of Ataluren as a PTC Therapeutics, Inc. Treatment for Nonsense $244,479.25 Mutation Genetic Disorders Development of a Novel PTC Therapeutics, Inc. Glioblastoma treatment that $206,480.50 $37,998.75 selectively reduces Bmi-1 Development of PTC299 as a PTC Therapeutics, Inc. Treatment for Cancer and other $244,479.25 Neoplastic Conditions Development of small PTC Therapeutics, Inc. $45,110.00 $17,140.50 molecules to treat spinal Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 muscular atrophy by a novel Implantable Heart Monitor and QRS Systems, Inc $244,479.24 Telemetry Reporting System TorsinA Activators for Disease QrxPharma Inc Modifying Activity in Protein $244,479.24 Misfolding Diseases MoxDuo CR- a controlled QRxPharma, Inc release oral treatment for $244,479.24 moderate to severe chronic pain. MoxDuo IR-an immediate QRxPharma, Inc release oral treatment for $244,479.24 moderate to severe acute pain. ORAL DRUGS REGULATING REDPOINT BIO INSULIN & INCRETIN $244,479.25 CORPORATION SECRETION FOR DIABETES TREATMENT Regado Biosciences, Inc. REG2 $244,479.24 Regado Biosciences, Inc. REG3 $244,479.24 Regado Biosciences,Inc. REG1 $244,479.24 Replication Medical Inc. GelStix $244,479.25 Samos Pharmaceuticals Oral and Parenteral Multi-day $53,230.00 $108,543.00 LLC Delivery of Drugs Savient Pharmaceuticals, Pegloticase $244,479.24 Inc Scivanta Medical Development of a Minimally- $112,500.00 $131,979.25 Corporation invasive Cardiac Monitor Percutaneous Transcatheter Secant Therapeutics, Inc. Direct Plication Annuloplasty $58,500.00 (DPA) Targeted Intracellular Semorex Incorporated $244,479.24 Photodynamic Therapy (TIP) Senesco Technologies, Use of SNSO1-T as a $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc Therapeutic for Multiple Myeloma Development of Novel Signum Biosciences Inc $188,551.00 $55,928.24 Therapeutics for Acne Development of Novel Signum Biosciences, Inc Therapeutics for Alzheimer's $244,479.24 Disease Development of Novel Signum Biosciences, Inc $182,012.50 $62,466.74 Therapeutics for Rosacea Development of Novel SIGNUM Therapeutics for Parkinson's $244,479.24 BIOSCIENCES, INC. Disease Simon Wiiliams Pharma VaccJect drug delivery sytem $244,479.25 Consulting LLC orBec (oral BDP) for the Soligenix,Inc. (formerly Treatment/Prevention of Acute known as DOR $244,479.25 Graft-versus-Host Disease BioPharma, Inc.) (GVHD) SOMNUS SKP-1041 CLINICAL TRIALS $244,479.25 THERAPEUTICS, INC. SVELTE MEDICAL Stent on a wire delivery system $244,479.25 SYSTEMS, INC Novel Antibiotic Drug TAXIS Pharmaceuticals, Development - Unique $106,853.50 $137,625.74 Inc. Mechanism of Action to Overcome Resistance Synthetic HIV-1 Tat epitope Thymon LLC $127,606.50 $116,872.74 vaccine Arikace Cystic Fibrosis (CF) Transave Inc $244,479.24 Program Arikace Nontuberculous Transave Inc $244,479.24 Mycobacteria (NTM) Program Arikace Non-CF Bronchiectasis Transave Inc $244,479.24 Program Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Treatment of muscular TRIM-edicine, Inc. dystrophy by protein $244,479.25 therapeutics. ASTRA Antibacterial il for Soft Tyrx Pharma, Inc Tissue ReINFORCEMENT $244,479.24 AND Infection Control AIGIS Product Family Antibacterial Mesh for Infection Tyrx Pharma, Inc. $244,479.24 Control in Cardiac Rhythn devices Unigene Laboratories Inc ANNEXIN $244,479.25 Unigene Laboratories, ORAL PTH $244,479.25 Inc Unigene Laboratories, SITE-DIRECTED BONE $188,972.00 $55,507.25 Inc GROWTH (SPBG) Unigene Laboratories, SATIETY $232,812.50 $11,666.75 Inc Surinate Bladder Management UROVALVE, INC $244,479.25 System V-GoTM Disposable Insulin Valeritas Inc $244,479.25 Delivery Device RESEAL Vascular Access Graft VASCULAR DEVICES for Early Access Hemodialysis - $243,000.00 $1,479.24 LLC For chronoc kidney disese Coll-R Collagen Rapamycin Vascular Therapies, LLC $244,479.25 Matrix Project Novel Vaccine Technology for Vaxinnate Corporation $244,479.24 Influenza VectraCor, Inc. VectraplexPDA Holter System $140,925.67 $103,553.57 Venenum CIP2A Development and high throughput screening Venenum Biodesign, of an assay designed to isolate. $102,851.50 $141,627.75 LLC Development and high throughout screening of an Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 assay designed to isolate small molecules blocking C-Myc binding to cancerous inhibitor of protein phosphatase 2A (CIP Venenum SIRNA: The corresponding proteins expressed by the cancer genes isolated…The isolation of novel Venenum Biodesign, biomarkers and cancer drug $99,135.50 $145,343.75 LLc targets through high throughput SiRNA screening for genes required for cancer cell viability. Vicus Therapeutics LLC VT-122 Development Program $192,251.49 $52,227.76 VYTERIS, INC. Lutrepatch™ $244,479.25 Glucagon-like peptide 1 (GLP- VYTERIS, INC. $244,479.25 1) Using nutrigenomics discovery WellGen, Inc tools for novel medical foods to $244,479.24 treat chronic disease XEME Biopharma Inc Therapeutic Cancer Vaccines $48,313.00 Phase III Trial of Myocet Tratuzumab (T) and ZBV II LLC $244,479.25 Paclitaxel(P) vs T&P for 1st Line HER2+MBC

New Mexico $4,423,671.65

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Accent Prostate Cancer Prevention $750.00 $116,500.00 Alternatives, Inc. Using Tocopherylquinone (TQ) Development of BiosparQ ATOF, Inc $244,479.25 Instrument for rapid microbial Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 characterization of clinical samples. C-Reactive Protein Therapy for Azano Lupus Nephritis in Systemic $53,920.50 $33,952.50 Pharmaceuticals Inc Lups Eryrhematosus Diagnostic Assay for Detection Biomoda, Inc. $244,479.25 of Early-Stage Lung Cancer Caldera Pharmaceuticals Diagnostics for Trauma Injuries $205,791.33 $38,687.91 Inc. Exagen Diagnostics Exagen Gastrointestinal $244,479.25 Inc Discoveries Exagen Exagen Autism Spectrum $19,164.00 $139,724.50 Diagnostics, Inc. Disorder Discoveries Noninvasive Glucose InLight Solutions, Monitoring for Gestational $151,661.50 $92,817.75 Inc Diabetes Biomarker Discovery Platform Intellicyt to Accelerate Development of $244,479.25 Corporation Cancer Therapies Recycling of the Cardiac Manhattan Isotope Imaging Agent, Strontium-82, $244,479.25 Technology from Spent Generators Point of care molecular Mesa Tech diagnostic device for respiratory $244,479.25 International, Inc. diseases Miniature NMR Pathogen nanoMR, Inc. $244,479.25 Detection System Samitaur Medical Neurological Stimulation for $90,000.00 Technologies, LLC Samitaur Medical Technologies A Biomagnetic Method for Senior Scientific Detecting and treating breast $152,704.00 $63,661.00 LLC cancer Senior Scientific A Biomagnetic Method for $79,805.50 $44,762.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC Determining Transplant Rejection and Monitoring Therapy Magnetic Biopsy Needle for Senior Scientific Minimum Residual Disease $130,914.00 $105,725.00 LLC Detection in Luekemia Biomagnetic In-vivo Imaging Senior Scientific and Image-Guided Therapy of $54,528.00 $70,799.50 LLC Ovarian Cancer Early Detection of skin cancer SK Infrared LLC using non-invasive infrared $35,283.64 imaging. SURGICAL SUITE UNIT: TECMED, INC. Automated Blood Analyte $5,502.50 $7,891.00 Monitoring System Noninvasive alcohol diagnostic TruTouch device for emergency care $169,386.21 $75,093.04 Technologies, Inc. facilities VeraLight Inc SCOUT $244,479.24 Visionquest Automatic eye disease diagnosis $244,479.25 Biomedical LLC system Stroke risk stratification through Visionquest plaque motion analysis of $39,853.78 Biomedical LLC longitudinal carotid Vista Therapeutics, NanoBiosensor for Continuous $244,479.25 Inc Biomarker Monitoring

New York $48,158,586.22

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 22nd Century Limited, X-22 Prescription Smoking $20,939.50 $223,539.75 LLC Cessation Aid Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of Light AccuVein, LLC Reflective Vein Visualization $244,479.25 Device - AV300 Novel Molecular Profiling Tool for Diagnosing, Guiding Adarza Biosystems, Inc. $169,837.27 $74,641.98 Therapy and Reducing Cancer Costs. Collagenase for Tissue Advance Biofactures Dissociation-New Cellular $51,186.62 $130,736.83 Corporation Therapies The use of Collagenase Therapy Advance Biofactures in the Treatment of Human $51,138.20 $193,341.05 Corporation Lipoma Bio-degradable Polymer Advanced BioMedical Orthopedic Internal Fixation $196,382.50 $48,096.75 Technologies Inc. Devices Development of an Interactive Advanced Monitoring Voice Rdsponse Clinical $244,479.25 Caregiving, Inc Application Development of a Predictive Advanced Monitoring Model for Assessing Telehealth $47,306.00 $74,189.50 Caregiving, Inc. Impactability Integration of a Clinical Advanced Monitoring Televideo Solution into a Web- $23,750.00 $112,199.00 Caregiving, Inc. Based Telehealth Software Application Novel therapy for the treatment Aggamin Pharmaceutics of preeclampsia in pregnant $244,479.24 LLC women Develpoment of a Compact, Ambulatory Monitoring High-Performance Wrist-Worn $151,083.00 $93,396.25 Inc Motionlogger Actigraph Device PROSTATE DISEASE ANDROBIOSYS, INC $166,822.00 $77,657.25 TREATMENT Angioblast Systems Inc Allogeneic Adult Stem Cells to $200,149.50 $44,329.74 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Treat and Reverse Wet Age Related Macular Degeneration Allogenic Adult Stem Cells to Angioblast Systems Inc Treat Reverse Congestive Heart $244,479.24 Failure Adult Stem Cells to Treat Type Angioblast Systems Inc 2 Diabetes by regenerating Beta $237,301.00 $7,178.24 Islet Cells Allogenic Adult Stem Cells for Angioblast Systems Inc the Treatment of Acute $237,509.50 $6,969.74 Myocardial Infarction (AMI) Cord Blood Expanded by Allogeneic Adult Stem Cells to Angioblast Systems Inc $244,479.24 Treat Hematologic Malignancies 4 Phenylphtalazione, other Angion Biomedica Corp projects: BB3, Ang797, Rec1, $244,479.24 Dual Kinase, Atra Angion Biomedica Rac1, $2,374.99 $56,433.08 Corporation BB3 Other projects: Ang797, Angion Biomedica Rac1, Dual Kinase, Atra, 4- $244,479.24 Corporation Phenylphalazionone Dual Kinase, Other Projects: Angion Biomedica BB3, Rac1, Atra, Ang797, 4 $61,001.01 Corporation Phenylphthalazinone ATRA, Other Projects: BB3, Angion Biomedica Ang797, Rac1, Dual Kinase, 4 $30,785.58 Corporation Phenylphthalazinone ANG-797, Other Projects: BB3, Angion Biomedica Rac 1, Dual Kinase, Atra, 4 $16,966.56 Corporation Phenylphthalazinone Anterios, Inc (formerly New Treatments for $244,479.24 known as Encapsion, Inc) Hyperhidrosis and Acne Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Research and Development Apath LLC Tools for the Treatment of Viral $244,479.25 Infections Drug Discovery: Specific and Apath, LLC $244,479.25 broad spectrum antivirals New diagnostics for epigenetic AptaMatrix, Inc. disorders with applications to $87,981.00 mental health diseases New diagnostics for AptaMatrix, Inc. thrombosis, bleeding disorders, $244,479.25 and proliferatives diseases TPI-287, a novel anti- Archer Biosciences Inc microtuble agent for the $244,479.25 Treatment of Cancer Ariston Pharmaceuticals, AST-726 for the treatment of $244,479.25 Inc. Vitamin B-12 Deficiency Prognostic Model for Active Aureon Laboratories, Inc Surveillance in Prostate Cancer $244,479.24 Patients Dityrosine (DT) stabilization of Avatar Medical, LLC an HIV-1 Env vaccine $53,960.00 $190,519.25 immunogen Biomedica Management Hemostatic Agent for use in $183,491.99 $60,987.26 Corporation non-compressible hemorrhage therapeutic Devices Using the Biomerix Corporation $244,479.25 Novel Biomerix Biomaterial BIO-SIGNAL GROUP Putting EEG in the Emergency $51,605.84 $192,873.40 CORP Department The Home Epilepsy Monitoring Bio-Signal Group Corp $190,184.75 $54,294.49 Unit IMPROVED MANUSCRIPT BIOSOF LLC SEARCH THROUGH $19,981.50 $34,272.00 PUBSEQ BioSource Pharm, Inc. Design and Synthesis of Novel $61,791.50 $182,687.75 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Antibiotics Against Resistant Gram Positive Bacteria Development of Dual Cargo Buffalo Biolabs LLC Liposomes Containing Cytoxiz $44,955.82 $97,977.53 Drugs and Reversan FertilArray: In Vitro Diagnostic Celmatix, Inc. for Oocyte (Egg) Quality and $16,125.00 $228,354.25 Female Infertility Celtic Pharma Development Services Xercept $244,479.25 America Inc Celtic Pharma Development Services TDT 067 $244,479.25 America, Inc. Cerebral Assessment Cognivue Development $244,479.25 Systems Inc CEROVENE INC New Dosage Latform Project $138,050.50 $106,428.74 DPP Multiplex Rapid Test for Chembio Diagnostic Detection of HIV P24 Antigen $51,575.50 $192,903.75 System Inc & HIV 1/2 Antibodies DPP® Multiplex Rapid Test for Chembio Diagnostic Detection of Antibodies to Hep- $118,840.00 $125,639.25 Systems , Inc C & HIV1/2 Sure-Check Unitized Home Use Chembio Diagnostic Finger-stick Whole Blood $244,479.25 Systems Inc Rapid HIV 1/2 Test DPP® Rapid Test for the Chembio Diagnostic Detection of Antibodies to $71,649.50 $172,829.75 Systems, Inc. Hepatitis-C DPP® Rapid Test for Detection Chembio Diagnostic of Antibodies to HIV1/2 in Oral $233,578.00 $10,901.25 Systems, Inc. Fluid Chembio Diagnostic DPP ® Multiplex Rapid Test $144,961.50 $99,517.75 Systems, Inc. for Diagnosing Active, Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Untreated Syphilis Cleveland BioLabs Inc Protectan CBLB502 $244,479.24 Vaccine against Respiratory Codevax $2,500.00 $18,500.00 Syncytial Virus (RSV) Anti-Autolysin Passive Codevax Immunity for MRSA $30,426.50 $60,250.00 Osteomyelitis CNDO102 for Treatment of Coronado Biosciences $244,479.25 Cancer CNDO101 for Treatment of Coronado Biosciences $244,479.25 Cancer Coronado Biosciences C1 for Treatment of Cancer $244,479.25 sST2 Guided Personalized Critical Care Diagnostics, Management of Cardiovascular $244,479.25 Inc. Disease and Cancer Treatment CM-AT Therapeutic FDA Curemark LLC authorized Phase III clinical $244,479.25 trials for the treatment of autism CYN 101 onvolytic vector for Cynvec LLC the diagnosis and treatment of $244,479.25 cancer Delcath Chemosaturation Delcath Systems, Inc $244,479.25 System Enhanced Genetic Sample Diffinity Genomics, Inc. $174,809.78 $69,669.47 Analyst and Use Dipexium Pexiganan cream for treatment $244,479.24 Pharmaceuticals, LLC of diabetic foot infection (DFI) Durata Therapeutics, Inc. Dalbavancin $244,479.25 Chemically-distinct low Egenix, Inc molecular weight compounds $244,479.24 against validated cancer targets ELLIQUENCE, LLC RD-ELL 10-1003 $197,000.00 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Non-invasive Bladder Cancer Empire Genomics LLC $244,479.25 Molecular Diagnostic test. Endocrine Technology, ET002 Therapy of Colon $244,479.24 L.L.C. Cancer Crolibulin novel small molecule EpiCept Corporation vascular disruption agent for the $244,479.25 treatment of solid tumors NP-1 is a novel approach in the EpiCept Corporation management of pain associated $244,479.25 with neuropathies. Ceplene, Immunotherapy for EpiCept Corporation $244,479.25 remission maintenance in AML ETN 002: Therapy of ET Neuron Inc Amyotrophic Lateral Sclerosis $244,479.24 (ALS) ETN 001: Therapy of ET Neuron Inc $244,479.24 Alzheimer's Disease ETR 001: Therapeutic Project ET Transplant, Inc. $244,479.24 for Renal Transplant Tolerance ETVaccine Technology, ETV003: Factor H binding $244,479.24 Inc. Meningococcal Vaccine Evidence-Based Evidence-Based Diagnostic $244,479.24 Solutions, Inc Device/Solution Diagnosis of Cancer, Staging Exosome Diagnostics Inc and Patient Stratification from $244,479.25 Exosome Content Analysis Fonar Upright MRI Diagnostic Fonar Corporation $244,479.25 Technology FST-200, a novel Otic Foresight Biotherapeutics Suspension for the Treatment of $244,479.25 Inc Acute Otitis FST-100, a Novel Ophthalmic Foresight Biotherapeutics Suspension for the Treatment of $244,479.25 Inc Adenoviral Conjunctivitis Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Novel Organo-Metallic Garnett McKeen Compounds in the Treatment of $244,479.25 Laboratory, Inc. Cancer Palladium-Lipoic Acid Garnett McKeen Formulation in the Treatment of $7,500.00 $95,000.00 Laboratory, Inc. Brain Cancer Manufacturing Therapeutic Glycobia, Inc. $52,269.43 $139,127.56 Glycoproteins in E. Coli Diagnosing Acute Coronary iCardiac Technologies, Syndrome in patients with $23,465.50 Inc. Chest Pain TEE Monitoring for Intensive ImaCor Inc $244,479.25 Care Immco Diagnostics, Inc. Autoimmune Disease Markers $65,480.00 IMMCO DETECTION OF CHRONIC $44,705.00 DIAGNOSTICS, INC. SINUS Therapeutic monoclonal Immune Pharmaceuticals antibody drug for the treatment $125,000.00 $119,479.25 Corp of IBD and Severe Asthma Monoclonal antibody for the Immune Pharmaceuticals treatment of the treatment of $50,000.00 $194,479.25 Corporation Graft versus Host Disease (GVHD) Immune Pharmaceuticals Therapuetic Targeting Cancer $237,500.00 $6,979.25 Corporation Stem Cells BI-specific anitbodies for the Immune Pharmaceuticals treatment of fatal Chronic $225,000.00 $19,479.25 Corporation Lymphocytic Leukemia (CLL) Optimizer III System (medical Impulse Dynamics USA, device) for Treatment of $244,479.25 Inc Chronic Heart Failure (CHF) Development of Curaxins as Incuron LLC $244,479.25 novel anticancer agents INSPIRION DELIVERY ABUSE DETERENT OPIOIDS $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 TECHNOLOGIES LLC Integrated Nano- An Automated Point-of-Care $244,479.25 Technologies, LLC Molecular Diagnostic System Intercept Pharmaceuticals INT-747 $244,479.25 INTERCEPT INT-777 $244,479.25 PHARMACEUTICALS Intra-Cellular Therapies, ITI-007 for the treatment of $244,479.25 Inc insomnia and sleep disorders Intra-Cellular Therapies, ITI-007 for the treatment of $244,479.25 Inc Schizophrenia and Depression Intra-Cellular Therapies, ITIPDE1 $244,479.25 Inc. Intra-Cellullar Therapies, PET Ligands $166,269.00 $78,210.25 Inc IRX-2 Patented novel biologic IRX Therapeutics Inc to treat newly-diagnosed $244,479.24 advanced head and neck cancer Skin Test: Patented novel IRX Therapeutics, Inc diagnostic device to determine $12,136.14 $96,923.56 immune competency. IRX-4: Patented novel IRX Therapeutics, Inc. therapeutic cancer vaccine to $244,479.25 treat prostate and brain cancer IRX-2 Patented novel IRX Therapeutics, Inc. therapeutic vaccine to treat $244,479.25 HPV infected women MIMP: Patented novel small molecule to restore immune IRX Therapeutics, Inc. $26,118.23 $218,361.02 protection against influenza A virus Drug Delivery from Isoflux Inc Nanoporous Inorganic $124,861.14 $119,618.10 Structures Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development & Clinical Trials JARVIK HEART, INC of Highly Miniaturized Heart $244,479.25 Assist Therapeutics Kadmon Corporation Targeted therapy for treatment $244,479.24 LLC of advanced gastric cancer Karos Pharmaceuticals, Novel tryptophan hydroxylase 1 $244,479.25 Inc. (TPH1) inhibitors Keryx Perifosine $244,479.24 Biopharmaceuticals, Inc Keryx Zerenex (ferric citrate) $244,479.25 Biopharmaceuticals, Inc. Kinentia Biosciences Flt-3 Kinase Inhibitor Program $1,641.50 $3,724.50 LLC Kinentia Biosciences, Mu Opioid Moderator Program $1,928.50 $10,323.50 LLC KINEX KX01 $244,479.24 PAHRMACEUTICALS KINEX PHARMACEUTICALS, KX03 $244,479.24 LLC KINEX PHARMACEUTICALS, KX02 $244,479.24 LLC Development of Adv-GM- CAIX: A Novel Kite Pharma, Inc. $23,027.14 $221,452.10 Immunotherapy for the Treatment of Cancer Electrical Inhibition of Human Lambda Max, LLC $2,605.00 $179,976.00 Preterm Uterine Contractions Non-Invasive Platform LighTouch Medical Inc Technology for The Molecular $205,000.00 $39,479.25 Analysis of Blood Analytes Development of a Novel Litron Laboratories Ltd $7,170.50 $6,032.00 method for quantifying splenic Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 function LB-1 an inhibitor of protein Lixte Biotechnology phosphatase 2A is a novel $127,994.00 $116,485.25 Holdings Inc effective anticancer drug VivaScope Confocal Imaging for the early detection of Lucid Inc $244,479.25 Melanoma and other skin cancers Lumetrics Inc Portable Fundus Camera $13,119.10 $71,223.75 A novel agent for colon cancer Medicon Inc. $7,722.00 $236,757.24 prevention Mela Sciences Inc MelaFind $244,479.25 Misonix Inc. Sonatherm 600i System $74,283.50 $40,107.00 Gene Expression Profiles (GEPs) for the Effective Myeloma Health LLC $12,786.00 $231,693.25 Treatment of Multiple Myeloma (MM) Development of mechanical cardiac and circulatory support MyoCardioCare Inc $164,982.41 $79,496.84 device for cardiac arrest patients Breast Cancer Precision NaniRx Therapeutics Inc $244,479.24 Immune Stimulants (PINS) Development of new drug Natrogen Therapeutics (Natura-alpha) for treating $244,479.24 International, Inc autoimmune diseases Advancing Two Novel Biomarkers for Diagnosing Neogenix Oncology Inc $244,479.25 Pancreatic and Colorectal Cancers. Development of h16C3 mAb as a Novel Treatment for Neogenix Oncology, Inc $244,479.25 Colorectal, Pancreatic & Lung Cancers Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 NPC-1C (ensituximab) as a Neogenix Oncology, Inc Target Therapy for Pancreatic $244,479.24 and Colorectal Cancers Nex Genix NX101 Novel Non-Surgical Pharmaceuticals Holdings Treatment for Dermal $35,292.76 $204,382.47 Inc Neurofibromas Hsp90 Inhibitors for Glioma NexGenix and Other Primary Tumors of Pharmaceuticals Holdings $244,479.25 the Central Nervous System Inc (CNS) NexGenix Hsp90Inhibitors for Pharmaceuticals $244,479.25 Neurodegenerative Diseases Holdings, Inc NexGenix Hsp90 Inhibitors for Solid Pharmaceuticals Tumors including Refractory $91,940.11 $152,539.14 Holdings, Inc Tumors with Brain Metastases Antimirobial resistance reversal Nomir Medical and bio-burden reduction of $244,479.25 Technologies Inc bacterial and fungal pathogens Terminal Sterilization of NovaSterilis Inc. $37,866.00 $170,050.00 Allograft Tissue Cr-enhanced insulin for the Nutrition 21, Inc. treatment of type 1 and type 2 $4,350.00 $100,000.00 diabetes Ohr Pharmaceutical, Inc. OHR/AVR118 for Cachexia $65,121.68 $179,357.56 Testing an Aerosol System fo ONY Inc. $40,000.00 Lung Surfactant Delivery Oratel Diagnostics LLC Saliva assay for endometriosis $43,298.00 $85,500.00 Ort, Inc F/K/A Oncology Clinical study to demonstrate Research Therapeutics, the use of in-vitro chemofit $21,679.50 Inc assay Orthocon Inc The ORTHOstat-L project $244,479.25 Oxyvita, Inc. OxyVita® $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Paylon Implantable Drug Palyon Corporation $244,479.25 Delivery System (IDDS) A0001, a coenzyme Q analog Penwest Pharmaceuticals for treatment of mitochondrial $244,479.25 Co diseases GP-531 AS A TREATMENT PERICOR FOR ACUTE HEART $244,479.25 THERAPEUTICS, INC FAILURE Automatic Home Medication Pharmadva, LLC $244,479.25 Dispenser (AHMD) PN 200: A New Topical PharmaNova Inc $63,611.94 $180,867.31 Treatment for Genital Herpes PN203: Targeted Nanoparticles PharmaNova Inc $60,893.93 $183,585.32 for Oncology Medicines Implantable, refillable, PharmaNova, Inc reprogrammable, rechargeable $17,852.88 $37,451.00 drug delivery device AP022 A New Topical PharmaNova, Inc. $28,100.12 $92,274.00 Treatment for Glaucoma Calfactant for Acute Pneuma Pharmaceuticals Respiratory Distress Syndrome $244,479.25 Inc (CARDS study) A rational & systematic Population Diagnostics approach to parkinson's disease $244,479.25 Inc ("PD") drug therapy development Population Diagnostics Development of an Autism $244,479.25 Inc early Detection Genetic Test Primros Therapeutics, Inc XL647 PKD Therapeutic $244,479.24 Progenics PSMA ADC $244,479.24 Pharmaceuticals Inc PROGENICS PHARMACEUTICALS, PRO 140 $244,479.24 INC Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 PROGENICS PHARMACEUTICALS, HCV ENTRY INHIBITOR $244,479.24 INC. Clinical Development of PsychoGenics Inc $244,479.24 Eltoprazine Discovery and development of PsychoGenics Inc. $244,479.24 Adenosine PsychoGenics Inc. Partnered Drug Discovery $244,479.25 Discovery and Development of PsychoGenics Inc. $244,479.24 Peptides for CNS Disorders Development of Novel PsychoGenics Inc. Nicotinics for Treatment of $244,479.24 Resistant Depression A PDGFR inhibitor for the Pulmokine, Inc treatment of pulmonary arterial $134,390.00 hypertension A novel JAK inhibitor for the Pulmokine, Inc. treatment of pulmonary arterial $115,043.00 hypertension Therapeutic Ultrasound For The Recor Medical Inc Treatment Of Mitral $244,479.24 Regurgitation Redox Pharmaceutical Doxovir ™ ("Doxovir") $244,479.25 Corporation Development of intravenous Remedy Pharmaceuticals glyburide to treat acute $244,479.24 Inc ischemic stroke Development of intravenous Remedy Pharmaceuticals glyburide to treat acute spinal $244,479.24 Inc cord injury IV glyburide to reduce edema Remedy Pharmaceuticals, and steroid use and improve $244,479.24 Inc outcomes following brain tumor surgery Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Sarentis Therapeutics, Neurotensin pain medication $69,755.00 $174,724.25 Inc. Sarentis Therapeutics, Silk Corneal Inlay (herein "Silk $244,479.25 Inc. Film") Development of a Safer Version Savvipharm Inc of Doxorubicin to Diminish $56,069.00 $188,410.24 Cardiotoxicy in Cancer Patients Development of Specialized Scientific Optics, Inc Contact Lens for Dyslexic and $83,956.02 $93,870.62 Macular Degeneration Patients Drugs inhibiting damage Senex Biotechnology, Inc response mechanism of cancer, $219,179.20 $25,300.04 Alzheimer's and viral diseases. Drug targeting Androgen Serometrix LLC receptor DNA binding to block $68,115.00 $176,364.25 progression of prostate cancer Peptimer Drugs That Inhibit Serometrix LLC Binding of PCSK9 to LDLR to $40,146.00 $119,593.00 lower Blood Cholesterol Sherrington Resiniferatoxin (RTX) $244,479.25 Pharmaceuticals Inc Development of Arenavirus SIGA Technologies, Inc $109,775.00 $87,503.50 Antivirals ST-246 Orthopoxvirus Antiviral SIGA Technologies, Inc. $244,479.24 Program SIGA TECHNOLOGIES, DENGUE ANTIVIRAL $111,466.50 $94,596.00 INC. DEVELOPMENT PROGRAM A novel dry AMD animal SKS Ocular, LLC model for drug screening and $244,479.25 mechanistic studies ASSESSMENT OF MUSCLE FORCE FOR DIAGNOSIS OF SONOSTICS, INC. $169,032.50 $75,446.74 MUSCULOSKELETAL DISEASE Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Stemline Therapeutics, SL-401 $244,479.24 Inc Synergy Pharmaceuticals Agonists of Guanylate Cyclase- $244,479.24 Inc C Thyroid hormone treatment of T3 Therapeutics LLC $84,000.00 $100,000.00 Diastolic Heart Failure Safety of Carboxyamidotriazole orotate in age-related macular Tactical Therapeutics Inc $244,479.24 degeneration Diabetic Retinopathy Safety of Carboxyamidotriazole oratate (CTO) in Adult Advanced and Metastatic Cancer Patients as Tactical Therapeutics inc Monotherapy and in $244,479.24 Combination with Temozolomide in Patients with Glioblastoma Multiforme in Phase I. Safety of Carboxyamidiotriazole orotate (CTO) in Pediatric Cancer Patients as Monotherapy and in Tactical Therapeutics, Inc $100,000.00 $144,479.24 Combination with Temozolomide in Pediatric Patients with Glioblastoma Multiform in Phase 1 Novel Agents for Treatment of Tartis, Inc. $5,848.47 $108,273.03 Hematological Diseases Development of Virus-Like TechnoVax Inc Particles {VLPs} Influenza $17,834.00 $226,645.24 Vaccines Development of Universal TechnoVax, Inc Influenza Vaccine using Virus- $41,800.00 like Particles (VLP's) TechnoVax, Inc Development of Universal $35,150.00 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Virus-Like Particles(VLP) based HIV vaccine Development of a Multivalent TechnoVax, Inc Dengue Virus-Like Particle $127,000.00 (VLP) Vaccine Respiratory Syncytial Virus TechnoVax, Inc. Vaccine Based on Virus-Like $41,800.00 Particles (VLPs) Tetra Express Protein Tetragenetics, Inc $244,479.25 Manufacturing Platform The SmartPill SmartPill Wireless Motility $244,479.24 Corporation Capsule {WMC} Therasis Inc Therasis Filter $190,861.00 $53,618.25 Development of Human Therasource LLC AM/AMBP-1 as Critical Care $200,076.50 $44,402.75 Therapeutics Preclinical Development of Alpha2A-Adrenoceptor TheraSource LLC $28,583.00 $46,404.00 Antagonist: A Novel Anti- Sepsis Therapy Therapeutics for the prevention and teatment of resistant Therex LLC $108,128.00 $42,887.50 Staphylococcus aureus infections. Rapid, Portable Molecular Thermal Gradient Inc. $56,152.00 $188,327.24 Diagnostic System Tracon Pharmaceuticals TRC105 $244,479.25 Inc Tracon Pharmaceuticals Inc % Paramount TRC102 $244,479.25 Biocapital Inc Tracon Pharmaceuticals, Inc.C/O Paramount TRCO93 $236,050.02 $8,429.23 Biocapital Inc. Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Collaborative IVR Platform for Transcendent Multilingual Patient Outreach $175,725.07 $68,754.18 International LLC and Treatment Adherence (a.k.a VoiceReach) TRANSLUMINAL VELOX CD $244,479.25 TECHNOLOGIES LLC Non-Invasive Continuous TransTech Systems Inc $45,777.76 $83,961.29 Glucose Monitor for Diabetes Research and Development of a Ultradian Diagnostics, Continuous Glucose Monitoring $134,180.00 $110,299.24 LLC System Humanized Antibody [UB-421] Targets HIV Receptor for United Biomedical, Inc $244,479.25 "Entry Inhibitor" Immunotherapy Preventative AIDS Vaccine by United Biomedical, Inc. $96,807.01 $147,672.24 Targeting HIV-1 gp120 Alzheimer's Disease Vaccine by United Biomedical, Inc. $227,385.87 $17,093.38 Targeting Amyloid-beta Peptide HIV Therapeutic Vaccine by United Biomedical, Inc. Targeting Host Cell HIV $244,479.25 Receptor Vaccinex, Inc VX-35 Project $244,479.24 Vaccinex, Inc. VX-5 Project $244,479.24 Vaccinex, Inc. VX-15 Project $244,479.24 Vitatex Functional Cell Vitatex Inc $33,874.61 $138,799.28 Adhesin Matrix (fCAM) Novel Small-Molecule Vivaldi Biosciences Inc Antiviral Therapeutics for $145,419.50 $99,059.75 Influenza Live Attenuated Influenza Vivaldi Bosciences Inc Vaccine (LAIV) for Greater $244,479.25 Efficacy in the Elderly Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Vybion, Inc. ProCode $127,412.00 $117,067.24 Body-fluids trace-element X-Ray Optical Systems, analyzer to detect disease and $244,479.25 Inc guide therapeutic decisions Improving the tolerability of Zeomedex, LLC $244,479.25 lipase inhibitors

North Carolina $35,707,613.85

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of a Digital Advanced Liquid Microfluidic Platform for $244,479.25 logic,Inc Newborn Screening and Other Diagnostics Localized delivery of Affinergy, Inc therapeutics for sugical hernia $103,735.44 $140,743.81 repair meshes Biologic Delivery Carrier for Affinergy, Inc $175,877.60 $68,601.64 Spine Fusion Peptide Linkers and Affinergy, Inc. antimicrobial therapeutics for $244,479.24 orthopedic surgery Enhanced Delivery of Protein Affinergy, Inc. Growth Factors for Trauma $244,479.24 Fractures A Biological Cell-Binding Affinergy, Inc. Matrix for Treating $109,816.62 $69,122.45 Cardiovascular Disease Mushrooms: A novel Platform Agarigen, Inc for the Accelerated Production $244,479.25 of Biopharmaceuticals Agile Sciences, Inc Development of Therapeutics $25,353.50 $111,250.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 for Treating Multidrug Resistant Bacterial Infections Treatment of Critical Limb Ischemia Patients-No Aldagen, Inc $244,479.25 Revascularization Options - (CLI) ALD-301 Tereatment of Ischemic Heart Disease Patients - No Aldagen, Inc. $244,479.25 Revascularization Options- ALD-201 Treatment of Post Acute Aldagen, Inc. Ischemic Stroke Patients - ALD- $244,479.25 401 Novel Analgesic Discovery Algynomics, Inc $65,881.50 $103,459.00 Project Diagnostic Genetic Tests for Algynomics, Inc. $85,428.00 $150,104.00 Chronic Pain Project AlphaVax Human Cytomegalovirus (CMV) $244,479.25 Vaccines Inc Vaccine AlphaVax Human Scale-up Program $244,479.25 Vaccines, Inc. Host Range Mutants of Dengue Arbovax, Inc Virus as Basis for Vaccine $230,000.00 Development Argos Therapeutics, AGS-004 $244,479.25 Inc Argos Therapeutics, AGS-003 $244,479.25 Inc Argos Therapeutics, AGS-009 (Intereron-alpha $244,479.25 Inc antibody) ASKLEPIOS Gene Transfer of AAV Galanin $149,171.00 $95,308.25 BioPharmaceutical, Inc for Epilepsy Asklepios Gene Transfer of AAV $220,191.00 $24,288.25 BioPharmaceuticals, Minidystrophin for Muscular Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc. Dystrophy Predicting resistance of cancer Attagene, Inc. to chemotherapy by profiling $244,479.25 activities of transcription factor Avioq Inc. Avioq HIV-1 Microelisa System $244,479.25 Avioq HTLV I/II Microelisa Avioq Inc. System for Use in Blood $67,913.46 $176,565.79 Screening and Diagnosis Targeted delivery of nucleic b3 bio, inc $244,479.24 acids to silence cancer genes Molecular Profiling of BioCytics Inc $133,946.50 $61,991.50 Circulating Tumor Cells Medical therapies utilizing BioDelivery Sciences BioErodible MucoAdhesive $244,479.25 International, Inc (BEMA) technology Development of an Oral BioKier, Inc. Therapeutic for the Treatment of $79,194.50 $165,284.75 Type 2 Diabetes Biolex Therapeutics, Locteron for the treatment of $244,479.24 Inc. chronic hepatitis C virus Novel calcium nanoparticles for BioLink Life Sciences, cancer detection & site-specific $4,426.50 $21,112.50 Inc drug delivery BioLink Life Sciences, Novel valproate salts with $186,238.00 $44,162.00 Inc enhanced patient benefits BioLink Life Sciences, Novel phosphate binders for $13,424.50 $231,054.74 Inc treatment of hyperphosphatemia A Phase 2 Clinical Study of a BioMarck COPD Therapeutic with a Novel $244,479.24 Pharmaceuticals Ltd Dual Mechanism of Action Development of molecular BioMedomics, Inc. diagnostic platforms & tests for $136,875.50 $107,603.74 personalized medicine diagnosis Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Formulation and Brighthaven Ventures Pharmacokinetics Study of $236,350.00 LLC Remogliflozin CALVERT Calvert T1-1081 $195,750.00 $48,729.25 RESEARCH, LLC Oral HNO donors for treatment Cardioxyl of Congestive Heart Failure $244,479.24 Pharmaceuticals, Inc (CHF) CXL-1020: A Novel Cardioxyl Intravenous Treatment for $244,479.24 Pharmaceuticals, Inc. Acute Decompensated heart Failure (ADHF) Peclinical Development of Catena VPC51299 a Novel LPA $7,500.00 $10,000.00 Pharmaceuticals Inc Receptor Antagonist CEM-102 (TAKSTA) Pre- CEM-102 clinical and clinical $244,479.25 Pharmaceuticals Inc development Cempra CEM-101 (Solithromycin) $244,479.25 Pharmaceuticals, Inc CeNeRx BioPharma TriRima $244,479.24 Inc CeNeRx BioPharma, Pivagabine $244,479.24 Inc. Centice Corporation PASS Rx $244,479.24 Diagnostic reader for cardiac Centice Corporation $244,479.25 biomarkers Chelsea Therapetics, Droxidopa $244,479.24 Inc Chelsea Therapeutics Antifolates RA $244,479.24 Inc CMX001 dsDNA Antiviral Chimerix Inc $244,479.25 Project Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 HCV Polymerase Inhibitors for Chimerix, Inc $244,479.25 the treatment of Hepatitis C CivaTech Oncology CivaTech Oncology Novel $178,979.00 Inc. Brachytherapy Device Novel Remyelinating Therapy Cognosci, Inc. $244,479.24 for Multiple Sclerosis Novel Targeted Therapy for Cognosci, Inc. $206,132.60 $38,346.64 Cancer Novel Therapy for Traumatic Cognosci, Inc. Brain Injury (TBI) and $244,479.24 Neurotrauma Lasmiditan (COL - 144) - CoLucid Neurally Acting Anti-Migraine $244,479.25 Pharmaceuticals, Inc. Agent Cytex Bioartificial Hip Replacement $18,086.00 $226,393.25 Therapeutics,Inc. DARA DB959 for Type 2 Diabetes & $244,479.24 Pharmaceuticals, Inc. Dyslipidemia DARA Therapeutics, KRN5500 for Neuropathic Pain $244,479.24 Inc in Patients with Cancer Diagnosoft, Inc Diagnosoft Heat Platform $149,187.00 $95,292.24 Develop Endacea's lead compound, L-97-1, as an oral Endacea Inc $10,150.00 $6,716.00 treatment for renal impairment with HF Optical Assay for the Endls Optics, Inc. Therapeutic Monitoring and $51,610.50 $152,184.08 Diagnosis of Cancer Exela Pharma Nitrofurantoin Sodium Injection $244,479.25 Sciences, LLC Liquid Fosfomycin FSC Laboratories, Inc $244,479.25 Tromethamine Furiex Pharmaceuticals JNJ-IBS $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Inc Furiex JNJ-Q2 $244,479.24 Pharmaceuticals, Inc Furiex PPD 10558 $244,479.24 Pharmaceuticals, Inc. Irritable Bowel Syndrome Genova Diagnostics, Evaluation & Treatment in $4,319.00 $80,078.00 Inc. Primary Care Novel Early Detection GlycoMark Inc Algorithm for Diabetes and Per- $244,479.25 Diabetes G-Zero Therapeutics G-Zero Pharmacoquiescence $46,989.00 $197,490.25 Inc and Companion Diagnostic HPP404 - H3 Antagonist - High Point Novel New Therapeutic for $244,479.25 Pharmaceuticals LLC Treatment of Obesity and Diabetes HPP593 - PPAR Delta Agonist - High Point Novel New Therapeutic for $244,479.25 Pharmaceuticals, LLC Dyslipidemia and Diabetes HPP854 - BACE Inhibitor - High Point Novel New Therapeutic for $244,479.25 Pharmaceuticals, LLC Treatment of Alzheimer's Disease HPP851-11B-HSD1 Antagonist High Point - Novel New Therapeutic for $244,479.25 Pharmeceuticals Primary Open Angle Glaucoma New Therapy for kidney failure Humacyte Inc $244,479.25 and vascular disease Hyperbranch Medical Therapeutic Hydrogels $244,479.24 Technology Inc Novel Selective Sodium Icagen, Inc Channel Drugs to Treat chronic $244,479.25 Pain Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Novel KCNQ Agonists for the Icagen, Inc. $244,479.25 Treatment of Epilepsy and Pain Novel TRPA1 Drugs to Treat Icagen, Inc. $244,479.25 Inflammatory Pain Percutaneous Implantable InnerPulse, Inc. Cardioverter-Defibrillator $244,479.25 (PICD) Rho kinase inhibitors for Inspire opthalmic and pulmonary $244,479.25 Pharmaceuticals Inc diseases Inspire Latrunculin Platform for $244,479.25 Pharmaceuticals Inc Glaucoma Inspire Blepharitis $244,479.25 Pharmaceuticals, Inc Inspire Denufosol Tetrasodium $244,479.25 Pharmaceuticals, Inc Kainos Medicine USA, NNRTI KM-023 $135,303.61 Inc. KeraNetics LLC Product for Fluid Resuscitation $205,053.00 $39,426.25 Product for Site-Directed Drug KeraNetics LLC $244,479.25 Delivery IMPACT OF LIPOPROTEIN LIPOSCIENCE, INC. PARTICLE ANALYSIS IN $39,875.00 $87,975.00 CARDIOVASCULAR RISK Nanoparticle Vaccines Using Liquidia Technologies PRINT Platform for Influenza $244,479.25 and other Diseases PRINT Particle Engineering Liquidia Technologies, Platform and Inhaled Antiviral $244,479.25 Inc. Therapeutics Development Mast Cell Effect of Ketotifen on $19,377.50 $51,962.00 Pharmaceuticals Inc Advfensiz Events Associates Medicago USA Demonstration of Scalable $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Manufacturing of Plant- Expressed Virus-Like Particles Vaccines Metabolon Inc Quantose Diagnostic $244,479.25 Metabolon, Inc Platform Technology $244,479.25 Auto-segmentation to Improve Morphormics, Inc. Radiation Therapy Cancer $244,479.24 Treatment MYCOSYNTHETIX NEW CANCER MEDICINES $25,244.50 $13,231.50 INC FROM UNUSUAL FUNGI New Antibiotics for TB from Mycosynthetix, Inc $56,676.00 $13,231.50 Unusual Fungi Nanocor Therapeutics Carfostin $244,479.25 Inc nContact's Focus: The Cure for nContact Surgical Inc $244,479.24 Atrial Fibrillation NextRay, Inc NextRay $69,255.20 $175,224.04 Nitric Oxide-Releasing Novan, Inc Technology (nitricil™) to Fight $244,479.25 Infection AMPK Activator for Cancer and NovaTarg $7,061.52 $216,500.00 Metabolic Diseases LKB1-AMPK Pathway NovaTarg $7,061.52 $237,417.72 Activator for Cancer NovaTarg (Kenneth Liver Selective AMPK $7,061.52 $237,417.72 William Batchelor) Activator for Type 2 Diabetes Identification of medicinal drug Ocean Therapeutics Inc candidates from marine $87,000.00 organisms Development of a new class of Ocean Therapeutics Inc anti infectives from culturable $104,500.00 marine organisms Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Development of Brevenal, a Ocean Therapeutics Inc $244,479.25 new therapy for Cystic Fibrosis Onconix, Inc. Cervical Cancer Blood Test $25,000.00 Development of optical biopsy device for detecting pre- Oncoscope, Inc. $244,479.24 cancerous tissue in the espohagus Photoacoustic Imaging and OptoSonics,Inc $244,479.24 Breast Cancer Therapy Oxygen Oxycyte drug for traumatic $244,479.25 Biotherapeutics brain and spinal cord injury Novel Treatment of Sjogren's Parion Sciences, Inc $244,479.24 Syndrome Xerostomia Novel Hydration Treatment for Parion Sciences, Inc. $227,856.50 $16,622.74 Dry Eye Disease Restoration of Host Defense Pathfinder Leading to Safe, Effective $38,426.00 $26,500.00 Pharmaceuticals, Inc Anticancer and Antiviral Drugs Piedmont Novel Head Lice Product $106,524.00 $103,892.50 Pharmaceuticals LLC Clinical Development of PT 107, Novel Therapy to Treat Pique Therapeutics Inc $101,250.00 $82,364.50 Non-Small Cell Lung Cancer(NSCLC) Pisgah Laboratories Inc Abuse Deterrent Hydrocodone $244,479.24 D/B/A Pisgah Labs, Inc Controlled Substance PLEXSTACK, A FOUR- DIMENSIONAL BIO-CHIP PLEXIGEN INC $180,657.50 $63,821.75 SYSTEM FOR PERSOALIZED MEDICINE POZEN Inc PA640 $244,479.25 POZEN Inc. PN400 / VIMOVO $244,479.25 POZEN Inc. PA32540 $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Precision BioSciences, BioProduction $190,983.76 $53,495.48 Inc. Salzburg Therapeutics, FdUMP(N)Therapeutics for $5,904.94 $1,880.84 Inc Cancer Treatment SCY-641 cyclophilin inhibitor SCYNEXIS Inc for treatment of $244,479.25 keratoconjunctivitis SCY-644 Single Drug Cyclophilin Inhibitor for HIV SCYNEXIS Inc $244,479.25 and HCV in Coinfected Population Cyclophilin D Inhibitors as SCYNEXIS Inc Protective Therapies in Muscle $244,479.25 Injury and Disease SCY-524 Oral Hepatitis C Scynexis, Inc $244,479.25 Therapy Pre-clinical development of a Seachaid novel glycopeptide for $114,330.50 $130,148.75 Pharmaceuticals Inc intravenous and oral delivery Seachaid Oral delivery of the intravenous $191,602.50 $52,876.75 Pharmaceuticals, Inc antibiotic cefepime Searchaid Development of Oratonin, and $244,479.25 Pharmaceuticals, Inc Oral Derivative of Calcitonin Sicel Technologies Inc DVS Dosimeter Lung Project $33,407.65 Sicel Technologies, DVS Electron Project $31,874.17 $5,000.00 Inc. Sicel Technologies, Ultra - HFT $40,760.50 Inc. Sicel Technologies, F-18 - Sensor Technology $546.75 $75,000.00 Inc. Sirga Advanced HIV drug development $87,179.00 $47,302.00 Biopharma, Inc SureMilk, LLC Diagnosing and treating low $34,877.00 $44,484.69 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 caloric content in breast milk by means of a modified surface Synecor LLC Interventional Autonomics $26,886.00 $217,593.25 Synecor, LLC Inventional Oncology $112,395.50 $132,083.75 RecA inhibitors to restore and Synereca potentiate antibiotic $896.50 $87,078.50 Pharmaceuticals, Inc. effectiveness Nueronal Nicotinic Receptor Targacept Inc Modulators as treatments for $244,479.25 Smoking Cessastion TC-5214 as a Treatment for Targacept, Inc Major Depressive Disorder $239,077.50 $5,401.75 (MDD) TC-6499 as a Treatment for Constipation Predominant Targacept, Inc $214,447.14 $30,032.11 Irritable Bowel Syndrome (IBS- C) TC-5619 as a Treatment for Targacept, Inc $244,479.25 Various Cognitive Disorders TC-6987 as a Treatment for Targacept, Inc. $244,479.25 Various Inflammator Disorders Neuronal Nicotinic Receptor Targacept, Inc. Modulators as Treatments for $244,479.25 Parkinson's Disease Thermal Pulsation System TearScience, Inc $244,479.24 ("LipiFlow") LipiView Ocular Surface TearScience, Inc $244,479.24 Interferometer ("LipiView" ) Melanocortin Ligands in Tensive Controls, Inc. $13,940.60 $46,965.09 Disease Cachexia Treatmentof Inflammatory TheraLogics, Inc disorders & cancer with $244,479.24 inhibitors of NF-kappaB Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Radiation dose reduction and TomoSoft image enhancement in medical $78,246.50 $166,232.75 Technologies, LLC diagnostic imaging Staph aureus Antibiotic Drug Trana Discovery, Inc $100,462.50 $144,016.75 Discovery Assay Application of a Novel Anti- Trana Discovery, Inc $63,719.00 $66,900.00 HIV Drug Discovery Assay Delivery of Therapeautic Nucleus Material Using a TranS1, Inc $244,479.25 Minimally Invasive Implant System The TransEnterix SPIDER Platform for Treatment of TransEnterix, Inc. $244,479.24 Obesity-Related Disorders and Cancer Modular Fusion Implant System TransS1, Inc for Fixation and Delivery of $244,479.25 Therapeutic Agents TTP4000-Rage Ligand Decoy - TRANSTECH Novel New Therapeutic for $244,479.25 PHARMA INC. Alzheimer's Disease TTP054 - Glucagon-like Peptide TRANSTECH 1 Agonist Novel New $244,479.25 PHARMA, INC Therapeutic for Type 2 Diabetes TTP-GLUCOKINASE ACTIVATOR - NOVEL NEW TRANSTECH THERAPEUTIC FOR $244,479.25 PHARMA, INC. TREATMENT of TYPE 2 DIABETES TTP607 Aurora Kinase TRANSTECH Inhibitor Novel New $244,479.25 PHARMA, INC. Therapeutic for treatment of cancer TRANZYME, INC TZP-102 $244,479.25 TRANZYME, INC. ULIMORELIN $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Treatment of IGF-1 mediated Vascular atherosclerosis in diabetics via $161,905.50 $82,573.74 Pharamaceuticals, Inc aVB3 receptor antagonism Novel Therapaeutic for the Viamet treatment of advanced prostate $244,479.25 Pharmaceuticals Inc cancer (APO) Novel Therapaeutic for the Viamet treatment of invasive fungal $244,479.25 Pharnaceuticals, Inc infection in humans Advanced Drus Access and Yukon Medical, LLC $151,615.00 $92,864.25 Delivery System Zinfandel Opportunity for the preventio of $132,056.50 $112,422.75 Pharmaceuticals Inc Alzheimers Disease Zor Pharmaceuticals, Virulizin ® $244,479.25 LLC

North Dakota $733,437.72

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Egc Superantigens for Aldevron LLC Treatment of Stage IIIB NSCLC $52,015.00 $192,464.24 with Pleural Effusion A Therapapeutic Vaccine for Altravax Inc Treatment of Chronic Hepatitis $244,479.24 B Infection NovaDigm Vaccine against Staphylococcus $244,479.24 Therapeutics, Inc aureus and Candida

Ohio $14,680,074.39 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 MultiStem IV to treat multiple ABT Holding diseases involving acute tissue Company (a subsidiary $244,479.24 damage & chronic of Athersys Inc) inflammation ABT Holding Development of proprietary Company (a subsidiary pharmaceutical products for the $244,479.24 of Athersys, Inc) treatment of obesity by ABT ABT Holding MultiStem-LD for treatment of Company (a subsidiary AMI (heart attack) and other $244,479.24 of Athersys, Inc) forms of cardiovascular disease Development of Surfactant Protein-D to Prevent Airway Therapeutics $1,338.50 $69,736.00 Occurrence of Bronchopulmonary Dysplasia AKB-6548 for anemia Akebia Therapeutics, associated with chronic kidney $244,479.24 Inc. disease Akebia Therapeutics, AKB-9778 for vascular leak $244,479.24 Inc. AKB-4924 for serious Akebia Therapeutics, infections and post-surgery $216,473.50 $28,005.74 Inc. wound healing PSA/SIA A new test for AnalizaDx, LLC improved diagonsis of Prostate $244,479.24 cancer ApneiCare, LLC Patient Study $116,000.00 $108,000.00 Arteriocyte Medical Development of Rapid, Point of $216,663.88 $27,815.36 Systems, Inc. Care Stem Cell Therapeutics Advanced Stem Cell Based Arteriocyte, Inc Cancer Diagnostics and Drug $65,810.00 $178,669.24 Discovery Nanomaterials Based Arteriocyte, Inc Production System for $239,575.00 Therapeutic Stem Cells Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 GeneSightRx Psychiatric AssureRx Health, Inc. Pharmacogenetics Product and $244,479.25 Clinical Development AtriClip Left Appendage Exclusion Clip Development AtriCure, Inc $244,479.25 and Associated EXCLUDE Clinical Trial Synergy RF Ablation AtriCure, Inc. Development and Associated $244,479.25 ABLATE clinical Trial AXIOMED SPINE FREEDOM ® LIMBAR DISC $244,479.25 CORPORATION Development of a Neonatal Bionix Development Lighted Endotracheal tube $7,020.16 $59,451.79 Corporation Stylet Development of a Non-Contact Bionix Development Electrocardiogram Monitoring $31,172.95 Corporation Pad for Infants Development of Bionix Development ThermoBrachytherapy Surface $39,398.45 $33,460.80 Corporation applicators for Treating Cancer Azimilide-A Late Phase III Blue Ash Approvable Ventricular $244,479.25 Therapeutics, LLC Antiarrhythmic CardioInsight CardioInsight Electrocardiograph Mapping $244,479.25 Technologies, Inc System Stroke Prevention through Development of Non-Invasive Cardiox Corporation $244,479.25 Method for Detection of Cardiac Shunts Cervilenz Inc Cervilenz $244,479.25 ChanRx Corporation Vanoxerine Development $76,000.00 $168,479.24 Checkpoint Surgical, Surgical instruments for $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC evaluating nerve integrity Cleveland Medical Movement Disorders $44,197.00 $52,573.00 Devices, Inc. Diagnostics Consolidated Research Zmachine for Chronic Insomnia $162,575.00 $81,904.24 of Richmond, Inc Copernicus Cystic Fibrosis Therapeutic $118,458.00 $126,021.25 Therapeutics, Inc Copernicus Retinitis Pigmentosa (RP) $244,479.25 Therapeutics, Inc Treatment Copernicus Parkinson's Diseases $28,348.00 $177,412.50 Therapeutics, Inc. Therapeutic Dermatopathology Advancing molecular probes Laboratory of Central $186,000.00 for melanoma diagnosis States Estrocept Diagnostics, Estrocept Breast Cancer Test $55,000.00 Inc Exercise stress cardiac EXCMR Ltd $27,391.88 $217,087.37 magnetic resonance imaging Miniaturized Distal Vibration Frantz Medical System for Penetrating $193,725.00 $50,754.25 Development, Ltd. Vascular Occlusions Development of B-Lock, an Great Lakes anti-biofilm catheter lock $244,479.25 Pharmaceuticals Inc solution Optical coherence Imalux Corporation tomography:use for preinvasive $244,479.24 and invasive epithelial cancer Jagle Biopharma LLC Formulation Development $35,000.00 Juventas Therapeutics JVS-100 for Treatment of $244,479.25 Inc Chronic Heart Failure Juventas Therapeutics JVS-100 for Treatment of $110,013.50 $134,465.75 Inc Critical Limb Ischemia Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Creation of molecular feature- Leadscope, Inc based QSAR toxicity prediction $244,479.24 models. m2m Imaging Cryogenic MRI Coil Project $168,994.74 $50,380.09 Corporation Metallopharm LLC Catalytic Metallodrugs $51,492.50 $127,000.00 MetaMol Theranostics Diagnostics and Therapies for $59,767.11 $38,625.00 LLC Cancer Metastasis Therapeutic relief of post- NDI Medical LLC $244,479.25 amputation pain NEO PROTEOMICS, Drug development for $150,000.00 INC. Serotonin Receptors Neoprobe Corporation Lymphoseek $244,479.24 Peripheral Nerve Block Neuros Medical, Inc Stimulation for Residual Limb $83,245.93 $161,233.31 Pain NeuroWave Systems NeuroSENSE Monitor $15,758.50 $63,400.50 Inc NovelMed Humanized YalcioMab for $244,479.24 Therapeutics, Inc Rheumatoid Arthritis Tumor-penetrating Optimum microparticles for treating $89,823.77 $65,105.67 Therapeutics, LLC peritoneal cancers Optimum Development of siRNA cancer $87,375.47 $56,021.15 Therapeutics, LLC therapeutics Instantaneous-release paclitaxel Optimum gelatin nanoparticles for $87,107.80 $157,371.45 Therapeutics, LLC treating superficial bladder cancer Clinical Development of Optimum suramin as a nontoxic $157,755.83 $86,723.42 Therapeutics, LLC chemosensitizer for treating advanced cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ConfirMEE - Ear Effusion OtoSonics Inc. Detection and Characterization $244,479.25 System Percuvision, LLC Visually Guided Catheter $244,479.25 Commercialization of Tissue Peritec Biosciences Lined for Stent for Peripheral $244,479.25 Ltd Arterial Disease PneumoScan-Non-Invasive PneumoSonics Inc $244,479.25 Pneumothorax Detector Polgenix Inc Two Photon Opthalmascope $108,557.48 $42,361.15 Prophylactic Therapies for Portal Capital LLC Diseases with Airborne $61,027.82 $111,375.00 Transmission Vectors Preciss (DBA Increasing Language Access in Language Access $222,413.39 $22,065.86 Clinical Environments Network, LLC) Navage Nasal Hygiene Clinical RhinoSystems Inc $25,000.00 Test Serial Tonometer for Sonogage Inc measurement of intraocular $73,549.73 $170,929.52 pressure Surgical Energetics, FiberSecure wound closure $50,000.00 Inc device Development of a Tracheal Syncro Medical Avoidance Feeding Tube with $244,479.25 Innovations, Inc. Bedside Confirmation Technology Medical Quality of Care Management $11,433.95 $93,774.17 Partners, L.L.C. System Tersus Commercial Development of $244,479.24 Pharmaceuticals Provinal ™ The Daavlin Staph Therapeutic Deliverly $4,889.50 $12,731.50 Distributing Company System The Utopia Group, Joey Spray Guard Delivery $88,082.69 $156,396.56 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 LLC System Treatment of Peripheral Artery TheraVasc Inc. Disease and Diabetic Ischemic $17,562.50 $226,916.75 Leg Problems with TV1001 Thermalin Diabetes Development of Next $11,538.39 $67,582.71 Incorporated Generation Insulin Analogs - 1 Thermalin Diabetes, Development of Next $244,479.24 LLC Generation Insulin Analogs - 2 Xycor Spinal Implant for Vertebration Inc Minimally Invasive Spine $244,479.25 Surgery The ViewRay Renaissance™ ViewRay Incorporated real-time image-guided $244,479.25 radiation therapy system ZIN Technologies Inc Vmetrics $37,370.25

Oklahoma $2,985,538.68

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 ALTH12: Novel combination Altheus Therapeutics, treatment for inflammatory $244,479.24 Inc bowel disease Nanotechnology-based Formulations for Efficient and Charlesson, LLC $244,479.24 Long-Term Ophthalmic Drug Delivery Development of a novel Stat3 inhibitor for the treatment of Charlesson, LLC $75,048.69 $169,430.55 Diabetic Retinopathy and AMD Preclinical development of Charlesson, LLC $216,861.53 $27,617.71 CLT-003 for the treatment of Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Diabetic Macular Edema COARE COARE PROJECT $244,479.25 BIOTECHNOLOGY Development of Small Molecule Therapeutics to DormaTarg, Inc. $84,821.78 $88,222.34 Target Micrometastatic Cancer Cells Immuno-Mycologics High Impact Point-of-Care $77,995.52 $85,538.45 Inc (IMMY) Cyptococcosis diagnostic test Identifying early Recurrence Midwest Medical of Braintumor using 18- $244,479.25 Isotopes LLC Fluorothymidine Staging and Monitoring Midwest Medical Therapy in Patients with $244,479.25 Isotopes LLC Prostate Cancer with 18 Fluorothymidine MNP technology for the NanoBioMagnetics Inc $33,960.15 $140,000.00 delivery of chemotherapeutics Magnetic Targeting of NanoMed Targeting Therapeutics for Atrial $244,479.24 Systems Inc. Fibrillation Diagnostic Test of Low Protein Levels For Early OMEDtech LLC $30,208.00 Detection and Prevention of Preterm Birth Selexys A Humanized Anti-P-selectin Pharmaceuticals Antibody to Treat Sickle Cell $244,479.24 Corporation Disease Development of TPST Siwa Biotech Inhibitors as Non_Hormonal $122,089.50 $122,389.75 Corporation Male Contraceptives

Oregon $5,447,316.68 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Commercialization of Novel 13therapeutics, Inc Therapeutic (P13) for Treatment $244,479.24 of Inflammatory Diseases Artielle Immuno Development of a T Cell Specific $244,479.24 Therapeutics, Inc. Drug Against Multiple Sclerosis Bioject Medical Dose Sparing Needle-free $244,479.25 Technologies, Inc. Injection Delivery Systems Blacktoe Medical Miniaturized Finger-Wearable $244,479.24 III, Inc Ultarsound Transducer Calypte Aware 2, A Rapid Test for Biomedical Corp Antibodies Against HIV-1/2 in $73,331.49 $171,147.76 & Sub Oral Fluid Cascade Prodrug Anti-cancer therapeutics targeting $244,479.25 Inc tumor hypoxia Chemica Agent to Enhance Tumor $45,708.50 $16,852.00 Technologies, Inc. Radiometal Uptake Dual-action drugs to overcome DesignMedix, Inc drug resistance in parasitic and $152,186.50 $92,292.74 bacterial disease Dense Array Electrical Electroencephalography (EEG) for $244,479.25 Geodesics, Inc. Neurosurgical Planning in Epilepsy Device of New Diagnosis and Epley Medical treatment of Benign Paroxysmal $149,875.00 $94,604.25 Inc. Dba Vesticon Positional Vertigo HOME DIALYSIS Development of Novel Portable $51,809.00 $192,670.25 PLUS, LTD. Nocturnal Hemodialysis System Inovise Medical, Cardiopulmonary Holder $244,479.24 Incorporated Mitosciences Inc MET3D $244,479.25 Molecular Diagnostics c-KIT Molecular MD Cancer Gene Mutation Assay for $103,615.00 $140,864.25 Corp Metastatic Melanoma patients Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular Diagnostics MolecularMD standardized BCR-ABL cancer $244,479.25 Corp gene quantization Molecular Diagnostics EGFR MolecularMD T790M Cancer Gene Mut Assy for $103,615.00 $140,864.25 Corp relapsing NSCLC patients Molecular Diagnostics b-RAF MolecularMD V600E Cancer gene Mutation $103,615.00 $140,864.25 Corp. Assay for metatastic melanoma Najit Development and optimization of $244,479.24 Technologies, Inc. dual-detection diagnostics Najit Development of a novel hydrogen $183,931.19 $60,548.05 Technologies, Inc. peroxide-based vaccine platform Breath Aldehyde Measurement Pulse Health LLC System for the Quantitative $244,479.25 Determination of Oxidative Stress River Point LLC, Cancer Detection and Radiation DBA Riverpoint $201,866.98 $42,612.27 Delivery Devices Medical Sedia Biosciences Rapid Oral Fluid HIV Test $10,279.00 $38,421.00 Corporation Sedia Biosciences Novel Collection Devices $4,125.00 $8,825.00 Corporation FlowDx: Clinical Tree Star Inc CytometryAnalysis Software with $70,507.00 $81,535.00 Automated Gating New Cancer Vaccine Technology UbiVac LLC Based on Dribbles Produced by $15,196.39 $229,282.86 Tumor Cells Microfluidics Transtymapanic Yainax Medical, Delivery System for Controlled $37,000.00 LLC Delivery of Drugs to Inner Ear

Pennsylvania $46,936,906.41

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 The CellPort Absorption Systems LP $146,819.00 $97,660.24 Technologies Project Acne E-Visit (Virtual Acne E-Visit Office Visit/Virtual $244,479.25 Doctors Office) Delta Opioid Receptor Adolor Corporation Agonists, ADL5859 and $244,479.25 ADL5747 Beloxepin Norepinephrine Adolor Corporation Reuptake Inhibitor/5HT $244,479.25 Antagonist Entereg (alvimopan), a Adolor Corporation peripherally acting mu- $244,479.25 opiod receptor agonist Peripherally acting mu Adolor Corporation opioid receptor $244,479.25 antagonists Blood-oxygenating and carbon dioxide removal Alung Technologies, Inc. $244,479.24 device, treating acute respiratory failure. New Drugs for Apogee Biotechnology Inflammatory Bowel $244,479.25 Corporation Diseases Apogee Biotechnology New Topoisomerase $375.00 $86,737.50 Corporation Inhibitors to Treat Cancer Apogee Biotechnology Improvement of Liver $3,000.00 $139,736.50 Corporation Transplantation Apogee Biotechnology New Drugs for $106,866.05 Corporation Lymphoma Apogee Biotechnology New Drugs Arthritis $90,742.54 $153,736.71 Corporation Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Aprecia Pharmaceuticals Aprecia Fast Metal $244,479.24 Company medication (AFMM) Aptagen LLC Aptabodies $44,862.13 $85,044.66 AT-406, an oral, pan-IAP inhibitor (SMAC Ascenta Therapeutics Inc $244,479.24 mimetic), for treatment of advanced malignancies AT-101, an oral, pan-Bcl- 2 family protein inhibitor, Ascenta Therapeutics Inc $244,479.24 for treatment of advanced malignancies Assistive Technology Products, HydroCare $36,464.50 $208,014.75 Inc. Cost Effective Point of Aviana Molecular Care Diagnostic Platform $32,036.50 $118,934.00 Technologies, LLC Technology Application of Avid Radiopharmaceuticals Florbenazine-F18 in $244,479.25 Inc. diagnosis of Parkinson's Disease and Diabetes Application of Avid Radiopharmaceuticals, Florbetapir-F18 in $244,479.25 Inc. diagnosis of Alzheimer's Disease A New Drug for Azevan Pharmaceuticals, Inc. $244,479.25 Depression Improved Stem Cell Bio Capture LLC Separation for Cell $191,024.50 Therapeutics NON-INVASIVE BIOFLUID TECHNOLOGY, URETHRO- $244,479.24 INC CYSTOMETER Metrobolic Imaging in 3 Biometric Imaging Inc Dimensions Apparatus $95,246.50 $149,232.74 and Clinical Trials Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of an advanced genome analysis BioNanomatrix Inc $244,479.24 system for use in research and diagnostics Precision Freehand Blue Belt Technologies, Inc $244,479.24 Sculptor (PFS) Development of Dual MetAP2 and Sirt1 BroadSources, Inc. $2,610.00 $114,480.50 Inhibitors as Anti-Cancer Drugs Caliber Therapeutics, Inc. TADD $244,479.25 Cardiokine Inc Lixivaptan $244,479.25 Carmell Therapeutics REPAIR bone putty $95,028.50 $149,450.74 Corporation Carmell Therapeutics REPAIR tendon repair $16,374.50 $142,726.50 Corporation scaffold Clinical development of G207 oncolytic HSV Catherex Inc. $212,433.00 cancer therapy for brain cancer. Clinical development of NV1020 oncolytic HSV Catherex Inc. $232,558.00 cancer therapy for bladder cancer. The Development of Celsense, Inc. Perfluorocarbon MRI Cell $244,479.24 Tracking Reagents Tissue Systems Pathology Cernostics, Inc for Barrett's Esophagus $115,894.81 $128,584.43 Testing DISCOVERING AND DEVELOPING SMALL COGNITION MOLECULE DISEASE- $244,479.25 THERAPEUTICS, INC. MODIFYING THERAPEUTICS FOR Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 ALZHEIMER'S DISEASE Clinical Trial of Cohera Medical, Inc. Preventative Therapy for $244,479.24 Post-surgical Seroma CONREX PHARMACEUTICAL Project RPM $129,367.00 $115,112.24 CORPORATION BACE 1 Inhibitors for Delaying the Onset and Controlled Chemicals, Inc. $56,936.70 $80,000.00 Progression of Alzheimer's Disease COR Innovations Preventing Heart Failure $113,000.00 $131,479.25 The Development of Cutanea Life Sciences, Inc. Omiganan Topical Gel for $244,479.25 Atopic Dermatitis CPSI-2364 A Small- Cytokine Pharmasciences, Inc Molecule Inhibitor of $244,479.24 Cytopkine Production The MISODEL Cytokine Pharmasciences, Inc. $244,479.24 VAGINAL INSERT CPSI-306 A SMALL Cytokine Pharmasciences,Inc MOLECULE $141,943.50 $102,535.75 INHIBITOR OF IVIF NP2 Chronic Pain Diamyd Incorporated $244,479.25 Therapy Diasome Pharmaceuticals, Inc HDV-Insulin $244,479.24 Pancreatic Cancer Clinical Digestive Care Inc Trial and Complete NDA $244,479.24 Requirements Aerosurf® (aerosoilized LUCINACTANT) for Discovery Laboratories, Inc. $244,479.25 prevention of neonatal RDS Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inhibitors of FN3K Dynamis Therapeutics, Inc Enzyme as a treatment for $115,528.00 $128,951.25 Diabetic Complications SEEMORE: NOVEL INTRACELLULAR EAGLE VISION MOLECULAR $79,637.00 $81,792.00 PHARMACEUTICAL CORP ENHANCEMENT FOR MAGNETIC RESONANCE IMAGING Novel Antimicrobial Agents Targeting Drug Enantigen Therapeutics Inc $28,060.00 $10,347.50 Resistant Bacterial Biofilms Development of a therapy Enantigen Therapeutics, Inc for Dengue Virus $72,652.50 $32,358.50 infection Capromab Pendetide Eusa Pharma (USA) Inc Scanning-Optimizing $32,786.19 $25,002.08 Patient Selection Samarium SM-153 Eusa Pharma (USA), Inc $137,957.66 $68,302.99 Combined with Docetaxel PROSTASCINT FOR BRACHYTHERAPY IN EUSA PHARMA (USA), INC. LOCALIZED $70,088.95 $55,489.78 PROSTATE ADENOCARCINOMA CAPHOSOL FOR THE REDUCTION OF EUSA PHARMA (USA), INC. MUCOSITIS IN HEAD $244,479.25 AND NECK CANCER PATIENTS MatchedFlicker: A Novel EyeIC Incorporated Tool for Early Detection $244,479.25 of Important Eye Diseases The Cancer BioChip Falcon Genomics, Inc. $76,417.50 $168,061.75 System Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Use of Dermodel ™ FemmePharma Global Danazol for the Treatment $244,479.25 Healthcare, Inc of Fibrocystic Breast Disease (FBD) PARDEL Oxybutynin, a FemmePharma Global Novel. Patented Delivery $244,479.25 Healthcare, Inc. for the Treatment of Interstitial Cystitis in Platform Autologous Fibrocell Technologies, Inc. $244,479.24 Fibroblast Therapy Flexuspine FSU (Functional Spinal Unit) FLEXUSPINE INC. $244,479.25 Total Spinal Segment Replacement Formula Pharmaceuticals, Inc WT-1 vaccine $244,479.25 Porphobilinogen Synthase Fox Chase Chemical Diversity Assembly-State $49,532.00 $102,250.50 Center Inc Regulators to Treat Infectious Disease. Small Molecule Fox Chase Chemical Diversity Therapeutics for $56,019.50 $156,958.00 Center Inc. Botulinum Neurotoxin A. Fox Chase Chemical Diversity Riluzole Prodrugs for $26,875.00 Center, Inc. Melanoma and ALS Development of Galactica's RAGE-Ig fusion protein through Galactica Pharamceuticals, Inc. completion of a first $94,189.50 $18,200.00 human proof-of-concept clinical trial in diabetic macular edema. Postoperative Pain Galleon Pharmaceuticals Inc $244,479.24 Prophylaxis Galleon Pharmaceuticals, Inc Apnea of Prematurity $33,004.56 $211,474.68 Galleon Pharmaceuticals, Inc. Prevention of Opiate $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Induced Respiratory Depression Gemin X Pharmaceuticals US, Obatoclax $244,479.24 Inc Improvement of RNA amplification methods for Genisphere LLC $12,668.50 $115,422.50 use in molecular diagnostics/progostics Improvement of microRNA labeling Genisphere, LLC technology for use in $34,953.00 $63,155.00 molecular diagnostics/prognostics Polymerizabel Reverse Gentis, Inc Emulsions as a Platform $244,479.25 Technology Clinical Development of NCE GLY-230 to Treat or GLYCADIA, Inc $200,620.00 $43,859.24 Prevent Complications of Diabetes ASTHMA TREATMENT- HALARE, LLC PRODUCT $244,479.24 DEVELOPMENT AND TRIALS Hemispherx Biopharma Inc Ampligen $244,479.25 Hemispherx Biopharma, Inc. Alferon N Injection $244,479.25 Development of 3-D HRP Imaging Technologies, gamma camera for high- $232,814.00 LLC resolution imaging intra- oro Development of Compact Hybridyne Imaging Gamma Camera for $56,479.25 Technologies, Inc Detection of Prostate Carcinoma Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Novel Small Molecule IMC Biotechnology Therapy for ANCA $15,641.86 $15,000.00 Associated Vasculitis Engineered Protien for Imiplex LLC Cancer and Alzheimers $6,170.04 $50,025.52 Disease Diagnostics Development of a native human antibody-based IMMUNOME, INC. $116,847.00 $127,632.24 therapeutic for C. difficile infection. Immunotherapeutic Immunomic Therapeutics Inc Vaccine for Treatment of $244,479.25 Cedar Pollenosis. Multiepitope therapeutic Immunotope Inc vaccine for drug resistant $77,830.00 $46,014.50 ovarian cancer Development of "ImmuChip" an Early Immunotope Inc Diagnostic Test for $157,720.50 Ovarian and Prostate Cancer Multieptipe Universal Immunotope Inc $24,081.50 $35,377.00 Dengue virus vaccine Synthetic Nanoparticle Immunotope Inc based Universal nfluenza $40,269.50 Vaccine Hepatocellular carcinoma (HCC) diagnostics Immunotope, Inc. $242,468.50 $2,010.75 defined by fucosylated serum biomarkers InfaCare Pharmaceuticals Corp Stanate $244,479.25 InfraRed Imaging Systems, Inc Vascular Viewer $157,520.03 $86,959.21 (INRIS) InfraScan, Inc. Infrascanner $159,484.11 $84,995.13 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 SYNCON ™ Vaccines for Inovio Pharmaceuticals Inc emerging infectious $244,479.25 disease Clinical Development of a novel Therapeutic INOVIO Pharmaceuticals Inc. $244,479.25 Vaccine for Cervical Cancer DEVELOPMENT OF A INOVIO UNIVERSAL $244,479.25 PHARMACEUTICALS, INC INFLUENZA VACCINE INRange Electronic INRange Systems, Inc Medication Management $244,479.25 Assistant (EMMA) Insituvue Inc. Sonic Flashlight $244,479.25 Isolating Antibodies and Mapping Immune Integral Molecular Inc $179,877.81 $64,601.44 Responses to Viral Vaccines and Pathogens Molecular Determinants Integral Molecular Inc of Drug and Antibody $144,693.13 $99,786.12 Recognition Detection of Dengue Integral Molecular Inc Neutralizing and $244,479.25 Enhancing Antibodies Influenza Drug Integral Molecular, Inc $104,554.83 $123,145.24 Development Integrated Technologies & Breast Cancer Diagnostic $90,015.78 $92,969.65 Services International LLC Test Iroko Pharmaceuticals, LLC Diclofenac $244,479.25 Iroko Pharmaceuticals, LLC Indomethacin $244,479.25 Iroko Pharmaceuticals, LLC Naproxen $244,479.25 JDP Therapeutics Inc JDP-205 $26,972.00 $217,507.25 Jenrin Discovery Inc Peripheral-Selective CB1 $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Antagonists as a New treatment Option for Metabolic Diseases Keystone Biologics, Inc. Ulcerative Colitis $244,479.25 Keystone Nano Inc. NanoJackets $244,479.25 Further drug-Like Clinical Validation for Kidney Kibow Biotech, Inc $36,916.50 $207,562.74 Health Probiotic Supplement Product KNS-760704 for treatment of ALS Knopp Neurosciences Inc $244,479.25 (Amyotrophic Lateral Sclerosis) GM1 Ganglioside for Lazarus Therapeutics, Inc. $150,177.50 $94,301.75 Parkinson's Disease Myostatin pro-peptide and regulation of muscle LifeSensors, Inc $244,479.25 growth: A Novel Therapeutic Approach Biomarker Discovery: LifeSensors, Inc. Ubiquitin Pathway Protein $231,140.06 $13,339.19 Microarrays Intravesical Liposomal Lipella Pharmaceuticals, Inc. $103,000.16 $141,479.08 Therapy THERAPEUTICS TO ADDRESS Locus Pharmaceuticals, Inc $244,479.25 CHEMOTHERAPY RESISTANCE VIP Hybridtide agonist Longevity Biotech, Inc for the treatment Small $30,967.51 Cell Lung Cancer VPAC1 Hydridtide Longevity Biotech, Inc antagonist for the $30,967.51 treament Colon Cancer Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Clinical and Finacial Longport, Inc. Impact of High Frequency $17,804.57 $18,329.56 Ultrasound Novel Diagnostic & Therapeutic Agency for Marillion Pharmaceuticals Inc $131,820.15 $6,000.00 Hormone Refractory Prostate Cancer Phase II study of a pilocarpine buccal insert Marillion Pharmaceuticals Inc $35,000.00 for the treatment of dry mouth Cellvizio- probe based Confocal Laser Mauna Kea Technologies Inc $244,479.25 Endomicroscopy (pCLE) system Melior Discovery, Inc MLR-1362 $149,799.48 $74,220.67 Melior Discovery, Inc MLR-1023 $244,479.24 Development of MDY- 1001 to Prevent Radiation Midway Pharmaceuticals, Inc $46,690.50 $6,163.00 Enteritis and Other GI Diseases Diagnosis Test for the Identification of MRSA Molecular Detection , Inc $244,479.24 Carriers as Part pf Hospital Based Screening Molecular Targeting Cardiac Imaging With tc- $234,444.50 $10,034.74 Technologies, Inc Glucarate Angioshield Vascular Neograft Technologies, Inc. Reinforcement for $244,479.25 Saphenous Veins Neotropix, Inc NTX-010 $244,479.24 Neuro Kinetics Inc Sports Concussion Project $26,950.00 $217,529.24 ShuntCheck, Thermal NeuroDX Development LLC $20,817.26 $78,017.43 Dilution Device for Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Detecting CSF Shunt Failure in Hydrocephalus NEUROINTERVENTIONAL NIT ISCHEMIC THERAPEUTICS, INC. STROKE D/B/A $182,020.00 $62,459.24 INTERVENTION NEUROINTERVENTIONS, SYSTEM INC. NeuroStar Transcranial Neuronetics, Inc. Magnetic Stimulation $244,479.25 (TMS) Therapy System Treatment of Tinea Pedis Nitric Bio Therapeutics, Inc. with Gaseous Nitric Oxide $244,479.24 (gNO) Treatment of Onychomycosis through Nitric BioTherapeutics, Inc. $38,706.50 $205,772.74 lontophoretic Delivery of Terbinafine Development of novel and first in class antiviral Novira Therapeutics $146,194.34 $98,284.91 therapeutic for HIV targeting viral assembly Development of a novel, first-in-class antiviral for Novira Therapeutics Inc $82,447.50 $104,873.00 Hepatitis B virus targeting viral assembly Numoda Biotechnology Inc. Vitreosolve $244,479.25 NuPathe Inc Zelrix $244,479.25 NuPathe Inc NP202 $161,000.00 NP201:Novel treatment for the syptomatic NuPathe Inc $177,100.00 $67,379.25 treatment of Parkinson's disease Nuron 200 recombinant Nuron Biotech Inc human Epidermal Growth $244,479.24 Factor Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 BaroFeron (Interferon Nuron Biotech, Inc beta-1b) for subcutaneous $244,479.24 injection Onconova Therapeutics, Inc. ON01910Na Therapeutic $244,479.24 Onconova Therapeutics, Inc. Anti-MPD Therapeutic $244,479.24 ON13105 Anti- Cancer Onconova Therapeutics, Inc. $188,572.21 $55,907.03 Therapeutic Onconova Therapeutics, Inc. Ex-Rad radioprotectant $244,479.24 Further Deveopment of a OPTINOSE US, INC device to deliver $244,479.25 pharmaceutical products. Further development of a Optinose US, Inc. device to deliver $244,479.25 pharamaceutical products. OT-551: A potential First- Othera Pharmaceuticals, Inc Ever Therapeutic for Dry $244,479.25 AMD OT-440: A Novel Othera Pharmaceuticals, Inc. Neuroprotectant $157,301.00 $11,340.00 Therapeutic for Glaucoma Aerosolized delivery of Cisplantin:an effective, Penn-Century Inc. $101,237.26 $143,241.99 less toxic, less costly lung cancer treatment Novel HBV Therapeutic with Potential for Pharmabridge Inc $91,944.62 $44,553.20 Treatment of Drug- Resistant Infection PB1023 (GLP-1-ELP- 120) a Novel Long Acting PhaseBio Pharmaceuticals Inc. $244,479.24 GLP-1 Analog for the Treatment of T2DM PB1120 (VIP-ELP-120) PhaseBio Pharmaceuticals Inc. $131,194.00 $113,285.24 Novel Long Acting VIP Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 for Resistant and Uncontrolled Essential HTN Miniaturized, Hi- Performance, MRI- Piezo Resonance Innovations, Compatible, $139,711.00 $75,884.00 Inc Bioinstrumentation Ultrasonic Motor Platform Active Medical Devices Piezo Resonance Innovations, for Clearing Feeding $71,629.00 $150,937.00 Inc Tubes In-situ A low -cost, personalized Pinmed Inc cardiorespiratory profiling $59,875.51 $53,765.14 and monitoring system Synthetic Defensin Biomimetics for Use in PolyMedix, Inc $244,479.25 treating Infectious Diseases Synthetic Anticoagulant PolyMedix, Inc. $244,479.25 Reversing Agent Extension of application Precision Therapeutics, Inc. of ChemoFx® Drug $244,479.24 Response Marker vPredict Optical Prescient Medical, Inc. $244,479.24 Diagnostic Catheter Hybrid Support Prime Synthesis, Inc. $115,877.44 $128,601.80 Technology USP20/33 inhibitor for Progenra Inc $244,479.25 treatment of renal cancer USP7 inhibitor for Progenra Incorporated treatment of multiple $244,479.24 myeloma inhibitors of MuRF-1 for Progenra, Incorporated $244,479.24 muscle wasting Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of PRM-151 Promedior Inc for the treatment and $244,479.25 prevention of fibrosis System to individually tailor therapeutics Pulsar Informatics Inc $174,902.50 $69,576.75 delivery with fewer visits to physician's office. QR Pharma Inc POSIPHEN $183,376.00 $61,103.25 A Phase 1 clinical trial utilizing a targeted Ras Therapeutics, Inc $53,361.50 $104,785.00 therapy for the treatment of pancreatic cancer Non-IV dexmedetomidine Recro Pharma, Inc $244,479.25 for pain RedPath Integrated Pathology Metastic vs. Primary $183,075.50 $61,403.75 Inc Cancer (MvPDx) RedPath Integrated Pathology PathFinderTG Pancreatic $244,479.25 Inc Cyst Assay Add-on device for treatment of various Richard J. Arnott $53,244.24 $127,688.25 respiratory conditions via metered variable pressure. Ferromagnetic Dense Particle-based Early Russell Biotech Inc. $55,691.00 $5,325.00 Diagnostic Test for Liver Cancer. Paciliaxel Dose Saladax Biomedical Inc $103,686.00 $140,793.24 Management Assay Docetaxel Dose Saladax Biomedical, Inc $106,285.50 $138,193.74 Management Assay Imatinib Dose Saladax Biomedical, Inc $112,542.00 $131,937.24 Management Assay Alzheimer's Disease Saladax Biomedical, Inc $244,479.24 Biomarker Assays Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Glycolipid Replacement Seneb BioSciences, Inc Therapy as a Treatment $28,753.40 for Parkinson's Disease Light Weight PORTABLE Medical Separation Design Group, LLC OXYGEN $144,533.42 $95,322.28 CONCENTRATOR (POC) SERENITY SER-120 $189,813.50 $54,665.75 PHARMACEUTICALS LLC Novel Antithrombotic Shifa Biochemical Corporation $23,602.84 $10,104.97 Drugs Drugs for Hormone Shifa Biomedical Corporation Refractory Prostate $35,163.69 Cancer Novel Modulators of Shifa Biomedical Corporation $198,898.33 $45,580.91 Cholesterol Metabolism Targeted Padiotherapy of Ovarian Cancer with a Solixia Inc. $4,015.88 $2,218.83 Novel, High Payload Radioligand Small molecule inhibitor of PI-3AKt/mTOR for Sonitu Pharmaceuticals LLC $21,153.00 $22,516.50 treatment of hepatocellular carcinoma Broad spectrum antidote/vaccines for Sonitu Pharmaceuticals LLC treatment of $60,425.00 Staphylococcal & Streptococcal Disease Specialty Pharmaceutical Advanced Therapeutic $143,722.91 $35,316.26 Products, L.L.C. SPP Systems Epitope-tagged Transcription Factor for SpectraGenetics LLc $71,581.00 $107,908.50 Epigenetic Signatures in Human Cancer Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Commercialization- Stemnion Proprietary cell Stemnion, inc $244,479.24 technology platform for regenerative medicine Oral recombinant calcitonin for prevention Tarsa Therapeutics, Inc. $244,479.24 & treatrment of post menopausal oteoporosis Non-covalent masking of therapeutic monocional TegoPharm Corporation $7,500.00 $20,000.00 antibodies to enhance the therapeutic index Tengion Neo-Kidney Tengion, Inc $244,479.25 Augment (NKA) Tengion Neo-Bladder Tengion, Inc. $244,479.24 Augment (NBA) Tengion Neo-Esophagus Tengion, Inc. $68,457.06 $166,049.83 Augment (NEA) Tengion Neo-Urinary Tengion, Inc. $244,479.25 Conduit (NUC) Development of Zanolimumab, a Fully TenX Biopharma Inc Humanized Anti CD4 $244,479.25 Monoclonal Antibody for Cancer Treatment of Traumatic Tetralogic Pharmaceuticals Brain Injury using $244,479.24 Corporation TL14077, a Selective Inhibitor of RP1 Kinase Treatment of Cancer using TetraLogic Pharmaceuticals a First in Class, Selective $244,479.24 Corporation IAP Antagonist, TL32711 Thar Pharmaceuticals:IV Thar Pharmaceuticals, Inc $211,486.50 $32,992.75 to Oral Zoledronic Acid Thermal Therapeutic Systems, Perfusion system to heat, $244,479.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc circulate and monitor chemotherapeutic solutions Third Eye Diagnostics, Inc. CerePress $51,095.00 $193,384.24 Novel and Safe Treatment Topaz Pharmaceuticals, Inc. of Head Lice Infections in $244,479.24 Children and Adults. Novel Reagents For The Toph Biologics Diagnosis of Cancer $31,812.50 specific Glycoforms. Ultrasonic Drug delivery Transdermal Specialties, Inc $244,479.25 System TM601 Tumor Targeting Transmolecular, Inc $244,479.25 Project Signal selective kappa opioid receptor ligand for Trevena, Inc $244,479.25 the management of chronic pain Signal selective mu opioid receptor ligand for the Trevena, Inc. $244,479.25 management of acute and chronic pain Signal selective angiotensin receptor Trevena, Inc. $244,479.25 ligand for the treatment of acute failure Amyloid Oligomer- Specific Antagonists as a TREVENTIS Corporation $33,837.50 $210,641.74 Therapeutic for Alzheimer's Disease Multifunctional Drugs Treating Varinel, Inc. Neurodegenerative $48,311.50 Diseases and Wound Healing Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of high- throughput assay for VascularStrategies LLC $46,450.00 measurement of global cellular cholesterol efflux Development of protein fusion vaccine protective VaxForm, LLC $5,498.53 against Streptococcus Pyogenes Vicept Therapeutics, Inc. V-101 $244,479.24 Development of Inhibitors Vironika,LLC of Latent Epstein-Barr $16,552.41 $118,226.61 Virus Infection NON-TOXIGENIC VIROPHARMA COLSTRIDIUM $244,479.25 INCORPORATED DIFFICILE (NTCD) Development of LXR Agonists for the Vitae Pharmaceuticals Inc $244,479.24 prevention and Treatment of Atherosclerosis Development of BACE Inhibitors for the Vitae Pharmaceuticals Inc $244,479.24 Treatment of Alzheimer's Disease Development of 11Beta- HSD1 inhibitors for Vitae Pharmaceuticals Inc $244,479.24 Treatment of Diabetes and Metabolic Syndrome Development of Renin inhibitor for Treatment of Vitae Pharmaceuticals Inc $244,479.24 Hypertension and Chronic Kidney Disease Continuous glucose Vytrace Corporation monitor for the acute care $122,501.00 $95,511.00 setting Biocellulose technology Xylos Corporation $244,479.25 solutions for the Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 treatment, repair, and replacement of human tissue Evaluation of Clearazide Yaupon Therapeutics, Inc. $244,479.24 for CTCL YM Biosciences USA Inc. Nimotuzumab $244,479.25 YM BioSciences USA Inc. CYT997 $244,479.25 Excellair: A New Frontier ZaBeCor Pharmaceuticals, in the Treatment of $244,479.24 LLC Asthma and Inflammation.

Rhode Island $4,681,937.18

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Engineered Spores as Fluorogenic Biological BCR Diagnostics, Inc. $158,237.00 $46,393.00 Indicators for Sterility Testing BTL-ng for a Reduction in Beech Tree Labs, Inc. $30,636.00 $133,237.50 Nicotine Craving Calmar Pain Relief, Calmar Pain Relief $51,501.00 $192,978.25 LLC Therapy- pain clinics COL-003 Extended- Collegium Release, Tamper-Resistant $244,479.24 Pharmaceutical, Inc Opiod ("COL-003") EpiVax Therapeutic HIV EpiVax, Inc. $26,625.06 $11,344.20 Vaccinc Development of Tregitopes EpiVax, Inc. as a Novel Therapeutic for $64,778.30 $149,973.96 Immune Modulation IlluminOss Medical Inc Photodynamic Therapeutic $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Bone Stabilization System Late Stage Melanoma In Cytu Inc $244,479.24 Vaccine Development Early (Stage I/II) In Cytu, Inc. Melanoma Cancer Vaccine $126,434.50 Development Lung Cancer Vaccine In Cytu, Inc. $3,105.00 $25,374.50 Development Glioma Cancer Vaccine InCytu, Inc. $21,062.00 $94,239.00 Development ISIS BIOPOLYMER, ISIS Patch $244,479.25 INC MultiCell Technologies MCT-475 $26,551.00 $217,928.24 Inc MultiCell MCT-465 $159,305.00 $85,174.24 Technologies, Inc MultiCell MCT-125 $244,479.24 Technologies, Inc Treatment of skeletal muscle weakness and MYOMICS, INC $208,970.50 $35,508.74 fatique disorders with MYO13 Development of Clinically NABsys, Inc. Relevant DNA Sequencing $244,479.25 Technology Neurotech USA Inc NT-502 $244,479.24 Neurotech USA Inc NT-501 $244,479.24 Neurotech USA, Inc NT-503 $244,479.24 PROTHERA Therapeutic Tole of Inter- $78,475.50 $166,003.75 BIOLOGICS LLC Alpha Inhibitor Proteins Rhode Island Mood & Rhode Island Mood & $123,308.50 Memory Research Memory Research Institute Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Institute Biglycan for the Treatment Tivorsan of Duchenne Muscular $75,423.88 $169,055.37 Pharmaceuticals Inc. Dystrophy

South Carolina $2,554,777.26

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Portable Secure Dispenser Avancen MOD For Oral Opioids To Promote $15,681.00 $139,588.50 Corporation Compliance and Prevent Diversion An Electronic Oral Avancen MOD Medication Device for $244,479.25 Corporation Hospital Pain Management Charleston Laboratories, Inc - Charleston CL - 108 a Novel approach to $244,479.25 Laboratories, Inc. pain management reducing OINV Development of antibodies to CharlestonPharma nucleolin for the treatment of $183,925.00 LLC cancer Heparin-infused Valve CreatiVasc Medical System to Assure Access for $244,479.24 LLC AV Graft Dialysis Patients Novel Treatment for FibroTherapeutics, Currently Untreatable Lung $16,500.00 Inc Diseases FirstString Research, ACT-1 Therapeutic $244,479.24 Inc. Automated aerosol drug IDTX Systems, Inc $115,738.50 delivery Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 The production of fully Immunologix, Inc. human therapeutic $244,479.24 monoclonal antibodies 3D Cell/Scaffold Constructs KIYATEC Inc for Drug Development and $33,261.37 $98,250.00 Personalized Medicine Bioactive Absorbable Poly-Med Inc. $85,841.00 $99,491.00 Polymeric Luminal Liners Development of a novel S & H Development molecule for the treatment of $244,479.25 Company, LLC solid tumors Acid Ceramidase, Target for SphingoGene $57,000.24 $123,074.62 cancer Vortex Biotechnology New Pim Protein Kinase $2,703.56 $116,847.00 Corporation Inhibitors to Treat Cancer

South Dakota $244,479.24

Grants Applicant Grants Awarded Project Name Awarded for Name for 2010 2009 Treatment of Human Obesity by a Braasch Therapeutic Vaccination $11,737.50 $232,741.74 Biotech LLC Approach.

Tennessee $6,731,451.41

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 13C-Spirulina Gastric Advanced Breath Emptying Breath Test $244,479.24 Diagnostics, LLC ("GEBT") Asklepion Citrulline $244,479.25 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Pharmaceuticals LLC Asklepion Cholic Acid $72,395.14 $172,084.11 Pharmaceuticals LLC BioMimetic Therapeutics Orthopedic Program $244,479.25 Inc BioMimetic Therapeutics Sports Medicine Research $244,479.25 Inc and Development Program Cumberland Cumberland TPr Antagonist $13,483.50 $230,995.75 Pharmaceuticals Inc Cumberland Cumberland Caldolor $57,556.50 $186,922.75 Pharmaceuticals Inc. Pediatrics Cumberland Cumberland Acetadote ALF $51,000.00 $77,229.50 Pharmaceuticals Inc. Cumberland Cumberland Acetodate EF $67,886.00 $176,593.25 Pharmaceuticals, Inc ED Laboratories, Inc EDL 2000 $104,060.50 $140,418.75 EDP Biotech Corporation ColoMarker $244,479.25 ExtraOrtho Inc Biopolymer Sponge $244,479.25 Belfort-Dildy Obstetric Glenveigh Tamponade System (BD $244,479.25 Pharmaceuticals LLC OTS) DEVICE FOR GLENVEIGH MEASURING CERVICAL PHARMACEUTICALS, $48,589.50 $32,607.50 DILATION DURING LLC ACTIVE LABOR Development of Therapeutic Glenveigh and Diagnostic for $109,469.00 $46,957.50 Pharmaceuticals, LLC Preeclampsia (Project DIF) GTx ALK Inhibition Therapy $244,479.24 GTx, Inc Toremifene 20mg $244,479.24 GTx, Inc. Ostarine $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 GTx, Inc. GTx-758 $244,479.24 GTx, Inc. Toremifene 80mg $244,479.24 Rapid multiparameter Hematotypes, Inc. immunophenotyping of $5,182.00 $3,956.00 target cell populations Novel Molecular Diagnostic Tests for Cancers Driven by Insight Genetics, Inc $244,479.25 Anaplastic Lymphoma Kinase (ALK) InVivoLink Implant InVivoLink, LLC $80,621.00 $163,858.25 Registry Molecular Design Compound 49b prevents $225,000.00 $19,479.24 International, Inc. retinopathy Development of novel NellOne Therapeutics Inc cardiac and skeletal muscle $113,397.50 $131,081.74 regenerating therapy Image-Guided Cancer Pathfinder Therapeutics, Therapeutic Delivery $244,479.25 Inc System Provectus Pharmaceutical agent PV-10 $244,479.24 Pharmaceuticals, Inc. RxBio, Inc. Rx100 $182,397.50 $62,081.75 Surgivision, Inc ClearPoint $244,479.25 SURGIVISION, INC. SafeLead $244,479.25

Texas $34,166,951.65

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Access Pharmaceutcals Tumor targeted docetaxel $65,000.00 $179,479.24 Inc nanoparticle Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Access Colalamin Insulin Oral drug $216,000.00 $28,479.24 Pharmaceuticals inc delivery Access Mucoadhesive Liquid Drug $168,750.00 Pharmaceuticals Inc Delivery Access Cobalamin siRNA Delivery $244,479.24 Pharmaceuticals Inc Vehicle Access ProLindac $244,479.24 Pharmaceuticals, Inc Access Thiarabine for the treatment of $15,000.00 $229,479.24 Pharmaceuticals, Inc hematologic cancers Access Polymer-Based Platinum (IV) $87,500.00 Pharmaceuticals, Inc Prodrugs Agennix, Inc TALACTOFERRIN $244,479.25 FENTANYL TAIFUN® AS A AKELA PHARMA RAPID-ACTING INHALED $244,479.25 USA INC OPIOID ANALGESIC FOR TREATING CANCER PAIN EPR Spectrometer for Sepsis and Albumetrix, Inc $244,479.25 Cancer Diagnostics America Stem Cell Inc Engraftin $244,479.25 Humanization and Rational Aperion Biologics, Inc Engineering of Xenograft Tissues $244,479.25 for Regenerative Medicine APOCELL INC DEP Technology $244,479.25 Apollo Endosurgery Overstitch TM Endoscopic $244,479.25 Inc Suturing System Apollo Endosurgery SuMO Submucosal Operation $244,479.25 Inc. Breath analysis for identification Applied Nanotech Inc $81,893.30 $78,942.24 of lung cancer AROG Development of Novel $244,479.24 Pharmaceuticals Anticancer Drug, PDGFR Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inhibitor, CP-868, 596 for Treatment of GIST Development of Novel AROG Anticancer Drug, PDGFR $244,479.24 Pharmaceuticals LLC Inhibitor, CP-868,596 for Pediatric Gliomas Development of Novel AROG Anticancer Drug, PDGFR $244,479.24 Pharmaceuticals LLC Inhibitor, CP-868, 596 for Adult Gliomas Development of Enteric-Coated AROG Tablet Formulation for Novel $95,850.00 Pharmaceuticals LLC Anti-Cancer Drug, CP-868,596 Improving Neuromuscular Electrical Stimulation for Articulate Labs Inc $4,308.37 $2,347.06 Ambulatory Osteoarthtitic Knee Treatment Assurance Biosciences, Salivary Breast Cancer Marker $235,443.00 Inc. Comprehensive Test for Fragile Asuragen Inc $112,026.00 $28,376.00 X Syndrone Comprehensive Molecular Asuragen Inc. Diagnostic Assay for Thyroid $67,481.00 $176,998.25 Cancer Assay for monitoring and early Asuragen, Inc $35,991.00 $188,136.50 detection of pancreatic cancer Cystic Fibrosis Test for Detection Asuragen, Inc. $10,518.50 $583.50 of Genetic Mutations BCR/ABL1 Quant™ Test for Asuragen, Inc. Monitoring Treatment in Chronic $53,827.00 $190,652.25 Myeloid Leukemia Diagnostic Assays for Detection Asuragen, Inc. $101,141.00 $71,369.00 of Cancer in Biofluids Atumida, Inc. Transforming Clinical Outcomes $29,104.10 $51,221.67 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 for Hemorrhagic Shock And Vascular Ischemic Diseases AuricX Oral Vancomycin $128,739.10 Pharmaceuticals Inc Clinical Development of AZAYA Liposomal Formulation of $244,479.25 THERAPEUTICS INC Docetaxel (AT1-1123) Development of Therapeutic Bellicum Vaccine BPX-101 for the $244,479.24 Pharmaceuticals, Inc Treatment of Prostate Cancer Device for the prevention and BiO2 Medical, Inc. treatment of Pulmonary $244,479.24 Embolism in hospitalized patients Evaluate Unique Antimicrobial Oral Rinse in a Human Trial of Biomedical Chronic Oral Imflammation and Development $22,550.53 $80,571.50 Investigate its Effects on Corporation Biological Markers indicative of Systemic Diseases BioNumerik Karenitecin Phase III $244,479.25 Pharmaceuticals, Inc Development Project BioNumerik Tavocept Phase III Lung Cancer $244,479.25 Pharmaceuticals, Inc Project BIOO SCIENTIFIC BIOO-2010-018-Rriptrp $15,000.00 $25,000.00 CORPORATION Rapid Microbial Identification by BioTex, Inc. MALDI-TOF Mass Spectrometry $166,817.51 $77,661.73 of Ribosomal RNA Novel Cancer Vaccine Protein BIOTHER Corporation Therapeutic T1-IR for Skin, $10,000.00 $234,479.24 Breast and Pancreatic Tumors Improvement of Survival, Rehospitalization Rates and Blue Box Health Inc. $244,479.25 Treatment Costs for Heart Failure Patie Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Proprietary DecisionDx family of Castle Biosciences, Inc. $122,741.50 $121,737.75 molecular diagnostic assays Diagnostic & Therapeutic Clear Vascular, Inc. Application of Tin- $244,479.24 117m/Annexin Conductance Admittance for Heart Failure $19,250.00 Technologies, Inc Detection Convergen CNVN Nanoparticle Targeted $244,479.25 LifeSciences, Inc. Therapy for Cancer Cormedics Corporation PeriPort Delivery Device $94,317.50 $103,500.00 Difusion Technologies, CleanFUZE antibiotic therapeutic $244,479.24 Inc delivery system DisperSol Novel drug formulation method $148,944.90 $95,534.35 Technologies, LLC based on thermokinetic mixing. Tumor-specific adenovirus DNAtrix, Inc. Delta24-RGD for malignant $65,752.50 glioma Therapeutic control of dietary DuoPhos, LLC phosphorus absorption in CRF, $117,563.50 $126,915.74 ESRD, and hypertension Electrochemical TransCu 02 Project $230,664.00 $13,815.24 Oxygen Concepts, Inc. Therapeutic siRNA for the Ensysce Biosciences treatment of cancer with delivery $186,436.50 $58,042.74 Inc. using SWCNT Entrigue Surgical, Inc. Middle Turbinate Implant $164,784.00 $72,127.50 Sinus Dilation and Patency Entrigue Surgical, Inc. $116,192.00 $128,287.25 System Fully Implantable Left EverHeart Systems Ventricular Assist Device $95,719.73 $56,414.03 (LVAD) System Excel Diagnostics, Ltd. 177Lu-DOTATATE $33,330.00 $133,750.00 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Fabre-Kramer Gepirone-ER $244,479.25 Holdings Inc G-115 Prodrug for teatment Of GenSpera, Inc $244,479.25 Prostate Cancer G-202 Prodrug for Solid Tumor GenSpera, Inc $244,479.25 Cancers Gradalis Inc FANG Vaccine $244,479.24 Gradalis inc bi-shRNA-1 lipopplex $160,052.17 $84,427.07 Gradalis, Inc (formerly Development of a bifunctional known as Murex shRNAstathmin (bi- $244,479.24 Pharmaceuticals, Inc shRNASTMN1) Gradalis, Inc. GNE Lipoplex $146,480.82 $97,998.42 Vaccine development for GreenVax, LLC $31,849.41 $212,629.84 pandemic diseases Zag as a therapeutic for the Halsa Pharmaceuticals, treatment of type 2 diabetes and $244,479.25 Inc obesity Cell Manufacturing and Testing Incell Corp LLC $118,391.50 $126,087.75 for personalized therapies Development of Drugs that Influmedix Inc Target the Influenza Virus M2 $244,479.25 Proton Channel Autologous Cell Therapy for InGeneron, Inc. Myocardial Infarction at Point- $244,479.25 of-Care Introgen Research Nanoparticle therapy for lung $78,566.50 $100,000.00 Institute Inc cancer Liquid Brachytherapy-A Novel Iso Therapeutics Treatment for Solid Inoperable $44,500.00 $188,500.00 Group, LLC Tumors A Novel Therapeutic IsoTherapeutics Group, Radiopharmaceutical for the $22,500.00 $219,000.00 LLC Treatment of Metastic Bone Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Cancer Diazonamide Analogs: A new Class of Anti-mitotic Cancer Joyian Pharmaceuticals $244,479.25 Therapeutic without Overt Toxicity Joyian Smac Mimetics as Novel Anti- $244,479.25 Pharmaceuticals, Inc. Cancer Therapy Intravaginally delivered Keraplast functional keratin for the $156,100.00 Technologies, Ltd treatment of atrophic vaginitis. Second Degree Burns Keratin Keraplast Efficacy vs. Standard of Care $244,479.25 Technologies, Ltd. Clinical Study Protocol, 2010- 010 LASER TISSUE LASER TISSUE WELDING- $16,996.00 $227,483.25 WELDING,INC PRE-CLINICAL RESEARCH MOBI-C CERVICAL DISC LDR SPINE USA, INC $244,479.24 PROSTHESIS An Improved Diagnostic for Lynntech Inc $42,115.50 Lyme Arthritis Lynntech Inc Xanapath $200,307.09 $18,497.25 A New Hyperspectral Image Lynntech Inc $24,156.08 Capture Tool for Evaluating TBI Ultrasensitive, Label-Free Lynntech, Inc $45,326.78 $8,967.86 Nanowire Biosensing Arrays Novel Nanostructures for Topical Lynntech, Inc $113,909.62 $20,417.96 Photodynamic Therapy Novel Fluid Management System Lynntech, Inc $188,810.52 $55,668.73 for Microfluidic Devices Photodynamic Therapy of Lynntech, Inc. Disseminated Peritoneal Tumor $101,600.83 $142,878.42 Using New Photosensitizers Lynntech, Inc. Compact, Lightweight, $44,234.95 $871.81 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Disposable Electrochemical Pump for Portable Drug Infusion with Direct Flow Monitoring Portable Cathode-Air-Vapor- Lynntech, Inc. Feed Electrochemical Medical $82,342.12 Oxygen Concentrator Phase II An Integrated Optical DNA Lynntech, Inc. $80,654.34 $65,854.53 Detector for Portable PCR Sequential Isoelectric Point Lynntech, Inc. Separation of Proteins Using $52,453.51 $136,615.77 Non-Gel, Microfluidic System Treatment for dry Age Related MacuCLEAR, Inc. $244,479.24 Macular Degeneration Marval Biosciences Inc NCTX-140 $236,215.14 $8,264.11 Development of diagnostic tests MDx BioAnalytical based on polypeptide biomarker $44,500.00 $199,979.24 Laboratory, Inc. panels med fusion, LLC med fusion clin-labs * clin-trials $244,479.25 Medical Targeted nanotubes for $63,868.00 Nanotechnologies, Inc photothermal ablation therapy ISF35 Active Immunogene Memgen, LLC Therapy for Chronic $244,479.25 Lymphocytic Leukemia Nifurtimox for treating MetronomX $244,479.25 neutoblastoma Breaking the Blood Brain Barrier MicroTransponder, Inc for Treatment of Glioblastoma $244,479.24 BBB MILLAR MPVS Cardia PV System $244,479.25 INSTRUMENTS INC Millar Instruments Inc Mikro-Cath $62,068.00 $17,571.50 Mirna Therapeutics, MicroRNA-Based Targeted $244,479.25 Inc. Therapies for Cancer Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Engineered Toxin Bodies Molecular Templates (ETBs), a new class of biologic $90,549.00 $153,930.24 Inc therapeutics, to treat cancers. Commercialization of p-STAT3 Moleculin, LLC $52,383.50 $192,095.74 inhibitor Mystic VersiDoser Drug Delivery $244,479.25 Pharmaceuticals, Inc Platform NanoMedical Systems, Development of Molecular Drug $244,479.24 Inc Delivery System NanoRelease Nanoparticle and Microparticle $75,836.50 $77,546.50 Technologies, LLC Vaccine Delivery Systems Multi-Functional Nanospectra Nanotheragnostic for Cancer $244,479.24 Biosciences Inc Identification and Ablation Novel Once Daily Extended Neos Therapeutics LP $218,184.00 $26,295.25 Release Therapeutics for ADHD The development of a Single Neuro Resource Group, Patient InterX that will fit into $244,479.24 Inc existing Medicare Reimbursement. Nimbic Systems, Inc Air Barrier System (ABS) $98,195.09 $146,284.16 HER2 Peptide Immunotherapy Norwell, Inc (GP2) for Breast Cancer in $244,479.25 Adjuvant Setting HspE7 Therapeutic Vaccine for Nventa Inc $43,762.50 $200,716.75 HPV Diseases Poly-ICR: A Toll-like Receptor Nventa, Inc agonist adjuvant for vaccine $43,762.50 $200,716.75 focusing on HPV. Preclinical Development of QseC Omm Scientific, Inc. Antagonists as novel $109,905.99 $115,000.00 antivirulence therapies for Gram On-X Life On-X Prosthetic Heart Valve $244,479.24 Technologies Inc (PROACT) Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 On-X Life On-X PreChords Mitral Chordae $147,251.50 $97,227.74 Technologies Inc Repair/Replacement Opexa Therapeutics, Tovaxin therapeutic $244,479.24 Inc Development of the KineGraph Ortho Kinematics Inc $244,479.24 Vertebral Motion Analyzer Biomarker Directed p53 Tumor p53 Inc. Suppressor Therapy of Head and $244,479.25 Neck Cancer Advanced Surface PALMAZ Nanotechnology and Therapeutic $244,479.25 SCIENTIFIC INC. Platform for Implantable Biomaterials Pecan Biotherapeutics Tat Oyi $244,479.25 Inc PHOTO IMMUNE METHODOLOGY FOR BIOTECHNOLOGY, DEVELOPMENT $85,913.00 INC PREVENTIVE Development of PDPK1 inhibitor PHusis Therapeutics PHT-427 for the treatment of non $1,500.00 $242,979.24 Inc. small cell lung cancer PL3100, 25 mg GI-safer PLx Pharma Inc $244,479.24 naproxen capsules PL2200, 325 mg GI-safer aspirin PLx Pharma Inc. $244,479.24 capsules Protec Maternity Wear, Prevention of Fetal $10,200.00 $90,000.00 LLC Electromagnetic Field Exposure Boosting the Innate Immune Pulmotect Inc. $71,260.28 $117,500.00 System of the Lungs Metabolic targeting imaging and RadioMedix, Inc. $123,639.67 $120,839.58 therapy of cancer Rarecells USA Inc. ISET Theranostics Project $1,322.08 $86,524.92 Reata Pharmaceuticals Development of RTA 744 for the $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc treatment of Brain Cancer. Reata Bardoxolone methyl Reata Pharmaceuticals (Bardoxolone) for Chronic $244,479.25 Inc Kidney Disease Reata Antioxidant Inflammation Reata Pharmaceuticals Modulators for Central Nervous $244,479.25 Inc. System Disease Reata Pharmaceuticals, Reata Antioxidant inflammation $244,479.25 Inc Modulators for Cancer Reata Antioxidant Inflammation Reata Pharmaceuticals, Modulators for Pulmonary $244,479.25 Inc. Diseases (Reata AIMs PD) Receptor Logic, Inc T Cell Receptor mimic (TCRm) $244,479.25 Activated audit marrow stronal Repair Technologies cells (aMSCs) for treatment of $244,479.24 Inc immune diseases Universal RS-MSC's for REPAIR Technologies Treatment of Ischemic $244,479.24 Inc. Cardiovascular Disease Repros Therapeutics Proellex $244,479.24 Inc Label-free, high throughput Resonant Sensors screening tool for medical $43,918.00 $144,275.00 Incorporated diagnostics and drug discovery Resonant Sensors Rapid diagnostic tool for $51,893.23 Incorporated microbial and toxin detection Portable photonic sensor system Resonant Sensors as an early detection tool for $35,467.35 $160,355.65 Incorporated ovarian cancer Risk Assessment PTD $244,479.25 Laboratories LLC Delivery of Antimicrobials for Rochal Industries LLP Biofilm Disruption and $28,604.50 $91,804.00 Prevention Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Development of molecular Rules Based Medicine diagnostic test for complex $244,479.25 Inc diseases RyMed Technologies, Chlorhexidine Silver $110,000.00 $110,000.00 Inc Salient CASAD Pharmaceuticals $244,479.25 COMMERCIALIZATION Incorporated Budesonide for Treatment of Savara, Inc $244,479.25 Non-Small Cell Lung Cancer Imagio Clinical System for Early Seno Medical Detection and Treatment of $244,479.24 Instruments Inc Cancer. Automated High Volume Smart Imaging Screening Technology for $164,927.00 Technologies Co. Routine IVD tests Midgestation Screen for Preterm Southwest Genetics PA $7,850.00 $50,900.00 Birth Biostat System for the relief of Spinal Restoration, Inc chronic discogenic lumbar back $244,479.24 pain Stematix Inc ALLOSTROME $244,479.25 An Innovative Drug Delivery and Telehealth Holdings, Adherence System for Oncology $183,757.50 $60,721.75 LLC Patients OPTOACOUSTIC BIOSENSOR TOMOWAVE FOR FAST AND SENSITIVE $119,500.00 LABORATORIES DETECTION OF PATHOGENS IN BLOOD Three-Dimensional Optoacoustic TomoWave tormography systems for $244,479.25 Laboratories diagnostic imaging of breast cancer Trinity Laboratories TLI-1026: A novel multi-modal $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Inc. therapy to treat Fibromyalgia and Diabetic Neuropathy Development of Novel Stable Trinity Laboratories, Lipid Nanoparticles of Docetaxel $167,309.78 $44,940.51 Inc. for Treatment of Cancer Tissue Bonding Cystostomy UroResearch Inc $27,149.50 $78,750.00 {TCB} Novel, non-opioid localized Vapogenix, Inc $119,191.12 $125,288.13 analgesics OnControl ™ Powered Bone VIDACARE Marrow Aspiration and Core $244,479.25 CORPORATION Biopsy System EZ-IO® Intraosseous Infusion Vidacare Corporation $104,053.25 $140,425.99 System Albuterpenoid Product ViroXis Corporation $25,682.50 $218,796.74 Development Project Wenzel Spine, Inc. VariLift Interbody Fusion System $244,479.24 Womens3D automated Womens3D, Inc $244,479.24 ultrasound breast imaging Xbiotech USA Inc MABp2 $122,915.52 ZS Pharma, Inc ZS-9 $244,479.25 An activated protein C variant ZZ Biotech LLC therapeutic for stroke and $244,479.25 neurological disorders

Utah $12,700,060.87

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Non-Invasive Treatment for Aciont Inc Severe Uveitis and Related $101,144.50 $143,334.75 Posterior Eye Inflammation Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Diseases Iontophoretic Treatment for Age- Aciont Inc related Macular Degeneration $51,409.00 $193,070.25 and Diabetic Retinophathy ActivaPatch Active Drug Activatek Inc $149,402.50 $95,076.74 delivery Multipotent Marrow Stromal Allocure Inc. $244,479.25 Cells for Acute Renal Failure BIOMERICS, LLC QUADRABAN $244,479.25 Bio-Path Holdings, Phase 1 Clinical Trial of $244,479.25 Inc. Liposomal Grb-2 BSD Medical MTX-180 $244,479.25 Corporation BSD Medical BSD-2000 Hyperthermia System $244,479.25 Corporation Catheter DualCap for infection control $167,500.11 $76,979.14 Connections Inc during infusion therapy COHEREX Left Atrial Appendage ("LAA") $244,479.25 MEDICAL INC Occlusion System Polymer-Based Closure System Coherex Medical, for Treatment of Patent Foramen $244,479.25 Inc Ovale ("PFO") DxNA, LLC DxNA GeneSTAT PCR System $244,479.25 Development of Tools to Study Echelon Biosciences Diseases Associated with Altered $23,265.29 $15,177.37 Inc Autotaxin and LPA Levels Sphingolipid Kinase Screening Echelon Platforms for the identification of $8,860.81 $4,815.64 Biosciences, Inc Novel Anti-Cancer Therapie Assays to detect RAGE- Echelon LIGAND INTERACTIONS IN $11,634.42 Biosciences, Inc DISEASE DETECTION AND DRUG DISCOVERY Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Broad-spectrum antibiotic Echelon Biosciences development targeting the MEP $15,542.50 Inc pathway Transthoracic Bioconductance Fresh Medical Scanning Device Development $136,133.50 $108,345.75 Laboratories Inc. as a Lung Cancer Diagnostic Frontier Scientific Biliverdin IX alpha as an anti- $3,677.50 $4,150.50 Inc inflamatory therapeutic agent Frontier Scientific Frontier Scientific Inc $106,321.00 $60,284.50 Inc Development of WNK kinase Frost Biologic, Inc $27,140.00 $217,339.24 inhibitors as anti-cancer drugs Sulphated Polysaccaride Glyco Mira LLC $104,784.50 $139,694.74 Derivatives Glycosan HyStem $42,879.50 $201,599.75 BioSystems Inc INTEGRATECH DEVELOPMENT OF SMALL PROTEOMICS MOLECULE HIV INTEGRASE $169,700.00 LLC INHIBITOR JSK Therapeutics, New Class of Cancer Therapy $52,600.00 $37,475.00 Inc (JSK-T) Drugs Identification of Genetic, LineaGen Inc Proteomic and Serological $23,885.00 $16,246.50 Biomarkers for COPD Development of Genetic Markers LineaGen, Inc for the Dagnosis of Autism $244,479.25 Spectrum Disorders Development of Genetic and LineaGen, Inc. Serological Markers for the $204,287.50 $40,191.75 Diagnosis of Multiple Sclerosis Oral Sirolimus for Treatment of Lipocine Inc Progressive Glioblastoma $160,092.50 $84,386.74 Multiforme (LPCN 1105) Lipocine Inc Oral Testosterone Replacement $244,479.24 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Therapy (LPCN 1021) ORAL PROGESTERONE FOR LIPOCINE INC HIGH-RISK PREGNANCY $5,242.00 $239,237.24 SUPPORT (LPCN 1002) Benzonatate for Opioid Resistant Lipocine Inc. Cough in Advanced Cancer $124,945.50 $119,533.74 Patients (LPCN 1035) Max International Project Heart-RiboCeine $244,479.25 LLC Max International, Max GlutathioCeine $244,479.25 LLC Myrexis Inc Azixa $244,479.25 Myrexis Inc MPC-9528 $244,479.25 Myrexis Inc MPC-3100 $244,479.25 Myrexis, Inc MPC-4326 $244,479.25 Myrexis, Inc MPI-485520 $244,479.25 Navigen SecinH3 project $244,479.25 Pharmaceuticals, Inc Navigen Semaphorin 3E - anti platelet $176,636.00 $67,843.25 Pharmaceuticals, Inc project Navigen Slit2N to Prevent Cytokine- Pharmaceuticals, $244,479.25 Induced Vascular Leak Inc. Development of Galanin-Based NeuroAdjuvants, Therapy for Treatment of $210,661.44 $33,817.81 Inc. Epilepsy NuView Life NuVIew Life Sciences Research $49,985.30 $194,493.94 Sciences, Inc and Development FXA-18 NuView Life NuView Life Sciences Research $244,479.24 Sciences, Inc and Development PCO-Cataract NuView Life NUView Life Sciences Research $10,362.50 $234,116.75 Sciences, Inc and Development Breast Cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 biomarker NuView Life NuView Life Sciences Research $244,479.24 Sciences, Inc and Development FMAU NuView Life Sciences Research NuView Life and Development Lymphoma $239,840.73 $4,638.51 Sciences, Inc. biomarker PPR Group, Inc. PRLX93936 $244,479.25 Human Glial Progenitor Cells for Q Therapeutics, Inc. Treatment of Amyotropic $174,764.62 $69,714.63 Lateral Sclerosis Sera Prognostics, Preterm Birth Serum Biomarker $74,479.17 $143,391.78 Inc. Test Preeclampsia and Preterm Labor Taueret Laboratories $244,479.25 Gene Mapping TK1 as a Diagnostic, Prognostic TK Biotech, Inc $60,550.00 $133,000.00 and Therapeutic Cancer Marker Development of siRNA TransDerm Inc Therapeutics for Treatment of $244,479.25 Skin Disorders 30-Day Intravaginal Ring for Prevention of Sexually- Viropan Inc $34,875.00 $209,604.25 Transmitted HPV Infection in Women Vital Access Vital Access' Venous Windowtm $177,017.28 $67,461.97 Corporation Needle Guide (VWNG) Vital Access - Access Device: a Vital Access novel minimally-invasive $244,479.25 Corporation medical device World Hearts Inc Levacor VAD $244,479.25 Flexicaine for Treating Post- ZARS Pharma, Inc. $221,565.00 $22,914.25 herpetic Neuralgia Triamcinolone DuraPeel TM to ZARS Pharma, Inc. $244,479.25 Treat Hand Dermatitis Vermont $244,479.24

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Ascension Development of magnetic and Technology optical medical navigation $120,659.09 $123,820.15 Corp technology

Virginia $10,613,092.92

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Adaptive Methods, Rapid Portable Biosensor $75,000.00 $169,479.25 Inc Therapeutic Flavonoid Api Genesis LLC $244,479.25 Formulations Axon Nutritioinals Food and Therapeutic Supplement $7,500.00 $1,000.00 Inc Development and Contaminant Amyloidosis Diagnostic Bioproximity, LLC Development via Global Proteomic $76,303.90 $64,787.94 Characterization Human Microblome Blowmarkers BIOSPHEREX LLC and Molecular Diagnostic $58,692.50 $185,786.75 Discovery Project Dimebon (BVA-101) Drug Biovista Inc Candidate for Projressive Multipie $151,577.50 $92,901.74 Sclerosis Dimebon (BVA-601) Drug Biovista, Inc $143,491.50 $100,987.74 Candidate for Epilepsy Pirlindol Mesylate (BVA-201), Biovista, Inc. Drug Candidate for Progressive $171,976.00 $72,503.24 Multiple Sclerosis Cary Quitpak Smoking Cessation Drug $5,600.22 $238,879.02 Pharmaceuticals Inc. CEL-SCI MULTIKINE $244,479.25 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 CORPORATION IMMUNOTHERAPY AGENT FOR HEAD AND NECK CANCER ("Multikine") CEL-SCI CEL-2000 Therapeutic drug for $83,182.50 $161,296.75 Corporation rheumatoid arthritis (CEL-2000) Leaps H1N1 Therapeutic Agent for CEL-SCI H1N1 Pandemic Influenza (Leaps $244,479.25 Corporation H1N1) Ceres Nanosciences Ceres Nanotrap $170,228.00 $74,251.25 Development of Universal Multivariate Biomarkers for Clavgen Predicting Chemotherapeutic $195,820.48 Therapeutics LLC Response in Bladder and Ovarian Cancers Dalos BiopHARMA Flavokine's effect in basal cell $24,000.00 LLC carcinomas Flavokine's effect in Dalos BioPharma, Staphylococcus bacterial infections, $24,000.00 LLC including MRSA Diffusion Trans Sodium Crocetinate (TSC) Pharmaceuticals, for the Treatment of Hypoxic $244,479.24 LLC Conditions BREAST SPECIFIC GAMMA IMAGING FOR EARLY DETECTION OF BREAST Dilon Technologies, CANCER AND MONITORING $100,361.00 $144,118.24 Inc OF TUMOR RESPONSE IN NEOADJUVANT CHEMOTHERAPY PATIENTS Euclid Systems Decorin Ophthalmic Solution $244,479.24 Corporation EYERX Research Lacritin, a novel therapeutic for dry $13,819.50 Inc eye Pre-Clinical Development for the Gencia Corp $224,164.00 $20,315.25 treatment of Alzheimer's and Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Sarcopenia Gene Solutions, Parkinson's Disease Diagnostic $17,147.50 $5,352.50 LLC Development GPB Scientific, Therapeutic Stem Cells from $244,479.25 LLC Umbilcal Cord Blood High Density Lipoprotein Health Diagnostic Associated Apolipoprotein E $244,479.25 Laboratory Inc Quantitation Health Diagnostic Vitamin and Mineral Testing for $244,479.25 Laboratory, Inc. Nutritional Status Human Surrogate Model of the HemoShear LLC $79,221.00 $165,258.24 Liver Human Surrogate Diabetes HemoShear, LLC $244,479.24 Vascular Model Targeted Therapeutics for Hypogen Inc Hypertension and/or Salt $5,000.00 Sensitivity Hypogen Inc Salt Sensitivity Urine Test $5,000.00 Innovative Breast Cancer Diagnostic $244,479.25 Technologies, LLC Drug(ITL-1636) Instantlabs Medical Enabling Accel. Real-Time Diagnostic Polymerase Chain Reaction (ART- $244,479.25 Corporation PCR) at point -of-need Jericho Sciences, Novel Long-term Antiviral $2,365.00 $242,114.24 LLC Therapeutic Alkalinization of Inhaled John F. Hunt $5,760.00 $3,667.00 Therapeutics. Targeting Tumor Hypoxia as New Lestoni Corp $99,303.00 $145,176.24 Cancer Therapy Medgenics, Inc. The Biopump Protein Factory $244,479.25 Medical Predictive Impact of HeRO Monitoring in $244,479.24 Science Corporation Neonates Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Accelerating Development of Molecules for Didox, a Unique Multifaceted $32,518.00 $119,588.50 Health, Inc Drug, Towards Clinical Usage OCUCURE OC-10X: Topical treatment of THERAPEUTICS, Macular Degeneration and Diabetic $244,479.24 INC. Retinopathy OCULAR OPTICS, Sapphire TM Auto Focal IOL $244,479.25 INC. Osteologix Inc NB S101 $244,479.24 A novel Nano-Pharmaceutical for Parabon NanoLabs the treatment of Glioblastoma $38,352.47 $92,028.90 Inc Multiforme Phthisis Diagnostics, R-Sphere Cypto-Giardia Detect $173,299.50 $71,179.74 LLC Phtsisis Diagnostics, R-Sphere Microsporidia Detect $35,916.50 LLC New Topical Antibiotic with PluroGen Unique Antimicrobial, Physical, $160,570.31 $83,908.94 Therapeutics, Inc. Bio-impace and Multi-function Pocket-Sized, Low-Cost, Pocketsonics Inc $143,783.00 $100,696.25 Ultrasound Imaging Device New therapies using human Revivicor Inc compatible cells and organs from $244,479.25 genetically engineered pigs Novel Therapeutic for Skyentia Neuroprotection in Stroke and $1,592.48 $1,790.41 Technologies, LLC Traumatic Brain injury SYNTHONICS INC METALLO-ZANAMIVIR $62,737.00 $86,333.50 Synthonics Inc Metallo-SAHA $64,834.50 $76,873.00 Synthonics Inc Metallo - Topiramate $61,746.50 $66,791.50 Synthonics, Inc Metallo-Levodopa $118,318.00 $126,161.25 Tau Therapeutics Interlaced Therapy with Mibefradil $169,518.52 $74,960.73 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 LLC for the Treatment of Glioblastoma Multiforme Glycofect Biodegradable Techulon, Inc. $48,619.50 $84,000.00 Transfection Reagent Botanical Drug for DIC in Toxem LLC snakebite, sepsis and traumatic $51,360.92 $193,118.33 brain injury WellAWARE WellAWARE $244,479.25 Systems, Inc Commercializing Micro/Nana Zansors LLC sensors for obesity detection using $244,479.24 bio-sensor technologies

Washington $33,108,644.56

Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Personalized treatment of AcciumBio Sciences, glioblastoma multiforme and $65,700.00 $178,779.25 Inc other cancers Adaptive TCR Prediction of Anti-TNF Response $146,958.50 Corporation in Patients with Crohn's Disease Development of a Pre- Adaptive TCR symptomatic Biomarker for Type $244,479.25 Corporation 1 Diabetes Adaptive TCR Prediction of Active Disease State $167,559.50 Corporation in Crohn's Disease Identification of Immune System Adaptive TCR Signatures in Patients with $244,479.24 Corporation Ovarian Cancer Adaptive TCR Immune System Profiling as a $244,479.24 Corporation Measure of Vaccine Efficacy ADVANCED Molybdenum-99 $205,129.00 $39,350.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 MEDICAL ISOTOPE CORPORATION ADVANCED MEDICAL Brachytherapy $244,479.24 ISOTOPE- CORPORATION A novel nucleic acid delivery Agave Pharma Inc $244,479.24 technology for RNAi therapeutics Alder ALD518 humanized monocional Biopharmaceuticals, $244,479.24 antibody therapeutic project Inc AZ01 treatment of Multiple Allozyne Inc $244,479.24 Sclerosis(MS) AZ17 for the treatment of Crohn's Allozyne Inc $244,479.24 Disease(CD) Polyamine-Based Therapy (PBT) Aminex Therapeutics, Approach for Head and Neck $6,980.73 $237,498.51 Inc Cancer An Immune Monitoring Test to Amnis Corporation prevent Kidney Transplant $244,479.25 Rejection Peptide Delivery for Anergix LLC Downregulating the Autoimmune $244,479.25 Response in Multiple Sclerosis Duchenne Muscular Dystrophy AVI BioPharma Inc $244,479.25 (DMD) Therapeutic Program AVI BioPharma Inc Junin Therapeutic Program $244,479.24 AVI BioPharma, Inc. Marburg Therapeutic Program $244,479.24 AVI BioPharma, Inc. Ebola Virus Therapeutic Program $244,479.25 Influenza (H1Na virus) AVI BioPharma, Inc. $244,479.25 Therapeutic Program Blood Cell Storage, Molecular Diagnostic Nucleic $244,479.25 Inc. Acid Extraction Device Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Blood Cell Storage, Device to improve efficacy of $244,479.25 Inc. therapeutic platelets CAL-263-Therapeutic for Calistoga Inflammation and Auto-immunity $244,479.25 Pharmaceuticals, Inc Targeting P13 Kinase Delta CAL-120-Therapeutics for Solid Calistoga Tumor Cancers Targeting the P13 $244,479.25 Pharmaceuticals, Inc Kinase Beta/Delta Pathway CAL-101-Therapeutic for Calistoga Hematologic Malignancies and $244,479.25 Pharmaceuticals, Inc other Cancers Guiding Therapeutic Radiation of Calypso Medical Tumors Without Respiratory $244,479.25 Technologies, Inc Motion Calypso Medical Guiding Therapeutic Radiation of $244,479.25 Technologies, Inc. Tumors With Respiratory Motion Development of Innovative Cancer Targeted Enzyme Inhibitors for Cancer $59,683.09 $124,245.06 Technology,LLC Treatment and Imaging CARDIAC Carillon Mitral Contour System $244,479.24 DIMENSIONS, INC. Cell Therapeutics Inc Pixantrone $244,479.24 & Subsidiary Cell Therapeutics Inc Bisplatinate $244,479.24 & Subsidiary Cell Therapeutics, Inc. BROSTALLICIN $244,479.24 & Subsidiary CELL THERAPEUTICS, OPAXIO $244,479.24 INC. & SUBSIDIARY Cerevast Sonothrombosis $153,880.34 $90,598.91 Therapeutics, Inc CG Therapeutics, Inc Cancer Vaccine Targeting Human $239,500.00 $4,979.24 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Chorionic Gonadotropin Influenza: New therapeutic and Cocrystal Discovery, technology for broad-spectrum $112,530.50 $131,948.74 Inc antivirals Human rhinovirus: New Cocrystal Discovery, therapeutic and technology for $168,796.50 $75,682.74 Inc broad-spectrum antivirals Hepatitis C: New therapeutic and Cocrystal Discovery, technology for broad-spectrum $244,479.24 Inc. antivirals Columbia Northwest PTSD $244,479.25 Pharmaceuticals LLC Columbia Northwest LifePro $12,831.00 $231,648.25 Pharmaceuticals, LLC Transfucer Performance EKOS Corporation $90,579.50 Improvement EKOS Corporation Mach4e Product Development $200,704.50 EKOS Corporation ULTIMA clincal study $6,400.00 Emergent Detection, BodyKey FatLoss Sensor $229,900.00 Inc. GlucaPen™ Emergency Auto- Enject, Inc. $244,479.24 Injector for Severe Hypoglycemia Epi-proColon, an in-vitro Epigenomics Inc diagonistic blood test for $244,479.25 colorectal cancer Development of a novel CEA Etubics Corporation Expressing Adenovirus for $244,479.24 Cancer Treatment Aldehyde Dehydrogenase Focused Scientific Inc $11,475.00 $11,757.00 Modulators Highly Integrative Biomaterial Healionics Structures for Therapeutic $244,479.25 Corporation Devices Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Hema Quest Novel Therapy for Cystic Fibrosis $111,169.50 $95,967.00 Pharmaceuticals Inc (CF) HemaQuest Novel Therapy for Beta- $244,479.25 Pharmaceuticals Inc Thalassemia HemaQuest Novel Therapy for Sickle Cell $244,479.25 Pharmaceuticals Inc Disease (SCD) HemaQuest Novel Treatment for EBV-related $244,479.25 Pharmaceuticals Inc Lymphoid Malignancies Topical Solutions and Devices for Hyprotek, Inc Antimicrobial Action and $8,549.00 $11,829.00 Reduction of CRBSI IDC-G103, a Therapeutic Vaccine Immune Design Corp for the Treatment of Herpes $244,479.25 Simplex Virus Type 2 A Therapeutic Vaccine for Prostate Cancer Based on a Immune Design Corp $244,479.25 Lentivirus Vector Delivery Platform Impel NeuroPharma, Pressurized Olfactory Delivery $112,886.11 $131,593.14 Inc (POD) device Implicit Bioscience Development of IC 14 for acute $10,706.50 $233,772.74 Inc. lung injury Inimex Amelioration of chemotherapy- Pharmaceuticals USA, induced mucositis in cancer $244,479.25 Inc patients Diagnosing Cardiovascular Insilicos LLC Disease Via Molecular Changes $218,730.00 $25,749.25 to HDL Particles An In Vivo Diagnostic for Early Integrated Diagnostics Detection of Lung Cancer Using $244,479.25 Inc Synthetic Antibodies A Molecular Diagnostic Test for Intergrated the Early Detection of $122,561.50 $121,917.75 Diagnostics Alzheimer's Disease Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 A molecular Diagnostic Test for Intergrated the Early Detection of Lung $24,310.00 $220,169.25 Diagnostics, Inc Cancer Brachytherapy Utilizing Balloon IsoRay Medical Inc & Liquid Radiation source for $852.00 $234,886.00 Operable Brain Cancer APBU using cesium-131 sources IsoRay Medical, Inc following lumpectomy for early $48,911.00 $127,308.00 stage breast cancer Cesium-131 Lung Brachytherapy IsoRay Medical, Inc. and Sub-Lobar Resection in Stage $59,553.00 $55,000.00 I NSCLC ShK-186 AUTOIMMUNE KINETA ONE, LLC $244,479.25 PROGRAM Kineta TWO, LLC. Antiviral protein Therapeutic $244,479.25 Kineta, Inc RIG-1 Antiviral Program $160,600.44 $83,878.81 KP-1461 An Innovative Therapy Koronis for the Treatment and Possible $244,479.25 Pharmaceuticals Inc Cure of HIV Kurve Technology, Controlled Particle Dispersion $132,374.54 $112,104.70 Inc Technology Platform (CPD) Light-Activated Talaporfin Light Sciences Sodium for Primary and $244,479.25 Oncology, Inc Secondary Liver Tumors Light-Activated Talaporfin Light Sciences Sodium for Treatment of Benign $244,479.24 Oncology, Inc. Prostatic Hyperplasia RNA-interference (RNAi) MDRNA, Inc. $244,479.24 Therapeutics MediQuest Vascana $244,479.24 Therapeutics, Inc Advancement of Novel Molecular Micronics, Inc. Diagnostic Platform for Acute & $244,479.24 Chronic Disease Detection Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Mirabilis HIFU device for the Mirabilis Medica Inc $244,479.24 treatment of uterine fibroids Novel MicroRNA Antagonists for Mirina Corporation $244,479.24 the Treatment of Cancer Novel MicroRNA Antagonists for Mirina Corporation the Treatment of Fibrotic Liver $146,478.18 $98,001.06 Disease Development of Novel Nanoquantum Photosensitizers with Cellular $51,790.46 $192,688.79 Sciences, Inc Targeting for Cancer Therapy The NanoString nCounter Breast NanoString Cancer Subtyping Molecular $244,479.24 Technologies, Inc. Diagnostic Test Microvascular assays for research Nortis Inc. and drug testing in cancer and $28,823.50 other diseases Development of a new tool for the Oasis Diagnostics collection of DNA from saliva $8,130.00 $6,237.00 Corporation specimens Development of PDE7 inhibitor Omeros Corporation as a novel approach for the $191,898.62 $52,580.63 treatment of Parkinson's disease. Development of Novel Treatment Omeros Corporation $64,477.37 $54,453.25 for Addiction Development of novel treatments Omeros Corporation for osteoarthritis and the $84,255.58 $53,024.81 protection of articular cartilage New Drug Product to Treat Pain, Omeros Corporation Inflammation and Spasm of the $204,440.36 $40,038.89 Urinary Tract, OMS201 MASP-2 MoAb Treatment for Omeros Corporation $244,479.25 Traumatic Injury Development of novel Omeros Corporation $244,479.25 medications for schizophrenia Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 treatment Intracameral OMS302 to Maintain Intraoperative Mydriasis Omeros Corporation $208,240.95 $36,238.30 and Reduce Pain and Inflammation Novel Drug Product to Improve Omeros Corporation Function and Reduce Pain $244,479.25 Following Arthroscopic Surgery Use of OGX-011 to Enhance the OncoGenex Effects of Chemotherapy in $244,479.25 Pharmaceuticals, Inc. Prostate Cancer OncoGenex Use of OGX-427 to Enhance the $244,479.25 Pharmaceuticals, Inc. Effects of Chemotherapy Onconome Inc Colon Cancer Rule Out Test $117,093.50 $113,923.00 Onconthyreon Inc PX-866 PI-3 Kinase Inhibitor $244,479.24 ONT 10 Novel Therapeutic Oncothyreon Inc $69,733.00 $174,746.24 Cancer Vaccine Nasal decolonization of Ondine Research methicillin-resistant $140,717.01 $103,762.24 Laboratories Inc Staphylococcus aureus (MRSA) Onkor Pivotal study of small cell lung $80,300.00 $28,582.50 Pharmaceuticals, Inc cancer therapeutic agent Onkor Pivotal study of hepatoma $1,169.00 Pharmaceuticals, Inc therapeutic agent Pacific Biomarkers, PBI Organ Injury Biomarker $73,350.00 $171,129.25 Inc. Initiative Pathway Medical Jetstream Catheter $244,479.25 Technologies Inc Polymeric Delivery System of PhaseRx, Inc Macromolecules (RNA) to $244,479.25 Hepatocytes Targeted Therapeutic Delivery PhaseRx, Inc. $121,525.00 $122,954.25 Polymers for Oncology Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Applications Improving and expanding testing PhenoPath available for detecting cancer and $244,479.25 Laboratories PLLC other diseases Phase 3 Studies of Picoplatin, a Poniard New-Generation Platinum-Based $244,479.25 Pharmaceuticals, Inc Chemotherapeutic Development of an In Vivo Presage Biosciences, Assessment Platform for $17,320.36 $227,158.88 Inc Preclinical and Clinical Testing of Novel Therapeutics PRO-0510: a Fibrin Sealant for ProFibrix Inc $244,479.24 Severe Bleeding Systebryl for the Treatment of Proteo Tech, Inc. $233,727.93 $10,751.32 Systemic AA Amyloidosis Synuclere for the Treatment of ProteoTech Inc. $244,479.25 Parkinson's Disease Pepticlere for the Treatment of ProteoTech, Inc. $52,550.57 $87,197.78 Alzheimer's Disease PET Imaging for Diagnosis of ProteoTech, Inc. $95,204.31 $90,276.21 Parkinson's Disease Exebryl-1 for the Treatment of ProteoTech, Inc. $134,205.07 $110,274.18 Alzheimer's Disease Qwell Development of Avicin D for $244,479.25 Pharmaceuticals, Inc. cancer treatment Detection and Characterization of RareCyte, Inc. $244,479.25 Circulating Tumor Cells Rhine Symmetrin $244,479.25 Pharmaceuticals LLC 24 mg Ondansetron Extended SCOLR Pharma nc $4,191.50 Release Tablets Scolr Pharma Inc Oral Dosage Form of Peramivir $2,417.00 Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 600 mg Ibuprofen - Extended SCOLR Pharma Inc $244,479.24 Release Therapeutic Electrical Silere Medical Neurostimulation Prosthesis for $244,479.24 Technology, Inc Suppression of Chronic Tinnitus Sound Otoprotection of noise hearing $244,479.25 Pharmaceuticals Inc loss Sound Regeneration of hearing after $95,123.00 $149,356.25 Pharmaceuticals Inc sensorineural hearing loss Chemoprotection in Sound chemotherapy receiving cancer $4,286.00 $240,193.25 Pharmaceuticals Inc patients Development of the novel FAST STB LTD Dressing for Immediate Control $244,479.25 of Life Threatening Bleeding Stratos Genomics Inc SBX™ Genome Analyzer $186,876.34 $57,602.91 M1-Tramadol: A new therapeutic Syntrix Biosystems $206,169.50 for patient to Tramadol Development of CXCR1/2 Antagonists for the Treatment of Syntrix Biosystems $207,498.73 $36,980.52 Pulmonary Inflammatory Diseases L/D-aminopterin as a novel once- Syntrix Biosystems weekly oral and low-cost $239,613.28 $4,865.97 alternative to costly biologics Syntrix Biosystems Snap-To-It Probes $151,226.36 $93,252.89 Inc Theraclone Sciences, Theraclone Anti-M2e Influenza $244,479.24 Inc. Monoclonal Antibody Project Theraclone Sciences, Theraclone Universal Anti-HIV $244,479.24 Inc. Monoclonal Antibody Project Theraclone Sciences, Theraclone Anti-HA Influenza $244,479.24 Inc. Monoclonal Antibody Project Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Theraclone Universal Anti- Theraclone Sciences, HCMV Monoclonal Antibody $166,838.50 $77,640.74 Inc. Project Resorbable Implant for Bone Tissue Regeneration Replacement and Regeneration in $244,479.24 Systems, Inc. Craniomaxillo Facial Surgery Trubion TRU-016 $244,479.24 Pharmaceuticals Inc Trubion Annika Vanghagen $244,479.24 Pharmaceuticals Inc Trubion X1 Scorpion $244,479.25 Pharmaceuticals Inc Trubion TSCORP $244,479.25 Pharmaceuticals Inc. Trubion X2 Scorpion $244,479.25 Pharmaceuticals, Inc. Unigen, Inc. Obesity Program $229,286.50 $15,192.75 Unigen, Inc. UP780 Diabetes Treatment $195,924.50 $48,554.75 BTVA FOR BRONCHOSCOPIC UPTAKE MEDICAL LUNG VOLUME REDUCTION $244,479.25 CORPORATION FOR SEVERE EMPHYSEMA Viral Logic Systems Human FcRn Antagonist (FcRn Technology $244,479.25 Antagonist) Corporation VLST is developing a novel product for the treatment of Rheumatoid arthritis (RA) and Viral Logic Systems other chronic inflammatory Technology $244,479.25 autoimmune diseases. VLST's Corporation human CD200-Fc agonist therapeutic delivers immunoregulatory signals Viral Logic Systems Anti-human Beta-Chemokine $244,479.25 Technology Antibody Grants Grants Applicant Name Project Name Awarded Awarded for 2009 for 2010 Corporation Microvascular assays for research VisionGate Inc. and drug testing in cancer and $32,318.50 $82,685.00 other diseases New 3D imaging platform for VisionGate Inc. diagnostic applications in lung $244,479.25 cancer and other diseases Non-Invasive Accurate Assessment of Atheroclerosis for VPDiagnostics Inc $244,479.25 Effective Stroke and MI Prevention Absorbable and Low-Cost XL Sci-Tech, Inc $96,780.87 $88,629.12 Radioseeds for Malignant Tumors An Innovative Ex Vivo Platform XORI Corporation for Discovery and Optimization $244,479.24 of Therapeutic Antibodies

West Virginia $488,958.50

Project Grants Awarded for Grants Awarded for Applicant Name Name 2009 2010 Nexeon Medsystems, Protex $244,479.25 Inc Protea Biosciences LAESI $147,899.50 $96,579.75 Inc.

Wisconsin $12,886,764.62

Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Addiction Addition Therapeutix - Opioid $2,308.75 $41,551.75 Therapeutix, Inc. Addiction Addiction Addiction Therapeutix- $40,922.00 $69,079.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Therapeutix, Inc. Alcoholism & Co-Morbid Anxiety Development of ITE into an AhR Pharmaceuticals Efficacious and Sustainable but $883.44 $3,550.00 Inc Low Side-Effect Therapeutic Agent in Combating Cancer Botulinum neurotoxin detection and antidotes/antagonists: A BioSentinel, Inc. model of cost-effective drug $244,479.24 development for unmet biothreat and patient safety needs Phase 1 IND Clinical Trial of Botanic Oil Novel Biotherapeutic for cancer $137,285.75 innovations, Inc. treatment Advanced Development of Anti- Cambridge Major Cancer Drug - Abiraterone $244,479.25 Laboratories Inc ACetate High Yield Protein Technology cdi Bioscience, Inc and Cell Lines for Biologic $197,160.50 $47,318.74 Therapeutics I-131-CLR1404 For Cancer Cellectar, Inc. $244,479.24 Therapy Efficient, large -scale and Cellular Dynamics parrallel manufacture of induced International Inc $244,479.25 pluripotent stem cell (iPSC) (DCI) panels. Cellular Dynamics Neurons derived from human International, Inc induced pluripotent stem cells $222,120.00 $22,359.25 ("CDI") (iPSCs) Cellular Dynamics Endothelial cells derived from International, Inc. human induced pluripotent stem $27,764.50 $216,714.75 ("CDI") cells (iPSCs) Cellular Dynamics Hepatocytes derived from human International, induced pluripotent stem cells $101,805.50 $142,673.75 Inc.("CDI") (iPSCs) Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Compact Particle Highly Compact and Lower Cost Acceleration $244,479.24 Proton Therapy System Corporation (CPAC) Novel Therapeutic for the Prevention of Catheter ConjuGon, Inc $126,059.50 $118,419.74 Associated Urinary Tract Infections Effects of a Novel Compound Core Products Ibuprofen Cream in the $31,750.00 $212,729.24 International, Inc Management of Back and Knee Pain Cytometix, Inc Peptide Therapy for Asthma $22,625.00 $141,119.50 Cytometix, Inc. Lipid Therapeutics for ain $92,000.00 $152,479.25 DAB-8 to control serum Deltanoid phosphorus in patients with $192,718.00 $51,761.24 Pharmaceuticals Inc chronic kidney disease (CKD) Deltanoid 2MD for treatment of $156,026.00 $32,395.00 Pharmaceuticals Inc postmenopausal osteoporosis 2MD to slow the progression of Deltanoid chronic kidney disease and $189,883.00 $54,596.24 Pharmaceuticals, Inc prevent end-stage renal disease NDC-1308: anovel anticancer ENDECE, LLC therapeutic for controlling tumor $244,479.24 growth Development and EraGen Biosciences commercialization of FDA $244,479.25 Inc approved HSV 1&2 molecular diagnostic kit New Approaches to a Minimally- Eso-Technologies Inc. Invasive Cardiac Monitoring $152,919.50 $91,559.75 System Exact Sciences' Next Generation Exact Sciences Colorectal Cancer (CRC) $244,479.24 Corporation Screening Test Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Flex Polymer: Novel Treatment Flex Biomedical, Inc. $210,510.00 $33,969.24 for Osteoarthritis FP-An Antiviral Against FluGen, Inc $147,914.50 Influenza Intradermal Microneedle Patch FluGen, Inc $244,479.24 for Influenza Vaccine Delivery. FluGen, Inc. Cell based M2KO LAIV $118,156.09 $87,495.79 Genetic Testing PF4 Rapid Test $85,899.00 $158,580.25 Institute, Inc Therapeutics to treat cardiac InvivoSciences, LLC $115,504.49 $128,974.76 fibrosis Directed Biocide ioGenetics LLC $244,479.25 anticryptosporidial therapeutics Novel system for early detection Isomark LLC of sepsis in the critically ill $5,734.45 $66,200.00 intensive care patient Unconditional MRI Compatible Kenergy, Inc. Implantable pacemaker and $244,479.24 Defibrillator Development of first-in-class M1 Mithridion, Inc and M4 agonist drugs for $244,479.24 Alzheimer's and schizophrenia. ELI 230 Value MORTARA Electrocardiograph for Early $244,479.25 INSTRUMENT, INC. Detection of Atrial Fibrillation Mortara ELI PC, Device for Low MORTARA Cost Digital Acquisition of ECG $200,069.50 $44,409.75 INSTRUMENT, INC. Data in New Drug Development NanoMedex Manotechnology Drug $93,257.94 $151,221.31 Pharmaceuticals Inc Formulation Preclinical development of a NanoOncology nanoparticle drug to treat lung $244,479.25 cancer Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Nerites Corporation Dural Membrane Sealant $244,479.25 Neuro-endocrine control as NeurEndo Pharma treatment for Type-2 diabetes and $72,500.00 $171,979.25 LLC other metabolic disorders. NeuWave Medical, Therapeutic Microwave Energy $244,479.25 Inc Delivery to Treat Cancer Tumors Production and purification of Ac225/Bi213 alpha-emitting NorthStar Medical isotopes used in delivery of $210,580.00 $33,899.25 Radiostopes LLC therapeutic molecules for the destruction of cancer cells Compsitions and Method for Perscitus Biosciences Protecting Cells from Toxic $32,866.50 $211,612.75 LLC Compounds Immune Tolerance Test (ITT)- Pharmasan Labs , Inc $172,146.03 $72,333.22 Cytokine Platform Project rhC1NH: Treatment of Pharming Healthcare Hereditary Angioedema and $244,479.25 Inc other Clinical Applications Recombinant Human Fibringen Pharming Healthcare for treatment of fibrinogen $244,479.25 Inc deficiencies High Density Gene-Centric PreventionGenetics Deletion and Amplification Array $79,250.50 LLC CGH Prevention of oral mucositis in ProCertus BioPharm patients receiving cancer $62,090.50 $111,598.00 Inc treatments Promentis Cystine-Glutamate Exchange $45,995.50 $198,483.74 Pharmaceuticals, Inc Project Naked Evade [tm] Rnase QBI- Quintessence 139 for cancer product $244,479.24 Biosciences Inc development Ratio Inc Development of a novel drug $12,652.00 $137,750.00 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 delivery device: Ratio's microneedle pump-patch Scarab Genomics, Treatment for Sepsis and Related $187,377.91 $57,101.34 LLC Syndromes Smoke-Break Liquid Nicotine Smoke-Break Inc $13,898.50 $169,460.50 Despenser Therapeutic management of Spectrocon venous congestion with $203,001.50 $41,477.75 International LLC AutoFlow, a novel medical device Antibody Stabilization StableBody Technology for Therapeutic Drug $232,436.00 Technologies, LLC Applications Stemina Biomarker Biomarkers of Cardiomyopathy $19,100.89 $20,134.23 Discovery Stemina Biomarker Biomarkers of Autism $785.29 $30,800.34 Discovery Development and Clinical Stratatech Evaluation of Novel Advanced $244,479.25 Corporation Wound Care Therapies Waypoint Health COPE Development Project $41,620.84 $124,853.17 Innovations, LLC Wilson-Hurd INEEDMD 12-Lead ECG Glove Manufacturing $139,950.00 $104,529.25 Project Company ZyStor Therapeutics, XC-701 for the treatment of $244,479.25 Inc. Pompe disease